,id,ticker,title,category,content,date,provider,url,article_id
102629,324144,ABC,Judge OKs ad blitz for opioid epidemic claimants,news,"The judge presiding over Purdue Pharma s bankruptcy has approved a nationwide noticing program for potential monetary award claimants that would reach  95  of U S  adults 
The  23M campaign will include mailings  television and internet advertisements  including Facebook and Spotify  
The deadline for filing claims is June 30 
Opioid crisis related tickers  McKesson  MCK  3 3    AmerisourceBergen  ABC  5 2    Cardinal Health  CAH  3 6    Mallinckrodt  MNK  7 1    Teva Pharmaceutical Industries  TEVA  4    Johnson   Johnson  JNJ  0 1    Endo International  ENDP  9  ",2020-01-24,Seeking Alpha,https://invst.ly/pmhny,2067346
102630,324145,ABC,What s In Store For AmerisourceBergen  ABC  In Q1 Earnings ,opinion,AmerisourceBergen Corporation   NYSE ABC   is scheduled to release first quarter fiscal 2020 results on Jan 30  before the opening bell In the last reported quarter  the company delivered a positive earnings surprise of 1 9   Further  it has an average four quarter positive surprise of 6 1  Let s take a look at how things are shaping up prior to this announcement Q1 EstimatesThe Zacks Consensus Estimate for first quarter fiscal 2020 revenues is pegged at  47 98 billion  indicating an improvement of 5 7  from the year ago quarter  The consensus estimates for earnings stands at  1 67  suggesting growth of 4 4  from the year ago reported figure Pharmaceutical Distribution Unit to Drive Q1Sustained growth in specialty product sales and expanding customer base at this segment are likely to have benefited the fiscal first quarter performance  Notably  this segment serves healthcare providers in the pharmaceutical supply channel  Solid organic growth rates in the U S  pharmaceutical market  population demographics and improving patient access to medical care are likely to have contributed to the to be reported quarter s top line The Zacks Consensus Estimate for Pharmaceutical Distribution stands at  46 37 billion  indicating an improvement of 6  from the year ago quarter Moreover  operating income at this segment is expected to improve in the low to mid single digit percent range in fiscal 2020  a trend that is likely to get reflected in the to be reported quarter AmerisourceBergen Corporation Price and EPS Surprise    Other Factors to ConsiderWorld Courier unitThe World Courier unit  in particular  is likely to have contributed to the Other segment s performance in the fiscal first quarter  Bolstering customer experience through new offerings  technology improvements and delivery of high tax logistics services is anticipated to get reflected in the company s fiscal first quarter results The company s fiscal first quarter top line is likely reflect solid demand for its high touch global specialty logistics Other SegmentThis segment consists of Global Commercialization Services and Animal Health  and includes World Courier  AmerisourceBergen Consulting and MWI  The segment is likely to have contributed to the top line in the to be reported quarter  backed by growth in Canadian operations and MWI In fact  the Zacks Consensus Estimate for fiscal first quarter revenues for this segment is pegged at  1 74 billion  suggesting growth of 4  year ago reported figure This apart  the company is likely to have benefited from generics growth in the to be reported quarter  Further  new product launches are likely to have contributed to overall performance Moreover  stiff competition  as the company operates in a highly competitive pharmaceutical distribution and related health care services market  is likely to have weighed on the fiscal first quarter performance Further  adjusted operating expenses in fiscal 2020 are estimated to increase in the mid single digit percent range  a trend that is likely to get reflected in the fiscal first quarter results What Our Quantitative Model SuggestsPer our proven model  the combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the chances of an earnings beat  This is the case here as you will see Earnings ESP  AmerisourceBergen has an Earnings ESP of  0 82   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  AmerisourceBergen carries a Zacks Rank  3 Stocks to ConsiderHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter Stryker Corporation   NYSE SYK   has an Earnings ESP of  0 60  and a Zacks Rank  3  You can see  DexCom  Inc    NASDAQ DXCM   has an Earnings ESP of  17 07  and a Zacks Rank  2 Zimmer Biomet Holdings  Inc    NYSE ZBH   has an Earnings ESP of  0 38  and a Zacks Rank  3 Zacks Top 10 Stocks for 2020 In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2020 Last year s 2019 Zacks Top 10 Stocks portfolio returned gains as high as  102 7   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys ,2020-01-24,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-amerisourcebergen-abc-in-q1-earnings-200501355,200501355
102633,324148,ABC,AmerisourceBergen Corp  ABC  Q1 2020 Earnings Call Transcript,news,"AmerisourceBergen Corp  NYSE ABC Q1 2020 Earnings CallJan 30  2020  8 30 a m  ETContents 

Prepared Remarks
Questions and Answers
Call Participants

Prepared Remarks 
OperatorGood morning and welcome to the First Quarter 2020 AmerisourceBergen Earnings Conference Call   Operator Instructions I would now like to turn the conference over to Bennett Murphy  Senior Vice President of Investor Relations  Please go ahead Bennett S  Murphy    Senior Vice President  Investor RelationsThank you  Good morning and thank you all for joining us to this conference call to discuss AmerisourceBergen s fiscal 2020 first quarter results  I m Bennett Murphy  Senior Vice President  Investor Relations  and joining me today are Steve Collis  President and CEO  and Jim Cleary  Executive Vice President and CFO On today s call we will be discussing non GAAP financial measures  Reconciliations of these measures to GAAP are provided in today s press release and also available on our website at investor amerisourcebergen com  We ve also posted a slide presentation to accompany today s press release on our investor website During this conference call  we ll make forward looking statements about our business and financial expectations on an adjusted non GAAP basis  including but not limited to EPS  operating income  and income taxes  Forward looking statements are based on management s current expectations and are subject to uncertainty and changes  For a discussion of key risks and assumptions  we refer you to today s press release and our SEC filings  including our most recent 10 K  AmerisourceBergen assumes no obligation to update any forward looking statements on this call  It cannot be rebroadcast without the expressed permission of the company You ll have the opportunity to ask questions after today s remarks by management  We ask that you limit your questions to one per participant in order for us to get to as many participants as possible within the hour With that  I will turn the call over to Steve Steven H  Collis    Chairman  President and Chief Executive OfficerThank you and good morning to everyone on today s call  Today I am pleased to discuss AmerisourceBergen s strong fiscal 2020 first quarter results  We delivered solid performance across both the Pharmaceutical Distribution and Global Commercialization Services   Animal Health groups  each delivering year over year growth in the first quarter  Revenues were up 5  to  48 billion for the quarter and our adjusted diluted EPS was  1 76 for the first quarter  an increase of 10  compared to the previous fiscal year period Before we provide more details on our first quarter results  I want to take a few moments to discuss the ongoing opioid litigation and the decision to exit the PharMEDium business  AmerisourceBergen and other parties continued the complex process of working toward a global resolution of the opioid litigation  while also continuing to prepare for upcoming trials  We are hopeful that the necessary parties understand and see the merits of the global framework as a practical path for global resolution  As we engage in discussions related to the global framework and continue to litigate  we are unable to comment deeply on these matters at this time  AmerisourceBergen remains committed to transparency and providing shareholders with updates as we are able Moving on to PharMEDium  At this point last year  we detailed how we had begun a comprehensive strategic and financial review of PharMEDium and engaged new cGMP expert consulting firm to work with the business s new seasoned  Phonetic  leadership team  As we stated at that time  we entered this review phase with a focus on pursuing a thoughtful and decisive course of action that was best for AmerisourceBergen and our shareholders  while respecting both the needs of our customers and other stakeholders Over the past year  we worked internally to optimize the business  continued discussions with regulators  and reached an agreement on the terms of a consent decree for PharMEDium with the FDA focused on remediating the business  Despite this progress  we still face considerable challenges in order to successfully move the business forward  including  ongoing regulatory challenges  continued operational issues  inability to make sufficient progress on remediation  and the continued financial burden of running the business  Given these factors  we made the difficult decision to shut down and exit the PharMEDium business  The decision is a difficult one and we are mindful of the impact this has on our associates and customers  We want to thank all PharMEDium associates for their dedication  and we are appreciative of their efforts As part of the shutdown process  we will provide impacted associates with the support and services they need  We are also disappointed that PharMEDium will no longer be able to serve its customers but believe exiting the business is appropriate path forward for AmerisourceBergen and its shareholders  Jim will provide financial details  including the decision s impact on fiscal 2020 guidance  later in the call Turning now to our first quarter results  AmerisourceBergen continues to benefit from our unique pharmaceutical centered strategy that positions us well within the US market  Additionally  the company s core strengths and capabilities regarding our unrivaled talent  Phonetic   expertise  and ability to provide comprehensive solutions continues to differentiate us from our peers  I want to thank our associates for their dedication  executional excellence  and focus on consistently creating and delivering value for all of our stakeholders  I am proud to work alongside our teams who remain relentless in their pursuit of opportunities to unlock value for pharmaceutical manufacturers  healthcare providers  and the patients they serve Within Pharmaceutical Distribution Services  the segment s success reflects its continued focus on customer experience  in addition to our ongoing strength in specialty distribution and overall growth in customer volumes  AmerisourceBergen is the leader in specialty distribution and our strong growth continues to be fueled by our deep expertise and key customer relationships  on organically growing market with favorable demographics  and increased pharmaceutical utilization resulting from innovation within specialty  particularly in the areas of oncology  ophthalmology  and rheumatology In these and other therapeutic categories AmerisourceBergen continues to deliver value and provide differentiated services and solutions to key customer segments such as our community physician practice partners  A key differentiator for our specialty business  our ION GPO remains a competitive advantage in our suite of offerings to oncology physician practices  As a market leading GPO for community oncologists  ION provides physicians with the contracting  analytics  and business practice solutions they need to run their practices more efficiently and profitably  At the same time  we continue to see positive early signs for biosimilar utilization  We believe that the right conditions exist in the US for increasing biosimilar commercialization success We continue to see signs that legislators and commercial plans are recognizing the potential of biosimilars to create better access and affordability for patients  AmerisourceBergen s market leading position in specialty strongly positions us to benefit from biosimilars  We have aligned ourselves with key customers and biosimilar manufacturers understand the value of contracting with ION as they seek to increase utilization of their products  These elements  combined with our scale  efficiency  state of the art distribution network  and competitive sourcing capabilities  position AmerisourceBergen to capitalize on market opportunities AmerisourceBergen is also well positioned to seize market opportunities in animal health and pharmaceutical manufacturer services through our Global Commercialization Services   Animal Health group  businesses that comprise approximately 20  of AmerisourceBergen s operating income  Our largest business in the segment  MWI  is a market leader in animal health solutions with the right strategic partnerships and capabilities should enhance operational efficiencies and deliver strong customer experience  while our portfolio of global commercialization services strengthens health outcomes  while supporting pharmaceutical innovation with data driven solution that advance and support patient access and adherence to therapy For example  Xcenda s health economics consulting and FieldTech  Phonetic  team reimbursement support services are helping manufacturers maximize market access for products  while the Lash Group s technology enabled patient access and adherence solutions are helping to reduce barriers for patients to start and stay on therapy Essential to pharmaceutical manufacturers ability to commercialize and improve access to innovative therapies is ability to transport trial products and unique patient treatments like cell and gene therapies on time and at the right temperature  World Courier  the global market leader in specialty and clinical trial logistics  is a trusted solutions part that services these complex needs for manufacturers around the world  Operating over 30 countries  this highly differentiated and innovative business continues to grow and expand  This business delivers unparalleled service offerings for its pharmaceutical partners in clinical trial logistics and commercial services For example  World Courier s Cocoon offering is the industry s most dependable and cost effective refrigerated container solution providing unprecedented reliability and driving strong momentum for the business this year  In addition  World Courier s Nova technology platform further improves operational excellence  scaling to meet the demand and complex requirements of our global customers  Looking ahead  World Courier will continue to design and deploy patient centric and forward thinking transport services in new areas like in home clinical trials making treatments in patients  home possible in virtually every therapeutic area I am proud of AmerisourceBergen s role as the global healthcare solutions leader and purpose driven organization  We are united in our responsibility to create healthier futures and recognize that there is always a patient connected to every product  Pharmaceutical care is still the most efficient form of healthcare and medication adherence provides positive health benefits for patients  while saving lives and the healthcare systems hundreds of billions of dollars annually  Adherence should be the goal for which all healthcare stakeholders are striving  As an enabler of access and creator of additional efficiencies  AmerisourceBergen will continue to engage in constructive dialog around benefit design and rising out of pocket cost for patients and the sustainability and efficiency of the healthcare system As a leader in the healthcare supply chain  AmerisourceBergen remains well positioned to create sustained long term value  Execution of our four key strategic pillars  strong customer base  leadership in specialty distribution and services  innovative services and solutions  and proven corporate stewardship positions us well to benefit from market trends within evolving market landscape As we move further into fiscal 2020  we will continue to advance our talent and culture and execute on our unique and differentiated business strategy  More than ever  we remain confident in our growth strategy  focused on execution and dedicated to delivering long term value for our associates  shareholders  partners  customers  and the patients they serve Thank you again for your interest in AmerisourceBergen  I will now turn the call over to Jim for a more in depth review of our first quarter fiscal 2020 results  Jim James F  Cleary    Executive Vice President and Chief Financial OfficerThanks  Steve  and good morning  everyone  My remarks today will focus primarily on our adjusted non GAAP financial results  Growth rates and comparisons are made against the prior year December quarter  unless otherwise noted  For a discussion of our GAAP results  please refer to our earnings release As Steve mentioned  we had a strong quarter with solid execution in our Pharmaceutical Distribution segment and continued growth in our Global Commercialization Services   Animal Health  Before I discuss our results in greater detail this morning  I want to take a moment to discuss the GAAP asset impairment charge that we took for PharMEDium as of December 31st and the January strategic decision to exit the business First  the GAAP asset impairment for PharMEDium  We updated our recoverability assessment of PharMEDium s long lived assets as of December 31 and made the determination that the estimated undiscounted future cash flows indicated that the assets should have a lower carrying value  As a result  we calculated the fair value of PharMEDium s long lived assets using undiscounted cash flow estimates as of December 31st and determined the asset impairment amount to be  138 million Second  I ll cover the decision to exit the PharMEDium business  As Steve said  the company has decided to exit the compounding business  and as a result  we ll cease all commercial and administrative operations related to the business  The decision to exit the PharMEDium business was not easy  but it is undoubtedly the right path forward for AmerisourceBergen and our shareholders  As Steve noted  the decision was based on a number of factors  notably continuing regulatory and operational challenges  including PharMEDium s decision earlier this month to suspend production at its New Jersey facility  In addition to the December quarter impairment charge  as a result of the decision in January to exit the business  the company expects to impair the majority of the remaining  55 million of tangible PharMEDium assets and all of the remaining  185 million of PharMEDium intangible assets in the March quarter Finally  as a result of the exit  we expect to claim an ordinary income tax deduction and estimate that we will realize a cash tax benefit in fiscal 2020 through fiscal 2022 totaling approximately  500 million to  600 million  This will benefit our GAAP P L and GAAP tax rate but will not impact our adjusted tax rate  However  it will have a positive impact on cash flows in the years in which the benefit is realized  As it pertains to the adjusted non GAAP results for the remainder of the year  our decision to exit PharMEDium will have a positive impact on our outlook for fiscal 2020  which I will provide greater detail on in a few minutes Turning now to our first quarter results  I ll provide commentary in two main areas this morning  First  I will detail our adjusted quarterly consolidated and segment performance  Second  I will cover our increased fiscal 2020 guidance  reflecting the continued strength of AmerisourceBergen s businesses  a lower share count  and the removal of PharMEDium for the remaining three quarters of fiscal 2020 We finished the quarter with adjusted diluted EPS of  1 76  an increase of 10   primarily due to higher operating income and a lower share count  Lower net interest expense was offset by an increase in income taxes  Also  our December quarter of last year had unfavorable bad debt expense  which benefits the current year over year comparison by a couple pennies Our consolidated revenue was  47 9 billion  up 5   driven by strong revenue growth in both segments  Gross profit increased 3   or  40 million  to  1 24 billion  Consolidated operating expenses increased 2  to  748 million  This quarter is an easier comparison on the balance of fiscal 2020 due to a few reasons that we have called out previously  First  we had not yet lapped the healthcare benefit design change that was implemented for calendar 2019  Second  much of the operational synergies related to our fiscal 2018 acquisition of H D  Smith were captured after the first quarter of fiscal 2019  Additionally  we executed on delivering better than expected expense management across the business in the quarter  most notably within the Pharmaceutical Distribution segment Consolidated operating income was  495 million  up 5  with our operating margin down one basis point  As I mentioned earlier  there were some favorable items related to bad debt expense comparison  healthcare  and the timing of H D  Smith synergy capture  Our businesses  with the exception of PharMEDium  are executing well and the strength of our business continues to show through in our financial results as we posted another solid quarter of growth in operating income As it pertains to PharMEDium  since the decision to exit the business was made in January  PharMEDium s adjusted operating loss for the first quarter of fiscal 2020 will remain in our full year fiscal 2020 results  The adjusted operating loss from PharMEDium in the first quarter was  20 million compared to an adjusted operating loss of  14 million in the first quarter of fiscal 2019 Moving below the operating income line  Net interest expense decreased 26  to  31 million  As a reminder  the adoption of the new lease accounting standard in fiscal 2020 has a favorable impact on the interest expense line as certain build to suit leases that were previously accounted for as finance leases are being accounted for as operating leases  resulting in an offsetting unfavorable impact on operating expenses and therefore operating income  In addition to the lower interest expense  we continue to benefit from interest income related to our higher average invested cash balance Moving now to income taxes  our adjusted income tax rate was 21   up from 19 9  in the prior year quarter  which benefited from a discrete state income tax item  Our diluted share count decreased 3  to 207 5 million shares  In the December quarter  we used opportunistic share repurchases to return  135 million of capital to our shareholders  While on the topic of returning capital to shareholders  this morning we also announced that the company s Board of Directors approved a dividend increase of 5   AmerisourceBergen has a balanced approach to capital deployment  and as evidenced by share repurchases and dividend increase  we have exhibited our ongoing commitment to returning capital to shareholders Regarding free cash flow and cash balance  in the December quarter we had free cash flow of  76 million as we experienced normal seasonality in the business and remain on track for hitting our adjusted free cash flow guidance  Adjusted free cash flow in the quarter was  134 million  As a reminder  the company defines adjusted free cash flow as net cash provided by operating activities  excluding significant unpredictable or non recurring cash payments or receipts relating to legal settlements minus capital expenditures  We ended the quarter with  3 2 billion in cash  of which  1 1 billion was held offshore and the majority was US denominated cash This completes the review of our consolidated results  Now I will turn to our segment results  beginning with Pharmaceutical Distribution Services  Segment revenue was  46 billion  up 5   as the segment continues to benefit from continued strength in the specialty distribution of specialty products in multiple channels and the growth of our customers overall  Our segment operating income increased 5  to  392 million  We continue to be encouraged by our team s ability to execute and deliver value for our partners  both upstream and down  particularly in our specialty physician services group As I mentioned earlier  the segment did benefit from favorable bad debt expense compared to the previous year quarter as well as the year over year comparison of no longer operating the H D  Smith distribution centers that we began transitioning to our existing distribution network in the second quarter of fiscal 2019 I will now turn to the other segment  businesses that focus on Global Commercialization Services   Animal Health  including World Courier  AmerisourceBergen Consulting  and MWI  In the quarter  revenue was  1 8 billion  up 10   driven by 8  growth for MWI and double digit growth in Global Commercialization Services  From an operating income standpoint  this group had operating income of  104 million  up 6   driven by growth in Consulting and World Courier The group is off to a solid start  and we are encouraged by the growth expectations for the business this year  The Global Commercialization Services and Animal Health group is a positive differentiator for AmerisourceBergen  As we look out into the future  we are focused on being leaders in providing key manufacturer services to support pharmaceutical innovation  and we are investing to fortify our strength and overall value proposition through projects like Fusion at Lash and Nova at World Courier  Additionally  MWI has continued to strengthen its customer relationships and commercial partnerships and is focused on execution to further enhance efficiency This completes the review of our segment results  Let me now turn to our fiscal 2020 guidance  As we said in this morning s press release  we are raising our fiscal 2020 EPS guidance from a range of  7 30 to  7 60 to an updated range of  7 55 to  7 80  which implies EPS growth of 6  to 10  and reflects the company s continued strong performance  opportunistic share repurchases in the first quarter  and our exit of the PharMEDium business which represents slightly less than half of the guidance increase Regarding operating income  we now expect to grow consolidated operating income in the mid single digit percent range to reflect the continued strength of our overall business and the year over year favorability of not having PharMEDium losses in our adjusted operating income results for the balance of the year  We now expect the operating income in Pharmaceutical Distribution Services segment to grow in the mid single digit percent range  As a result of exiting the PharMEDium business  our fiscal second  third  and fourth quarters will have a favorable comparison to the respective fiscal 2019 quarters in which we recorded adjusted PharMEDium operating losses of  14 million   9 million  and  18 million  respectively  In total  the fiscal 2020 adjusted operating loss from PharMEDium is solely what we recorded in Q1   20 million  The total adjusted operating loss from PharMEDium in fiscal 2019 was  55 million  Therefore  the exit of PharMEDium results in a fiscal 2020 operating income tailwind of  35 million versus the prior year Since we will not be revising our previously reported adjusted non GAAP operating results  we are providing this additional level of detail as part of our focus on being as transparent as possible on the financial impact of the PharMEDium exit and providing key information for your modeling purposes Regarding share repurchases  given the level of share repurchases in the December quarter  we now expect to finish the year around 208 million weighted average shares outstanding  Lastly  while we do not have specific guidance metrics  broadly speaking  both brand and generic pricing are trending relatively in line with our original expectations for the year Regarding our fiscal second quarter EPS expectations  while we do not provide quarterly guidance  I will note that our second quarter EPS growth is likely to be at the low end of the 6  to 10  EPS guidance growth range for the year as we expect an increase in our operating expense growth in the quarter  On our second quarter call last year  I noted that there were some positive general and administrative expense items that benefited that quarter  We do not expect those items to repeat in 2020 In closing regarding PharMEDium  our review has been both thoughtful and decisive  but there comes a point in time where you have to make a decision that the path you ve been on is no longer appropriate and our decision to exit the business is the right path forward from here Despite this strategic change  the key differentiators of AmerisourceBergen remain unchanged  We have strong customer relationships in each customer segment  our businesses are focused on execution and bringing innovative services and solutions to our partners  We have leadership in key specialty markets  notably specialty distribution and commercialization services  And finally  AmerisourceBergen is purpose driven and focused on creating shareholder value through thoughtful corporate stewardship with a balanced and strategic approach to capital allocation and a clear emphasis on advancing our talent and culture  AmerisourceBergen is executing very well across the business  Our value proposition through our partners is undeniable  and we are well positioned to create long term value for all of our stakeholders Thank you for your interest in AmerisourceBergen  Now I will turn the call back to the operator to start our Q A Questions and Answers Operator Operator Instructions  The first question will come from Robert Jones of Goldman Sachs Robert Jones    Goldman Sachs   Co  LLC    AnalystI guess just to focus on the pharma segment guidance change and PharMEDium  I guess  Steve  first  maybe could you talk a little bit about whether or not there was a sale process around PharMEDium  any discussions maybe with the FDA about the ramifications or potential ramifications from exiting this business just on thinking about the largest compounding pharmacy business out there  And then you gave a lot of detail  Jim  around the change in the pharma segment guidance as far as the impact in the quarter and the balance of the year from PharMEDium  I guess maybe just to take a step back  did any of your other assumptions change outside of the PharMEDium math you provided as far as thinking about 2Q through 4Q Steven H  Collis    Chairman  President and Chief Executive OfficerYeah  Bob  I ll start with the PharMEDium question  Obviously a disappointing day for ABC  But I think that Jim s script was excellent  And by the way  I apologize to everyone  I think the quality of the sound was not quite what we would hope and we ll really endeavor to better next time  But I think Jim s comments were excellent  You can see from the financial disclosures  we ve displayed a lot of perseverance with this business  And it s just  I think the 503B changes have made it very difficult to scale the business and get to the sort of consistent quality that we  AmerisourceBergen  would like to deliver to our customers And we continue to experience ongoing regulatory challenges and challenges with the remediation program we put in place  We announced on this call that our New Jersey facility recently had to close  And so we really went into this year with an attitude of wanting to protect our profits for our shareholders and other stakeholders  And we had a lot of  I think  perseverance with this business  And I think that we reached this decision and we think that given where the business is  it would be very difficult to enter into a sales process We have certainly been in close communication with the FDA throughout the consent decree negotiation and the consent decree implementation  We think that we ve approached this as a good stakeholder  We certainly regard regulators as a stakeholder  and we will work collaboratively and transparently with them and professionally with them through the closure Jim  you want to answer the second part of the question James F  Cleary    Executive Vice President and Chief Financial OfficerYeah  sure  Bob  the second part of the question  my understanding had to do with guidance impact and other than PharMEDium  which I really went into a lot of detail on in the call  what were the other things that impacted guidance  particularly as it relates to our Pharmaceutical Distribution business  And as I said during my prepared remarks  if you look at our increase in guidance  the exit of the PharMEDium business represents slightly less than half of the guidance increase  And so if you look at the  0 20 increase in guidance at the top end of the range  the exit of PharMEDium represents slightly less than half the guidance increase  the benefit of excluding those losses in Q2 through Q4 And so that means that the rest of the business is performing quite well  and we are seeing really good performance in the core pharma distribution business  As we talked about  we re seeing a lot of strength in specialty distribution  in particular  our specialty physician services business  We re seeing good volume growth in the Pharma Distribution business  We re seeing 5  volume growth  That s due to  of course  our balanced portfolio of customers  And so we really feel good about our Q1 performance and the impact that that s having on our full year guidance  And of course  it relates to our Pharma Distribution business you asked about  but also good volumes and good performance in our Global Commercialization Services   Animal Health business  which had 10  revenue growth in the quarter  and so that positively impacts our fiscal year guidance also  Bob OperatorThe next question will come from Eric Percher of Nephron Research Eric Percher    Nephron Research LLC    AnalystContinuing with PharMEDium  I know over the last two years it s been pretty clear that hospitals don t particularly want to be in this business  and at one point  this was an effort to extend the hospital relationship  As you shutter it  do you see any impact on the other business that you have focused on the hospital and particularly with respect to the specialty business  How do you help ensure that those relationships don t sour and impact specialty Steven H  Collis    Chairman  President and Chief Executive OfficerObviously  of course  we thought about associates and our customers  and unfortunately since the closure of members  we ve never really been able to deliver the consistent customer experience that an AmerisourceBergen company would like to have  And there is a lot of reasons for it  And in the six years since of passage of the 503B legislation  I think there was a really strong expectation to move to a very high cGMP standard immediately  And as you pointed out correctly  we were by far the largest  So I think having that leadership position  there were very high expectations that put on us  And I think we really  along with some talented associates  dedicated associates  and some new leadership team  some new outside experts  we really did a tremendous effort to meet the high bar  But there is a lot of    we do  Indecipherable  lot of powder products in the marketplace  It s hard to reach scale  and there s tremendous consequences if something doesn t go    if something goes badly  like at least as far as the FDA expectations So for ABC  which we have our purpose  we have our stakeholder value set  we just made a decision that this is not a business that really fits into our portfolio  Our customers have been understanding  I think  somewhat disappointed  but I think it reflects the reality of where we are with regulators  where we are with the powder products in this market  where we are with the economics in the overall health system  And again  we don t want to be in a business where we can t provide a very reliable exceptional efficient service  So I think that s about all we can say there OperatorThe next question will come from Lisa Gill with JPMorgan Lisa Gill    JP Morgan Securities LLC    AnalystSteve  how are you thinking about IPI pricing  Clearly  specialty is a sweet spot for ABC  But there is a lot of talk about changes around reimbursement  And I m just curious how you re thinking about that  Do you think anything will change here in your fiscal 2020  What are your conversations with the actual providers in the marketplace  that community based physician  Just any color you can help us understand how you re thinking about this would be helpful Steven H  Collis    Chairman  President and Chief Executive OfficerI d say this is our number two concern is specialty  Our number one concern is physician reimbursement and making sure that that those community staff  Phonetic  can continue to serve patients in the community setting  Manufacturers are obviously another key stakeholder  but they re large  they re sophisticated  and I think that there ll be some very legitimate conversations  And in fact  often when these conversations start  actions change in the marketplace in anticipation of those changes  and I think you see some changes  You ve seen very moderate inflation  In fact  on the Part B products  there s always been moderate inflation because of the ASP reimbursement So if there is International Reference Pricing  as we discussed in January  Lisa  I hope that it will be a thoughtful transition that it will give manufacturers time to adjust  I think that a lot of noise is not actually factual  The price differentials are not quite as high as one would have you believe and sometimes people tend to take steeper prices and there are a lot of things that are behind the wholesale acquisition cost and ASP with commercial payers that aren t always recognized And one thing as well  with government and single payer systems  the price gets negotiated upfront and then there is no changes  So that s one of the nuances that are different in the US system  So complex topic  You can  Indecipherable  even at the CEO level  I m very engaged and very passionate about it  I saw the head of our government affairs officers today  We re talking about it  Barry Fortner  who heads up our physician services businesses  is in Washington constantly  Our business ION  as you can imagine  is very involved with practice management  So we are going to be a part of the discussion  and we look forward to participating in any changes and hope that are sensible and logical in the context of Part B reimbursement Lisa Gill    JP Morgan Securities LLC    AnalystIs it still anticipated that it will be under some kind of competitive acquisition program  And so if that s the case  do you see maybe potential incremental opportunity for ABC  So I understand what you re saying around the pricing dynamic is already starting to change  And so maybe we don t see a huge impact of pricing  but is there the potential for you to either gain or potentially lose some amount of market share around a competitive acquisition program Steven H  Collis    Chairman  President and Chief Executive OfficerI feel like we re going back to the  90s with the Medicare Modernization Act  At the time  I think there was great anticipation that ABC with our suite of our businesses  we would participate  And actually it was the 2000s  of course  the Bush administration  And there was no economically feasible way for us to participate  And I ll tell you  we brought in people especially to evaluate CAP provider mainly to ensure that our customers would be able to carry on participating and it was just    it was impossible to make the numbers work We don t believe it s very efficient  We ve seen so called white bagging and brown bagging programs tried to be implemented by different payers  more on the commercial side  and they just haven t worked  And the original CAP program didn t work  So there is potential wastage which with these programs  We believe that the current system works very well with oncologist having the financial responsibility for the preparation of the infusions And we will carry on assisting with that  If there were to be a new type of reimbursement and there was differentiated reimbursement or some sort of encouragement to more toward the CAP program  we would look to work with what are some very large  much more aggregate community oncologists  We would look to work with them to provide solutions to payers and regulators OperatorThe next question will come from Glen Santangelo of Guggenheim Glen Santangelo    Guggenheim Securities LLC    AnalystJim  I just want to follow up on the guidance question  I appreciate all the detail  You seem to suggest that over the next three quarters  there will be about a  35 million tailwind from eliminating the losses from PharMEDium  which I understand the EPS impact  But if we could just look at it from an operating income perspective  that  35 million seems to be about a 2  tailwind  which seems like it would fully explain the change in your guidance from low  to mid single up to mid single  I m just trying to understand is there    has anything changed with respect to your assumptions around the core distribution business because I just want to try to reconcile that versus the much stronger than expected first quarter  which seemed to incorporate a bigger than expected loss from PharMEDium  So if you could just sort of reconcile those that d be great James F  Cleary    Executive Vice President and Chief Financial OfficerYeah  And so I will cover that  And you re right  we indicated that PharMEDium is a  35 million tailwind year over year versus last year  And so that s kind of the benefit that we ll see year over year compared to last year  And as we look at guidance  as I said before  taking PharMEDium out of the last three quarters  it s about half the increase to guidance And we are seeing strength throughout the businesses  Of course  guidance is a range  So going from the low  to mid single digits  PharMEDium was a big part of that  but we re also seeing strength throughout the businesses that s impacting our guidance increase also  and it s pretty broad based  We talked about specialty physician services  but we re seeing strength throughout the business One thing that I ll mention  as you talked about the first quarter  During the first quarter  one thing we benefited from is low growth in operating expenses  Our operating expenses grew 2  during the first quarter and that included some year over year benefits  which we don t expect to continue through the rest of the year  And so that was a favorable experience on bad debt expense  favorable experience on our internal healthcare costs  There is a benefit design change in calendar year 2019 that we were still benefiting from year over year  And then also the operational synergies related to consolidating the H D  Smith distribution centers And so that s kind of one thing which benefited the first quarter  which doesn t continue for the rest of the year  And then as we said  the second quarter    we re expecting the growth in the second quarter  the EPS growth  to be at the lower end of our 6  to 10  EPS growth range  because last year we had particularly favorable operating expense experience in the second quarter  which we are expecting to repeat in the second quarter of this year  And so I think that gives you some additional color there  Glen Glen Santangelo    Guggenheim Securities LLC    AnalystYeah  That s all really helpful  Thanks  Jim  And Steve  I just wanted to follow up with you with one quick question on the balance sheet  As of this quarter  you have about  900 million in net debt  and based on your free cash flow assumptions  you re going to be cash    have positive cash on the balance sheet here in the next two to three quarters  And so I m just kind of wondering with PharMEDium now in the rearview mirror  has any    have your thoughts changed at all with respect to the balance sheet or capital deployment priorities and how should we think about that going forward Steven H  Collis    Chairman  President and Chief Executive OfficerNo  we ve had a very consistent capital deployment strategy  I think last year we returned    in fiscal year 2019  we returned  1 billion to shareholders of which was approximately 30  dividend  70  share buybacks and that s approximate numbers  And we like to have financial flexibility  So our first option is to invest in the business  and we re bullish about projects like Fusion  for example  and we talked about the strong growth of World Courier  which in part is because of the Nova and the Cocoon investments So those are good investments  And a couple years ago we were making tremendous investments with ABC order and the distribution networks  Those are very good examples of core business investments  We remain interested in that  We are of course    our replenishment center in Ohio is a good example of another core investment that we re doing  So that s the first priority We then look    we d look at the right sort of acquisitions  Unfortunately  it s been really a seller s market  and the quality of I think if we found really the right asset and the management team was convinced that we had in our company with a leadership position  with the right sort of a fit for our customers  and the patients and physicians that we support  I think we could be talking to paying significantly more than our multiple because we understand that that s probably it s what s required in this market  But we really haven t seen the sort of asset and that motivates us It s about two years ago since we acquired H D  Smith with close to  1 billion  That s worked out really  really well  There s not really opportunities on the regional side  So  we just haven t seen great opportunities  I think where we re interested is in the commercialization services  expansion of the MWI business  That could be something we re very interested in  We ve made a couple more investments in our Brazil and Canadian businesses where we have a solid presence  management team that we can invest behind  So those all things And then  of course  we ll continue to be very thoughtful where we re increasing our dividend we announced this morning  So you ll continue to see us be very thoughtful about returns to shareholders  I hope that makes sense OperatorThe next question will come from Charles Rhyee of Cowen Charles Rhyee    Cowen and Company LLC    AnalystSteve  I think earlier on you talked about biosimilars and sort of the growth there  If you look at the data    if we look at the data last year  we did see a big    starting to really see a big uptick in sort of adoption particularly when you look at something like Neulasta or Epogen  How much are you monitoring here  sort of the shift particularly with the biosimilar insulin  Is that an opportunity for you guys because that looks like will be deemed interchangeable  And then if you have any thoughts on when you expect other biologics to become interchangeable  And would that create a market for biosimilars that mimic more of the traditional generics market and perhaps bring more purchasing power back toward the supply chain side Steven H  Collis    Chairman  President and Chief Executive OfficerJust in general  the biosimilar numbers are encouraging  I think we talked about at the end of fiscal  19 just how the growth in our expectations  And I wouldn t say that trend continues  The numbers are still small  but ABC has we think an important place to play in adoption of biosimilars with the market presence we have particularly in oncology and other specialty markets  Diabetes is a very important market for our Good Neighbor Pharmacy customers because that was sort of complex  chronic conditions are exactly what we think community pharmacy is very well set up to play a role in  So definitely we d be interested I think one of the ways and I m really proud ABC has developed is on our sourcing side  We have I d say over the last decade or so since I moved up here  we ve really invested lot of resources there  We have very proficient people on the manufacturing side that really are working I think very competently and positioning us well for the long term to be the key player in biosimilar adoption  particularly on the injectable and infusible side So we like what we see  and it s something that we monitor very  very closely and are staying close to  as you would expect  We regard it as one of the key opportunities that ABC has for the next couple of years  so thanks OperatorThe next question will come from Ricky Goldwasser of Morgan Stanley Ricky Goldwasser    Morgan Stanley   Co  LLC    AnalystSo one guidance question and one just follow up on PharMEDium  So on the PharMEDium side  if we think about PharMEDium from a pro forma basis and we just kind of like exclude the losses that you incurred from them last year  what would be the pro forma EBIT growth for the Pharmaceutical Distribution segment  So that s on them And then secondly  if we think about kind of like your guidance for the remainder of the year  it seems that the top line guidance seems to be skewed toward an acceleration 2Q to 4Q  if you think about the midpoint from what you reported in the first quarter  So where are you seeing that incremental growth coming from  Is it additional volume coming from existing customers  I know that last quarter we talked about the potential of gaining more business from Cigna or anything else that you re seeing in the marketplace  maybe on the specialty side  that you can provide color on that drives the acceleration for the rest of the year James F  Cleary    Executive Vice President and Chief Financial OfficerYeah  And so we re seeing broad based growth across the business  seeing particularly strong growth in specialty distribution  but really broad based growth in many parts of the business  We have called out the Cigna volume being added to Express Scripts  which is    we indicated that that is approximately one quarter of our revenue growth  And while it s inherently lower margin business  it is positive for growing revenue and operating income dollars  But we re seeing growth in several businesses  And as you noted  we re seeing particularly good growth in our Global Commercialization Services   Animal Health business And then you asked about growth if we exclude PharMEDium  And I think we provided  Ricky  really good detail on that in our prepared remarks that the impact on PharMEDium if we re looking year over year  is a  55 million adjusted operating loss last year and this year in our adjusted results will be  20 million adjusted operating loss  And so if we look year over year  it is a  35 million tailwind to the business  but we are seeing excluding that good growth throughout our various businesses  in particular  our specialty distribution business  but throughout the business OperatorThe next question will come from Steven Valiquette of Barclays Steven Valiquette    Barclays Capital  Inc     AnalystSo just a question on the financial hurdle on the sale versus shutdown decision for PharMEDium  And I guess to my mind I feel like any asset that was arguably worth  2 6 billion in the marketplace only four years ago would still have some value today  either in the hands of private equity or another strategic buyer  I m guessing that the private transaction value of PharMEDium today is probably not zero dollars  What I wanted to just sort of dig into quickly here is  generally speaking  should we conclude that the cash tax benefits of  500 million to  600 million that ABC is receiving from shutting it down that outweigh the benefits of any after tax proceeds you might have received in the sale transaction  or would you have gotten or received those cash tax benefits even in a low price sale transaction  I m just trying to better understand what was the financial hurdle on the sale versus shut decision that was probably something well above zero dollars  but I just wanted to understand that a little bit better James F  Cleary    Executive Vice President and Chief Financial OfficerYeah  We felt that the business was not saleable due to the ongoing regulatory challenges  continued operational issues  continued challenges to achieving the remediation timetable which was extending  and the continued financial burden of running the business  And so due to that we made the decision to shut the business down as the most appropriate path forward for AmerisourceBergen and our shareholders  As you noted  we do have that cash tax benefit of  500 million to  600 million that we ll recognize between fiscal year  20 and fiscal year  22  That will benefit our GAAP P L  It will not benefit our adjusted P L  But there will be a benefit to cash flow over that    over that time period OperatorThe next question will come from George Hill of Deutsche Bank George Hill    Deutsche Bank AG    AnalystI ve got a quick follow up kind of on the balance sheet outlook  And Steve or Jim  I guess  can you talk about whether or not you guys feel the need to kind of war chest cash in anticipation of an opioid settlement  Or do you guys feel like you have continued flexibility to put money to work in the opioid settlement that we    I guess people expect to occur at some point is kind of own bucket  Phonetic   so to speak Steven H  Collis    Chairman  President and Chief Executive OfficerNo  as I said  our priorities for capital deployment are    I detailed them  We don t feel the need to war chest at all  because if you look at the framework that was announced  it was an 18 year settlement  So I think that s in anticipation of this sort of long term characteristics of the industry for not only us but our peers  our competitors as well So again that s the proposed framework  but that s a sort of framework that we d be interested in  So it s a sort of    it really plays  Indecipherable  long term  which also has the benefit of providing consistent support for the patient services that we think will be needed to transition population health management for this crisis  so in a way  if you want to call it that So no  it s not    we don t feel the need at all  It is a lot of cash in absolute terms  In relative terms  it s relative to a couple of hundred million dollars a day  Phonetic  in sales  It s not that much  And some of it is out the country  And there is tremendous seasonality in our business as well  So we like being in a strong cash position  but again we are mindful of fair returns to our shareholders and the internal and external opportunities that may be in the marketplace So with that  I think we are going to close this first quarter call  and we appreciate your interest in AmerisourceBergen  I must say that this is probably the most difficult decision that we have made since I became CEO almost nine years ago  And the management team has really tried to persevere with this business  but it s    and it s been a very difficult decision  And we are  of course  especially conscious of the impact on our customers and our associates who we are committed to treating with utmost respect and transparency and dignity But I think it s incumbent on us to talk about the key strengths and the key differentiators of AmerisourceBergen  which remain unchanged  as I think Jim commented on so well in his remarks  So as we stand here today  commercially  we have extremely strong customer relationships  partnerships  and leadership in key markets and services  Culturally  we are a purpose driven organization that feels united in  Phonetic  our responsibility to create healthier futures and AmerisourceBergen  I can assure you  is focused on creating long term growth and value for all its stakeholders  And again  we thank you for your time and attention this morning  Have a good day  Bye Operator Operator Closing Remarks Duration  59 minutesCall participants Bennett S  Murphy    Senior Vice President  Investor RelationsSteven H  Collis    Chairman  President and Chief Executive OfficerJames F  Cleary    Executive Vice President and Chief Financial OfficerRobert Jones    Goldman Sachs   Co  LLC    AnalystEric Percher    Nephron Research LLC    AnalystLisa Gill    JP Morgan Securities LLC    AnalystGlen Santangelo    Guggenheim Securities LLC    AnalystCharles Rhyee    Cowen and Company LLC    AnalystRicky Goldwasser    Morgan Stanley   Co  LLC    AnalystSteven Valiquette    Barclays Capital  Inc     AnalystGeorge Hill    Deutsche Bank AG    Analyst
More ABC analysis
All earnings call transcripts",2020-01-30,The Motley Fool,https://invst.ly/pp4ss,2072344
102635,324150,ABC,Anthem  ANTM  Gears Up For Q4 Earnings  What s In Store ,opinion,Anthem Inc    NYSE ANTM   will release fourth quarter 2019 results on Jan 29  before market open In the last reported quarter  the company delivered earnings of  4 87 per share  marginally beating the Zacks Consensus Estimate by 0 6   Additionally  the bottom line improved 27 8  year over year on the back of higher revenues Let s see how things are shaping up prior to the announcement The company s performance is likely to have been driven by increased revenues  The Zacks Consensus Estimate for fourth quarter revenues stands at  26 8 billion  implying a 15 2  increase from the prior year reported number The Zacks Consensus Estimate for the to be reported quarter s earnings is pegged at  3 90  suggesting a 59 8  surge from the year ago reported figure  This impressive upside is likely to have been aided by the company s solid revenue base The consensus mark for Government business revenues indicates an 11 8  improvement from the year earlier reported figure  The company s Commercial   Specialty Business segment might have also contributed to its top line  The consensus estimate for the same hints at a 1 9  increase from the prior year reported number Moreover  Medicaid members are expected to have risen on account of contract wins  The company s Medicare Advantage members are also likely to have increased in strength  riding on attractive plan designs and value based care Additionally  total medical membership for the quarter to be reported is likely to have bumped The Zacks Consensus Estimate for medical enrollment implies 2 6  growth from the year ago reported figure Also  Anthem is likely to have benefited from a steady cash flow in the fourth quarter of 2019 However  the company might have incurred heavy selling  general and administrative expenses due to growth related investments What the Quantitative Model StatesOur proven model does not conclusively predict an earnings beat for Anthem this season  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the chances of beating estimates  But that s not the case here  You can uncover the best stocks to buy or sell before they re reported with our  Earnings ESP  Anthem has an Earnings ESP of  1 15   This is because the Most Accurate Estimate is pegged at  3 86  lower than the Zacks Consensus Estimate of  3 90   You can see Anthem  Inc  Price and EPS Surprise   Zacks Rank  Anthem carries a Zacks Rank  3  which increases the predictive power of ESP  However  the company s negative ESP makes surprise prediction difficult for the stock this time around Stocks to ConsiderSome stocks worth considering from the medical sector with the perfect mix of elements to surpass estimates in the next releases are as follows AmerisourceBergen Corporation   NYSE ABC   has an Earnings ESP of  0 82  and a Zacks Rank of 3  The company is set to report fourth quarter earnings numbers on Jan 30 Molina Healthcare  Inc   NYSE MOH   has an Earnings ESP of  0 48   This Zacks  3 Ranked company is set to report fourth quarter earnings performance on Feb 10 Teladoc Health  Inc    NYSE TDOC   is slated to release fourth quarter financial figures on Feb 26  The stock has an Earnings ESP of  11 17  and is  3 Ranked Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2019  while the S P 500 gained and impressive  53 6   five of our strategies returned  65 8    97 1    118 0    175 7  and even  186 7  This outperformance has not just been a recent phenomenon  From 2000   2019  while the S P averaged  6 0  per year  our top strategies averaged up to  54 7  per year ,2020-01-26,Zacks Investment Research,https://www.investing.com/analysis/anthem-antm-gears-up-for-q4-earnings-whats-in-store-200501794,200501794
102636,324151,ABC,HCA Healthcare  HCA  Q4 Earnings Beat Estimates  Rise Y Y,opinion,HCA Healthcare  Inc    NYSE HCA   reported fourth quarter 2019 adjusted earnings of  3 09 per share  surpassing the Zacks Consensus Estimate by 0 9   Moreover  the bottom line inched up 3 3  year over year on the back of higher revenues and increased admissions Quarterly DetailsHCA Healthcare generated revenues of  13 5 billion  beating the Zacks Consensus Estimate by 1 6   The top line was also up 10 2  from the year ago period Same facility equivalent admissions increased 5  year over year while same facility admissions rose 4 7   Same facility revenue per equivalent admission also grew 1 1  year over year Salaries and benefits  supplies and other operating expenses increased 10 6   year over year to  10 8 billion Adjusted EBITDA totaled  2 7 billion  up 9 2  year over year As of Dec 31  2019  HCA Healthcare operated 184 hospitals HCA Healthcare  Inc  Price  Consensus and EPS Surprise   Financial UpdateAs of Dec 31  2019  the company had cash and cash equivalents of about  621 million  total debt of  33 72 billion and total assets of  45 05 billion In the reported quarter  capex came in at  1 27 billion minus acquisitions Cash flows provided by operating activities were  2 5 billion  up 15 2  year over year Dividend and Share Repurchase UpdateHCA Healthcare announced a quarterly cash dividend of 43 cents per share payable Mar 31 to its stockholders of record at the close of business on Mar 2 The company bought back shares worth  272 million in the fourth quarter and had  1 24 billion remaining under its current repurchase authorization as of Dec 31  2019 Full Year ResultsThe company reported 2019 revenues of  51 3 billion  up 9 95  year over year Net income of the company was  10 07 per share  down 5 5  year over year 2020 OutlookFollowing fourth quarter results  the company has provided its 2020 guidance It expects its 2020 revenues in the band of  53 5  55 5 billion  Adjusted EBITDA is projected to a new range of  10 25 10 65 billion Capital expenditures are anticipated in the range of  4  4 2 billion The company expects its EPS in the bracket of  11 30  12 10 per share Zacks RankHCA Healthcare carries a Zacks Rank  3  Hold   You can see Upcoming Releases From Medical SectorSome stocks worth considering from the medical sector with a perfect mix of elements to surpass estimates in the upcoming quarterly releases are as follows AmerisourceBergen Corporation   NYSE ABC   is slated to announce fourth quarter earnings on Jan 30  The stock has an Earnings ESP of  0 82  and is Zacks  3 Ranked Molina Healthcare  Inc   NYSE MOH   has an Earnings ESP of  0 48  and a Zacks Rank of 3  The company is scheduled to release fourth quarter earnings on Feb 10 Teladoc Health  Inc    NYSE TDOC   is set to report fourth quarter earnings on Feb 26  The stock is  3 Ranked and has an Earnings ESP of  11 17  5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2020-01-27,Zacks Investment Research,https://www.investing.com/analysis/hca-healthcare-hca-q4-earnings-beat-estimates-rise-yy-200502228,200502228
102637,324152,ABC,Medical Products  Jan 30 Earnings Roster  TMO  EW   More,opinion,Per the latest   the  sector  is expected to report positive earnings growth in the fourth quarter  Medical sector earnings are expected to be up 3 6  on 5 4  higher revenues However  the projections indicate a sequential decline from the third quarter  Notably  the third quarter witnessed earnings growth of 6 2  on 7 2  revenue improvement The  companies  an integral part of this broader Medical sector  are expected to put up an impressive show this earnings season  The Medical Products companies have been performing impressively over the last few quarters in spite of certain quarterly volatilities  In fact  the ongoing US China trade war is likely to have impacted the fourth quarter performance of the industry participants  Nonetheless  favorable growth in the emerging markets and benefits obtained from innovation are likely to get reflected in the industry players  performance this earnings season Over the past few months  the medical device space has witnessed exceptional progress with regards to innovation   R D to be precise  Boston Scientific s   NYSE BSX   heart failure predictor HeartLogic and Edwards Lifesciences  Inspiris Resilia for patients with aortic heart valve are some path breaking innovations that deserve mention in this context  Moreover  with AI powered launches like polyp detector  autonomous AI imaging system for detecting skin cancer  diabetic retinopathy using retinal images  talking algorithm  drugstore chatbots and many more  the medical device space has been going from strength to strength Strong demand in the emerging markets is likely to have driven the performance of the industry participants in this reporting cycle  According to a  report  as stated by Moody s in 2019   the medical device makers are likely to exhibit mid single digit revenue growth fueled by product innovation across most of the companies and categories throughout 2019  Additionally  sales in emerging markets are expected to display a double digit percentage rise this year  Consequently  this trend is likely to get reflected in the performance of the industry players in this reporting cycle In the fourth quarter  the government came up with its funding bills where it suspended Medical Device tax of 2 3   This tax was originally enacted in 2013 as part of the Affordable Care Act  ACA   The burden of this 2 3  tax used to fall on the device manufacturer or importer  The suspension has come as a relief for medical device manufacturers  enabling them to channelize their funds into R D  This is expected to have impacted fourth quarter performance of the industry players However  the U S  China trade war triggered a short term downtrend in the Medical Instruments sector  Despite a series of recent exemptions by the U S  Trade Representative  USTR  and the introduction of the phase one trade deal  the industry is apprehensive about the impact that the trade war may have had on the fourth quarter  Going by a Forbes report   medical device makers say there is impact to the industry and the threat of more tariffs to come in an ongoing trade war with China is troubling  hitting various parts of the medtech industry  What Our Model SaysPer our proven model  the combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the chances of an earnings beat You can uncover the best stocks to buy or sell before they re reported with our  Considering the above factors  we take a look at the following four Medical Products behemoths that are set to release quarterly results on Jan 30 Thermo Fisher Scientific Inc    NYSE TMO    Product launches through the second half of 2019 are expected to have driven revenues for the life science solutions segment in the fourth quarter of 2019   For the past few quarters  Thermo Fisher has been witnessing robust revenue growth and improvement in earnings performance  driven by continued focus on significant value creation from its R D investments  In the last reported quarter  Thermo Fisher benefited from the launch of analytical instruments for the diagnostic laboratory  The company is expected to have continued gaining from the same in the fourth quarter Apart from this  the addition of Brammer Bio  a leader in viral vector manufacturing for gene and cell therapies   which expanded the company s offering in the fast growing gene therapy market  is likely to have contributed significantly to its fourth quarter top line   Read more   Thermo Fisher has a Zacks Rank  3 and an Earnings ESP of  0 25   You can see  Thermo Fisher Scientific Inc  Price and EPS Surprise    Edwards Lifesciences Corporation   NYSE EW    The company s fourth quarter 2019 results are expected to reflect strength in the core Critical Care product group  The segment has been showing solid growth across all product categories and geographies over the last few quarters  Management is optimistic about robust customer adoption of the HemoSphere all in one monitoring platform  particularly in the United States and Europe   Further  within the Surgical Structural Heart Group  the company is gaining traction from solid aortic unit volume and continued adoption of its latest premium aortic valves  Strong rollout and steady acceptance of the INSPIRIS RESILIA aortic valve globally is likely to get reflected in the fourth quarter sales Within the Transcatheter Aortic Valve Replacement  TAVR  arm  the company is expected to report strong fourth quarter numbers on robust therapy adoption across all geographies with notable strength in the United States  The recent FDA indication expansion for SAPIEN 3 and SAPIEN 3 Ultra systems is also expected to have driven the company s TAVR revenues in the fourth quarter   Read more   Edwards Lifesciences has a Zacks Rank  3 and an Earnings ESP of  4 48  Edwards Lifesciences Corporation Price and EPS Surprise    Baxter International Inc    NYSE BAX    New product launches  including PrisMax in the United States  and rising global demand for the company s continuous renal replacement therapies is anticipated to have contributed to Baxter s Acute Therapies business in the fourth quarter of 2019  This  in turn  is likely to have driven the segment s fourth quarter performance  Continued geographic expansion is expected to get reflected in the company s fourth quarter revenues  Notably  per the company s preliminary announcement  revenues are anticipated to total  3 billion  up 7  year over year on a reported basis and 9  on an operational basis Moreover  the top line is anticipated to have benefited from Baxter s strong product portfolio  and the planned launch of therapies and products  Per the preliminary announcement  geographic regions and all of the company s six global business units is likely to have contributed to the fourth quarter sales   Read more   Baxter has a Zacks Rank of 3 and an Earnings ESP of  0 66  Baxter International Inc  Price and EPS Surprise    AmerisourceBergen Corporation   NYSE ABC    Sustained growth in specialty product sales and expanding customer base at the company s Pharmaceutical Distribution segment are likely to have benefited the fiscal first quarter 2020 performance  Notably  this segment serves healthcare providers in the pharmaceutical supply channel  Solid organic growth rates in the U S  pharmaceutical market  population demographics and improving patient access to medical care are likely to have contributed to the to be reported quarter s top line  Further  the World Courier unit  in particular  is likely to have contributed to the Other segment s performance in the fiscal first quarter This apart  the company is likely to have benefited from generics growth in the to be reported quarter  Further  new product launches are likely to have driven overall performance   Read more   AmerisourceBergen has a Zacks Rank of 3 and an Earnings ESP of  0 82  AmerisourceBergen Corporation Price and EPS Surprise    Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2020-01-28,Zacks Investment Research,https://www.investing.com/analysis/medical-products-jan-30-earnings-roster-tmo-ew--more-200502679,200502679
102638,324153,ABC,Anthem s  ANTM  Q4 Earnings Miss Estimates  Rise Y Y,opinion,"Anthem Inc  s   NYSE ANTM   fourth quarter earnings of  3 88 per share missed the Zacks Consensus Estimate of  3 90 by 0 5  due to high expenses  However  the bottom line surged 59  year over year  driven by solid revenues and the successful launch of IngenioRx Anthem posted operating revenues of  27 1 billion  surpassing the Zacks Consensus Estimate by 1   The top line was also up 16 4  year over year  boosted by higher premium revenues derived from membership growth across all businesses as well as rate surges to cover overall cost trends  The results were supported by growth in value added services including pharmacy and integrated health offerings  partially offset by the one year waiver of the health insurance tax in 2019 Quarterly Operational UpdateAnthem s benefit expense ratio of 89  improved 220 basis points  bps  from the prior year quarter  aided by the one year waiver of the health insurance tax in 2019 SG A expense ratio of 12 9  contracted 260 bps from the year ago quarter on the back of growth in operating revenues and a year long waiver of the health insurance tax in 2019 Total expenses of the company increased 15 2  year over year to  26 3 billion Anthem  Inc  Price  Consensus and EPS Surprise   Strong Segmental ResultsCommercial   Specialty BusinessOperating revenues of  9 3 billion in the fourth quarter rose 5 5  year over year Operating gain totaled  535 million  up 69 3  year over year  led by the launch of IngenioRx and a greater penetration of value added services However  the same was partially offset by margin normalization in the Individual business Operating margin was 5 7   up 210 bps year over year Government BusinessOperating revenues of  16 2 billion ascended 12 6  from the prior year quarter Operating gain was  583 million  up 29 3  year over year  This uptick reflects the impact of higher premiums from rate adjustments and more members in the Medicaid business  However  the same was offset to some extent by higher selling  general and administrative expenses Operating margin was 3 6   expanding 50 bps year over year OtherThe Other segment generated operating revenues of  3 8 billion skyrocketed 835 5  year over year However  this segment incurred an operating loss of  20 million  wider than  17 million in the year earlier period Financial UpdateAs of Dec 31  2019  Anthem had cash and cash equivalents of  4 9 billion  up 25 5  from 2018 end level As of Dec 31  2019  its long term debt inched up 3 3  to  17 7 billion from the figure at 2018 end Operating cash outflow was  1 3 billion for the fourth quarter of 2019 Capital DeploymentDuring the fourth quarter  the company paid out a quarterly dividend of 80 cents per share  leading to a distribution of cash totaling  202 million   Moreover  the company announced a first quarter 2020 dividend of 95 cents per share  payable Mar 27 to its shareholders as of Mar 16  2020 The company also bought back shares worth  306 million during the quarter under review  As of Dec 31  2019  it had  3 8 billion board approved share repurchase authorization left Full Year UpdateFor 2019  operating revenues totaled  103 1 billion  up 12 9  year over year As of Dec 31  2019  Medical enrollment inched up 2 7  year over year to 41 million members  This upside was primarily driven by higher total risk enrollment  fee based enrollment  Government Business enrollment and Commercial   Specialty Business enrollment Operating cash flow of the year soared 58 4  year over year to  6 1 billion Guidance for 2020Following the company s fourth quarter results  Anthem issued its outlook for 2020 Adjusted net income for the current year is projected to be more than  22 30 per share Medical membership is expected in the range of 41 9 42 3 million Operating revenues are anticipated around  117 billion including premium revenues of  101  103 billion Also  the company estimates operating cash flow of more than  6 4 billion The company predicts the benefit expense ratio at 85 8   plus or minus 50 basis points For the current year  investment income is expected to be  970 million Anthem envisions its SG A ratio in the range of 12 8  plus or minus 30 basis points Zacks RankAnthem carries a Zacks Rank  3  Hold   You can see Upcoming Releases From Medical SectorSome stocks worth considering from the medical sector with a perfect mix of elements to surpass estimates in the upcoming quarterly releases are as follows AmerisourceBergen Corporation   NYSE ABC   is slated to announce fourth quarter earnings on Jan 30  The stock has an Earnings ESP of  0 82  and is Zacks  3 Ranked Molina Healthcare  Inc   NYSE MOH   has an Earnings ESP of  0 48  and a Zacks Rank of 3  The company is scheduled to release fourth quarter earnings on Feb 10 Teladoc Health  Inc    NYSE TDOC   is set to report fourth quarter earnings on Feb 26  The stock is  3 Ranked and has an Earnings ESP of  11 17   
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2020-01-28,Zacks Investment Research,https://www.investing.com/analysis/anthems-antm-q4-earnings-miss-estimates-rise-yy-200502737,200502737
102639,324154,ABC,AmerisourceBergen  ABC  Q1 Earnings Beat  Revenues Miss,opinion,AmerisourceBergen Corporation   NYSE ABC   reported first quarter fiscal 2020 adjusted earnings per share  EPS  of  1 76 surpassing the Zacks Consensus Estimate of  1 67 by 5 4   The figure also improved 10  year over year The better than expected bottom line performance can be attributed to increase in adjusted operating income  lower share count and reduced net interest expense Revenues improved 5 4  to  47 86 billion in the reported quarter  However  the figure missed the Zacks Consensus Estimate by 0 3  Segmental AnalysisPharmaceutical Distribution SegmentRevenues at this segment totaled  46 04 billion  improving 5 2  on a year over year basis  Consistent robust specialty product sales and increase in volume related to growth of some of its largest customers contributed to the improvement Segmental operating income was  391 7 million  up 5  year over year  Increase in gross profit drove the upside Other SegmentThis segment includes AmerisourceBergen Consulting Services  ABCS   World Courier and MWI Veterinary Supply Revenues at this segment came in at  1 85 billion  up 10 5  year over year  This upside was driven by growth in MWI  ABCS and World Courier Operating income in the segment was  104 5 million in the quarter  up 14 9  year over year primarily on the back of the performance of World Courier and ABCS AmerisourceBergen Corporation Price  Consensus and EPS Surprise    Margin AnalysisIn the quarter under review  AmerisourceBergen reported adjusted gross profit of  1 24 billion  up 3 3  on a year over year basis  As a percentage of revenues  adjusted gross margin was 2 6  in the quarter  down 5 bps from the year ago quarter AmerisourceBergen reported adjusted operating income of  495 2 million  up 5  year over year  As a percentage of revenues  adjusted operating margin was 1  in the quarter  which was down 1 basis point from the prior year quarter  Fiscal 2020 Guidance UpdatedAmerisourceBergen has updated fiscal year 2020 outlook  reflecting the company s strong performance  prudent share buybacks and the exit of the PharMEDium business Adjusted EPS is now estimated in the range of  7 55  7 80  up from the previously guided range of  7 30  7 60   The Zacks Consensus Estimate is currently pegged at  7 53  which is below management s guided range Adjusted operating income is now projected to grow in the mid single digit percent range  up from the previously guided low to mid single digit percent range Operating income at Pharmaceutical Distribution Services segment is now anticipated to improve in the mid single digit percent range up from the low to mid single digit percent range Further  the company now anticipates weighted average diluted shares to be around 208 million  down from the previously guided band of 209 210 million  Nonetheless  the company has reaffirmed all the other previously communicated aspects of its fiscal 2020 guidance and assumptions  which are as follows The company estimates revenue growth in the mid to high single digit percent range For the Other segment the metric is estimated to grow in the high single digit percent range Adjusted operating expenses is projected to increase in the mid single digit percent range Adjusted free cash flow is estimated to be around  1 5 billion The company anticipates adjusted effective tax rate in the range of 21 22  Summing UpAmerisourceBergen exited the fiscal first quarter on a strong note  wherein both earnings and revenues beat the consensus mark  The company continues to gain from its Pharmaceutical segment and World Courier business  which have been generating huge profits since quite some time  Its specialty distribution business also continues to contribute significantly to the top line  A strong fiscal 2020 outlook instills investor optimism in the stock In late January 2020 AmerisourceBergen decided to exit the PharMEDium compounding business and  consequently  the company will cease all commercial and administrative operations related to this business  Given the decision to exit this business  the company anticipates to claim an ordinary income tax deduction and estimates that it will realize a cash tax benefit in fiscal 2020 through fiscal 2022 totaling around  500  600 million Meanwhile  company faces other headwinds like conversion of branded drugs and lower price generics  Cutthroat competition in the MedTech space adds to woes  Zacks RankCurrently  AmerisourceBergen carries a Zacks Rank  3  Hold  Key PicksSome better ranked stocks in the broader medical space are SeaSpine Holdings Corporation   NASDAQ SPNE    STERIS plc   NYSE STE   and DexCom  Inc    NASDAQ DXCM    all three carrying a Zacks Rank of 2  Buy   You can see  The Zacks Consensus Estimate for SeaSpine s fourth quarter 2019 revenues is pegged at  43 6 million  suggesting growth of 14 7  from the prior year reported figure  The same for loss per share is anticipated at 44 cents  indicating an improvement of 16 9  from the year ago reported figure The Zacks Consensus Estimate for STERIS s third quarter fiscal 2020 revenues is pegged at  749 7 million  indicating an improvement of 7 7  from the year earlier reported figure  The same for adjusted earnings per share stands at  1 43  indicating growth of 13 5  from the year ago reported figure The Zacks Consensus Estimate for DexCom s fourth quarter 2019 revenues is pegged at  457 million  suggesting growth of 35 2  from the prior year reported figure  The same for adjusted earnings per share stands at 72 cents  indicating an improvement 33 3  from the prior year reported figure Breakout Biotech Stocks with Triple Digit Profit Potential The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  50    83  and  164  in as little as 2 months  The stocks in this report could perform even better ,2020-01-29,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-abc-q1-earnings-beat-revenues-miss-200503128,200503128
102640,324155,ABC,McKesson  MCK  To Report Q3 Earnings  What s In The Offing ,opinion,"McKesson Corporation s   NYSE MCK   third quarter fiscal 2020 results are scheduled to release on Feb 4  before market open For the last reported quarter  the company has an earnings surprise of 0 00   Further  it has an average positive surprise of 4 2  for the trailing four quarters Let s take a look at how things are shaping up prior to this announcement How Are Q3 Estimates Placed The Zacks Consensus Estimate for McKesson s fiscal third quarter earnings per share is pegged at  3 52  suggesting year over year growth of 3 5   The same for revenues stands at  59 42 billion  indicating growth of 5 7  from the year ago reported figure Factors to ConsiderMcKesson expects fiscal third quarter results to reflect segmental strength The U S  Pharmaceutical and Specialty Solutions segment is likely to have acted as a key catalyst Notably  the segment is likely to have benefited from branded  generic and over the counter pharmaceuticals  Also  the company s broad spectrum of specialty biopharmaceutical providers and manufacturers are expected to have contributed majorly in the third quarter  Per management  the company s ClarusONE Sourcing venture is also expected to have driven the segment substantially  Independent pharmacies  who are important customers for McKesson  are also believed to have aided U S  Pharmaceutical and Specialty Solutions Reflective of these  the Zacks Consensus Estimate for the segment s third quarter revenues is pegged at  45 39 billion  calling for a rise of 2 5  year over year McKesson Corporation Price and EPS Surprise
    Apart from this  management is optimistic about contributions from the Medical Surgical Solutions segment  driven by acquisitions and growth in the Primary Care and Extended Care businesses  Notably  the takeover of Medical Specialties Distributor is expected to have proven accretive in the quarter to be reported The Zacks Consensus Estimate for the segment s third quarter revenues is pinned at  2 13 billion  suggesting 6  growth year over year Meanwhile  revenues at the European Pharmaceutical Solutions unit are expected to remain flat year over year  after a disappointing show in the last reported quarter  Notably  the Zacks Consensus Estimate for the segment s third quarter revenues stands at  6 91 billion  The company s recent joint venture with MedTech giant Walgreens   NASDAQ WBA   is expected to have boosted McKesson s European Pharmaceutical Solutions segment  In fact  management at McKesson expects revenues to improve in Europe in the second half of fiscal 2020 compared to the first half Earnings WhispersPer our proven model  a stock needs to have a positive Earnings ESP and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise  That is precisely the case here as you will see below Earnings ESP  McKesson has an  of  0 63   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  McKesson carries a Zacks Rank  2   You can see  Other Stocks Worth a LookHere are a few other medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter DexCom   NASDAQ DXCM   has an Earnings ESP of  17 07  and a Zacks Rank  2 AmerisourceBergen   NYSE ABC   has an Earnings ESP of  0 82  and a Zacks Rank  3 Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  50    83  and  164  in as little as 2 months  The stocks in this report could perform even better ",2020-01-30,Zacks Investment Research,https://www.investing.com/analysis/mckesson-mck-to-report-q3-earnings-whats-in-the-offing-200503019,200503019
102641,324156,ABC,AmerisourceBergen  ABC  Tops Q1 Earnings Estimates,opinion,"AmerisourceBergen  NYSE ABC  came out with quarterly earnings of  1 76 per share  beating the Zacks Consensus Estimate of  1 67 per share  This compares to earnings of  1 60 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 5 39   A quarter ago  it was expected that this prescription drug distributor would post earnings of  1 58 per share when it actually produced earnings of  1 61  delivering a surprise of 1 90  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
AmerisourceBergen  which belongs to the Zacks Medical   Dental Supplies industry  posted revenues of  47 86 billion for the quarter ended December 2019  missing the Zacks Consensus Estimate by 0 25   This compares to year ago revenues of  45 39 billion  The company has topped consensus revenue estimates two times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
AmerisourceBergen shares have added about 5 7  since the beginning of the year versus the S P 500 s gain of 1 3  
What s Next for AmerisourceBergen 
While AmerisourceBergen has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for AmerisourceBergen was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  2 30 on  46 07 billion in revenues for the coming quarter and  7 53 on  190 30 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Dental Supplies is currently in the bottom 37  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2020-01-30,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-abc-tops-q1-earnings-estimates-200503082,200503082
102642,324157,ABC,ABIOMED  ABMD  To Report Q3 Earnings  What s In The Offing ,opinion,ABIOMED  Inc    NASDAQ ABMD   is scheduled to release third quarter fiscal 2020 results on Feb 6  before market opens  We believe that despite the persistent foreign currency woes  solid Impella product line prospects are expected to reflect on the results  ABIOMED delivered an earnings surprise of 10 8  in the last reported quarter  the trailing four quarter earnings surprise being a positive 3 7   on average  Q3 Estimates Picture The Zacks Consensus Estimate for ABIOMED s third quarter earnings per share is pegged at  1 09  indicating a year over year improvement of 12 4   Let s see how things are shaping up prior to the earnings release ABIOMED  Inc  Price and EPS Surprise   Impella Likely to Drive Q3 Results ABIOMED s flagship product line  Impella  has consistently boosted the company s top line  Impella  a support system of percutaneous  catheter based devices offering hemodynamic support to the heart  is expected to have driven fiscal third quarter earnings as well  Notably  the treatment success rates of ABIOMED s SmartAssist  Impella Connect  IQ Impella Quality Assurance Database and Impella 5 0 is expected to reflect in the quarterly results  Apart from these  the recent post approval studies for Impella 5 5 have received a nod from the FDA  which signifies increasing adoption of the device  Additionally  recent FDA approval of the Impella 5 5 with SmartAssist and plans to launch the same in the United States also buoy optimism  Moreover  Impella 2 5 and CP with SmartAssist are currently much in demand  Notably  ABIOMED s preliminary results project U S  patient usage growth of 16  year over year and international growth of 24   U S  revenues are expected to have grown 8  year over year to  185 6 million  Internationally  revenues are estimated at  36 0 million  suggesting a 29  year over year rise on strength in Germany and Japan  Thus  quarterly revenues are anticipated at  221 6 million  suggesting a 10  year over year rise but the metric is expected to lag the consensus mark  Resultantly  the company slashed its fiscal 2020 revenue guidance  Revenues are now expected within  846  877 million  indicating an increase of 10 14  year over year  This compares to the earlier projected range of  885  925 million  calling for a 15 20  rise year over year  However  ABIOMED faces stiff competition in the global MedTech space and fluctuations in currency exchange rates  Earnings Whispers Per our proven model  a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise  That is not the case here as you will see below  Earnings ESP  ABIOMED has an Earnings ESP of 0 00   You can uncover the best stocks to buy or sell before they re reported with our   Zacks Rank  ABIOMED carries a Zacks Rank  3  You can see   Stocks Worth a Look Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter  DexCom   NASDAQ DXCM   has an Earnings ESP of  17 07  and a Zacks Rank  2  AmerisourceBergen   NYSE ABC   has an Earnings ESP of  0 82  and a Zacks Rank  3  HealthEquity   NASDAQ HQY   has an Earnings ESP of  18 56  and a Zacks Rank  2  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2019  while the S P 500 gained and impressive  53 6   five of our strategies returned  65 8    97 1    118 0    175 7  and even  186 7   This outperformance has not just been a recent phenomenon  From 2000   2019  while the S P averaged  6 0  per year  our top strategies averaged up to  54 7  per year ,2020-01-30,Zacks Investment Research,https://www.investing.com/analysis/abiomed-abmd-to-report-q3-earnings-whats-in-the-offing-200503666,200503666
102643,324158,ABC,All You Need To Know About AmerisourceBergen  ABC  Rating Upgrade To Buy,opinion,"AmerisourceBergen  NYSE ABC  appears an attractive pick  as it has been recently upgraded to a Zacks Rank  2  Buy   This upgrade primarily reflects an upward trend in earnings estimates  which is one of the most powerful forces impacting stock prices 
The Zacks rating relies solely on a company s changing earnings picture  It tracks EPS estimates for the current and following years from the sell side analysts covering the stock through a consensus measure    the Zacks Consensus Estimate 
The power of a changing earnings picture in determining near term stock price movements makes the Zacks rating system highly useful for individual investors  since it can be difficult to make decisions based on rating upgrades by Wall Street analysts  These are mostly driven by subjective factors that are hard to see and measure in real time 
As such  the Zacks rating upgrade for AmerisourceBergen is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price 
Most Powerful Force Impacting Stock Prices
The change in a company s future earnings potential  as reflected in earnings estimate revisions  has proven to be strongly correlated with the near term price movement of its stock  That s partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company s shares  An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock  and institutional investors typically buy or sell it  Their transaction of large amounts of shares then leads to price movement for the stock 
For AmerisourceBergen  rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company s underlying business  And investors  appreciation of this improving business trend should push the stock higher 
Harnessing the Power of Earnings Estimate Revisions
As empirical research shows a strong correlation between trends in earnings estimate revisions and near term stock movements  tracking such revisions for making an investment decision could be truly rewarding  Here is where the tried and tested Zacks Rank stock rating system plays an important role  as it effectively harnesses the power of earnings estimate revisions 
The Zacks Rank stock rating system  which uses four factors related to earnings estimates to classify stocks into five groups  ranging from Zacks Rank  1  Strong Buy  to Zacks Rank  5  Strong Sell   has an impressive externally audited track record  with Zacks Rank  1 stocks generating an average annual return of  25  since 1988  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here      
Earnings Estimate Revisions for AmerisourceBergen
For the fiscal year ending September 2020  this prescription drug distributor is expected to earn  7 60 per share  which is a change of 7 2  from the year ago reported number 
Analysts have been steadily raising their estimates for AmerisourceBergen  Over the past three months  the Zacks Consensus Estimate for the company has increased 0 2  
Bottom Line
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations  the Zacks rating system maintains an equal proportion of  buy  and  sell  ratings for its entire universe of more than 4000 stocks at any point in time  Irrespective of market conditions  only the top 5  of the Zacks covered stocks get a  Strong Buy  rating and the next 15  get a  Buy  rating  So  the placement of a stock in the top 20  of the Zacks covered stocks indicates its superior earnings estimate revision feature  making it a solid candidate for producing market beating returns in the near term 
You can learn more about the Zacks Rank here    
The upgrade of AmerisourceBergen to a Zacks Rank  2 positions it in the top 20  of the Zacks covered stocks in terms of estimate revisions  implying that the stock might move higher in the near term ",2020-02-03,Zacks Investment Research,https://www.investing.com/analysis/all-you-need-to-know-about-amerisourcebergen-abc-rating-upgrade-to-buy-200503998,200503998
102675,324190,ABC,Teva s proposed opioid settlement could cost drugmaker pennies on the dollar,news,"By Michael Erman and Nate Raymond NEW YORK BOSTON  Reuters    Teva Pharmaceutical Industries  NYSE TEVA  Ltd s proposed  23 billion drug giveaway to settle thousands of U S  opioid lawsuits will likely cost the company a fraction of that figure due to how it has valued those medicines  according to a Reuters review of pricing data and industry analysts  When Teva  TA TEVA  announced the value of the donated medicine   a generic version of opioid addiction treatment Suboxone   it based the figure on the drug s list price  which does not account for significant discounts routinely provided by the drugmaker  If based on the estimated cost to manufacture the drugs  the value could be as low as  1 5 billion  drug pricing consultants and industry analysts say  A Teva spokeswoman declined to comment on the cost analysis for generic Suboxone  a combination of buprenorphine and the opioid reversal agent naloxone  In interviews with Reuters  lawyers representing local governments in the opioid litigation said the figure proposed by Teva inflates the real value of the drugs  They said the proposal will not be enough to address a nationwide addiction crisis that has claimed some 400 000 lives over the last two decades   The deal is  overvalued to make the settlement look better   said Hunter Shkolnik  a lawyer on the plaintiffs executive committee that is managing more than 2 300 federal lawsuits consolidated in the U S  District Court in Cleveland    I don t believe a no cash payment from Teva  one of the largest generic manufacturers in the world  is appropriate   he told Reuters  Israel based Teva is looking to reach a nationwide settlement over its role in selling opioid painkillers  together with drugmaker Johnson   Johnson  N JNJ  and the three largest U S  drug distributors  AmerisourceBergen Corp  N ABC    Cardinal Health  Inc  N CAH  and McKesson Corp  N MCK   Negotiations between these companies and four state attorneys general leading the talks on behalf of their counterparts have focused on a total settlement value worth about  48 billion  including cash and free medicines   On Monday  Teva signaled progress in talks over its contribution aimed at directly helping addiction victims of this major public health crisis  Attorneys general of the four states had agreed on a proposed settlement under which Teva would provide  23 billion worth of generic Suboxone and pay  250 million in cash over 10 years  the company said   Teva said the donated drugs should meet most of the currently estimated U S  patient need for the next decade  The free drugs in lieu of cash would also help Teva avoid adding new debt to its balance sheet at a time that it is struggling to return to growth  Teva shares rose 8  after it disclosed details of the proposed settlement  The company denies any wrongdoing in its sale of opioids  saying it did not actively promote its generic versions of the painkillers with doctors  Many of the current lawsuits accuse drugmakers of aggressively marketing the medicines in a way that downplayed their potential addiction risk  INFLATED LIST PRICES Scrutiny of Teva s proposed settlement followed the company s disclosure on Monday that it would use a benchmark called  wholesale acquisition cost   WAC  to determine the value of the drugs provided for free   WAC   frequently referred to as the list price of a drug   does not include discounts or rebates and is often several times higher than what patients actually pay at the pharmacy    WAC cannot be trusted as a pricing benchmark for generic drugs   said Eric Pachman  founder of pharmaceutical consultancy 3 Axis Advisors   According to 3 Axis data  Teva s list price for its generic Suboxone ranged from 3 to 5 times what retail pharmacies paid  on average  for it in August  And that price represents a premium over the company s manufacturing costs   Jefferies analyst David Steinberg estimated that the cost of the donated drugs would be around  1 5 billion  while Bernstein analyst Ronny Gal suggested they could cost about  2 3 billion to produce  JP Morgan analyst Chris Schott s estimate of manufacturing costs for generic Suboxone was higher  ranging from  5 75 billion to  9 2 billion  still a long way from the company s projected  23 billion value  Avoiding significant cash costs is important for Teva  which is working to pay down nearly  27 billion in net debt  a legacy of its ill timed 2016 purchase of Allergan Plc s  N AGN  generic drugs business  Actavis  generics  The profit margin for generic drugs has fallen sharply since   Ori Hershkovitz  an independent consultant to pharmaceutical companies  previously held a mostly short position in Teva while at Nexthera Capital  a New York based healthcare focused investment firm   Teva s proposed settlement  if accepted  should help allay investor concerns over the opioid cases  Hershkovitz said  But he still doubts the company will be able to correct its most fundamental problems   
 The high debt load and the situation in the generics market will make it impossible to repay this debt   he predicted   They might have won the opioid battle but they are going to lose the overall war  ",2019-10-23,Reuters,https://www.investing.com/news/stock-market-news/tevas-proposed-opioid-settlement-could-cost-drugmaker-pennies-on-the-dollar-2002509,2002509
102676,324191,ABC,Several states wary of  48 billion opioid settlement proposal,news,"By Tom Hals and Nate Raymond  Reuters    Several U S  states that have been ravaged by the opioid epidemic are pushing back on a proposed  48 billion settlement framework that would resolve thousands of lawsuits against five drug companies accused of fueling the addiction crisis   The proposal would bring an end to all opioid litigation against AmerisourceBergen Corp  N ABC    Cardinal Health  Inc  N CAH  and McKesson Corp  N MCK   drugmaker Teva Pharmaceutical Industries Inc  TA TEVA   N TEVA   and Johnson   Johnson  J JNJ    The companies have proposed paying  22 25 billion cash mostly over 18 years  while services and drugs to treat addiction valued at  26 billion by the companies would be provided over the coming decade  mostly by Teva  Officials in states such as Ohio  New Hampshire and West Virginia    all hard hit by the deadly drug addition crisis    voiced concerns about the proposal  James Boffetti  the associate attorney general for New Hampshire  said in an interview he was troubled that payments were stretched over many years   The concern is  I think  the states need money now to create the infrastructure for treatment   he said   Small states fear the money will be divvied up by population rather than need   Any global opioid settlement that doesn t reflect the unique and unprecedented damage imposed on West Virginia through the opioid epidemic should be DOA   West Virginia Attorney General Patrick Morrisey said on Twitter on Tuesday   Some 400 000 U S  overdose deaths between 1997 and 2017 were linked to opioids  according to government data  Roughly 2 600 lawsuits have been brought nationwide by states  local and tribal governments  The three distributors in a joint statement said they were committed to finalizing a global settlement and would continue working with the other parties on the details of the framework  Teva declined to comment   J J said in a securities filing on Wednesday the deal would lower third quarter profit by  3 billion  The proposal  announced on Monday  was hammered out by the companies and attorneys general in North Carolina  Pennsylvania  Tennessee and Texas   It will need broad support among state attorneys general and will have to overcome opposition from the lawyers representing local governments that sued  Those lawyers declined to sign on when presented the proposal last week  Under the settlement framework  money for each state would be divvied up  with 15  going to the state treasury  15  for local governments that filed lawsuits and 70  going to a proposed state fund aimed at addressing the crisis  Boffetti predicted it would takes weeks for states to determine whether they back the settlement framework  North Carolina s attorney general  Josh Stein  acknowledged that a detailed term sheet needs to be developed   There are a lot of details and mechanics that need to be added to it   Stein told Reuters in an interview   That will happen in the coming weeks    The proposal did win a major supporter on Tuesday  Tom Miller of Iowa  the longest serving attorney general  publicly backed the proposal  calling the framework  an important step in addressing the crisis   Colorado s attorney general  Phil Weiser  called it a  very promising development   The lawsuits accuse distributors of failing to flag and halt a rising tide of suspicious orders and drugmakers of overstating the benefits of opioids while downplaying the risks  The companies have denied any wrongdoing  Drugmakers say their products carried government approved labels that warned of the addictive risks of opioids  while distributors argue their role was to make sure medicines prescribed by licensed doctors were available for patients   The proposed deal has widened a fault line between attorneys general and local governments  Cities and counties generally hired private attorneys to bring their cases  and attorneys general want to limit the amount of the settlement that goes to pay private lawyers  The attorneys for local governments also generally opposed Teva contributing opioid treatment drugs to the settlement  instead of cash  in part because of concerns that the framework placed an inflated value on those drugs   Last week s talks failed to reach a global deal  and on Monday  the three wholesale distributors and Teva struck a last minute  260 million settlement with two Ohio counties  averting the first federal trial over opioids  North Carolina s Stein said he looked forward to resolving concerns about the proposal and warned that settling lawsuits individually was unsustainable  
 If we proceed on the current path and each county and city brings their case and extracts whatever amount they may be able to get from these companies  the companies will end up bankrupt   he said   The opioid crisis is a national problem that demands a national solution  ",2019-10-24,Reuters,https://www.investing.com/news/stock-market-news/several-states-wary-of-48-billion-opioid-settlement-proposal-2003085,2003085
102677,324192,ABC,Justice Department issues grand jury subpoenas in J J opioid probe  filing,news,"CHICAGO  Reuters    Johnson   Johnson  N JNJ  received grand jury subpoenas in August from the U S  attorney s office for the Eastern District of New York related to its opioid medication policies  the company said in a regulatory filing on Monday  J J said the subpoenas were related to anti diversion policies and procedures and the distribution of its opioid medications developed by its Janssen pharmaceuticals unit  The company said in the filing it believes the investigation relates to monitoring and reporting programs by manufacturers and distributors of opioids under the Controlled Substances Act   Like other companies that have manufactured opioid medications  Janssen has received subpoenas and investigative demands from various government entities  and this includes the August 2019 subpoena from the United States Attorneys Office for the Eastern District of New York   the company said in a statement emailed to Reuters  J J said it understands the subpoenas are part of a  broader  industry wide investigation  and said the company believes its anti diversion policies and procedures complied with the law  Johnson   Johnson last week lowered its previously reported third quarter profit to account for a proposed  4 billion cash settlement related to the opioid crisis  That followed a Reuters report citing sources that drug distributors McKesson Corp  N MCK   AmerisourceBergen Corp  N ABC  and  Cardinal Health   N CAH  had offered to pay  18billion in cash over 18 years  while J J would pay  4 billion in cash   The drug industry faces roughly 2 600 lawsuits brought bystate and local governments  hospitals and other entities seeking to hold drugmakers and distributors responsible for the toll of opioid abuse  
In August  an Oklahoma judge ordered J J to pay  572 1 million to the state for its part in fueling an opioid epidemic  a sum that was substantially less than investors had expected ",2019-10-28,Reuters,https://www.investing.com/news/stock-market-news/justice-department-issues-grand-jury-subpoenas-in-jj-opioid-probe-filing-2006071,2006071
102678,324193,ABC,Exclusive  Walgreens has explored taking drug store chain private   sources,news,"By Greg Roumeliotis and Mike Spector  Reuters    Walgreens Boots Alliance Inc  O WBA  has been exploring whether to go private following private equity interest in the U S drug store chain  which has a market value of more than  55 billion  according to people familiar with the matter  In recent months  Walgreens has held preliminary discussions with some of the world s largest private equity firms about putting together what would be the biggest ever leveraged buyout  the sources said   Walgreens has tasked investment bank  Evercore Partners Inc   N EVR  with exploring whether a transaction can be put together  the sources said  cautioning that a deal is far from certain  Many private equity firms have pushed back on the idea  concerned about Walgreens  business prospects and the challenges of financing the deal  the sources added   A leveraged buyout of Walgreens would likely require participation of several private equity firms  each writing large checks  at a time when many of them have lost their appetite for teaming together on so called club deals  Many of those takeovers were completed during a boom preceding the 2008 financial crisis and subsequently struggled or collapsed   Walgreens Chief Executive Stefano Pessina  who is the company s largest shareholder with a 16  stake  could roll his equity into the deal to help finance the transaction  one of the sources said  Walgreens has also contemplated divesting some of its assets  such as its 27  stake in drug wholesaler AmerisourceBergen Corp  N ABC   to provide more funding  one of the sources added  The sources asked not to be identified because the matter is confidential  Walgreens and Evercore declined to comment  Walgreens shares rose 8  to  64 12 in New York after Reuters was first to report the news on Tuesday  It later gave back some of those gains and was up about 3   The stock had lost 28  of its value in the last 12 months  compared to a 13  rise in the S P 500 Index  INX    Walgreens  deliberations over going private reflect the challenges its business faces  Last week  it warned it did not expect its adjusted earnings to grow in fiscal 2020 because of the low reimbursement rates for prescription drugs  especially generics  and competition from online retailers such as Amazon com Inc  O AMZN    The Deerfield  Illinois based company  which operates Walgreens and Duane Reade pharmacies in the United States and Boots in Britain  has been closing stores and launching cross selling partnerships with companies such as grocer  Kroger Co   N KR  and weight loss clinic operator Jenny Craig  as it seeks to cut costs and boost its growth prospects   Some analysts said that going private could allow Walgreens to avoid the prying eyes of Wall Street  and invest in its business and offerings without having to worry about quarterly earnings  But many questioned whether such a large leveraged buyout was possible   Given poor industry fundamentals  seemingly never ending margin pressures faced in the healthcare supply chain  and  let s face it  ongoing uncertainty about unpredictable items such as opioids exposure  we would struggle to see a monster premium beyond this current run up  in the stock    Baird analyst Eric Coldwell wrote in a note  DEALMAKING Walgreens  approach toward alliances and joint ventures stands in stark contrast to the strategy of rival CVS health Corp  N CVS   which acquired U S  health insurer  Aetna Inc   NYSE AET  for  70 billion last year  CVS shares have performed better than Walgreens in the last 12 months  down about 7    In 2017  Walgreens dropped a  17 2 billion deal to buy smaller peer  Rite Aid Corp   N RAD  after failing to win U S  antitrust approval  Instead  it agreed to acquire 1 932 Rite Aid stores  about 42  of its total  The retail footprint proved too big for Walgreens  which has been gradually closing some locations  Last year  Walgreens explored other deals  including buying out the rest of AmerisourceBergen and buying a stake in U S  health insurer  Humana Inc   N HUM   as well as selling a stake to it  It did not pursue those transactions  although it has been expanding its partnership with Humana by providing primary care services and support for seniors inside Walgreens stores   Pessina  78  would not be the first company boss to be involved in talks to take his firm private  Dell Technologies Inc  N DELL  CEO Michael Dell  for example  took the computer maker private in 2013 in a  24 9 billion deal backed by private equity firm Silver Lake  After a string of acquisitions  Dell returned to the stock market as a public company last year and now has a market value of  39 billion  But Dell owned about three quarters of his company at the time of the leveraged buyout  making its funding easier   
Last year  former  Qualcomm Inc   O QCOM  executive chairman Paul Jacobs briefly explored a long shot bid to take the U S  semiconductor company  which has a market capitalization of  103 billion  private ",2019-11-05,Reuters,https://www.investing.com/news/stock-market-news/exclusive-walgreens-has-explored-taking-drug-store-chain-private--sources-2012576,2012576
102679,324194,ABC,Judge shields OxyContin maker Purdue from litigation until April,news,"By Tom Hals  Reuters    Purdue Pharma LP and the company s Sackler family owners will be shielded until April 8  2020  from sprawling opioid litigation to give the maker of OxyContin time to try to reach a legal settlement the company says is worth  10 billion  U S  Bankruptcy Judge Robert Drain said on Wednesday he would approve an order extending a stay on more than 2 600 lawsuits that accuse Purdue and the Sacklers of fueling a crisis that contributed to 400 000 U S  deaths between 1999 and 2017  Drain  whose court is in White Plains  New York  ordered a brief stay of the litigation in October  While the litigation is on hold  Purdue and the Sacklers committed to share information with the states  municipalities  Native American tribes  hospitals  individuals and others who have sued  Purdue filed for bankruptcy in September to try to corral the parties to one court and build support for its proposed settlement  which will now be evaluated through the discovery process with the company and the Sacklers  The bulk of the parties that have sued Purdue support the settlement  and the main opposition comes from about two dozen state attorneys general  At Wednesday s hearing  a lawyer for the official creditors committee said the billionaire Sackler family was being slow to respond to demands for financial records  Drain warned that the family runs the risk of being exposed to litigation when his order expires if they do not cooperate   This is not a free pass   he said  Under the proposed deal  control of Purdue will be transferred to the parties suing it  The Sackler family will contribute at least  3 billion to the deal  and in return will be released from further lawsuits  the deal says  The company has also committed to appointing an independent monitor during ongoing negotiations to ensure it ceased practices that allegedly contributed to the addiction crisis  such as promoting its drugs and rewarding sales teams  In addition to Purdue  several manufacturers  distributors and pharmacy chains have been sued by the same groups over the opioid crisis   
In October  distributors AmerisourceBergen Corp  N ABC    Cardinal Health  Inc  N CAH  and McKesson Corp  N MCK   drugmaker Teva Pharmaceutical Industries Inc  TA TEVA   N TEVA   and Johnson   Johnson  J JNJ  proposed settling the litigation against them for  48 billion ",2019-11-06,Reuters,https://www.investing.com/news/stock-market-news/judge-shields-oxycontinmaker-purdue-from-litigation-until-april-2013993,2013993
102680,324195,ABC,Federal prosecutors open criminal probe of opioid makers  distributors  WSJ,news, Reuters    Federal prosecutors have opened a criminal investigation into whether pharmaceutical companies intentionally allowed opioid painkillers to flood communities  the Wall Street Journal reported on Tuesday  citing people familiar with the matter  At least six companies have received grand jury subpoenas from the U S  attorney s office in the Eastern District of New York   Teva Pharmaceutical  NYSE TEVA  Industries Ltd  TA TEVA    Mallinckrodt  Plc  N MNK   Johnson   Johnson  N JNJ  and Amneal Pharmaceuticals Inc  N AMRX  and distributors AmerisourceBergen Corp  N ABC  and McKesson Corp  N MCK   the Journal reported  Shares of Amneal  Teva and McKesson fell between 3  and 7   while AmerisourceBergen and Mallinckrodt were down marginally  The subpoenas were in connection with a Brooklyn federal probe  the Journal reported  A spokesman for the Brooklyn U S  attorney s office declined to comment   The probe is in early stages and prosecutors are expected to send subpoenas to other companies in the coming months  the report said  citing one of the sources  The companies did not immediately respond to Reuters  requests for comment  Teva  J J  Amneal and Mallinckrodt disclosed in recent regulatory filings that they received subpoenas from the U S  attorney s office in Brooklyn  which the companies generally described as regarding their anti diversion policies and procedures and distribution of opioid medications   The companies said it was part of a broader investigation into manufacturers  and distributors  monitoring programs and reporting under the Controlled Substances Act   Teva  Mallinckrodt and J J also said they had received subpoenas from the New York State Department of Financial Services as part of an industry wide inquiry into the effect of opioid prescriptions on New York health insurance premiums   Opioid manufacturers  distributors and pharmacy chains have been defending themselves against thousands of lawsuits by state attorneys general  local governments and class actions accusing them of fueling an addiction crisis  Opioids have contributed to more than 400 000 deaths since 1997  according to government statistics ,2019-11-26,Reuters,https://www.investing.com/news/stock-market-news/federal-prosecutors-open-criminal-probe-of-opioid-makers-distributors-wsj-2028693,2028693
102681,324196,ABC,Canadian drug distributors say no to Trump import plan,news,"By Allison Martell
TORONTO  Reuters    Many of Canada s drug suppliers cannot  or will not  agree to ship cheaper prescription medicines into the United States  a new challenge to the Trump administration s push to reduce drug prices  companies and industry officials told Reuters 
The administration on Wednesday proposed new regulations that would allow states to import prescription drugs from Canada  They would require a state such as Florida to partner with a wholesaler licensed by Health Canada  which regulates drugs 
Florida and other states have said they are eager to start importation programs  and the proposal took the federal government one step closer to approving that plan  But there are practical barriers to actually bringing in drugs 
Two drug distributors and two Canadian industry groups that between them represent all of the potential suppliers named in a proposal published by Florida in August said they are not interested in participating 
 We have not been contacted and we are not planning to participate   said  Loblaw Companies Ltd   TO L   which owns Canada s largest pharmacy chain Shoppers Drug Mart   Canadian patients currently face product and drug shortages and we are concerned this initiative may exacerbate what is already a critical issue  
Daniel Chiasson  president of the Canadian Association for Pharmacy Distribution Management  CAPDM   said none of its members would participate because their first priority was ensuring a safe and stable supply of medication for Canadians 
 It surprised everyone when their names appeared on that list   said Chiasson 
Mary Mayhew  secretary of the Florida Agency for Health Care Administration  said she was  excited and enthusiastic  about Wednesday s announcement 
 We are optimistic that Canadian suppliers will be interested  as the rule is understood  as there is more dialogue around this new and historic federal action   she said 
Chiasson said agreements between manufacturers and distributors prevent the export of products made for the Canadian market  creating a commercial risk and deterrent to exporting 
 These are issues we continue to consider and are committed to exploring how we might overcome any challenges and issues as we advance the proposed rule   U S  Food and Drug Administration spokesman Michael Felberbaum said in a statement 
Some of Canada s major distributors are subsidiaries of U S  companies  who are unlikely to participate in a program to lower prices  since their revenue reflects a cut of the value of the drugs they provide to pharmacies in the much larger U S  market 
McKesson Canada  a subsidiary of McKesson Corp  N MCK  referred questions to Chiasson  The organization is also a listed member of the Alliance for Safe Online Pharmacies Canada  a lobby group that opposes drug exports to the United States 
AmerisourceBergen  N ABC  said that protecting bottom lines was not the issue  because importation implied that distributors could buy low cost drugs and sell them in high cost markets 
 The reality is that legal and contractual barriers  as well as significant threat to the integrity of the supply chain  all stand in the way of importation being a viable solution   it said in a statement 
Kohl   Frisch  a large closely held distributor  did not respond to requests for comment   Metro Inc   TO MRU  which owns major pharmacy chain Jean Coutu  declined to comment 
One company on Florida s list is not a distributor in any traditional sense  but makes self serve pharmacy kiosks that resemble vending machines  They confirmed they would have no role in any import plan 
The remaining companies are members of the Association qu b coise des distributeurs en pharmacie  which takes the same position as CAPDM 
 Our members have no intention to sell drugs across the border  particularly in light of the rapidly increasing drug shortages in the Qu bec marketplace   said Director General Hugues Mousseau in a statement ",2019-12-20,Reuters,https://www.investing.com/news/stock-market-news/canadian-drug-distributors-say-no-to-trump-import-plan-2046377,2046377
102692,324207,ABC,AmerisourceBergen  ABC  Q4 Earnings And Revenues Surpass Estimates,opinion,"AmerisourceBergen  NYSE ABC  came out with quarterly earnings of  1 61 per share  beating the Zacks Consensus Estimate of  1 58 per share  This compares to earnings of  1 45 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 1 90   A quarter ago  it was expected that this prescription drug distributor would post earnings of  1 63 per share when it actually produced earnings of  1 76  delivering a surprise of 7 98  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
AmerisourceBergen  which belongs to the Zacks Medical   Dental Supplies industry  posted revenues of  45 64 billion for the quarter ended September 2019  surpassing the Zacks Consensus Estimate by 0 68   This compares to year ago revenues of  43 30 billion  The company has topped consensus revenue estimates three times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
AmerisourceBergen shares have added about 13 9  since the beginning of the year versus the S P 500 s gain of 22 7  
What s Next for AmerisourceBergen 
While AmerisourceBergen has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for AmerisourceBergen was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 75 on  47 42 billion in revenues for the coming quarter and  7 57 on  187 94 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Dental Supplies is currently in the top 40  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-11-07,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-abc-q4-earnings-and-revenues-surpass-estimates-200483368,200483368
102693,324208,ABC,Fed Reportedly Opens Criminal Investigation On Opioid Makers,opinion,"A criminal investigation has been launched by federal prosecutors in Brooklyn on opioid manufacturers and distributors who are being blamed for aggravating the country s opioid epidemic  per a Wall Street Journal  WSJ  report on Tuesday Reportedly subpoenas have been sent by the U S  Attorney s office in the Eastern District of New York to drug manufacturers  Teva pharmaceuticals   NYSE TEVA    Mallinckrodt   NYSE MNK    Johnson   Johnson   NYSE JNJ   and Amneal Pharmaceuticals   NYSE AMRX   besides two wholesale drug distributors McKesson Corporation   NYSE MCK   and AmerisourceBergen   NYSE ABC    Some of these companies have reported having received subpoenas in their recent regulatory filings The WSJ story also mentioned that subpoenas may be sent to some more companies and the probe is only in its early stage Shares of all the above companies were in the red yesterday in response to this report  Teva declined around 8  while Mallinckrodt was down 3 9   AmerisourceBergen dipped 3  and Amneal dropped more than 10  while McKesson fell roughly 5   J J s stock also saw a marginal slip  Endo Pharmaceuticals   NASDAQ ENDP    which has also been named in opioid lawsuits but not cited in the latest WSJ report  also slid 5 5  on the same day Opioid drugs  which are used as painkillers  have high abuse potential  Use of drugs like morphine  codeine  oxycodone and fentanyl are opioid based and highly controlled by the FDA Going by the Centers for Disease Control and Prevention estimate  in the past two decades  death toll rose to 400 000 due to opioid based drug abuse  The report also states that 130 Americans die annually  on average  from an opioid overdose With significant increase in the number of deaths or instances of such substance abuse and high costs related to opioid overdose  the issue has intensified into a public menace  Several government organizations are taking steps to contain the widespread abuse of drugs  Lawsuits have been slapped against pharma companies across multiple states holding them responsible for the opioid epidemic crisis and deaths due to opioid overdose Many states aim to generate funds through penalties for abatement plans  A few of these companies have been penalized with hefty fines by district courts in some states  Meanwhile  others preferred out of court settlements by shelling out lump sum amounts to avoid trials Per the Controlled Substances Act  opioid manufacturing drugmakers are supposed to report large infrequent or suspicious orders of controlled substances like opioids to the government  which may imply that the drugs are in use for nonmedical purposes  The federal prosecutors are enquiring if this rule was violated by the drugmakers distributors who are brought to book The investigation may induce criminal charges  which will further escalate these companies  already exorbitant legal costs due to the lawsuits 
J J  Teva  Mallinckrodt  McKesson and AmerisourceBergen carry a Zacks Rank  3  Hold  each  You can see  Looking for Stocks with Skyrocketing Upside  Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-11-27,Zacks Investment Research,https://www.investing.com/analysis/fed-reportedly-opens-criminal-investigation-on-opioid-makers-200488309,200488309
102694,324209,ABC,AmerisourceBergen  ABC  Up 5  Since Last Earnings Report  Can It Continue ,opinion,"It has been about a month since the last earnings report for AmerisourceBergen  NYSE ABC   Shares have added about 5  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is AmerisourceBergen due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  AmerisourceBergen Q4 Earnings   Revenues Beat EstimatesAmerisourceBergen Corporation reported fourth quarter fiscal 2019 adjusted earnings per share of  1 61 surpassing the Zacks Consensus Estimate of  1 58 by 1 9   The figure also improved 11  year over year The better than expected bottom line performance can be attributed to increase in adjusted operating income  lower share count and reduced net interest expense Revenues improved 5 4  to  45 64 billion in the reported quarter  Moreover  the figure beat the Zacks Consensus Estimate by 0 7  FY19 at a GlanceFor fiscal 2019  the company reported adjusted earnings of  7 09 per share  up 9 2  from the year ago period  The metric exceeded the Zacks Consensus Estimate of  7 05 per share Revenues totaled  179 56 billion  up 6 9  year over year  which beat the Zacks Consensus Estimate of  179 37 billion Segmental AnalysisPharmaceutical Distribution SegmentRevenues at this segment totaled  43 87 billion  improved 5 1  on a year over year basis  Consistent robust specialty product sales and increase in volume related to growth of some of its largest customers contributed to the improvement Segmental operating income was  369 3 million  up 3 5  year over year  Increase in gross profit drove the upside  However  an increase in operating expenses partially offset the uptick Other SegmentThis segment includes AmerisourceBergen Consulting Services  ABCS   World Courier and MWI Veterinary Supply Revenues at this segment came in at  1 79 billion  up 12 6  year over year  This upside was driven by ABCS s growth in Canadian operations and MWI Operating income in the segment was  86 7 million in the quarter  up 14 9  year over year primarily on the back of the results at MWI  World Courier and ABCS s Lash Consulting Services Margin AnalysisIn the quarter under review  AmerisourceBergen reported adjusted gross profit of  1 25 billion  up 6 9  on a year over year basis  As a percentage of revenues  adjusted gross margin was 2 7  in the quarter  which remained marginally flat year over year AmerisourceBergen reported adjusted operating income of  456 1 million  up 5 5  year over year  As a percentage of revenues  adjusted operating margin was 1  in the quarter  which remained flat from the prior year quarter  Fiscal 2020 GuidanceThe company estimates revenue growth in the mid to high single digit percent range Adjusted EPS is now estimated in the range of  7 30  7 60  The Zacks Consensus Estimate is currently pegged at  7 57  which is within management s guided range Adjusted operating income is projected to grow in the low to mid single digit percent range Operating income at Pharmaceutical Distribution Services segment is expected to improve in the low to mid single digit percent range  For the Other segment the metric is estimated to grow in the high single digit percent range Adjusted operating expenses is projected to increase in the mid single digit percent range Adjusted free cash flow is estimated to be around  1 5 billion The company anticipates adjusted effective tax rate in the range of 21 22  Further  the company anticipates weighted average diluted shares to range between 209 million and 210 million 
How Have Estimates Been Moving Since Then 
Fresh estimates followed a downward path over the past two months 
VGM Scores
Currently  AmerisourceBergen has a strong Growth Score of A  though it is lagging a bit on the Momentum Score front with a B  Charting a somewhat similar path  the stock was allocated a grade of A on the value side  putting it in the top quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
AmerisourceBergen has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-12-06,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-abc-up-5-since-last-earnings-report-can-it-continue-200490955,200490955
102695,324210,ABC,Will AmerisourceBergen  ABC  Beat Estimates Again In Its Next Earnings Report ,opinion,"Have you been searching for a stock that might be well positioned to maintain its earnings beat streak in its upcoming report  It is worth considering AmerisourceBergen  NYSE ABC   which belongs to the Zacks Medical   Dental Supplies industry 
When looking at the last two reports  this prescription drug distributor has recorded a strong streak of surpassing earnings estimates  The company has topped estimates by 4 94   on average  in the last two quarters 
For the last reported quarter  AmerisourceBergen came out with earnings of  1 61 per share versus the Zacks Consensus Estimate of  1 58 per share  representing a surprise of 1 90   For the previous quarter  the company was expected to post earnings of  1 63 per share and it actually produced earnings of  1 76 per share  delivering a surprise of 7 98  
Price and EPS Surprise

Thanks in part to this history  there has been a favorable change in earnings estimates for AmerisourceBergen lately  In fact  the Zacks Earnings ESP  Expected Surprise Prediction  for the stock is positive  which is a great indicator of an earnings beat  particularly when combined with its solid Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
AmerisourceBergen has an Earnings ESP of  0 60  at the moment  suggesting that analysts have grown bullish on its near term earnings potential  When you combine this positive Earnings ESP with the stock s Zacks Rank  3  Hold   it shows that another beat is possibly around the corner  The company s next earnings report is expected to be released on January 30  2020 
When the Earnings ESP comes up negative  investors should note that this will reduce the predictive power of the metric  But  a negative value is not indicative of a stock s earnings miss 
Many companies end up beating the consensus EPS estimate  though this is not the only reason why their shares gain  Additionally  some stocks may remain stable even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2020-01-10,Zacks Investment Research,https://www.investing.com/analysis/will-amerisourcebergen-abc-beat-estimates-again-in-its-next-earnings-report-200498023,200498023
102696,324211,ABC,Q4 Earnings Scorecard   Today s Top Stock Research Reports ,opinion,"Thursday  January 16  2020The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Johnson   Johnson  NYSE JNJ   JNJ   BHP Group  BHP  and Moody s  MCO   These research reports have been hand picked from the roughly 70 reports published by our analyst team today You can see We have also included the real time scorecard on the ongoing Q4 earnings season  Including all of this morning s reports  we now have Q4 results from  35 S P 500 members  Total earnings for these 35 index members are down  4 2  from the same period last year on  4 1  higher revenues  with 74 3  beating EPS estimates and an equal proportion beating revenue estimates  For the Finance sector  we now have results from 37 1  of the sector s total market cap in the S P 500 index  Total earnings for these Finance companies are down  0 3  from the same period last year on  6  higher revenues  with 66 7  beating EPS estimates and 83 3  beating revenue estimates  This is a modestly better growth pace relative to what we saw from this group of Finance companies in the preceding quarter  but fewer companies are beating EPS estimates For a more detailed look at the Q4 earnings season and expectations for the coming quarters  please check out our weekly Trends report     Johnson   Johnson s shares have modestly underperformed the Zacks Large Cap Pharmaceuticals industry over the past year   14 1  vs   14 8    likely reflecting a combination of litigation overhang and generic biosimilar headwinds in the Pharma unit However  the unit is performing above market levels  supported by contribution from new drugs like Tremfya and successful label expansion of cancer drugs like Imbruvica and Darzalex and immunology drug  Stelara  J J is also making rapid progress with its pipeline line extensions  However  headwinds like biosimilar generic competition and pricing pressure remain  Moreover  J J faces numerous lawsuits  which allege personal injuries to patients caused by the use of its products  These are overhangs on the stock   Estimates have risen slightly ahead of Q4 results  J J has a positive record of earnings surprises in the recent quarters  You can  Shares of BHP have gained  16 2  in the past three months against the Zacks Mining   Miscellaneous industry s rise of  19 1   The Zacks analyst believes that trade volatility and slowdown in global growth have made investors apprehensive and affected commodity markets  which will weigh on BHP Group s results  BHP Group anticipates unit costs to be higher in fiscal 2020 thanks to natural field decline at conventional petroleum  falling copper grades  lower by product credits and higher deferred stripping costs at Escondida With iron ore supply from Australia expected to hit record highs  iron ore prices will be under pressure  However  metal prices will recover eventually driven by demand supply imbalance Thus  BHP Group is poised to gain from its investment plans in petroleum  copper  iron ore and potash  Further  the company s efforts to make operations efficient by adopting smarter technology across its value chain will also drive results  Strong cash flow and lower debt also bode well  You can  Moody s shares have gained  25 8  over the past six months against the Zacks Financial Services industry s decline of  4 6   The Zacks analyst believes that the company remains well positioned on the back of its dominant position in the credit rating industry Also  the company has an impressive earnings surprise history  having surpassed the Zacks Consensus Estimate in three of the trailing four quarters  Moreover  the earnings estimates have been going up ahead of its fourth quarter 2019 results Also  its diverse revenue base  strategic inorganic initiatives and strong balance sheet position bode well for future  However  volatility in macro environment and slowdown in global bond issuance volumes along with mounting expenses mainly owing to investments in franchise are expected to hurt profitability  Also  the divestiture of the Analytics Knowledge Services business is expected to be dilutive to 2019 GAAP earnings  You can  Other noteworthy reports we are featuring today include NVIDIA  NVDA   Vale S A   VALE  and Delta Air Lines  NYSE DAL   DAL  Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain Sheraz MianDirector of ResearchNote  Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly and reports  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read
J J s  JNJ  Pharma Unit Shines Amid Generic Litigation Woes


Operational Efficiency Aid BHP Group  BHP   Low Prices Ail


Buyouts Diversify Moody s  MCO  Revenues Amid Rising Costs


Featured Reports
NVIDIA  NVDA  Gets a Boost From Gaming Business Recovery
Per the Zacks analyst  NVIDIA is benefiting from the rising traction of GeForce desktop and notebook GPUs in the gaming market 

Low Debt  Cost Control Support Vale  VALE  Amid Low Prices
Per the Zacks analyst  lower debt levels and focus on improving quality  productivity and lowering costs will drive Vale s growth despite the impact of lower commodity prices 

Dividends  Buybacks   Passenger Revenues Buoy Delta  DAL 
The Zacks Analyst likes the uptick in passenger revenues  up 6  in 2019  backed by strong air travel demand  Delta s efforts to reward its shareholders   3 billion in 2019  are impressive too 

 Public Storage  NYSE PSA  Gains from Buyouts  Supply Woes Remain
Per the Zacks Analyst  Public Storage is poised to gain from its high brand value  favorable demographic changes and strategic acquisitions  However  rising supply remains a concern 

Pharmaceutical Distribution Unit Aids AmerisourceBergen  NYSE ABC 
Per the Zacks analyst  Pharmaceutical Distribution segment  fueled by rising volume and expanding customer base  continues to aid AmerisourceBergen  But higher operating expenses remains a concern 

Nasdaq  NDAQ  Banks on Buyouts  Expenses Rise
Per the Zacks analyst  buyouts have aided Nasdaq in gaining access to Canadian equity markets and widened technology offering 

Denbury  DNR  to Gain from CCA CO2 EOR Pipeline Project
Denbury s CCA CO2 EOR Pipeline is expected to support its rising production in the Cedar Creek Anticline 

New Upgrades
 6B Investment  Renewable Energy Focus Aid Evergy  EVRG 
Per the Zacks analyst Evergy s  6 billion investment in the 2019 2023 time frame to strengthen its operation and plans to produce more electricity from renewable sources will boost its performance 

Xerox  NYSE XRX  Benefits From Post Sale Driven Business Model
Per the Zacks analyst  Xerox s post sale driven business model provides significant recurring revenue and cash generation  enabling it to make strategic investments and new market entry 

Wix  WIX  Rides on Growth in Collections   Registered Users
Per the Zacks analyst  Wix has been gaining from rise in registered users of its applications  Moreover  new products and efficient pricing strategies are likely to keep boosting collection revenues 

New Downgrades
Women s Category Softness a Worry for Kohl s  KSS  Comps
Per the Zacks analyst  Kohl s has been troubled by softness in its women s category and higher promotions  This weighed on its holiday comps and led to slightly lowered earnings view for fiscal 2019 

SBS Segment   Elevated Costs a Worry for Sally Beauty  SBH 
Per the Zacks analyst  Sally Beauty s SBS segment is battling hurdles in Europe  along with currency headwinds  Also  SG A expenses are likely to rise in fiscal 2020 on high wage rates and investment 

Core Labs  CLB  Hurt by Slower Offshore Project Progress
The Zacks analyst is concerned over the slower than expected progress in the large international and offshore projects  which will weigh on Core Labs  Reservoir Description unit 
undefined undefined",2020-01-16,Zacks Investment Research,https://www.investing.com/analysis/q4-earnings-scorecard--today39s-top-stock-research-reports-200499384,200499384
102697,324212,ABC,Can Value Investors Choose AmerisourceBergen  ABC  Stock ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value  One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put AmerisourceBergen Inc    NYSE ABC   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  AmerisourceBergen has a trailing twelve months PE ratio of 13  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 stands at about 20 78  If we focus on the long term PE trend  AmerisourceBergen s current PE level puts it below its midpoint of 14 39 over the past five years  Moreover  the current level stands well below the highs for the stock  suggesting that it can be a solid entry point Further  the stock s PE also compares favorably with the Zacks Medical sector s trailing twelve months PE ratio  which stands at 23 51  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers We should also point out that AmerisourceBergen has a forward PE ratio  price relative to this year s earnings  of just 12 12  so it is fair to say that a slightly more value oriented path may be ahead for AmerisourceBergen stock in the near term too P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings  Right now  AmerisourceBergen has a P S ratio of about 0 11  This is a bit lower than the S P 500 average  which comes in at 3 59x right now  Also  as we can see in the chart below  this is well below the highs for this stock in particular over the past few years If anything  this suggests some level of undervalued trading at least compared to historical norms Broad Value OutlookIn aggregate  AmerisourceBergen currently has a Value Score of A  putting it into the top 20  of all stocks we cover from this look  This makes AmerisourceBergen a solid choice for value investors  and some of its other key metrics make this pretty clear too  For example  the PEG ratio for AmerisourceBergen is just 1 63  a level that is far lower than the industry average of 2 05  The PEG ratio is a modified PE ratio that takes into account the stock s earnings growth rate  Clearly  ABC is a solid choice on the value front from multiple angles  What About the Stock Overall Though AmerisourceBergen might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth Score of A and a Momentum Score of C  This gives ABC a Zacks VGM score   or its overarching fundamental grade   of A   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been dismal at best  The current quarter has seen none estimates go higher in the past sixty days compared to two lower  while the full year estimate has seen none up and two down in the same time period  This has had a negative impact on the consensus estimate though as the current quarter consensus estimate has dropped by 0 6  in the past two months  while the full year estimate has inched lower by 0 1   You can see the consensus estimate trend and recent price action for the stock in the chart below AmerisourceBergen Corporation Price and Consensus   Apart from this somewhat sluggish trend  the stock has a Zacks Rank  3  Hold  which is why we are looking for in line performance from the company in the near term  Bottom LineAmerisourceBergen is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  Further  a strong industry rank  among Top 46  of more than 250 industries  instills our confidence  However  over the past two years  the Zacks Medical   Dental Supplies industry has clearly underperformed the broader market  as you can see below So  value investors might want to wait for estimates and analyst sentiment to turn around in this name first  but once that happens  this stock could be a compelling pick  The Hottest Tech Mega Trend of All Last year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2020-01-22,Zacks Investment Research,https://www.investing.com/analysis/can-value-investors-choose-amerisourcebergen-abc-stock-200501047,200501047
102733,324248,ABC,Judge summons drug company CEOs to discuss opioid settlement  source,news,"By Nate Raymond  Reuters    The chief executives of the three largest U S  drug distributors and a drugmaker have been summoned to appear before a federal judge to discuss a proposal to resolve thousands of lawsuits alleging they fueled the U S  opioid crisis  a person familiar with the matter said on Thursday  The order by U S  District Judge Dan Polster in Cleveland  Ohio  came as distributors McKesson Corp  NYSE MCK    Cardinal Health  Inc  NYSE CAH   AmerisourceBergen  NYSE ABC  Corp and Israel based drugmaker Teva Pharmaceutical Industries  NYSE TEVA  Ltd moved to reach a deal ahead of a trial before Polster that begins on Monday  Those companies  along with Johnson   Johnson  NYSE JNJ   have been negotiating a settlement they value at roughly  50 billion that would allow them to resolve 2 600 lawsuits brought nationwide  mostly by states and localities  people familiar with the matter said  All of those companies except J J are set to be defendants in the trial before Polster  who oversees the bulk of the litigation  Polster has pushed for a deal that could  do something meaningful to abate this crisis   The companies have been discussing the settlement with four state attorneys general whose cases are not before Polster  sources told Reuters on Wednesday  Lawyers for the local governments say they have not decided whether to back it  Late Thursday  Ohio Attorney General Dave Yost raised concerns about the proposed deal with his counterparts in North Carolina  Pennsylvania  Tennessee and Texas  who are leading negotiations  Yost  in a letter seen by Reuters  said he feared the four attorneys general were not consulting with other states  He said that threatened to repeat the problems of a proposed  10 billion settlement with OxyContin maker Purdue Pharma LP  which has divided states between supporters and opponents of the deal  He also said opioid settlement funds must go to addressing the crisis  not general budget purposes  He worried attorneys for the local governments could be paid hundreds of millions of dollars for their work  and he wanted that reduced   Yost also said only a few states filed claims against the drug distributors and it would be unfair to treat all states the same in a settlement  The letter was posted on the cleveland com website and Reuters also received a copy  Under the proposal  McKesson  AmerisourceBergen and Cardinal Health would pay  18 billion over 18 years and J J would pay  4 billion  according to two people familiar with the matter  Teva has offered to give away medications it values at  15 billion as part of an overall deal it values at roughly  28 billion under which it would also provide distribution services  the people said  Spokespeople for Cardinal CEO Michael Kaufmann and AmerisourceBergen CEO Steven Collis declined to say if they would be in Cleveland on Friday  Representatives for Teva CEO Kare Schultz and McKesson CEO Brian Tyler did not respond questions of whether they would be in court  Opioids were responsible for roughly 400 000 overdose deaths in the United States from 1999 to 2017  according to the U S  Centers for Disease Control and Prevention  The lawsuits accuse drug manufacturers of deceptively marketing opioids in ways that downplayed their risks  and drug distributors of failing to detect and halt suspicious orders  They deny wrongdoing  
    The cases prompted OxyContin maker Purdue Pharma LP to file for bankruptcy protection in September after reaching a tentative deal it says is worth at least  10 billion to resolve the cases ",2019-10-17,Reuters,https://www.investing.com/news/stock-market-news/judge-summons-drug-company-ceos-to-court-to-discuss-opioid-settlement-source-1998315,1998315
102734,324249,ABC,Judge s unorthodox approach has huge opioid settlement within reach,news,"By Tom Hals and Nate Raymond  Reuters    From the start of the sprawling U S  litigation seeking to hold drugmakers and distributors liable for the country s opioid epidemic  Judge Dan Polster has made one thing clear  he never wanted a trial  On Friday  Polster will make his most dramatic bid yet to avoid a landmark trial that is scheduled to start on Monday  The federal judge has summoned the top executives from several large healthcare companies to his Cleveland court to try to hammer out a settlement that could be worth around  50 billion  Polster has a knack for getting bitter adversaries into a conference room  making them feel understood and reaching a resolution  said Seema Saifee  a law clerk for the judge from 2004 to 2006   There would be times when I would be working on a draft opinion and he would come out of a conference room and say  settled that one   And I would take the draft and duly throw it out   said Saifee  a senior staff attorney with the non profit Innocence Project in New York    A colleague said he could probably settle the Palestinian Israeli conflict   said Saifee  If no deal is reached  Polster will play the part of the reluctant trial judge  guiding what promises to be some of the most complex litigation in U S  history    We don t need a lot of briefs and we don t need trials   said Polster at an initial hearing last year  after a federal panel assigned him to coordinate federal opioid cases from around the country   None of those are going to solve what we ve got   Polster is overseeing more than 2 300 lawsuits by towns  cities  counties and tribal governments that seek to hold drugmakers  distributors and pharmacies liable for their role in a U S  public health crisis that has taken a terrible toll  Opioids were involved in around 400 000 overdose deaths between 1997 and 2017  and have cost the country hundreds of billions of dollars in emergency services  addiction treatment and lost worker productivity   The lawsuits allege that drug manufacturers aggressively marketed their painkillers while downplaying the risks of addiction  and claim drug distributors failed to halt and report suspicious orders for opioids  The companies deny the allegations   In a last ditch effort to avoid a trial  Polster asked the chief executive officers of McKesson Corp  N MCK    Cardinal Health  Inc  N CAH  and AmerisourceBergen Corp  N ABC    the three largest U S  drug distributors   and Israel based drugmaker Teva Pharmaceutical  NYSE TEVA  Industries Ltd  TA TEVA  to meet on Friday to discuss a proposal they have made to settle the cases   REALLY INNOVATIVE  Polster  a native of his northern Ohio jurisdiction who has said he cycles 10 miles  16 km  to work  has taken an aggressive approach to getting a deal on opioids  He invited state attorneys general  whose cases were not before him  to participate in settlement talks  and he ordered the federal government to turn over confidential data showing where each manufacturers  opioids were distributed in the United States  He also recently endorsed a novel  negotiation class  framework that could be used to allow thousands of local governments to vote on potential settlements   If it looks like he is doing things that are really innovative  he is   said Mary Davis  the interim dean at the University of Kentucky College of Law   If talks fail  Monday will mark the start of a two month trial that will pit Ohio s Cuyahoga and Summit counties against some companies in a bellwether  or test  trial that allows parties to see a jury s reaction to the allegations  The outcome will be watched closely by plaintiffs and defendants in future trials  including U S  healthcare conglomerate Johnson   Johnson  N JNJ   to help them reach what is known as a global settlement of all opioid litigation   Maybe this isn t what a court should do   Polster told a gathering at Harvard Law School in April 2018 about aggressively pushing settlements   The courts didn t ask for this     This one cried out for some effort to come together   The judge has his critics  A Reuters investigation showed that Polster has been more willing to seal documents than other judges involved in opioid litigation  raising concerns that important information about the crisis remains secret  Polster declined to comment on that report  The major drug distributors and retailers  including CVS Health Corp  N CVS  and Walmart Inc  WMT   took the rare step of trying to remove the judge from the case based on his appearance of bias  in part due to his unusual habit of discussing the case in the media and his push for a settlement  An appeals court backed Polster  
 Publicly acknowledging this human toll does not suggest I am biased  it shows that I am human   Polster wrote in a court filing ",2019-10-18,Reuters,https://www.investing.com/news/stock-market-news/judges-unorthodox-approach-has-huge-opioid-settlement-within-reach-1998997,1998997
102735,324250,ABC,Opioids settlement could be near  lawyer for local governments says,news,"By Kathy Gray
CLEVELAND  Reuters    Executives from several large healthcare companies and state attorneys general were progressing toward what is expected to be a multibillion dollar deal to resolve the sprawling litigation over the U S  opioid epidemic  a plaintiffs  lawyer said on Friday 
 I think we can get a long way   said Peter Weinberger  a lawyer for local governments that have sued the companies  when asked by a reporter if a deal was possible on Friday 
U S  District Court Judge Dan Polster summoned to his court executives from the largest U S  drug distributors  McKesson Corp  N MCK    Cardinal Health  Inc  N CAH  and AmerisourceBergen Corp  N ABC   and Israel based drugmaker Teva Pharmaceutical  NYSE TEVA  Industries Ltd  TA TEVA  to try to hammer out a deal before a landmark federal trial starts on Monday 
Weinberger said Polster was shuttling between healthcare executives and state attorneys general and other plaintiffs  lawyers who were huddled privately in separate rooms in the Cleveland federal courthouse 
Polster is overseeing thousands of lawsuits by local governments that allege the companies fueled a public health crisis responsible for roughly 400 000 U S  deaths from 1999 to 2017  according government statistics 
Earlier this week  the companies proposed a deal that could be worth  50 billion to settle the litigation  two sources told Reuters 
Weinberger said smaller distributor  Henry Schein  Inc  O HSIC  was also participating in the talks  and the general counsel from pharmacy chain Walgreen Boots Alliance Inc  O WBA  was at the courthouse but not in the negotiations 
Those two companies round out the defendants in the trial that is scheduled to start on Monday 
If the parties make progress at Friday s talks  Polster has the option of postponing Monday s trial to give them more time to negotiate 
The complex litigation pits thousands of towns  cities  counties and tribal governments against numerous companies across the healthcare industry involved in the manufacture and distribution of opioids 
The governments are seeking to recover some of the billions of dollars spent on emergency services  treatment and policing as a result of increased addiction rates 
Attorneys general are separately suing in their own state courts  and while Polster does not have jurisdiction over those cases he invited them to join the talks to try to reach a deal 
The distributors have been accused of failing to flag and halt suspicious orders for opioids  while drugmakers are accused of promoting benefits of the drugs while playing down their risks 
The distributors have insisted that they were shipping FDA approved medicines prescribed by doctors  The drugmakers have also denied any wrongdoing 
Shares of the companies have risen this week in anticipation of a possible deal that could end the litigation  despite the possibility that each company could be on the hook for billions of dollars 
A settlement would remove uncertainty and allow the companies to distance themselves from a politically charged crisis  said a research note from Morningstar on Wednesday 
Monday s scheduled proceeding is a so called bellwether or test trial with two Ohio counties  Cuyahoga and Summit  serving as plaintiffs  A bellwether trial gives the parties a chance to assess a jury s reaction to the allegations  which could then shape a settlement of all the litigation 
Other defendants in lawsuits overseen by Polster include Johnson   Johnson    Mallinckrodt  Plc  N MNK   Endo International Plc  O ENDP   Walmart Inc  N WMT  and Allergan Plc  N AGN   among others 
OxyContin maker Purdue Pharma  viewed as one of the main culprits in fueling the opioid crisis  is also no longer part of the Ohio trial after declaring bankruptcy ",2019-10-18,Reuters,https://www.investing.com/news/stock-market-news/opioids-settlement-could-be-near-lawyer-for-local-governments-says-1999387,1999387
102736,324251,ABC,Drug companies reach  260 million opioid settlement with Ohio counties  averting landmark trial,news,"By Kathy Gray CLEVELAND  Reuters    Four large drug companies reached a last minute  260 million legal settlement on Monday over their role in the U S  opioid addiction epidemic  striking a deal with two Ohio counties to avert the first federal trial over the crisis  However  drug distributors AmerisourceBergen Corp  N ABC    Cardinal Health  Inc  N CAH  and McKesson Corp  N MCK  and drugmaker Teva Pharmaceutical Industries Ltd  TEVA  fell short of a wider deal worth tens of billions of dollars to end all opioid litigation against them  The distributors  which handle around 90  of U S  prescription drugs  will pay a combined  215 million immediately  Israel based drugmaker Teva is paying  20 million in cash and will contribute  25 million worth of Suboxone  an opioid addiction treatment  according to Hunter Shkolnik  an attorney for the counties   Teva  the world s largest generic drugmaker  will makes its contribution over 18 months  according to Shkolnik  The deal settles claims brought by Ohio s Cuyahoga and Summit counties  which had accused the companies of fueling a nationwide opioid crisis  Some 400 000 U S  overdose deaths between 1997 and 2017 were linked to opioids  according to government data   While the companies strongly dispute the allegations made by the two counties  they believe settling the bellwether trial is an important stepping stone to achieving a global resolution and delivering meaningful relief   the distributors said a joint statement  Teva declined to comment  The so called bellwether or test trial was meant to help shape a broader settlement of some 2 600 lawsuits pending over the toll opioids have taken on local communities and the nation  Late on Friday  talks collapsed that were aimed at reaching a  48 billion global settlement of all opioid litigation against the same defendants  Shares in the companies had risen last week in anticipation of a broader deal  On Monday  shares of the big three drug distributors were down from more than 2  to 4   having trimmed some earlier losses   We are not surprised to see distributor shares giving back some of last week s gains as uncertainty persists in this extremely complex litigation   Baird analyst Eric Coldwell wrote in a note   STILL AT THE TABLE  The settlement  if extrapolated to nationwide deal resolving all litigation for the four defendants  suggests a settlement value of around  48 billion  based on a court approved allocation formula    We re still at the table   said Joe Rice  an attorney for the local governments  who indicated the timing of payments was a sticking point   This should be a global settlement  but it s got to be fair and it s got to be now    The judge overseeing the case  Dan Polster  said he would work out a new trial date for the remaining defendant  pharmacy chain operator Walgreens Boots Alliance Inc  O WBA   Lawyers representing the local governments said in a statement on Monday that the litigation had revealed the country s pharmacy system  has played a greater role in the opioid epidemic than previously realized   Walgreens said in a statement on Monday that it only sold opioids to fill a valid prescription written by a licensed physician  It said it was diligent to prevent the diversion of controlled substances  A sixth defendant  the smaller distributor  Henry Schein  Inc  O HSIC   said on Monday it had been dismissed as a defendant from the trial after agreeing to a deal worth around  1 25 million  The lawsuits accuse drugmakers of overstating the benefits of opioids while downplaying the risks  Distributors allegedly failed to flag and halt a rising tide of suspicious orders  shipping vast amounts of the pills across the country  Drugmakers have denied wrongdoing  arguing their products carried U S  Food and Drug Administration approved labels that warned of the addictive risks of opioids  They say they did not cause the toll the epidemic has had on states and localities  Distributors had argued that they made up only  one component of the pharmaceutical supply chain  and their role was to make sure medicines prescribed by licensed doctors were available for patients  Monday s settlements add to deals worth  66 4 million that the two Ohio counties earlier struck with drug companies  Mallinckrodt  Plc  N MNK   Endo International Plc  O ENDP   Johnson   Johnson  N JNJ  and Allergan Plc  N AGN   Armond Budish  county executive of Cuyahoga  said Friday s proposed global settlement  which had the support of state attorneys general  would have distributed funds over 18 years  not immediately   People are dying now   he said  Cuyahoga County has said it will use the funds to expand residential treatment beds  increase emergency care follow up and to create alternatives to jailing low level drug offenders  among other initiatives  Polster  has aggressively pushed for a settlement that  could do something meaningful to abate this crisis   
Pharmacy chains and drug distributors unsuccessfully tried to remove the outspoken judge from the case  saying he was biased and had pressed too hard for a costly settlement ",2019-10-21,Reuters,https://www.investing.com/news/stock-market-news/reckoning-with-us-opioid-crisis-as-8-billion-ohio-trial-kicks-off-2000193,2000193
102737,324252,ABC,Drugstore drones  UPS will fly CVS prescriptions to U S  customers,news,By Lisa Baertlein LOS ANGELES  Reuters     United Parcel  Service Inc s  N UPS  new Flight Forward drone unit will soon start home prescription delivery from CVS Health Corp  N CVS   The service  which will debut in one or two U S  cities in the coming weeks  shows how the parcel delivery company plans to expand its upstart drone business beyond hospital campuses    Flight Forward will work with new customers in other industries to design additional solutions for a wide array of last mile and urgent delivery challenges   UPS Chief Strategy and Transformation Officer Scott Price said   The Atlanta based company this month won the U S  government s first approval to operate a drone airline  leapfrogging rivals like Amazon com Inc  O AMZN  and Alphabet Inc s  O GOOGL  Wing and clearing the way for the expansion of Flight Forward  UPS  which owns 251 jet aircraft and charters nearly 300 more  is building its Flight Forward business at a time when U S  drone delivery is in its infancy  Regulations for operating those unmanned vehicles in U S  airspace are not expected until 2021   On Monday  Flight Forward and partner Matternet also announced a deal to deliver biological samples and other cargo on University of Utah Health hospital campuses  That will be similar to the service at North Carolina s WakeMed Hospital  where Flight Forward operates about 10 flights per day  said Bala Ganesh  vice president of the advanced technology group at UPS   Flight Forward has also signed a hospital campus deal with healthcare provider Kaiser Permanente  UPS said   In addition  the company said pharmaceutical distributor AmerisourceBergen Corp  N ABC  will use Flight Forward drones to move pharmaceuticals  supplies and records to select U S  medical campuses it serves  UPS rival FedEx Corp  N FDX  last week delivered a residential package to a home in Christiansburg  Virginia  as part of a trial service with Alphabet s Wing Aviation  Dan Gagnon  vice president of global healthcare strategy at UPS  said Flight Forward  is not a one and done business model  We re looking for scale and repetition  ,2019-10-21,Reuters,https://www.investing.com/news/technology-news/drugstore-drones-ups-will-fly-cvs-prescriptions-to-customers-2000590,2000590
102748,324263,ABC,Will Genetic Testing Drive Invitae s  NVTA  Q3 Earnings ,opinion,Invitae Corporation   NYSE NVTA   is scheduled to report third quarter fiscal 2019 results on Nov 6  after market close In the last reported quarter of 2019  the company s loss per share of 52 cents was wider than the Zacks Consensus Estimate by 8 3   However  the company delivered a negative earnings surprise in two of the trailing four quarters  the average four quarter miss being 0 4  Let s take a look at how things are shaping up prior to this announcement Factors at PlayOver the last few quarters  genetic testing  one of Invitae s key business segments  has been consistently delivering robust performance Lately  the company has been witnessing a rise in the number of oncology patients undergoing genetic testing  In the last reported quarter  the company accessioned more than 11000 samples for genetic testing  which reflected a 52  year over year increase  This trend is expected to have continued in the third quarter Invitae Corporation Price and EPS Surprise    With the recent launch of its proactive offering  the company has enabled access to genetic testing for a completely new set of customers  This development has led to increased customer adoption and is expected to have driven the top line in the to be reported quarter The launch of non invasive prenatal screening  NIPS  using maternal cell free DNA earlier this year has been strengthening the company s portfolio of comprehensive women s health genetic testing services  This is expected to show on third quarter results Invitae is focused on widening its genome network and signing biopharma partnerships since the beginning of 2019  Earlier this year  the company expanded its Behind the Seizure program with BioMarin by partnering with two additional companies   Stoke Therapeutics and Xenon Pharmaceuticals  In the last reported quarter  Invitae acquired Singular Bio and Jungla for technologies to enhance the quality and scale of business  These developments are likely to have contributed to the company s top line in the third quarter Which Way Are Estimates Treading Overall  the Zacks Consensus Estimate for total revenues of  55 million implies growth of 47 2  from the prior year quarter s reported figure  Also  the consensus mark for a loss of 52 cents is 15 6  wider than the year ago quarter s reported figure Earnings WhispersPer our proven model  a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise  That is not the case here as you will see below Earnings ESP   Invitae has an Earnings ESP of 0 00   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Invitae carries a Zacks Rank  2 Stocks Worth a LookHere are a few medical stocks worth considering from the same space with the right mix of elements to surpass expectations this earnings season DENTSPLY SIRONA   NASDAQ XRAY   has an Earnings ESP of  5 05  and a Zacks Rank  3  You can see  AmerisourceBergen Company   NYSE ABC   has an Earnings ESP of  0 55  and a Zacks Rank  3 Cardinal Health   NYSE CAH   has an Earnings ESP of  0 69  and a Zacks Rank  3 Free  Zacks  Single Best Stock Set to Double Today you are invited to download our just released Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2019-10-31,Zacks Investment Research,https://www.investing.com/analysis/will-genetic-testing-drive-invitaes-nvta-q3-earnings-200480623,200480623
102749,324264,ABC,AmerisourceBergen  ABC  To Post Q4 Earnings  What s In Store ,opinion,"AmerisourceBergen Corporation   NYSE ABC   is scheduled to release fourth quarter fiscal 2019 results on Nov 7  before the opening bell In the last reported quarter  the company delivered a positive earnings surprise of 7 9   Further  it has an average four quarter positive surprise of 5 8  Let s take a look at how things are shaping up prior to this announcement Which Way are Q4 Estimates Treading The Zacks Consensus Estimate for fourth quarter revenues is pegged at  45 33 billion  indicating an improvement of 4 7  from the year ago quarter  The consensus estimates for earnings stands at  1 58  suggesting growth of 8 9  from the year ago reported figure Pharmaceutical Distribution Unit to Drive Q4Increasing volume and expanding customer base at this segment are likely to have driven the fourth quarter revenues  This segment serves healthcare providers in the pharmaceutical supply channel  Continued strength in Specialty Distribution  solid organic growth rates in the U S  pharmaceutical market  and improving patient access to medical care are likely to have contributed to the to be reported quarter s top line The Zacks Consensus Estimate for Pharmaceutical Distribution stands at  43 68 billion  indicating an improvement of 4 7  from the year ago quarter However  the company has narrowed guidance for operating income growth in this segment  The metric is estimated to be in the low single digit percentage range AmerisourceBergen Corporation Price and EPS Surprise
    Other Factors to ConsiderWorld Courier unitThe World Courier unit  in particular  is likely to have contributed to the Other segment s performance in the fourth quarter  Bolstering customer experience through new offerings  technology improvements and delivery of high tax logistics services is anticipated to get reflected in the company s fourth quarter results The company s fourth quarter top line is likely reflect solid demand for its high touch global specialty logistics Other SegmentThis segment consists of Global Commercialization Services and Animal Health  and includes World Courier  AmerisourceBergen Consulting and MWI  The segment is anticipated to have driven the top line in the to be reported quarter  backed by growth in Canadian operations and World Courier unit and revenues from MWI In fact  the Zacks Consensus Estimate for fiscal fourth quarter revenues for this segment is pegged at  1 73 billion  suggesting growth of 8 6  year ago reported figure This apart  the company is likely to have benefited from generics growth in the to be reported quarter  Further  new product launches are likely to have contributed to overall performance However  for fiscal 2019  the company anticipates PharMEDium to be a headwind of around 3   which represents an adjusted operating loss of approximately  50 million Consequently  this trend is likely to have affected the upcoming quarterly results Moreover  stiff competition  as the company operates in a highly competitive pharmaceutical distribution and related health care services market  is likely to get reflected in the fourth quarter performance The company has raised adjusted EPS guidance for fiscal 2019  currently adjusted EPS is estimated in the range of  7 00  7 10  up from the previously guided range of  6 70  6 90   The company s fourth quarter bottom line is likely to reflect the impact of lower share count  possible higher operating income and lower net interest expense What Our Quantitative Model SuggestsPer our proven model  a combination of   a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    increases the chances of an earnings beat  This is the case here as you will see Earnings ESP  AmerisourceBergen has an Earnings ESP of  0 55   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  AmerisourceBergen carries a Zacks Rank  3 Other Stocks Worth a LookHere are some other medical stocks worth considering as these too have the right combination of elements to post an earnings beat this quarter Tandem Diabetes Care  Inc    NASDAQ TNDM   has an Earnings ESP of  33 33  and a Zacks Rank  2  You can see   Neovasc Inc    NASDAQ NVCN   has an Earnings ESP of  16 87  and a Zacks Rank  3 ShockWave Medical  Inc    NASDAQ SWAV   has an Earnings ESP of  3 55  and a Zacks Rank  3 
7 Best Stocks for the Next 30 Days
Just released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  
Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 5  per year  So be sure to give these hand picked 7 your immediate attention ",2019-10-31,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-abc-to-post-q4-earnings-whats-in-store-200481442,200481442
102750,324265,ABC,Can All Line Growth Boost CVS Health s  CVS  Q3 Earnings ,opinion,CVS Health Corporation   NYSE CVS   is scheduled to report third quarter 2019 results on Nov 6  before the opening bell  In the last reported quarter  the company delivered a positive surprise of 11 18   the average trailing four quarter beat being 5 93  Let s take a look at how things are shaping up prior to this announcement Factors at PlayWithin Pharmacy Services  despite a tough pricing competition  CVS Health has been gaining on high level of service and execution  competitive pricing and a unique integrated model  Regarding PBM  the company s new guaranteed net cost pricing model is garnering interest from clients and benefit consultants  which is likely to have led to strong client wins in the third quarter  This  in turn  might have a bearing on the company s third quarter results CVS Health Corporation Price and EPS Surprise   In terms of the company s ongoing store expansion strategy  CVS Health has already started to register strong results in the initial hub locations including increased customer traffic and incremental sales in pharmacy front store and Minute Clinics  This too is likely to have contributed to the company s third quarter top line With respect to the newly incorporated Health Care Benefits segment  the company earlier expected to see government programs gaining momentum  driven by industry leading Medicare growth and the key Medicaid wins through the third quarter  Hopefully  this might get reflected in the to be reported results This Health Care Benefits business has already started to register top line contributions for the company  In the second quarter  this segment had posted significant Medicare Advantage membership growth  particularly in the government space  SilverScript Medicare Part D business is showing a strong revenue performance as well  This trend has most likely continued in the third quarter However  this segment might take a hit in anticipation that certain one time benefits realized by Aetna  NYSE AET  in 2018 are not likely to recur in 2019  This too might have affected the segmental performance in the September quarter Within the Retail Long Term Care Segment  CVS Health is likely to have thrived in the third quarter on the back of higher prescription volumes and consistently solid adjusted script growth owing to the steady success of the pharmacy clinical care program that improved patient retention  Additionally  CVS Health earlier projected an uptick in the recently formed Medicare partnerships and the new regional preferred alliances forged in the ongoing year  The continued uptake of the company s Patient Care Programs in collaboration with PBM and its preferred status in a number of Medicare Part D networks are expected to have aided the third quarter top line Meanwhile  the Zacks Consensus Estimate for third quarter adjusted EPS of  1 77 suggests a 2 31  rise from the year ago reported figure  The consensus estimate for revenues is currently pegged at  63 03 billion  indicating 33 3  growth from the year earlier reported number Here is What the Quantitative Model Predicts Per our proven model  a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise  This is exactly the case here as you will see below Earnings ESP   CVS Health has an Earnings ESP of  0 05   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  CVS Health carries a Zacks Rank  3 Other Stocks Worth a LookHere are a few other medical stocks worth considering from the same space with the right mix of elements to also surpass expectations this earnings season DENTSPLY SIRONA   NASDAQ XRAY   has an Earnings ESP of  5 05  and a Sacks Rank of 3  You can see  AmerisourceBergen Company   NYSE ABC   has an Earnings ESP of  0 55  and is Sacks  3 Ranked Cardinal Health  Inc    NYSE CAH   has an Earnings ESP of  0 69  and is a  3 Ranked stock 7 Best Stocks for the Next 30 DaysJust released  Experts distil 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 5  per year  So be sure to give these hand picked 7 your immediate attention ,2019-10-31,Zacks Investment Research,https://www.investing.com/analysis/can-allline-growth-boost-cvs-healths-cvs-q3-earnings-200481405,200481405
102751,324266,ABC,Should You Buy AmerisourceBergen  ABC  Ahead Of Earnings ,opinion,Investors are always looking for stocks that are poised to beat at earnings season and AmerisourceBergen Corporation   NYSE ABC   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because AmerisourceBergen is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings   with the most up to date information possible   is a pretty good indicator of some favorable trends underneath the surface for ABC in this report In fact  the Most Accurate Estimate for the current quarter is currently at  1 59 per share for ABC  compared to a broader Zacks Consensus Estimate of  1 58 per share  This suggests that analysts have very recently bumped up their estimates for ABC  giving the stock a Zacks Earnings ESP of  0 55  heading into earnings season AmerisourceBergen Corporation Price and EPS Surprise   Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that ABC has a Zacks Rank  3 and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see Clearly  recent earnings estimate revisions suggest that good things are ahead for AmerisourceBergen  and that a beat might be in the cards for the upcoming report Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 5  per year  These 7 were selected because of their superior potential for immediate breakout ,2019-11-05,Zacks Investment Research,https://www.investing.com/analysis/should-you-buy-amerisourcebergen-abc-ahead-of-earnings-200482896,200482896
102752,324267,ABC,Medical Products  Nov 7 Earnings Roster  ABC  CAH   More,opinion,The  companies within the broader  sector have been performing impressively in spite of certain quarterly volatilities  In fact  the ongoing US China trade war is likely to have impacted the third quarter performance of the industry participants  Nonetheless  favorable growth in the emerging markets and benefits obtained from innovation are likely to get reflected in the industry players  performance this earnings season Over the past few months  the medical device space has witnessed exceptional progress when it comes to innovation   R D to be precise  Some of the path breaking inventions such as wireless brain sensors  Bluetooth enabled smart inhalers  artificial pancreas  human brain pacemaker  precision medicine  among others  have helped the medical device space to grow significantly  Abbott   NYSE ABT   registered strong top line growth in the recently reported third quarter  banking on regulatory approvals for MitraClip  Alinity and FreeStyle Libre line Strong demand in the emerging markets is likely to have bolstered the performance of the industry participants in this reporting cycle  According to a  report  as stated by Moody s  the medical device makers are likely to exhibit mid single digit revenue growth fueled by product innovation across most of the companies and categories throughout 2019  Additionally  sales in emerging markets are expected to display a double digit percentage rise over the same timeframe  Consequently  this trend is likely to get reflected in the performance of the industry players in this reporting cycle Backed by rising medical awareness and economic prosperity  emerging economies have been witnessing strong demand for the medical products  In fact  a geriatric population  relaxed regulations  cheap skilled labor  increasing wealth and the government focus on healthcare infrastructure make these markets attractive to the global medical device players  In this regard  Varian Medical   NYSE VAR   has been leveraging its capability to treat cancer in emerging economies that are slightly under equipped to address the prevalence of the same  According to a  report  in May 2019  Varian Medical strengthened presence in India by acquiring Cancer Treatment Services International for  283 million However  the U S  Medical Products industry has been bearing the brunt of headwinds pertaining to the U S  China trade war  Per a Medical Imaging   Technology Alliance  MITA  survey  tariffs will cost the companies nearly  138 million every year  This is anticipated to get reflected in the third quarter performance of the companies in this space The latest  anticipates the Medical sector to deliver positive earnings surprises this time around although a sequential decline can be seen  For the quarter under review  earnings growth rate is projected at 6 1  on 7 1  revenue growth  compared with second quarter reported earnings growth of 9 8  on 6 6  revenue growth What Our Model SaysPer our proven model  the combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the chances of an earnings beat You can uncover the best stocks to buy or sell before they re reported with our  Considering the above factors  we take a look at the following four Medical Products behemoths that are set to release quarterly results on Nov 7 AmerisourceBergen Corporation   NYSE ABC    Increasing volume and expanding customer base at the Pharmaceutical Distribution segment are likely to have driven the fourth quarter fiscal 2019 revenues  This segment serves healthcare providers in the pharmaceutical supply channel  Continued strength in Specialty Distribution  solid organic growth rates in the U S  pharmaceutical market  and improving patient access to medical care are likely to get reflected in the to be reported quarter s top line  This apart  the company is likely to have benefited from generics growth in the to be reported quarter  Further  new product launches are likely to have contributed to overall performance   Read more   AmerisourceBergen has a Zacks Rank  3 and an Earnings ESP of  0 55   You can see  AmerisourceBergen Corporation Price and EPS Surprise    Cardinal Health  Inc    NYSE CAH    Cardinal Health s Pharmaceutical segment is the second largest pharmaceutical distributor in the United States  Probable sales growth from pharmaceutical distribution and specialty customers is anticipated to get reflected in the Pharmaceutical segment s first quarter bottom line  Better than expected performance at this segment is likely to have driven the company s first quarter fiscal 2020 performance Cardinal Health s Medical unit is likely to have contributed significantly to the overall third quarter performance  In fact  the segment manufactures products such as single use surgical drapes  gowns and apparel  exam and surgical gloves  which are anticipated to have driven sales in the to be reported quarter   Read more   Cardinal Health has a Zacks Rank  3 and an Earnings ESP of  0 69  Cardinal Health  Inc  Price and EPS Surprise    DENTSPLY SIRONA Inc    NASDAQ XRAY    DENTSPLY SIRONA s growth strategy focuses on product innovation  and research and development  R D  focus  which is likely to get reflected in the top line in the third quarter  Apart from this  a solid track record of innovation and dedicated  passionate workforce is likely to have contributed to the third quarter performance  The company s CAD CAM is a dental imaging platform and a major foundation in global dental markets  Product launches and innovation in this area are likely to have fueled CAD CAM sales in the to be reported quarter and consequently the top line in the United States Execution of cost saving opportunities is likely to impact the bottom line in 2019  a trend that that is likely to get reflected in the third quarter   Read more   DENTSPLY SIRONA has a Zacks Rank of 2 and an Earnings ESP of 0 00  DENTSPLY SIRONA Inc  Price and EPS Surprise    Penumbra  Inc    NYSE PEN    Penumbra is an interventional therapies company  It designs  develops  manufactures and markets medical devices  The company s portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs  Neuro products include Neurovascular Access  Neuron Access System  BENCHMARK Intracranial Access System  Penumbra System  3D  Penumbra Coil 400  Penumbra SMART Coil and LIBERTY stent  Peripheral vascular products include Ruby Coil System  Penumbra Occlusion Device and Indigo System The Zacks Consensus Estimate for third quarter 2019 revenues is pegged at  133 4 million  indicating growth of 19 3  from the year ago reported figure  The same for earnings stands at 18 cents  suggesting an improvement of 5 9  from the year ago quarter  In the preceding four quarters  the company outpaced the consensus mark  the average being 147 6  Penumbra has a Zacks Rank  3 and an Earnings ESP of 0 00  Penumbra  Inc  Price and EPS Surprise    Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 5  per year These 7 were selected because of their superior potential for immediate breakout ,2019-11-05,Zacks Investment Research,https://www.investing.com/analysis/medical-products-nov-7-earnings-roster-abc-cah--more-200483060,200483060
102753,324268,ABC,AmerisourceBergen  ABC  Q4 Earnings   Revenues Beat Estimates,opinion,AmerisourceBergen Corporation   NYSE ABC   reported fourth quarter fiscal 2019 adjusted earnings per share  EPS  of  1 61 surpassing the Zacks Consensus Estimate of  1 58 by 1 9   The figure also improved 11  year over year The better than expected bottom line performance can be attributed to increase in adjusted operating income  lower share count and reduced net interest expense Revenues improved 5 4  to  45 64 billion in the reported quarter  Moreover  the figure beat the Zacks Consensus Estimate by 0 7  FY19 at a GlanceFor fiscal 2019  the company reported adjusted earnings of  7 09 per share  up 9 2  from the year ago period  The metric exceeded the Zacks Consensus Estimate of  7 05 per share Revenues totaled  179 56 billion  up 6 9  year over year  which beat the Zacks Consensus Estimate of  179 37 billion AmerisourceBergen Corporation Price  Consensus and EPS Surprise    Segmental AnalysisPharmaceutical Distribution SegmentRevenues at this segment totaled  43 87 billion  improved 5 1  on a year over year basis  Consistent robust specialty product sales and increase in volume related to growth of some of its largest customers contributed to the improvement Segmental operating income was  369 3 million  up 3 5  year over year  Increase in gross profit drove the upside  However  an increase in operating expenses partially offset the uptick Other SegmentThis segment includes AmerisourceBergen Consulting Services  ABCS   World Courier and MWI Veterinary Supply Revenues at this segment came in at  1 79 billion  up 12 6  year over year  This upside was driven by ABCS s growth in Canadian operations and MWI Operating income in the segment was  86 7 million in the quarter  up 14 9  year over year primarily on the back of the results at MWI  World Courier and ABCS s Lash Consulting Services Margin AnalysisIn the quarter under review  AmerisourceBergen reported adjusted gross profit of  1 25 billion  up 6 9  on a year over year basis  As a percentage of revenues  adjusted gross margin was 2 7  in the quarter  which remained marginally flat year over year AmerisourceBergen reported adjusted operating income of  456 1 million  up 5 5  year over year  As a percentage of revenues  adjusted operating margin was 1  in the quarter  which remained flat from the prior year quarter  Fiscal 2020 GuidanceThe company estimates revenue growth in the mid to high single digit percent range Adjusted EPS is now estimated in the range of  7 30  7 60  The Zacks Consensus Estimate is currently pegged at  7 57  which is within management s guided range Adjusted operating income is projected to grow in the low to mid single digit percent range Operating income at Pharmaceutical Distribution Services segment is expected to improve in the low to mid single digit percent range  For the Other segment the metric is estimated to grow in the high single digit percent range Adjusted operating expenses is projected to increase in the mid single digit percent range Adjusted free cash flow is estimated to be around  1 5 billion The company anticipates adjusted effective tax rate in the range of 21 22  Further  the company anticipates weighted average diluted shares to range between 209 million and 210 million Summing UpAmerisourceBergen exited the fiscal fourth quarter on a strong note  wherein both earnings and revenues beat the consensus mark  The company continues to gain from its Pharmaceutical segment and World Courier business  which have been generating huge profits since quite some time  Its specialty distribution business also continues to contribute significantly to the top line  A strong fiscal 2020 outlook instills investors  optimism in the stock UPS announced its drone logistics partnership with AmerisourceBergen  The collaboration will deploy the UPS Flight Forward drone airline to transport certain pharmaceuticals  supplies and records to qualifying medical campuses  which are served by AmerisourceBergen throughout the United States  and then extend its use to other sites of care Meanwhile  company faces other headwinds like conversion of branded drugs and lower price generics  Cutthroat competition in the MedTech space adds to woes Zacks RankCurrently  AmerisourceBergen carries a Zacks Rank  3  Hold   Earnings of Other MedTech Majors at a GlanceSome better ranked stocks that reported solid results this earning season are Edwards Lifesciences   NYSE EW    Thermo Fisher Scientific Inc    NYSE TMO   and ResMed Inc    NYSE RMD    each carrying a Zacks Rank  2  Buy   You can see  Edwards Lifesciences delivered fourth quarter 2019 adjusted EPS of  1 41  outpacing the Zacks Consensus Estimate by 15 6   Fourth quarter net sales of  1 09 billion surpassed the Zacks Consensus Estimate by 5 5  Thermo Fisher delivered fourth quarter 2019 adjusted EPS of  2 94  which surpassed the Zacks Consensus Estimate by 2 1   Revenues of  6 27 billion outpaced the Zacks Consensus Estimate by 1 3  ResMed reported fourth quarter 2019 adjusted EPS of 93 cents  which beat the Zacks Consensus Estimate of 87 cents by 6 9   Revenues were  681 1 million  surpassing the Zacks Consensus Estimate by 3 6  Wall Street s Next Amazon  NASDAQ AMZN  Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2019-11-06,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-abc-q4-earnings--revenues-beat-estimates-200483373,200483373
102783,324298,ABC,Companies ask judge in U S  opioid trial to recuse himself,news,"WASHINGTON  Reuters    Major drug wholesalers and retailers facing a massive lawsuit for allegedly fostering the nation s opioid crisis asked the judge hearing the case to recuse himself on Saturday 
The companies argued in a court filing that U S  District Judge Dan Polster  who is hearing the case in a federal court in Cleveland  Ohio  had made statements in court indicating that he was not impartial in the case and improperly pushed the companies to settle without going to trial 
The companies said that Judge Polster had also made improper public comments about the case  including to reporters 
Opioids were involved in 400 000 overdose deaths from 1999 to 2017  according to the U S  Centers for Disease Control and Prevention 
In the filing  the companies noted that plaintiffs had sought  8 billion  Defendants in the case include McKesson Corp  N MCK   AmerisourceBergen Corp  N ABC    Walgreen Co   NASDAQ WBA  and Walmart Inc  N WMT  
 Defendants do not bring this motion lightly  Taken as a whole and viewed objectively  the record clearly demonstrates that recusal is necessary   the companies said in a court filing on Saturday 
In particular  the companies said that on Jan  9  2018  in the first hearing  Polster said that the country was in the grips of an  opioid crisis   adding  150 Americans are going to die today  just today  while we re meeting  
  E veryone shares some of the responsibility  and no one has done enough to abate it   he said  including  the manufacturers  the distributors  the pharmacies  the doctors  the federal government and state government  local governments  and  hospitals 
 My objective is to do something meaningful to abate this crisis   he said at the hearing  according to the filing 
The request for recusal comes days after Judge Polster approved the substance of a proposal by lawyers representing cities and counties suing drug companies over the U S  opioid epidemic that would bring every state and municipality in the country into their settlement talks 
The proposal  part of litigation consolidating about 2 000 lawsuits against opioid manufacturers  retailers and others seeking damages for the epidemic  calls for creating a class of up to 3 000 counties and 30 000 cities  towns and villages that could vote on whether to accept any settlement the plaintiffs reach with the defendants 




Any proposed settlement would need to win support of at least 75 percent of class members to be approved ",2019-09-14,Reuters,https://www.investing.com/news/economy/companies-ask-judge-in-us-opioid-trial-to-recuse-himself-1978105,1978105
102784,324299,ABC,Opioid plaintiffs fight bid to disqualify U S  judge before trial,news,"By Nate Raymond
 Reuters    Lawyers for cities and counties suing drug companies over the opioid epidemic on Monday objected to a bid by pharmaceutical distributors and pharmacies to disqualify the federal judge overseeing the cases  saying it had no basis and came too late 
The plaintiffs  lawyers moved swiftly to fight the request companies including AmerisourceBergen Corp  N ABC    Cardinal Health  Inc  N CAH  and McKesson Corp  N MCK  had made on Saturday for U S  District Judge Dan Polster in Cleveland  Ohio  to step aside from the litigation 
In Monday s brief  lawyers for the plaintiffs said the defendants had waived their ability to seek Polster s recusal  noting they were relying on statements he made more than a year ago to belatedly seek his disqualification 
 If these Defendants really thought recusal was necessary  they were required to raise the issue sooner   much sooner   the plaintiffs  lawyers wrote 
More than 2 500 lawsuits by state and local governments are pending nationally  accusing drug manufacturers of deceptively marketing opioids in ways that downplayed their risks  and drug distributors of failing to detect and halt suspicious orders 
The companies deny wrongdoing  Nearly 2 100 of the lawsuits are before Polster  while others are in state courts 
The companies had argued in Saturday s motion that Polster  who has long pushed for a settlement that could  do something meaningful to abate this crisis   had made a series of public statements since 2018 that could cause a reasonable person to question his impartiality 
They said those statements  made in court hearings and media interviews  raised the prospect that he had improperly prejudged their liability ahead of the first trial on Oct  21 involving two Ohio counties seeking  8 billion 
In Monday s brief  the plaintiffs  lawyers said the companies did not take action when Polster made those comments and actively participated in court overseen settlement talks without objection 
Polster  has at no time expressed improper or biased views about the liability of any defendant  much less views based on extra judicial sources   the lawyers wrote 
The companies who joined Saturday s motion also include CVS Health Corp  N CVS  and Walmart Inc  N WMT   The defendants did not respond to requests for comment 
Opioids were involved in 400 000 overdose deaths from 1999 to 2017  according to the U S  Centers for Disease Control and Prevention 
OxyContin maker Purdue Pharma  one of the lead defendants  filed for bankruptcy protection on Monday after reaching a tentative deal to resolve claims in the federal litigation and by 24 U S  states ",2019-09-16,Reuters,https://www.investing.com/news/stock-market-news/opioid-plaintiffs-fight-bid-to-disqualify-us-judge-before-trial-1979114,1979114
102785,324300,ABC,U S  judge overseeing opioid litigation won t disqualify himself,news,"By Jonathan Stempel
 Reuters    The U S  judge overseeing nationwide litigation over the opioid epidemic on Thursday refused to disqualify himself  after major pharmacies and drug distributors said he was biased against them and pressing too hard for a costly settlement 
Calling the opioid epidemic  one of the greatest tragedies of our time   U S  District Judge Dan Polster in Cleveland admitted he had been  very active  in encouraging a settlement but said he was  confident that no reasonable person can legitimately question my impartiality  
He also said addressing the epidemic should be the job of the government s executive and legislative branches but  these are not ordinary times   and that not settling could overwhelm the courts and drive  most  of the defendants into bankruptcy 
 It is important for our citizens to know what I am doing and to have confidence that the judicial branch is up to the task   Polster wrote   The moving defendants complain that I have had a  personal mission  from the start of the case  That is true  but it does not suggest any bias or partiality  
Polster oversees more than 2 000 lawsuits by state and local municipalities over opioids  including a bellwether trial by Ohio s Cuyahoga and Summit counties scheduled for October 21 
The companies that sought Polster s disqualification included the retailers CVS Health Corp  N CVS    Rite Aid Corp   N RAD   Walgreens Boots Alliance Inc  O WBA  and Walmart Inc  N WMT   and distributors AmerisourceBergen Corp  N ABC    Cardinal Health  Inc  N CAH    Henry Schein  Inc  O HSIC  and McKesson Corp  N MCK  
Their lawyers did not immediately respond to requests for comment  Lawyers representing the counties had no immediate comment 
The request for Polster s disqualification followed a series of rulings by him in the counties  favor  including that they could try to show that various corporate defendants created a public nuisance 
Opioid addiction claimed roughly 400 000 lives in the United States form 1999 to 2017  according to the U S  Centers for Disease Control and Prevention 
The companies had argued that Polster tipped his hand beginning as early as January 2018 when the litigation that they would have to foot the bill for the epidemic 
They have also said the potential costs could be enormous  saying the plaintiffs in the Ohio case were seeking  8 billion in cash to cover fallout 
Polster  however  said the main point of his public comments was to show that the judiciary was  up to the task  of addressing the crisis  whether through fairly negotiated settlements or fairly fought litigation 
 The burden to sustain a motion to disqualify a judge is exceedingly high   he added   and the moving defendants have not met it  
Purdue Pharma LP  the maker of Oxycontin and one of the main defendants  filed for Chapter 11 bankruptcy protection on Sept  15 after reaching an agreement to settle claims in the litigation and by 24 U S  states ",2019-09-26,Reuters,https://www.investing.com/news/stock-market-news/us-judge-overseeing-opioid-litigation-wont-disqualify-himself-1986954,1986954
102786,324301,ABC,Johnson   Johnson settles Ohio lawsuits to avoid federal trial,news,"By Shubham Kalia  Reuters    Johnson   Johnson  N JNJ  said on Tuesday it will pay  20 4 million to settle claims by two Ohio counties  allowing the U S  healthcare giant to avoid an upcoming federal trial seeking to hold the industry responsible for the nation s opioid epidemic  J J became the fourth drugmaker to settle claims ahead of the Federal Court trial against multiple manufacturers and distributors in Cleveland scheduled for later this month  The case is considered a bellwether for more than 2 600 lawsuits by state and local governments that are pending nationally   The settlement allows the company to avoid the resource demands and uncertainty of a trial as it continues to seek meaningful progress in addressing the nation s opioid crisis   J J said in a statement    The company recognizes the opioid crisis is a complex public health challenge and is working collaboratively to help communities and people in need   it added  Opioids were involved in 400 000 overdose deaths in the United States from 1999 to 2017  according to the U S  Centers for Disease Control and Prevention  J J which formerly marketed the painkillers Duragesic and Nucynta  said the settlement includes no admission of liability  The company will pay  10 million to Cuyahoga and Summit counties  reimburse  5 million of their legal and other expenses and provide  5 4 million to non profit organizations that run opioid related programs in the counties   Mallinckrodt  Plc  N MNK  finalized a  24 million settlement with the same two counties on Monday  Endo International Plc  O ENDP  and Allergan Plc  N AGN  also settled with the two counties in August to avoid going to trial  The remaining defendants in the Oct  21 federal trial include McKesson Corp  N MCK   AmerisourceBergen  N ABC    Cardinal Health   N CAH   Teva Pharmaceutical  NYSE TEVA  Industries Ltd  TA TEVA   Walgreens Boots Alliance Inc  O WBA  and  Henry Schein  Inc  O HSIC    OxyContin maker Purdue Pharma LP succumbed to pressure from the lawsuits and filed for bankruptcy protection in September  Some plaintiffs  lawyers have compared the opioid cases to litigation by states against the tobacco industry that led to a  246 billion settlement in 1998  Earlier in the year  an Oklahoma judge ordered Johnson   Johnson to pay  572 1 million to the state for its part in fueling an opioid epidemic by deceptively marketing addictive painkillers  
Purdue Pharma and Teva had settled claims by Oklahoma s attorney general for  270 million and  85 million  respectively ",2019-10-01,Reuters,https://www.investing.com/news/stock-market-news/jj-settles-with-ohio-counties-ahead-of-opioid-trial-1990544,1990544
102787,324302,ABC,Drug firms offer to settle U S  opioid suits with  50 billion package  sources,news,"By Nate Raymond and Shanti S Nair  Reuters    Five drugmakers and distributors are offering  22 billion in cash as well as drugs and services they value at  28 billion to resolve lawsuits alleging the industry fueled the U S  opioid crisis  two sources familiar with the matter said on Wednesday  The drug industry faces roughly 2 600 lawsuits brought by state and local governments  hospitals and other entities seeking to hold drugmakers and distributors responsible for the toll of opioid abuse  Local governments seek funds to cover costs of services in their communities  Distributors McKesson Corp  N MCK   AmerisourceBergen Corp  N ABC  and  Cardinal Health   N CAH  have offered to pay  18 billion in cash over 18 years  while drugmaker Johnson   Johnson  N JNJ  would pay  4 billion in cash  two people familiar with the matter told Reuters   Teva Pharmaceutical  NYSE TEVA  Industries Ltd  TA TEVA  has offered to give away medications it values at  15 billion as part of the deal and provide distribution services it values in the billions  one of the people said  Both said that Teva s proposed agreement would run over 10 years and had a total estimated value of around  28 billion  However  it is not clear how the valuation was reached  and one source said some states are asking whether Teva should pay cash as well  The negotiations are being led by the attorneys general for Texas  Tennessee  North Carolina and Pennsylvania  one person said  Teva and the three distributors are all defendants in a landmark trial set to begin in federal court in Cleveland  Ohio  on Monday  U S  District Judge Dan Polster  who has long pushed for a global settlement of the litigation  will preside over the trial  The distributors  accused of failing to halt and report suspicious drug orders  are pushing for a settlement to be agreed to before the trial begins on Monday  one source said  The second source added that a sticking point was compensation for lawyers who typically are paid a percentage of settlements and represent many of the state and local plaintiffs  The sources cautioned that there was no guarantee a deal would be struck  One source said lawyers for the thousands of cities and counties with cases pending in federal court have not yet agreed to back the proposal the states are negotiating  In a joint statement late on Wednesday  the lead attorneys for the cities and counties pursuing federal lawsuits   Joe Rice  Paul Farrell and Paul Hanly   called media reports that they were tentatively supporting the settlement proposal  inaccurate    We await the fine print of the settlement framework so that we can work alongside the 2 600 communities we represent to determine the best path forward   they said  Jury selection went ahead on Wednesday in anticipation of opening statements on Monday  Other defendants in the trial are Walgreens Boots Alliance Inc  O WBA  and  Henry Schein  Inc  O HSIC   Opioid addiction claimed roughly 400 000 lives in the United States from 1999 to 2017  according to the U S  Centers for Disease Control and Prevention  
The companies did not respond to requests for comment on Wednesday  J J had said on Tuesday it was open to a settlement ",2019-10-16,Reuters,https://www.investing.com/news/stock-market-news/teva-to-donate-over-15-billion-worth-of-drugs-in-opioid-settlement-source-1997468,1997468
102797,324312,ABC,HCA Healthcare  HCA  To Post Q3 Earnings  What To Expect,opinion,HCA Healthcare  Inc    NYSE HCA   is scheduled to release third quarter 2019 results on Oct 29 The Zacks Consensus Estimate for the to be reported quarter s earnings is pegged at  2 14  suggesting a 1  dip from the year ago reported figure In the second quarter  HCA Healthcare reported adjusted earnings of  2 21 per share  missing the Zacks Consensus Estimate by 11 2   Moreover  the bottom line declined 3 5  year over year  mainly due to higher expenses Let s see how things are shaping up prior to the announcement The company s third quarter results are likely to reflect higher salaries and benefits  supplies plus other operating costs  Higher expenses might have weighed on the company s margins The company s leverage might have also remained at elevated levels as it incurs debt to finance its acquisitions However  this downside is expected to have been partially offset by increased admissions  licensed beds  number of hospitals  etc   which in turn  might have led to improved revenues  The Zacks Consensus Estimate for the licensed number of beds is pegged at 48 6 million  implying a 3 1  improvement from the prior year reported figure The Zacks Consensus Estimate for third quarter admissions and equivalent admissions indicates respective growth of 7 2  and 6 2  from the year ago reported numbers  attributable to the network expansion initiatives taken by HCA Healthcare The Zacks Consensus Estimate for licensed beds also hints at a 3 2  rise from the year earlier reported figure  Licensed beds of the company are likely to have expanded on the back of higher number of hospitals  The Zacks Consensus Estimate for revenues stands at  12 5 billion  implying 9 2  growth from the prior year reported number In order to enhance shareholder value  the company might have continued with share buybacks to further favor its bottom line in the upcoming quarterly release What the Quantitative Model StatesOur proven model does not conclusively predict an earnings beat for HCA Healthcare this season  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  But that s not the case here  You can uncover the best stocks to buy or sell before they re reported with our  Earnings ESP  HCA Healthcare has an Earnings ESP of 0 00   This is because both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at  2 14   You can see HCA Healthcare  Inc  Price and EPS Surprise   Zacks Rank  HCA Healthcare carries a Zacks Rank  3  which increases the predictive power of ESP  However  the company s 0 00  ESP makes surprise prediction difficult for the stock this time around Stocks to ConsiderSome stocks worth considering from the medical sector with the perfect mix of elements to surpass estimates in the next releases are as follows Mednax  Inc   NYSE MD   is set to report third quarter earnings on Nov 1  The stock has a Zacks Rank of 3 and an Earnings ESP of  1 10  AmerisourceBergen Corporation   NYSE ABC   is slated to announce third quarter earnings on Nov 7  The stock has an Earnings ESP of  0 55  and is Zacks  3 Ranked Molina Healthcare  Inc   NYSE MOH   is set to report third quarter earnings on Oct 29  The stock has a Zacks Rank of 1 and an Earnings ESP of  0 92  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-10-24,Zacks Investment Research,https://www.investing.com/analysis/hca-healthcare-hca-to-post-q3-earnings-what-to-expect-200477747,200477747
102798,324313,ABC,McKesson  MCK  To Report Q2 Earnings  What s In The Offing ,opinion,"McKesson Corporation s   NYSE MCK   second quarter fiscal 2020 results are scheduled to release on Oct 30 In the last reported quarter  the company delivered a positive earnings surprise of 8 9   Further  it has an average positive surprise of 6 6  for the trailing four quarters Let s take a look at how things are shaping up prior to this announcement McKesson Corporation Price and EPS Surprise
    Which Way Are Q2 Estimates Headed The Zacks Consensus Estimate for McKesson s fiscal second quarter earnings per share is pegged at  3 60  The same for revenues stands at  54 94 billion  suggesting growth of 3 5  from the year ago reported figure Factors to ConsiderMcKesson expects its fiscal second quarter results to reflect segmental strength The U S  Pharmaceutical and Specialty Solutions segment is likely to have acted as a key catalyst  In the last reported quarter  the segment had accounted for 79 3  of total revenues Notably  the segment is likely to benefit from branded  generic and over the counter pharmaceuticals  Also  the company s broad spectrum of specialty biopharmaceutical providers and manufacturers are expected to have contributed majorly in the second quarter Apart from this  management is optimistic about contributions from the Medical Surgical Solutions segment  driven by acquisitions and growth in the Primary Care and Extended Care businesses  Notably  the acquisition of Medical Specialties Distributor is expected to have proven accretive in the quarter to be reported Reflective of these  McKesson has raised its fiscal 2020 view  The company now expects adjusted earnings per share in the range of  14  14 60 versus the previous  13 85  14 45 However  management expects the European Pharmaceutical Solutions unit s adjusted operating profit growth to be at the low end of its original assumption  thanks to headwinds in Europe  Earlier  concerns in the U K  had affected McKesson s fiscal 2019 performance Earnings WhispersPer our proven model  a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise  That is not the case here as you will see below Earnings ESP  McKesson has an Earnings ESP of  1 11   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  McKesson carries a Zacks Rank  2   You can see  Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter Edward Lifesciences Corporation   NYSE EW   has an Earnings ESP of  0 35  and a Zacks Rank  3 AmerisourceBergen Corporation   NYSE ABC   has an Earnings ESP of  0 55  and a Zacks Rank  3 Cardinal Health  Inc    NYSE CAH   has an Earnings ESP of  1 50  and a Zacks Rank  3 Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-10-24,Zacks Investment Research,https://www.investing.com/analysis/mckesson-mck-to-report-q2-earnings-whats-in-the-offing-200477399,200477399
102799,324314,ABC,PerkinElmer  PKI  To Report Q3 Earnings  What s In Store ,opinion,PerkinElmer  Inc    NYSE PKI   is slated to release third quarter 2019 results on Oct 30  after the closing bell  In the last reported quarter  the company delivered a negative earnings surprise of 0 9   Further  it has an average four quarter positive surprise of 0 8  Which Way Are Estimates Treading For the quarter to be reported  the Zacks Consensus Estimate for earnings per share is pegged at  1 01  suggesting an improvement of 12 2  from the year ago quarter  The same for revenues stands at  722 5 million  indicating growth of 7 2  from the year ago reported figure Let s see how things are shaping up prior to the announcement PerkinElmer  Inc  Price and EPS Surprise    Diagnostics Revenues  A Key CatalystPerkinElmer s Diagnostics segment is likely to have contributed substantially to its third quarter  results  Sustained growth across the company s reproductive health  immunodiagnostics and applied genomics business lines is anticipated to get reflected in the segment s revenues in the third quarter Rising demand for earlier diagnosis and increase in adoption of new technologies has been fueling growth across all three of segments of reproductive health  immunodiagnostics and genomics  a trend that is likely to have continued in the to be reported quarter Further  the continued rise in infectious and autoimmune diseases  especially in emerging markets  is likely to have benefited the segment Reflective of these  the Zacks Consensus Estimate for the segment s third quarter revenues stands at  297 million  indicating an improvement 10 8  year over year Other Factors at PlayPerkinElmer is likely to have witnessed solid international growth in the to be reported quarter  Improved growth momentum in APAC  robust growth trend in the United States and moderate improvement in the low single digits in Europe is likely to have contributed to the third quarter performance Acquisitions and strategic partnerships are likely to get reflected in PerkinElmer s third quarter performance  In fact  the Cisbio buyout is anticipated to contribute  35 million in revenues and around 2 cents of adjusted earnings per share to the company in 2019  a trend that is likely to get reflected in the to be reported quarter Additionally  the company s Discovery product portfolio is likely to have seen strong demand on the back of probable robust performance by life sciences  PerkinElmer is likely to have witnessed substantial organic revenue growth in the company s imaging and detection product lines  which is anticipated get reflected in Discovery and Analytical Solutions segment s third quarter performance The company s bottom line is anticipated to reflect expected organic revenue growth and better margin expansion  In fact  for the third quarter  earnings per share is estimated at  1 01  In terms of revenues  the company projects reported revenues of  724 million in the third quarter  representing 6 7  organic revenue growth Productivity initiatives and volume leverage are likely to have contributed to the company s improvement in gross and operating margins in the third quarter  New product introductions are likely to have improved product mix and thereby gross margin Additionally  the company has been implementing plans to invest in high growth areas  shift the organization to a more unified structure  thereby this likely to have aided expansion in operating margins However  PerkinElmer estimates a headwind of  1 million or less in to be reported quarter from China  Moreover  the company is likely to have borne the impact of tariffs in the Discovery   Analytical Solutions unit at the high end since the company exports products from the United States to China Additionally  PerkinElmer anticipates foreign exchange to affect third quarter 2019 results by approximately  7 million Here s What the Quantitative Model SuggestsPer our proven model  a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise  This is not the case here as you will see below   Earnings ESP  PerkinElmer has an Earnings ESP of 0 00   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  PerkinElmer carries a Zacks Rank  4  Sell  Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter AmerisourceBergen Corporation   NYSE ABC   has an Earnings ESP of  0 55  and a Zacks Rank  3  You can see  Cardinal Health  Inc    NYSE CAH   has an Earnings ESP of  0 69  and a Zacks Rank  3 Patterson Companies  Inc    NASDAQ PDCO   has an Earnings ESP of  2 44  and a Zacks Rank  3 5 Stocks Set to Double Each was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-10-24,Zacks Investment Research,https://www.investing.com/analysis/perkinelmer-pki-to-report-q3-earnings-whats-in-store-200478422,200478422
102800,324315,ABC,What s In Store For Tandem Diabetes   TNDM  Q3 Earnings ,opinion,"Tandem Diabetes Care  Inc    NASDAQ TNDM   is slated to report third quarter 2019 results on Nov 4  after market close  In the last reported quarter  the company delivered a positive earnings surprise of 86 9   Tandem Diabetes  earnings beat the Zacks Consensus Estimate in the last four quarters  the average being 60 9  Let s take a look at how things are shaping up prior to this announcement Key CatalystsTandem Diabetes  strong earnings growth trajectory is expected to have continued in the third quarter  courtesy of a strong global surge in sales of its t slim X2  insulin pump  Particularly  the pump has been registering strong momentum within the Animas customer segment The positive customer reception for the pump and the Tandem Device Updater are expected to have driven growth for the company during the third quarter Tandem Diabetes Care  Inc  Price and EPS Surprise
    Solid adoption of the recently launched Basal IQ technology among healthcare providers is also expected to have contributed to the company s top line during the quarter Internationally  over the recent past  majority of the company s sales have been driven by an increasing number of Animas conversions  We expect this trend to have continued through the to be reported quarter Earnings WhispersPer our proven model  a stock needs to have a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise  This is exactly the case here as you will see below Earnings ESP   Tandem Diabetes has an Earnings ESP of  33 33   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank Tandem Diabetes carries a Zacks Rank  2 Other Stocks Worth a LookHere are a few other medical stocks worth considering from the same space with the right mix of elements to surpass expectations this earnings season Patterson Companies   NASDAQ PDCO   has an Earnings ESP of  2 44  and a Zacks Rank  3  You can see  AmerisourceBergen Company   NYSE ABC   has an Earnings ESP of  0 55  and a Zacks Rank  3 Cardinal Health  Inc    NYSE CAH   has an Earnings ESP of  0 69  and a Zacks Rank  3 Breakout Biotech Stocks with Triple Digit Profit Potential The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-10-28,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-tandem-diabetes-tndm-q3-earnings-200479482,200479482
102801,324316,ABC,Can BD Medical Drive Becton  Dickinson s  BDX  Q4 Earnings ,opinion,"Becton  Dickinson and Company s   NYSE BDX    popularly known as BD  fourth quarter fiscal 2019 results are scheduled to release on Nov 5  before market opens  While the results are likely to show steady growth in the core BD Medical segment  headwinds in the Drug Coated Balloon   DCB   business and unfavorable foreign exchange rates might have partially impacted performance BD delivered a positive earnings surprise of 1  in the last reported quarter and has a positive average earnings surprise of 0 5  for the trailing four quarters Which Way Are Estimates Treading For the quarter to be reported  the Zacks Consensus Estimate for BD s earnings per share  EPS  is pegged at  3 30  suggesting a year over year decline of 12 6   The same for revenues stands at  4 57 billion  indicating an increase of 3 8  Let s see how things are shaping up prior to the earnings release Becton  Dickinson and Company Price and EPS Surprise
    BD Medical Likely to Drive Q4 EarningsBD Medical  a major revenue driver  is expected to drive fiscal fourth quarter results  The segment is likely to have benefited from strong year over year growth in revenues from needles  syringes and intravenous catheters for medication delivery  prefilled IV flush syringes  syringes and pen needles for diabetes care It is encouraging to note that for the fiscal fourth quarter  the Zacks Consensus Estimate for the segment s revenues is pegged at  2 44 billion  suggesting a rise of 4 2  year over year  In fact  for fiscal 2019  management at BD expects the Medical segment to grow 5  to 6  Management expects to have gained from the launch of the BD Pyxis ES System version 1 6 in May  Also  integration of three technologies   BD Pyxis ES Refrigerator  BD Pyxis Track and Deliver  and BD HealthSight Data Manager   in the segment might have boosted the quarterly performance Notably  the sub segments   Medical Surgical Systems  Pharmaceutical Systems and Diabetes Care   are expected to have driven the unit in the to be reported quarter The Zacks Consensus Estimate for Medical Surgical Systems  fiscal fourth quarter revenues stands at  1 02 billion  calling for a year over year rise of 5 6   The growth is expected to have been driven by strength in vascular access and infusion disposables For Diabetes Care  the Zacks Consensus Estimate for fourth quarter revenues stands at  290 million  suggesting a rise of 1 8  year over year  Steady uptake of the new pen needle Nano Pro and solid show in emerging markets are expected to reflect in the results Also  for Pharmaceutical Systems  the Zacks Consensus Estimate for fourth quarter revenues is pinned at  419 million  suggesting a year over year rise of 4   The sub segment is expected to have gained from strength in Europe Other Factors at PlayStrong performance by the BD Life Sciences and BD Interventional arms might reflect on the company s fourth quarter results The Zacks Consensus Estimate for BD Life Sciences  fourth quarter revenues is pinned at  1 14 billion  marking a year over year upside of 3   Strength in the segment s molecular and diagnostic systems and continued adoption of BD MAX and Phoenix panels are encouraging aspects Also  the Zacks Consensus Estimate for BD Interventional s fourth quarter revenues is pegged at  984 million  showing a sequential increase of 0 3   The segment offers a wide spectrum of products like the 4 French WavelinQ  Covera and Venovo  which might have driven the quarterly performance Reflective of these  BD kept its fiscal 2019 guidance intact Notably  the company expects revenue growth of 8 9   At constant currency  cc   revenues are anticipated to increase 5 6  Adjusted EPS is expected between  11 65 and  11 75  indicating growth of 12  at cc However  the recent market reaction to the FDA letter regarding the DCB business is expected to build near term pressure on BD  Notably  sales from the DCB Business are expected to reduce by 50  through the remaining of fiscal 2019 That s not all  Management at BD expects incremental foreign exchange pressure in the remaining of fiscal 2019  which was pronounced in the last reported quarter as well What Does Our Model Say Per our proven model  a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise  But that is exactly the case here Earnings ESP  BD has an Earnings ESP of  0 61   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  BD carries a Zacks Rank  4  Sell  Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this time around DENTSPLY SIRONA   NASDAQ XRAY   has an Earnings ESP of  5 05  and a Zacks Rank  3  You can see  AmerisourceBergen Corporation   NYSE ABC   has an Earnings ESP of  0 55  and a Zacks Rank  3 Cardinal Health  Inc    NYSE CAH   has an Earnings ESP of  1 50  and a Zacks Rank  3 Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-10-30,Zacks Investment Research,https://www.investing.com/analysis/can-bd-medical-drive-becton-dickinsons-bdx-q4-earnings-200480040,200480040
102802,324317,ABC,Can Dental Growth Drive Henry Schein s  HSIC  Q3 Earnings ,opinion,"Henry Schein  Inc    NASDAQ HSIC   is scheduled to report third quarter 2019 results on Nov 5  before market open  In the last reported quarter  the company s earnings beat the Zacks Consensus Estimate by 1 2   Overall  the metric surpassed estimates in each of the trailing four quarters  the average positive surprise being 2 3  Let s see how things are shaping up prior to this announcement Factors at PlayIn the third quarter  Henry Schein is expected to have witnessed solid growth across all segments  namely  Dental  Medical and Technology plus Value Added Services  Meanwhile geographically  the company is gaining traction in all regions  We expect this trend to get reflected in the upcoming quarterly results Favorable Dental Business Trend  The company has been making concerted efforts to expand in the field of digital dentistry globally  It is well positioned to benefit from the ongoing phase of digitalization in the international dental market Within North America  the company has been witnessing strong sales of CAD CAM solutions lately  Internationally  CAD CAM equipment sales registered double digit growth during the last reported quarter  This trend is expected to have continued through the third quarter  The robust performance of the Primescan system in Europe and the United States is also expected to have contributed to the company s top line during the to be reported quarter Henry Schein  Inc  Price and EPS Surprise
    In June 2019  the company acquired Hayes Handpiece franchise  a leading provider of dental handpiece products and services in the United States  Canada  and the United Kingdom  Recently  the company took over Cliniclands  which caters to dentists in Sweden  Denmark and Norway by providing dental consumables  implants  prosthetic  and orthodontic solutions and equipment  These acquisitions are expected to have driven the dental business of the company in the third quarter The Zacks Consensus Estimate for third quarter North American dental revenues is pegged at  977 million  suggesting a 2 7  rise from the year ago reported figure  The consensus estimate for international Dental revenues stands at  641 million  implying 13 9  growth from the prior year reported number Strong Technology and Value Added Services Business  Henry Schein is steadily progressing with an array of product launches within this business  The company s third quarter performance is expected to have benefited from consistent contribution of its joint venture  JV  with Internet Brands on dental technology that resulted in the formation of Henry Schein One  In recent times  Henry Schein One rolled out several key platform updates for patient engagement  patient financing and clinical decision support solutions  In July 2019  the company acquired Italian dental practice management software company  Elite Computer Italia  The recent acquisitions of Lighthouse  a provider of easy to use dental practice management patient communication software  and Kopfwerk  a leading dental practice management solution company in Austria  are also projected to have contributed to the company s top line in the third quarter Growing Medical and Animal Health Business  Henry Schein is consistently working to boost its Medical segment  Its worldwide Medical revenues rose 7 6  year over year in the second quarter  We expect to see another quarter of strong organic growth from the existing customer base and new patient traffic  The recent acquisition of North American Rescue  a leading provider of mission critical medical products for the defense and Public Safety markets  is likely to show on the upcoming quarterly results Meanwhile  the company completed the spin off of its global Animal Health business in February 2019 which has in all probability impacted the segment s performance in third quarter 2019 Earnings WhispersPer our proven model  a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise  That is exactly the case here as you will see below Earnings ESP  Henry Schein has an Earnings ESP of  0 87   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Henry Schein carries a Zacks Rank  3 Other Stocks Worth a LookHere are a few other medical stocks worth considering from the same space with the right mix of elements to surpass expectations this earnings season DENTSPLY SIRONA   NASDAQ XRAY   has an Earnings ESP of  5 05  and a Zacks Rank  3  You can see  AmerisourceBergen Company   NYSE ABC   has an Earnings ESP of  0 55  and a Zacks Rank  3 Cardinal Health  Inc    NYSE CAH   has an Earnings ESP of  0 69  and a Zacks Rank  3 Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-10-30,Zacks Investment Research,https://www.investing.com/analysis/can-dental-growth-drive-henry-scheins-hsic-q3-earnings-200480028,200480028
102803,324318,ABC,AmerisourceBergen  ABC  Earnings Expected To Grow  What To Know Ahead Of Next Week s Release,opinion,"AmerisourceBergen  NYSE ABC  is expected to deliver a year over year increase in earnings on higher revenues when it reports results for the quarter ended September 2019  This widely known consensus outlook gives a good sense of the company s earnings picture  but how the actual results compare to these estimates is a powerful factor that could impact its near term stock price 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on November 7  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This prescription drug distributor is expected to post quarterly earnings of  1 58 per share in its upcoming report  which represents a year over year change of  9  
Revenues are expected to be  45 33 billion  up 4 7  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for AmerisourceBergen 
For AmerisourceBergen  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  0 55  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination indicates that AmerisourceBergen will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that AmerisourceBergen would post earnings of  1 63 per share when it actually produced earnings of  1 76  delivering a surprise of  7 98  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
AmerisourceBergen appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-10-30,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-abc-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release-200480897,200480897
102839,324354,ABC,Trump says he is holding big Pharma accountable in opioid fight,news,"By Roberta Rampton ATLANTA  Reuters    U S  President Donald Trump touted progress in the fight against opioid abuse on Wednesday and promised to hold drugmakers accountable for their part in the crisis  a day after his administration brought its first related criminal charges against a major drug distributor and company executives  America s opioid epidemic  especially damaging in rural areas where Trump is popular  has been a focus for the Republican president  On Tuesday  the government charged drug distributor Rochester Drug Co operative Inc and company executives for their role in fueling the epidemic  The company agreed to pay  20 million and enter a deferred prosecution agreement to resolve charges it turned a blind eye to thousands of suspicious orders for opioid pain killers   We are holding big Pharma accountable   Trump said at the Rx Drug Abuse and Heroin Summit in Atlanta   Deaths from opioid overdose in the United States jumped 17 percent in 2017 from a year earlier to more than 49 000 according to the Centers for Disease Control and Prevention  Deaths from potent synthetic opioids like fentanyl surged 45 percent in that time  according to the CDC  Hundreds of lawsuits by state and local governments accuse drugmakers such as Purdue Pharma of deceptively marketing opioids  and distributors such as AmerisourceBergen  NYSE ABC  Corp   Cardinal Health  Inc  NYSE CAH  and McKesson Corp  NYSE MCK  of ignoring that they were being diverted for improper uses  Trump said he convinced Chinese President Xi Jinping in a December meeting in Argentina to designate fentanyl as a controlled substance  China last month listed all fentanyl related substances as controlled narcotics after criticism from Trump  though its government blamed U S  culture for abuse of the drug and said the amount of fentanyl going from China into the United States was  extremely limited    Almost all fentanyl comes from China   Trump said on Wednesday   They are going to make it a major crime    Little has come of Trump s earlier calls for executing drug dealers  But the administration has taken some action to address the crisis on other fronts   Trump declared the opioid crisis a public health emergency in October 2017  Last week  U S  health officials said they will spend  350 million in four states to study ways to best deal with the opioid crisis on the local level  with a goal of reducing opioid related overdose deaths by 40 percent over three years in selected communities in those states  The Democratic National Committee said in a statement before Trump s remarks that his proposed Medicaid cuts and efforts to overturn the Affordable Care Act  popularly known as Obamacare  could make the opioid problem worse   
Trump has used the crisis to support his call for building a wall on the border with Mexico  saying it would help keep out heroin and other illegal drugs and curb the crisis ",2019-04-24,Reuters,https://www.investing.com/news/politics-news/after-drug-distributor-charged-trump-sets-speech-on-opioid-fight-1844187,1844187
102840,324355,ABC,Four Leading US Drug Companies Join Blockchain Project to Manage Chargebacks,news,"Pfizer  Inc   NYSE PFE  and other leading American pharmaceutical companies have joined a project to build a blockchain network for the health and pharmaceutical industry  according to a press release on May 2   
McKesson Corporation  NYSE MCK   AmerisourceBergen  NYSE ABC  Corporation  Premier Inc  and Pfizer Inc  have joined the MediLedger Project Contracting and Chargebacks working group ",2019-05-03,Cointelegraph,https://www.investing.com/news/cryptocurrency-news/four-leading-us-drug-companies-join-blockchain-project-to-manage-chargebacks-1856390,1856390
102841,324356,ABC,Five more U S  states sue OxyContin maker Purdue Pharma over opioid epidemic,news,"By Jonathan Stempel  Reuters    Five U S  states on Thursday filed lawsuits accusing Purdue Pharma LP of illegally marketing and selling opioids  escalating the wave of litigation over a nationwide abuse epidemic  Iowa  Kansas  Maryland  West Virginia and Wisconsin joined 39 states to file lawsuits targeting Purdue Pharma and its leaders  including former president Richard Sackler and his family  Officials accused Purdue Pharma of repeatedly making false and deceptive claims that opioids  including OxyContin  were safe for a wide range of patients seeking to reduce pain   This is a bipartisan effort   Iowa Attorney General Tom Miller  a Democrat  said on a conference call  The lawsuits were announced six days after a North Dakota judge dismissed that state s lawsuit accusing Purdue Pharma of overstating the benefits and trivializing the addiction risks of prolonged opioid use  North Dakota is expected to appeal  Purdue Pharma called the new lawsuits  misleading attacks   and said it will defend itself against them   These complaints are part of a continuing effort to try these cases in the court of public opinion rather than the justice system   the Stamford  Connecticut based company said  Opioids  including prescription painkillers and heroin  played a role in a record 47 600 U S  overdose deaths in 2017  the U S  Centers for Disease Control and Prevention has said  State and local governments have filed hundreds of lawsuits accusing drugmakers such as Purdue Pharma of deceptive marketing  and distributors such as AmerisourceBergen  NYSE ABC  Corp   Cardinal Health  Inc  NYSE CAH  and McKesson Corp  NYSE MCK  of ignoring how opioids were being used illegally  Oklahoma reached a  270 million settlement with Purdue Pharma and the Sacklers on March 26  The prospect that Purdue Pharma might eventually seek bankruptcy protection is a reason that Sackler family members have been named as defendants in some lawsuits  On the conference call  Maryland Attorney General Brian Frosh said the family has  left a trail of addiction and death   In the North Dakota case  Bismarck based Judge James Hill rejected the state s argument that Purdue Pharma s conduct created a public nuisance   Purdue cannot control how doctors prescribe its products and it certainly cannot control how individual patients use and respond to its products  regardless of any warning or instruction Purdue may give   Hill wrote  The Sacklers have long been prolific cultural benefactors  but their alleged role in the opioid crisis has led some major museums to distance themselves  
On Wednesday  New York s Metropolitan Museum of Art  whose Sackler Wing contains the popular Temple of Dendur  said it would stop accepting donations from the Sacklers ",2019-05-16,Reuters,https://www.investing.com/news/stock-market-news/five-us-states-sue-purdue-pharma-over-opioids-1870515,1870515
102842,324357,ABC,U S  Drug distributors propose  10 billion to end state lawsuits over opioids  Bloomberg,news," Reuters    Drug wholesalers AmerisourceBergen Corp  N ABC   McKesson Corp  N MCK  and  Cardinal Health  Inc  N CAH  have proposed a  10 billion settlement for claims that they played a part in the U S  opioid epidemic  Bloomberg reported on Tuesday  citing people familiar with negotiations 
Hundreds of lawsuits by states and cities have been filed nationally accusing drugmakers of deceptively marketing opioids and distributors such as AmerisourceBergen Corp  Cardinal Health Inc and McKesson Corp of ignoring suspicious orders 
Shares of AmerisourceBergen  McKesson and Cardinal Health were down about 5  
The National Association of Attorneys General  negotiating on behalf of more than 35 states  countered with a demand for  45 billion to cover costs  according to the Bloomberg report 
 We regularly engage with the state attorneys general  but the company has made no settlement offers   McKesson said in a statement 
Cardinal Health and AmerisourceBergen did not immediately respond to Reuters  request for comment ",2019-08-06,Reuters,https://www.investing.com/news/stock-market-news/us-drug-distributors-propose-10-billion-to-end-state-lawsuits-over-opioids-bloomberg-1946828,1946828
102843,324358,ABC,Drugmakers Endo  Allergan agree to  15 million in settlements in major opioid case,news,"By Nate Raymond  Reuters    Endo International Plc  O ENDP  and Allergan Plc  N AGN  have agreed to pay  15 million to avoid going to trial in October in a landmark case by two Ohio counties accusing various drug manufacturers and distributors of fueling the U S  opioid epidemic  The tentative deals disclosed on Tuesday came ahead of the first trial to result from 2 000 lawsuits pending in federal court in Cleveland largely by local governments seeking to hold drug companies responsible for the deadly epidemic  Endo announced said it had reached an agreement in principle to pay Cuyahoga and Summit counties  10 million to and provide them up to  1 million worth of two of its of its drug products free of charge  Allergan has tentatively agreed to pay  5 million to resolve claims involving its branded opioids  though the deal does not resolve claims involving generic painkillers  said Frank Gallucci  a lawyer for Cuyahoga County  Allergan did not respond to requests for comment  The accords are the first to result from the counties  cases  which were selected for the first bellwether  or test  trial in the litigation to allow parties to gauge the value of the remaining claims and inform potential settlement talks  Other companies still set to face trial on Oct  21 include drugmakers Purdue Pharma LP  Teva Pharmaceutical  NYSE TEVA  Industries Ltd  TA TEVA  and Johnson   Johnson  N JNJ  and drug distributors McKesson Corp  N MCK    Cardinal Health  Inc  N CAH  and AmerisourceBergen Corp  N ABC   Endo s chief legal officer  Matthew Maletta  called the settlement a  favorable outcome  and stressed its value should not be extrapolated to any other opioid related cases  Endo  which in 2017 withdrew its painkiller Opana ER from the market  said the settlement includes no admission of wrongdoing  Opioids were involved in 400 000 overdose deaths from 1999 to 2017  according to the U S  Centers for Disease Control and Prevention  More than 2 300 lawsuits by state and local governments are pending nationally  accusing drug manufacturers of deceptively marketing opioids in ways that downplayed their risks and drug distributors of failing to detect and halt suspicious orders  The companies deny wrongdoing  saying they complied with their legal obligations and did not cause the epidemic  Most of the lawsuits are before U S  District Judge Dan Polster in Cleveland  who has pushed for a settlement and will preside over the bellwether trial  Purdue and Teva this year settled claims by Oklahoma s attorney general for  270 million and  85 million  respectively  ahead of a trial before a state court judge  
The state subsequently took J J to trial  A ruling is expected next week ",2019-08-20,Reuters,https://www.investing.com/news/stock-market-news/drugmaker-endo-to-pay-10-million-to-settle-opioid-lawsuit-1959252,1959252
102844,324359,ABC,Purdue Pharma in discussion on  10 billion  12 billion offer to settle opioid lawsuits  sources,news,"By Mike Spector and Jessica DiNapoli
 Reuters    OxyContin maker Purdue Pharma LP and its owners  the Sackler family  are in discussion to settle more than 2 000 opioid lawsuits against the company for  10 billion to  12 billion  two people familiar with the matter said on Tuesday 
Purdue is among several drugmakers and distributors that have been sued for fueling an opioid addiction crisis in the United States  which claimed 400 000 lives from 1999 to 2017  according to the U S  Centers for Disease Control and Prevention 
The lawsuits have accused the Stamford  Connecticut based Purdue Pharma of aggressively marketing prescription opioids while misleading prescribers and consumers about risks from their prolonged use  Purdue and the Sacklers have denied the allegations 
Purdue said it was actively working with state attorneys general and other plaintiffs to reach a resolution  without specifying a settlement amount 
There is currently no agreement and the settlement discussions could collapse  the sources said 
Representatives for Purdue and the Sackler family held discussions with cities  counties and states on the contours of the potential multibillion dollar settlement last week in Cleveland  said a person familiar with the matter 
During the meeting  Purdue outlined a plan to file for Chapter 11 bankruptcy protection as a mechanism for implementing the settlement  which the company hopes will address the lawsuits  the person said 
The Sacklers would cede control of Purdue under the settlement terms discussed last week  the person said 
All the parties face a Friday deadline to update a federal judge on the status of the negotiations  the person said 
The company has said the U S  Food and Drug Administration approved labels for OxyContin that warned about risk and abuse associated with treating pain  The Sacklers have argued they were passive board members who approved routine management requests rather than micromanaging the marketing of OxyContin 
RESTRUCTURING
The settlement offer was first reported by NBC  Paul Hanly  a lead attorney for the plaintiffs  in an email  replied only  Made up  Ridiculous   when asked to confirm NBC s report  Asked to clarify after Reuters confirmed the report  he did not respond 
Representatives for the Sackler family declined to comment and a representative for the state attorneys general did not immediately respond to a request for comment 
The plan under discussion envisions Purdue restructuring into a for profit  public benefit trust  that would last for at least a decade  one of the people familiar with the matter said 
Purdue would contribute between  7 billion and  8 billion to the trust  with some of the money coming from the sales of its drugs  including those that combat opioid overdoses  the person said  Additional payments would come from the company s cash and insurance policies  the person said  Three experts would be approved by a bankruptcy judge as trustees who would select board members to run the trust  this person said 
The Sackler family  which has amassed an estimated  13 billion fortune over the years  is also weighing a possible sale of another pharmaceutical firm it owns called Mundipharma  with some of the proceeds potentially going toward the settlement under discussion  the person said  The settlement terms contemplate the Sacklers initially contributing  3 billion 
David Sackler  one of a handful of family members who previously sat on Purdue s board  has taken on a significant role in the recent discussions  which included at least 10 state attorneys general  the person said 
Purdue is set on Oct  21  along with several other drug manufacturers and distributors  to face the first trial to result from federal court proceedings that have consolidated around 2 000 lawsuits brought largely by local governments accusing the companies of fueling the epidemic 
Other companies set to face trial include drugmakers Teva Pharmaceutical Industries  NYSE TEVA  Ltd and Johnson   Johnson and drug distributors McKesson Corp  NYSE MCK    Cardinal Health  Inc  NYSE CAH  and AmerisourceBergen  NYSE ABC  Corp 
U S  District Judge Dan Polster in Cleveland  Ohio  who oversees the lawsuits  has been pushing for settlements that could  do something meaningful to abate this crisis  
Purdue  the Sacklers and the communities involved face high stakes negotiations and Purdue has been preparing for filing for bankruptcy protection in case it cannot reach an agreement 
Going into Chapter 11 would give Purdue the exclusive right for several months to propose a reorganization plan  which if approved by a U S  bankruptcy judge could be forced on any local governments that decide to hold out 
Some state attorneys general have said they will resist any attempt by Purdue to use bankruptcy 
New York Attorney General Letitia James subpoenaed Wall Street banks  Purdue corporate entities and family offices in mid August for records related to the Sackler family s finances  according to court records 
In a letter to a judge and an earlier lawsuit  her office characterized payouts to the Sacklers from Purdue as fraudulent conveyances  a legal designation for clawing back money during bankruptcy proceedings 
 The opioid epidemic has ravaged American communities for over a decade  while a single family has made billions profiting from death and destruction   James said in a statement   We won t let up until we have delivered justice  




A lawyer representing the Sackler family said in a statement that the New York attorney general s  current claims are without merit and the subpoenas are improper  ",2019-08-28,Reuters,https://www.investing.com/news/economy/opioid-drugmaker-purdue-pharma-offers-1012-billion-to-settle-opioid-claims-nbc-news-1964691,1964691
102845,324360,ABC,U S  judge says opioid litigation can proceed toward trial,news,"By Jonathan Stempel
 Reuters    A U S  judge on Tuesday rejected efforts by drugmakers  distributors and pharmacies to dismiss claims that they caused the nation s opioid crisis  clearing the way for a scheduled landmark trial even as he pushes for a nationwide settlement 
U S  District Judge Dan Polster  who oversees roughly 2 000 opioid lawsuits by state and local governments  said the plaintiffs could try to prove that drugmakers  deceptive marketing of the painkillers caused a harmful  massive increase in supply that distributors and pharmacies did not do enough to stop 
 A factfinder could reasonably infer that these failures were a substantial factor in producing the alleged harm suffered by plaintiffs   the Cleveland based judge wrote 
The ruling was among seven decisions and orders totaling 80 pages issued by Polster ahead of a scheduled Oct  21 trial by two Ohio counties against Purdue Pharma  the OxyContin maker accused of fueling the epidemic  and several other defendants 
Polster also refused to dismiss civil conspiracy claims against the drugmakers  distributors and pharmacies  and said federal law did not preempt a variety of the plaintiffs  claims 
Opioid addiction claimed roughly 400 000 lives in the United States from 1999 to 2017  according to the U S  Centers for Disease Control and Prevention  Critics of the industry said opioid makers hid the addiction and abuse risks of prolonged use from consumers 
Defendants in the litigation also include the drugmaker Endo International Plc  pharmacy operators CVS Health Corp  NYSE CVS   Rite Aid Corp  Walgreens Boots Alliance  NASDAQ WBA  Inc and Walmart  NYSE WMT  Inc  and major distributors AmerisourceBergen  NYSE ABC  Corp   Cardinal Health  Inc  NYSE CAH  and McKesson Corp  NYSE MCK   among others 
Polster also rejected separate dismissal requests by the generic drugmakers Teva Pharmaceutical Industries  NYSE TEVA  Ltd and Allergan  NYSE AGN  Plc 
Lawyers for the respective defendants did not immediately respond to requests for comment or declined to comment 
Paul Hanly  a lawyer for the counties  said the plaintiffs were pleased that Polster  almost uniformly  agreed with their positions on the dismissal motions and whether various testimony should be admitted 
Purdue Pharma and its owners  the Sackler family  have been in talks on a possible  10 billion to  12 billion nationwide settlement of opioid claims  two people familiar with the matter said last week 
That accord could include a bankruptcy filing for the Stamford  Connecticut based company  Purdue and the Sacklers have denied the allegations 
The case is In re National Prescription Opiate Litigation  U S  District Court  Northern District of Ohio  No  17 md 02804 ",2019-09-03,Reuters,https://www.investing.com/news/world-news/us-judge-says-opioid-litigation-can-proceed-toward-trial-1969244,1969244
102855,324370,ABC,What s In The Cards For Centene s  CNC  Earnings In Q3 ,opinion,Centene Corporation   NYSE CNC   will release third quarter 2019 results on Oct 22  before the market opens The Zacks Consensus Estimate for the to be reported quarter s earnings is pegged at 95 cents  suggesting a 5 6  rise from the year ago reported figure In the last reported quarter  the company delivered adjusted earnings per share of  1 34  beating the Zacks Consensus Estimate by 8 1   Also  the bottom line improved 48 9  year over year on the back of higher revenues   Let s see how things are shaping up prior to the announcement Earnings Catalysts for Q3The Government and Medicaid businesses are most likely to have continued performing well in the third quarter of 2019 The company is expected to have witnessed membership growth  in the to be reported quarter  on the back of new contracts  leading to an enhanced top line  The consensus mark for total membership implies an increase of 2 2  from the year ago count   Centene s marketplace business is also expected to have provided cushion to its revenues  The Zacks Consensus Estimate for third quarter revenues stands at  18 3 billion  indicating a nearly 13 5  improvement from the prior year reported number New contracts and increased membership might have led to surge in premiums as well  The Zacks Consensus Estimate for third quarter premiums hints at an uptick of 13 3  from the year earlier reported figure Moreover  expenses are expected to have reduced in the to be reported quarter owing to the company s operating initiatives  The Zacks Consensus Estimate for third quarter general and administrative expense ratio is pegged at 9 49   denoting a decline from the year ago reported figure of 12 60  Further  Centene is likely to have witnessed a steady cashflow in the third quarter of 2019 However  long term debt might have persistently dented the margins in the to be reported quarter  Additionally  interest expenses of the company are likely to have escalated at a constant pace Key Developments in Q3Centene and WellCare announced that the pending buyout of WellCare Health won approval from the insurance departments of 17 states  The merger is estimated to be completed in the first half of 2020  The combined entity will have a wider scale and diversification with more than 12 million Medicaid and around 5 million Medicare members The company also announced that it will expand its offering in the 2020 Health Insurance Marketplace or exchange  It is enhancing its existence across 10 markets  namely Arizona  Florida  Georgia  Kansas  North Carolina  Ohio  South Carolina  Tennessee  Texas and Washington What the Quantitative Model StatesOur proven model does not conclusively predict an earnings beat for Centene this season  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  But that s not the case here  You can uncover the best stocks to buy or sell before they re reported with our  Earnings ESP  Centene has an Earnings ESP of  1 12   This is because the Most Accurate Estimate is pegged at 94 cents  lower than the Zacks Consensus Estimate of 95 cents   You can see Centene Corporation Price and Consensus   Zacks Rank  Centene carries a Zacks Rank  3  which increases the predictive power of ESP  However  the company s negative ESP leaves surprise prediction difficult for the stock this time around Stocks to ConsiderSome stocks worth considering from the medical sector with the perfect mix of elements to surpass estimates in the next releases are as follows Mednax  Inc   NYSE MD   is set to report third quarter earnings on Nov 7  The stock has a Zacks Rank of 3 and an Earnings ESP of  1 10  AmerisourceBergen Corporation   NYSE ABC   is slated to announce third quarter earnings on Nov 7  The stock has an Earnings ESP of  0 55  and is Zacks  3 Ranked Molina Healthcare  Inc   NYSE MOH   is set to report third quarter earnings on Oct 29  The stock has a Zacks Rank of 1 and an Earnings ESP of  0 92  7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 50  per year  So be sure to give these hand picked 7 your immediate attention ,2019-10-17,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-cards-for-centenes-cnc-earnings-in-q3-200474395,200474395
102856,324371,ABC,Centene s  CNC  Q3 Earnings And Revenues Beat Estimates,opinion,Centene Inc    NYSE CNC   delivered third quarter 2019 adjusted earnings per share of 96 cents  beating the Zacks Consensus Estimate by 1 1   Also  the bottom line improved 5 6  year over year on the back of higher revenues In the third quarter  total revenues rose 17  to  19 billion from the year ago period  primarily aided by the Health Insurance Marketplace business  expansions and new programs across many states in 2018 as well as 2019  Moreover  the top line surpassed the Zacks Consensus Estimate by nearly 3 3   However  this upside was offset by the health insurer fee moratorium to some extent Quarterly Operational UpdateAs of Sep 30  2019  managed care membership came in at 15 3 million  up 6  year over year Health Benefit Ratio  HBR  for the reported quarter was 88 2  compared with 86 3  in the prior year period Adjusted Selling  General   Administrative  SG A  expense ratio was 8 8  for the third quarter of 2019 compared with 10  for the same period last year Centene Corporation Price  Consensus and EPS Surprise   Financial UpdateAs of Sep 30  2019  the company s cash and cash equivalents totaled  6 2 billion  up 16 3  from the figure at 2018 end As of Sep 30  2019  total assets were up 10 8  from the level as of Dec 31  2018 Centene s long term debt summed  6 9 billion  up 4 9  from 2018 end level For the first nine months of 2019  cash outflow from operations was  2 1 billion  up 14 2  year over year 2019 Outlook RetainedFollowing solid third quarter results  the company has reiterated its 2019 guidance It expects revenues in the range of  73 6  74 2 billion  same as the earlier projection Adjusted EPS is still expected in the band of  4 29  4 49 HBR is predicted within 86 6 87 1  Adjusted SG   A expense ratio is maintained between 9 1  and 9 6  HighlightsCentene s pending buyout of WellCare won approval from the insurance departments of 17 states  Nods came from the regions  namely Alabama  Arkansas  Florida  Kansas  Kentucky  Maine  Michigan  Mississippi  Missouri  Nebraska  New Hampshire  North Carolina  Oklahoma  South Carolina  Tennessee  Vermont and Washington Centene and WellCare announced that the latter s subsidiary will be selling its Missouri and Nebraska Medicaid plans to Anthem  NYSE ANTM   Inc  However  this sale is subject to certain closing conditions  The strategic move is related to the  17 billion worth pending merger of Centene with WellCare  which is expected to be completed in the first half of 2020 Centene announced the expansion of its offering in the 2020 Health Insurance Marketplace or exchange  It is extending its existence across 10 markets that are Arizona  Florida  Georgia  Kansas  North Carolina  Ohio  South Carolina  Tennessee  Texas and Washington Zacks RankCentene carries a Zacks Rank  4  Sell  You can seeUpcoming Releases From Medical SectorSome better ranked stocks from the medical sector are as follows Molina Healthcare  Inc   NYSE MOH   is set to report third quarter 2019 earnings performance on Oct 29  The stock has a Zacks Rank  1 and an Earnings ESP of  0 92  MEDNAX  Inc   NYSE MD   is set to report third quarter 2019 earnings on Nov 1  The stock has an Earnings ESP of  1 10  and a Zacks Rank  3  Hold  AmerisourceBergen Corporation   NYSE ABC   has an Earnings ESP of  0 55  and a Zacks Rank of 3  The company is set to report third quarter earnings on Nov 7 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 50  per year  So be sure to give these hand picked 7 your immediate attention ,2019-10-21,Zacks Investment Research,https://www.investing.com/analysis/centenes-cnc-q3-earnings-and-revenues-beat-estimates-200476246,200476246
102857,324372,ABC,Can Global Industrial Unit Drive Ecolab s  ECL  Q3 Earnings ,opinion,"Ecolab Inc    NYSE ECL   is scheduled to report third quarter 2019 results on Oct 29  before market opens  The company s core Global Industrial unit is expected to have contributed significantly in the quarter despite foreign exchange headwinds Ecolab delivered a positive earnings surprise of 0 7  in the last reported quarter  the average of the trailing four quarters being a positive 0 1  Which Way Are Q3 Estimates Treading For the to be reported quarter  the Zacks Consensus Estimate for revenues is pegged at  3 89 billion  suggesting an improvement of 3 7  from a year ago  The same for earnings is at  1 72  indicating an increase of 12 4  Let s delve deeper Ecolab Inc  Price and EPS Surprise
    Global Industrial Likely to Drive Q3The Global Industrial segment has likely gained from the Water  Food   Beverage and Life Sciences sub units in the third quarter  Not to forget  the segment accounted for 36 7  of net sales in the last reported quarter It is encouraging to note that positive developments are expected to have boosted the Global Industrial arm For instance  Ecolab s subsidiary Nalco Water has unveiled LegionGuard LG25  which is designed to lower the waterborne pathogen Legionella pneumophila in drinking water systems Additionally  Nalco opened a customer experience center at its production plant to demonstrate the company s technologies  This is expected to have broadened Ecolab s customer base Reflective of these  the Zacks Consensus Estimate for the segment s third quarter earnings is pegged at  1 46 billion  suggesting a year over year increase of 3 6  Other Factors at WorkThe company s Global Institutional unit is also expected to have seen a solid quarter The consensus for revenues is pinned at  1 37 billion  indicating a rise of 1 9  from the year ago quarter Coming to the Global Energy unit  the Zacks Consensus Estimate for third quarter revenues stands at  890 million  remaining flat on a year over year basis Notably  lucrative acquisitions in the Global Institutional arm are expected to have driven performance in the quarter to be reported  Management is optimistic about the Chemstar Corporation buyout  which is expected to have boosted the company s Food   Beverage unit That s not all  Ecolab has expanded its offerings in the healthcare information technology space  The company has added digital dashboards  which will provide greater visibility  measurement and analysis of current practices  including predictive analytics to help forecast and reduce infection rates  This is expected to have driven Ecolab s Healthcare business Reflective of these  Ecolab expects its third quarter earnings per share within  1 65  1 75  indicating a year over year improvement of 8 14  Adjusted gross margin is expected to be 42 43  However  management at Ecolab expects foreign currency translation to have an unfavorable impact of 11 cents on the third quarter 2019 earnings results Earnings WhispersPer our proven model  a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise  This is not the case here as you will see below Earnings ESP  Ecolab has an Earnings ESP of 0 00   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Ecolab carries a Zacks Rank  3   You can see  Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter Edward Lifesciences Corporation   NYSE EW   has an Earnings ESP of  0 35  and a Zacks Rank  3 AmerisourceBergen Corporation   NYSE ABC   has an Earnings ESP of  0 55  and a Zacks Rank  3 Cardinal Health  Inc    NYSE CAH   has an Earnings ESP of  1 50  and a Zacks Rank  3 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2019-10-22,Zacks Investment Research,https://www.investing.com/analysis/can-global-industrial-unit-drive-ecolabs-ecl-q3-earnings-200476949,200476949
102858,324373,ABC,What s In The Offing For Stryker s  SYK  Earnings In Q3 ,opinion,Stryker Corporation   NYSE SYK   is scheduled to release third quarter 2019 results on Oct 29 after the closing bell  In the last reported quarter  the company delivered a positive earnings surprise of 2 6   Further  it has an average four quarter positive surprise of 1 7  Which Way Are Estimates Trending The Zacks Consensus Estimate for third quarter earnings per share is pegged at  1 91  indicating an improvement of 13  from the year ago quarter The same for revenues stands at  3 58 billion  suggesting growth of 10 5  from the prior year quarter Let s take a look at how things are shaping up prior to this announcement Stryker Corporation Price and EPS Surprise    MedSurg in FocusThis segment consists of surgical instruments plus endoscopic and emergency medical equipment  Notably  it has been consistently driving Stryker s top line  a trend that is likely to have continued in the third quarter Notably  the Zacks Consensus Estimate for the segment s revenues for the third quarter stands at  1 58 billion  up 9 6  year over year MedSurg has three subsegments   Endoscopy  Instruments and Medical Growth across its aforementioned three subsegments is likely to have benefited MedSurg s third quarter performance  The segment is anticipated to have witnessed considerable worldwide organic growth in the to be reported quarter on better than expected performance at instruments Other Factors at PlayThe company s third quarter performance is likely to reflect broad based strength across its divisions and regions  In fact  robust performance in emerging markets and Europe is expected to get reflected in the upcoming quarterly results  This is reflected in the third quarter earnings projection wherein the adjusted EPS is estimated between  1 87 and  1 92 per share  Further  sales growth at the high end of MedTech is likely to have contributed to the third quarter bottom line Further  the company s Orthopaedics segment is likely to have witnessed strong organic growth on the back of solid performance at the Knee sub segment  Moreover  sustained strong demand for Mako TKA  Total Knee Arthoplasty  platform or cementless knee and other 3D printed products is anticipated to get reflected in the segment s third quarter performance  For the quarter to be reported  the Zacks Consensus Estimate for this segment s sales is pegged at  1 24 billion  indicating a year over year improvement of 6 1  With respect to Neurotechnology   Spine segment  a bankable performance within the NeuroTech product lines and the K2M buyout is likely to have contributed to the company s third quarter performance  Moreover  sustained solid demand in Europe  China and Japan might have impacted segmental growth  internationally  For the upcoming quarterly announcement  the Zacks Consensus Estimate for the segment s sales stands at  758 million  suggesting year over year growth of 20 7  The company remains on track to achieve its full year target of 30 to 50 basis points operating margin expansion backed by the top line and continued progress in cost transformation growth initiatives  a trend is likely to have continued in the third quarter However  probable high debt and unfavorable pricing is likely to have affected Stryker s top line in the third quarter Here s What the Quantitative Model SuggestsPer our proven model  a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise  This is not the case here as you will see below  Earnings ESP  Stryker has an Earnings ESP of 0 00   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Stryker carries a Zacks Rank  2   Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter AmerisourceBergen Corporation   NYSE ABC   has an Earnings ESP of  0 55  and a Zacks Rank  3  You can see  Cardinal Health  Inc    NYSE CAH   has an Earnings ESP of  1 50  and a Zacks Rank  3 Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  0 87  and a Zacks Rank  3 Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-10-23,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-offing-for-strykers-syk-earnings-in-q3-200477571,200477571
102894,324409,ABC,MarketPulse  Healthcare Slips as Bristol Myers Squibb Sinks,news,"Investing com   Healthcare fell out of favor Monday  weighed down by a slump in shares of Bristol Myers Squibb and AmerisourceBergen 
Bristol Myers  NYSE BMY  shares fell nearly 6  after the U S  Food and Drug Administration extended the review period for the company s new cancer drug application by three months on the back of new data from the company s cancer clinical trial 
The FDA said it expected to reach an approval decision on the drug by or on May 20 
AmerisourceBergen  NYSE ABC  fell nearly 3  as the company came under legal scrutiny amid a probe into whether it had breached fiduciary duties to Amerisource and its shareholders 
Celgene  NASDAQ CELG  fell about 2  despite positive data from the Phase III study for its chemotherapy combination treatment for triple negative breast cancer patients 
The study  which tested the efficacy of the company s breast cancer treatment Abraxane in combination with Atezolizumab against Abraxane as a standalone treatment had  significantly reduced the risk of disease worsening or death   Celegene said 
The S P 500 health care sector  fell nearly 1  at time of print  paring some of its gains from last week  which had followed an increased demand for health care stocks as investors de risked their portfolios  reducing exposure to higher growth sectors like tech ",2018-10-22,Investing.com,https://www.investing.com/news/stock-market-news/marketpulse-healthcare-slips-as-bristolmyers-squibb-sinks-1654090,1654090
102895,324410,ABC,AG nominee Barr to back off previous attack on antifraud law  source,news,By Alison Frankel  Reuters    U S  President Donald Trump s attorney general nominee William Barr is expected to back away from prior criticism of an anti fraud law that allows private individuals to bring lawsuits on behalf of the government  a source familiar with the matter said on Wednesday  Barr will clarify his current thinking on the U S  False Claims Act  which he has previously called an unconstitutional  abomination   when he goes before the U S  Senate Judiciary Committee in a confirmation hearing in coming months  the source said  Barr did not immediately respond to a request for comment sent to his law firm email account  The law allows whistleblowers who expose fraud against the U S  government to bring private lawsuits and keep a percentage of any damages awarded  In October  for example  the Justice Department agreed to a  93 million bounty for three whistleblowers after drug wholesaler AmerisouceBergen Corp  N ABC  paid  625 million to resolve their allegations of Medicaid fraud  Business groups  including the U S  Chamber of Commerce  have criticized the False Claims Act  FCA  as primarily benefiting plaintiffs  lawyers and their clients instead of taxpayers   But the Justice Department has raked in nearly  60 billion in FCA settlements and judgments since the law was overhauled in 1986  including nearly  3 billion last year   The law also still enjoys the strong support of Iowa Republican and Senate Judiciary Chairman Chuck Grassley  who was an architect of 1986 amendments that increased the FCA s potency  In 1991  during Barr s previous confirmation hearing to serve as attorney general under President George H W  Bush  Grassley explicitly asked Barr to pledge support to the FCA s whistleblower provisions  As a high ranking Justice Department official in the Bush administration  Barr had authored a 1989 memorandum that concluded the law s whistleblower provisions violated the separation of powers doctrine and other constitutional requirements  Barr later said in a 2001 interview for an oral history of the Bush presidency that he wanted the Justice Department to attack the constitutionality of the law but was opposed by then Solicitor General Kenneth Starr  The U S  Supreme Court ruled unanimously in 2000 that private whistleblowers can sue on behalf of the U S  government  Barr has recently told others that his prior comments are outdated  according to the source  Barr believes DOJ s current handling of FCA cases protects federal interests and no longer thinks a constitutional challenge is warranted  the source said  Grassley is expected to cede chairmanship of the Judiciary Committee to Lindsey Graham  a Republican from South Carolina  before Barr s confirmation hearing  He hailed President Trump s nomination of Barr in a statement last month  Grassley s spokesman did not respond to a request for comment ,2019-01-02,Reuters,https://www.investing.com/news/world-news/ag-nominee-barr-to-back-off-previous-attack-on-antifraud-law-source-1735605,1735605
102896,324411,ABC,Top Picks 2019  Cardinal Health CAH,news,"Cardinal Health   NYSE CAH  is one of 3 large pharmaceutical distributors in the United States that together account for more than 90  of the pharmaceutical distribution market share  explains Ben Reynolds  income expert and editor of Sure Dividend 
What makes Cardinal Health stand apart from its competitors AmerisourceBergen  NYSE ABC  and McKesson  MCK  is its extraordinary dividend history  Cardinal Health is a Dividend Aristocrat   an S P 500 stock with 25  years of rising dividends   thanks to its 32 consecutive years of dividend increases 
While Cardinal Health has a long history of growth as shown by its excellent dividend history  the company has struggled in recent years along with the entire pharmaceutical distribution industry  Cardinal Health generated earnings per share of  5 24 in fiscal 2016  versus  5 00 in fiscal 2018  The company expects earnings per share to barely grow in fiscal 2019 
Weakness in the pharmaceutical industry is a result largely of declining margins   Margins are declining due to several reasons 
  Pricing pressure from competitors
  Social and political pressure from distributor s role in the opioid epidemic
  Hints that Amazon  NASDAQ AMZN  could enter the industry
All of these factors have weighed on margins and the stock prices of pharmaceutical distributors  But with pessimism comes low valuations   and opportunity 
Cardinal Health appears deeply undervalued  The company s stock price reached a high of over  90 back in 2015   It traded under  50 in December of 2018  while earnings per share are 14  higher in fiscal 2018 versus fiscal 2015   
Cardinal Health s management has taken advantage of low share prices by engaging in significant share repurchases  The company reduced its share count by 2 5  in fiscal 2018   And the rate of share repurchases has increased since 
We don t expect Cardinal Health to return to the double digit earnings per share growth rates that it has generated in the past  But we do expect earnings per share growth to stabilize after fiscal 2019 and return to growth of around 5  annually driven by a combination of share repurchases and organic growth 
This growth combined with the company s high dividend yield of around 4  gives investors expected total returns of approximately 9  annually at Cardinal Health before valuation multiple gains 
With Cardinal Health being deeply undervalued  we expect significantly higher returns for shareholders when the current negative environment for pharmaceutical distributors improves   In the meantime  investors will benefit from Cardinal Health s high dividend and share repurchases 
Subscribe to Ben Reynolds  Sure Dividend here ",2019-01-15,Money Show,https://www.investing.com/news/stock-market-news/top-picks-2019-cardinal-health-cah-1747125,1747125
102897,324412,ABC,Exclusive  Teva s generic EpiPen launch stalls months after approval,news,"By Michael Erman and Jilian Mincer NEW YORK  Reuters    Many of the largest U S  pharmacies and drug distributors do not have Teva Pharmaceutical Industries  NYSE TEVA  Ltd s generic version of the life saving EpiPen allergy treatment five months after it was approved for sale in the United States  pharmacy chains and a group that tracks drug shortages told Reuters  The short supply represents a missed opportunity for Teva to compete with Mylan  NASDAQ MYL  NV in a roughly  750 million a year U S  market  Mylan s EpiPen dominates that market  but has been in short supply since May  leaving many patients and their families keen for alternatives   The generic version of EpiPen Auto Injector is currently available and we are continuing to build supply   Teva said in an emailed statement   We are actively manufacturing and shipping product throughout the country   The company did not say why its drug was in short supply  Israel based Teva  the world s largest generic drugmaker  received U S  approval for its version of EpiPen in August after several years of delay  At the time  the company pledged its  full resources to this important launch in the coming months   The U S  Food and Drug Administration hailed the product as a lower cost option for patients who depend on access to the EpiPen and similar handheld devices that make it easier to deliver epinephrine in the case of a severe allergic reaction  such as to bee stings or exposure to peanuts  Mylan s EpiPen has been in short supply due to manufacturing problems at the lone  Pfizer  Inc  NYSE PFE  plant that makes the auto injectors   We are continuing to get panicked phone calls from parents because they can t get epinephrine for their kids   said Kim Mudd  nurse manager of Johns Hopkins University s pediatric allergy unit  In late November  Teva said its generic EpiPen for adults was available in limited supply in the United States and promised that more of the product  as well as a version for children  would be available in 2019  Reuters checks in late January suggest that even the available supply has dwindled   We get reports from pharmacies and we ve been able to confirm with the suppliers that they are on back order   said Erin Fox  a professor at the University of Utah  Fox maintains an independent drug shortages list for the American Society of Health System Pharmacists  ASHP   and added the Teva version of EpiPen to the roster this week  The device also appears on the FDA list of drugs in shortage  CVS Health Corp  NYSE CVS  said it had received limited supplies of the Teva device late last year  but does not currently have any in stock  Walmart  NYSE WMT  Inc is not currently carrying Teva s EpiPen in its pharmacies  according to a source familiar with the matter   Fox said pharmacies are also currently unable to order the devices through major distributors  Cardinal Health  Inc  NYSE CAH  or AmerisourceBergen  NYSE ABC  Corp  An AmerisourceBergen spokeswoman declined to comment and Cardinal Health did not immediately respond to a request for comment  Walgreens said it currently has limited supply of certain generic epinephrine products  including Teva s  in some of its pharmacies  Cigna  NYSE CI  Corp s Express Scripts  NASDAQ ESRX  unit said it has limited supply of the Teva devices in its home delivery pharmacy   POTENTIAL PROFIT BOOSTER  Wall Street has viewed the EpiPen rival as a welcome profit booster for Teva as it contends with sharply declining U S  margins for its older generic medicines and a series of costly acquisitions  The drugmaker has fired thousands of employees and worked to reduce its debt  When the device s approval was announced last year  Teva s U S  listed shares jumped about 6 percent  Wall Street analysts suggested then that it could add  250 million to Teva s revenue annually  and account for an additional 4 cents to 6 cents per share in earnings   Analysts  on average  expect the company to post earnings per share of  2 80 in 2019  according to IBES data from Refinitiv  Teva s devices represented only 3 percent of the EpiPen market for the week of Jan  18  according to a research note from Leerink citing IQVIA data on prescription volume  That is down from 7 percent a month earlier and compares with roughly the 64 percent market share held by Mylan s branded and authorized generic EpiPens   Lisa Gable  chief executive of patient advocacy group Food Allergy Research   Education  had hoped Teva s approval would help alleviate the shortage of EpiPen devices  particularly as families look to renew prescriptions ahead of summer camp or the new school year  
     The community has been affected by shortages because of a relatively small supplier base   Gable said ",2019-01-31,Reuters,https://www.investing.com/news/stock-market-news/exclusive-tevas-generic-epipen-launch-stalls-months-after-approval-1765263,1765263
102898,324413,ABC,N Y  accuses opioid maker Purdue of illegal fund transfers to Sacklers,news,"By Nate Raymond  Reuters    Purdue Pharma LP fraudulently transferred funds to members of the wealthy Sackler family who control the OxyContin maker despite knowing it faced major liabilities that had made it already insolvent  New York s attorney general alleged on Thursday  New York Attorney General Letitia James made the claims in a revised lawsuit already pending against Purdue over its role in the opioid epidemic that added members of the Sackler family and other drug manufacturers and distributors as defendants  The lawsuit alleged Purdue and other manufacturers engaged in deceptive marketing that downplayed the dangers of the addictive painkillers and accused distributors of failing to detect the diversion of the drugs for illicit purposes   As the Sackler family and the other defendants grew richer  New Yorkers  health grew poorer and our state was left to foot the bill   James said in a statement  The revised lawsuit also added as defendants units of opioid manufacturers Johnson   Johnson  NYSE JNJ   Endo International Plc  Teva Pharmaceutical Industries  NYSE TEVA  Ltd and distributors McKesson Corp  NYSE MCK    Cardinal Health  Inc  NYSE CAH  and AmerisourceBergen  NYSE ABC  Corp  In a statement  the Sackler family called the lawsuit  a misguided attempt to place blame where it does not belong for a complex public health crisis   Representatives for the other defendants did not respond to requests for comment  The case is among roughly 2 000 lawsuits filed by state and local governments seeking to hold Purdue and other pharmaceutical companies responsible for the U S  opioid crisis  Opioids were involved in a record 47 600 overdose deaths in 2017 in the United States  according to the U S  Centers for Disease Control and Prevention  The complaint came after Purdue and the Sacklers on Tuesday reached a  270 million settlement with Oklahoma resolving similar allegations  Purdue had been exploring filing for bankruptcy prior the accord s announcement  In her lawsuit  James accused Purdue of seeking to  intimidate  states pursuing lawsuits against it by threatening bankruptcy  which would hinder their cases and limit their ability to recover damages  Yet James said Purdue  which is fighting lawsuits by 34 other states and hundreds of localities  has continued in the face of its liabilities to pay millions of dollars to the Sacklers  The lawsuit argued Purdue was either insolvent or near insolvency when it transferred those funds  making the transfers illegal under New York law  
The payments meant Purdue  which had average annual sales of  3 billion  no longer had assets that could satisfy the state s claims  the lawsuit said ",2019-03-28,Reuters,https://www.investing.com/news/stock-market-news/ny-accuses-opioid-maker-purdue-of-illegal-fund-transfers-to-sacklers-1821139,1821139
102899,324414,ABC,Stocks   Dow Downed by Walgreens  Slump in Energy,news,"Investing com   The Dow closed lower Tuesday  struggling to shake off a slump in Walgreen Boots Alliance and weakness in energy stocks 
The Dow Jones Industrial Average fell 0 30   The S P 500 closed flat  while the Nasdaq Composite gained 0 25  
Wall Street was unable to replicate its swashbuckling gains from a day earlier as Walgreens   NASDAQ WBA  earnings miss and dour guidance served as a reminder that corporate profit growth may face headwinds in the quarters to come  The shares fell 12 8  
Analysts are projecting a 3 9  earnings decline for S P 500 companies in the first quarter  the first year on year decline since the second quarter of 2016  according to FactSet 
Falling energy stocks also kept traders on the sidelines  even as oil prices continued to add to gains amid expectations petroleum data due Wednesday will show a draw in U S  crude supplies 
But airline stocks offered investors some reprieve amid a surge in Delta Air Lines  NYSE DAL  of about 6 1  after the carrier lifted its earnings guidance for the first quarter amid  healthy  demand 
United Continental  NASDAQ UAL  was up 2 4   and  American Airlines Group   NASDAQ AAL  gained 2  
The communications services sector  which houses the bulk of the FANG stocks  also supported the broader market thanks to a 3 3  rally in shares of Facebook  NASDAQ FB  amid an upbeat assessment from  Deutsche Bank   DE DBKGn  
 We think a more streamlined E Commerce experience on Instagram could add an incremental  10  billion  of revenue in 2021  and we see  Checkout with Instagram  as a key step towards unlocking this opportunity   Deutsche Bank analyst Lloyd Walmsley wrote in a note to investors on Monday 
Chip stocks were also in favor  helping drive gains in broader tech  led higher by gains for  Western Digital   NASDAQ WDC   up 2 2    Advanced Micro Devices  NASDAQ AMD   up 1 5   and Texas Instruments  NASDAQ TXN   up 1 5   
In other company news  DowDuPont s spinoff   Dow Chemical   NYSE DOW   made its trading debut on the NYSE today  ending the day more than 5  higher  Dow s emergence from DowDuPont marked the first of a trio of splits into three new companies focusing on commodities  agriculture and specialty products  Dow Chemical  which replaced DowDuPont in the Dow Jones Industrial Average  trades under the ticker DOW 
Corteva  the agriculture unit  is set to separate from the new specialty chemical maker DuPont  NYSE DWDP  on June 1 
On the economic front  The Commerce Department said core durable goods orders rose 0 1  in February  missing economists  forecasts for a 0 3  rise  The non defense capital goods orders  excluding aircraft  a closely watched proxy for business spending plans  fell 0 1  in February 
Top S P 500 Gainers and Losers Today 
Delta Air Lines  NYSE DAL   Wynn Resorts  NASDAQ WYNN  and Facebook  NASDAQ FB  were among the top S P 500 gainers for the session 
Walgreens Boots Alliance  NASDAQ WBA   AmerisourceBergen  NYSE ABC  and  Cardinal Health   NYSE CAH  were among the worst S P 500 performers of the session ",2019-04-02,Investing.com,https://www.investing.com/news/stock-market-news/stocks--dow-downed-by-walgreens-slump-in-energy-1825482,1825482
102908,324423,ABC,Medtronic Names Next CEO As Omar Ishrak To Step Down In 2020,opinion,Shares of Medtronic plc    NYSE MDT   slipped a marginal 0 1   to close at  107 89 on Aug 30  following the company s retirement announcement of Omar Ishrak  its current chairman and CEO since 2011  This was a period that wrote the triumph of this MedTech stalwart in golden letters As planned  Ishrak has to step down from the CEO s post on Apr 26  2020 after the company exits its current fiscal year as by that time  he will attain the mandatory retirement age of 65 years This is a big news in itself as during Ishrak s tenure  among a host of enormous achievements that he made  annual revenues of the company doubled and its market capitalization increased by more than  100 billion Per a Mass Device article   Ishrak will be most widely remembered for the largest ever medtech merger   the  50 billion buyout of Covidien in early 2015   and the raft of other M A moves that defined his time at Medtronic   The Covidien acquisition is still the most gigantic one in the history of medical device industry The Successor to OmarThe market seems pretty positive about the board of directors  decision regarding the successor to fill Ishrak s shoes  Notably  Medtronic announced that Geoff Martha  the current executive vice president  EVP  of the company s Restorative Therapies Group  RTG   will take over the reins effective Apr 27  2020  Meanwhile  Nov 1 onward  Martha will assume the newly created role as Medtronic s president and also join its board members Like Ishrak  Martha s feat was also significant for Medtronic as he headed the company s path breaking acquisition of Covidien  In July 2014  he was named the CEO for the integration of Covidien into Medtronic and later became the president of RTG in 2015  Prior to Medtronic  Martha spent 19 years handling a variety of business development  strategic marketing and sales management roles at GE Healthcare and GE Capital Meanwhile  Brett Wall  the present senior vice president and president of RTG s Brain Therapies division  will be appointed as EVP and group president of RTG in November 2019  During his term  the Brain Therapies division generated double digit annual growth and introduced devices like the Solitaire Revascularization for minimally invasive treatment in case of ischemic stroke Share Price PerformanceOver the past year  shares of Medtronic have outperformed the   The stock has returned 14 4  compared with the industry s 2 8  rise Zacks Rank and Other Stocks Worth a LookMedtronic currently has a Zacks Rank  2  Buy   A few other top ranked stocks in the broader medical space are AmerisourceBergen Corporation   NYSE ABC    Baxter   NYSE BAX   and NuVasive   NASDAQ NUVA    each carrying the same solid Zacks Rank as Medtronic  You can see  AmerisourceBergen s long term historical earnings growth rate is estimated at 14 3  Baxter s long term earnings growth rate is projected at 12 8  NuVasive s long term earnings growth rate is expected to be 12 75  Legalizing THIS Could Be Even Bigger than Marijuana Americans spend an estimated  150 billion in this industry every year  more than twice as much as they spend on marijuana  Now that 8 states have fully legalized it  with several more states following close behind   Zacks has identified 5 stocks that could soar in response to the powerful demand  One industry insider described the future as  mind blowing    and early investors can still get in ahead of the surge ,2019-09-02,Zacks Investment Research,https://www.investing.com/analysis/medtronic-names-next-ceo-as-omar-ishrak-to-step-down-in-2020-200461107,200461107
102909,324424,ABC,ABC Vs  WST  Which Stock Should Value Investors Buy Now ,opinion,"Investors interested in Medical   Dental Supplies stocks are likely familiar with AmerisourceBergen  NYSE ABC  and West Pharmaceutical Services  WST   But which of these two stocks presents investors with the better value opportunity right now  Let s take a closer look 
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system  The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions  while our Style Scores work to identify stocks with specific traits 
Currently  both AmerisourceBergen and West Pharmaceutical Services are holding a Zacks Rank of   2  Buy   This means that both companies have witnessed positive earnings estimate revisions  so investors should feel comfortable knowing that both of these stocks have an improving earnings outlook  But this is just one factor that value investors are interested in 
Value investors analyze a variety of traditional  tried and true metrics to help find companies that they believe are undervalued at their current share price levels 
Our Value category highlights undervalued companies by looking at a variety of key metrics  including the popular P E ratio  as well as the P S ratio  earnings yield  cash flow per share  and a variety of other fundamentals that have been used by value investors for years 
ABC currently has a forward P E ratio of 12 08  while WST has a forward P E of 48 22  We also note that ABC has a PEG ratio of 1 53  This popular figure is similar to the widely used P E ratio  but the PEG ratio also considers a company s expected EPS growth rate  WST currently has a PEG ratio of 4 21 
Another notable valuation metric for ABC is its P B ratio of 5 76  Investors use the P B ratio to look at a stock s market value versus its book value  which is defined as total assets minus total liabilities  By comparison  WST has a P B of 7 55 
Based on these metrics and many more  ABC holds a Value grade of A  while WST has a Value grade of C 
Both ABC and WST are impressive stocks with solid earnings outlooks  but based on these valuation figures  we feel that ABC is the superior value option right now ",2019-09-04,Zacks Investment Research,https://www.investing.com/analysis/abc-vs-wst-which-stock-should-value-investors-buy-now-200461976,200461976
102910,324425,ABC,5 Stocks In The Limelight After Recent Broker Rating Upgrade,opinion,Broker ratings are often the decisive factor behind investment decisions  Arriving at such decisions is by no means easy for individual investors as these involve picking the right stocks from diverse industries  In fact  the process is as demanding as spotting a needle in a haystack  especially if the investor is unaided This is where guidance from brokers comes into play  Of the three types of brokers analysts  sell side  buy side and independent   sell side analysts dominate the investment world  Various brokerage firms employ them to provide unbiased opinion to investors after thorough analysis  Buy side analysts are employed by hedge funds  mutual funds  and others while the independent ones simply sell their reports to investors Brokers not only scrutinize the publicly available financial documents but also attend company conference calls and other presentations  Naturally  it is in the best interest of investors to pay heed to such well researched information as they aim to rake in maximum returns from their portfolio Earnings Estimate Revisions   A Winning PointerSince the action of brokers is guided by sound logic  the direction of estimate revisions serves as an important pointer regarding the price of a stock  For example  an earnings beat by a company generally leads to upward estimate revisions with prices moving north  Similarly  a stock may fall out of analysts  favor due to adverse events like pipeline failure  for a biotech player   Trimming of earnings estimates by brokers often leads to stock price depreciation  Naturally  investors look to dump such stocks on the basis of broker advice One of the well accepted investment strategies is to maintain a diversified portfolio to generate handsome returns irrespective of the market conditions  For instance  in the face of extremely low oil prices  analysts adopt a bullish stance on airline stocks and consequently raise estimates   Naturally  adding such stocks to one s portfolio in such a scenario might prove to be a winning strategy Making the Most of Broker OpinionsThe above write up clearly suggests that by following broker actions  one can arrive at a winning portfolio of stocks  Keeping this in mind  we have designed a screen to shortlist stocks based on improving analyst recommendation and upward revisions to earnings estimates over the last four weeks  Also  since the price sales ratio is a strong complementary valuation metric in the presence of analyst information  it has been included  The price sales ratio takes care of the company s top line  making the strategy foolproof Screening Criteria   Up  Down Rating   Total  4 weeks   Top  75  This gives the list of top 75 companies that have witnessed net upgrades over the last 4 weeks   change in Q  1  est   4 weeks    Top  10  This gives the top 10 stocks that have witnessed earnings estimate revisions over the past 4 weeks for the upcoming quarter To ensure that the strategy is a winning one  covering all bases  we have added the following screening parameters Price to Sales   Bot 10  The lower the ratio the better  companies meeting this criteria are in bottom 10  of our universe of over 7 700 stocks with respect to this ratio Price greater than 5  A stock trading below  5 will not likely create significant interest for most investors Average Daily Volume greater than 100 000 shares over the last 20 trading days  Volume has to be significant to ensure that these are easily traded Market value    mil    Top  3000  This gives us the top 3000 stocks in terms of market  Com  This eliminates the ADR and Canadian stocks Here are five of the 10 stocks that made it through the screen Anixter International   NYSE AXE   is a leading global distributor of network  security  electrical  and utility power products and services  The company  sporting a Zacks Rank  1  Strong Buy   is headquartered in Glenview  IL  The company s current quarter earnings are projected to grow 5 6  while that of its are expected to decline 12 9   You can see  CVS Health   NYSE CVS   is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care  The company  carrying a Zacks Rank  2  Buy   is headquartered in Woonsocket  RI  The company has a solid earnings surprise history having surpassed estimates in each of the past four quarters by an average of 5 9  AmerisourceBergen   NYSE ABC   is one of the world s largest pharmaceutical services companies  This Zacks Rank  2 company focuses on providing drug distribution and related services to reduce health care costs and improve patient outcomes  The Zacks Consensus Estimate for current year earnings has increased 2 8  in the past 60 days AECOM   NYSE ACM   is a leading solutions provider for supporting professional  technical and management solutions for multiple industries across end markets like transportation  facilities  government as well as those in environmental  energy and water businesses  The company  carrying a Zacks Rank  3  Hold   is headquartered in Los Angeles  CA  The Zacks Consensus Estimate for current year earnings indicates increase of 3 5  from 2018 reported level Best Buy Company   NYSE BBY    carrying a Zacks Rank  3  is headquartered in Richfield  MN  The company is a multinational specialty retailer of consumer electronics  home office products  entertainment software  communication  food preparation  wellness  heath  security  appliances and related services  The Zacks Consensus Estimate for current quarter earnings has increased 8 3  in the past 60 days You can get the rest of the stocks on this list by signing up now for your 2 week free trial to the Research Wizard and start using this screen in your own trading  Further  you can also create your own strategies and test them first before taking the investment plunge The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material Disclosure  Performance information for Zacks  portfolios and strategies are available at   ,2019-09-15,Zacks Investment Research,https://www.investing.com/analysis/5-stocks-in-the-limelight-after-recent-broker-rating-upgrade-200465012,200465012
102911,324426,ABC,Zacks com Featured Highlights Include  Anixter International  CVS Health  AmerisourceBergen  AECOM And Best Buy,opinion,For Immediate ReleaseChicago  IL   September 17  2019   Stocks in this week s article are Anixter International   NYSE AXE    CVS Health   NYSE CVS    AmerisourceBergen   NYSE ABC    AECOM   NYSE ACM   and Best Buy Company   NYSE BBY   5 Stocks in the Limelight After Recent Broker UpgradesBroker ratings are often the decisive factor behind investment decisions  Arriving at such decisions is by no means easy for individual investors as these involve picking the right stocks from diverse industries  In fact  the process is as demanding as spotting a needle in a haystack  especially if the investor is unaided This is where guidance from brokers comes into play  Of the three types of brokers analysts  sell side  buy side and independent   sell side analysts dominate the investment world  Various brokerage firms employ them to provide unbiased opinion to investors after thorough analysis  Buy side analysts are employed by hedge funds  mutual funds  and others while the independent ones simply sell their reports to investors Brokers not only scrutinize the publicly available financial documents but also attend company conference calls and other presentations  Naturally  it is in the best interest of investors to pay heed to such well researched information as they aim to rake in maximum returns from their portfolio Earnings Estimate Revisions   A Winning PointerSince the action of brokers is guided by sound logic  the direction of estimate revisions serves as an important pointer regarding the price of a stock  For example  an earnings beat by a company generally leads to upward estimate revisions with prices moving north  Similarly  a stock may fall out of analysts  favor due to adverse events like pipeline failure  for a biotech player   Trimming of earnings estimates by brokers often leads to stock price depreciation  Naturally  investors look to dump such stocks on the basis of broker advice One of the well accepted investment strategies is to maintain a diversified portfolio to generate handsome returns irrespective of the market conditions  For instance  in the face of extremely low oil prices  analysts adopt a bullish stance on airline stocks and consequently raise estimates   Naturally  adding such stocks to one s portfolio in such a scenario might prove to be a winning strategy Making the Most of Broker OpinionsThe above write up clearly suggests that by following broker actions  one can arrive at a winning portfolio of stocks  Keeping this in mind  we have designed a screen to shortlist stocks based on improving analyst recommendation and upward revisions to earnings estimates over the last four weeks  Also  since the price sales ratio is a strong complementary valuation metric in the presence of analyst information  it has been included  The price sales ratio takes care of the company s top line  making the strategy foolproof For the rest of this Screen of the Week article please visit Zacks com at Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material About Screen of the WeekZacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine   But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has more than doubled the market from 1988 through 2016  Its average gain has been a stellar  25  per year  Follow us on Twitter   Join us on Facebook  NASDAQ FB    Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Contact  Jim GiaquintoCompany  Zacks comPhone  312 265 9268Email  Visit  Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer   Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-09-16,Zacks Investment Research,https://www.investing.com/analysis/zackscom-featured-highlights-include-anixter-international-cvs-health-amerisourcebergen-aecom-and-best-buy-200465401,200465401
102912,324427,ABC,Here s Why You Should Retain Cardinal Health Stock For Now,opinion,"Cardinal Health Inc    NYSE CAH   is well poised for growth backed by diversified product portfolio  acquisition driven strategy and robust pharmaceutical segment  However  integration risks remain a concern The stock currently carries a Zacks Rank  3  Hold  Price PerformanceShares of Cardinal Health have gained 5 8   compared with the  s growth of 9 7  on a year to date basis  Further  the S P 500 Index rallied 16 8  in the same timeframe 
What s Weighing on the Stock The company s acquisition driven strategy makes it susceptible to integration risks Moreover  intense competition in each of the business segments remains a concern Factors to Bolster Cardinal HealthCardinal Health s Medical and Pharmaceutical offerings provide the company a competitive edge in the niche space  It offers industry expertise and an expanding portfolio of safe products The company follows an acquisition driven strategy and remains committed toward investment in key growth businesses to gain market traction and bolster profits The company s Pharmaceutical segment boasts of being the second largest pharmaceutical distributor in the United States  The segment s products and services consist of pharmaceutical distribution  manufacturer and specialty services  and nuclear and pharmacy services  These in turn are anticipated to drive the company in the days ahead In terms of costs  Cardinal Health announced in fourth quarter fiscal 2019 earnings call that it anticipates incremental cost savings of  130 million associated with actions intended to optimize and simplify its operating model and cost structure In fact  the company has already delivered  130 million in fiscal 2019  The company remains confident when it comes to generating more than  500 million in savings in comparison with its fiscal 2018 baseline in five years or less  This is likely to aid the company s margins in the days ahead Which Way Are Estimates Headed For fiscal 2020  the Zacks Consensus Estimate for revenues is pegged at  152 71 billion  indicating an improvement of 4 9  from the year ago period  For adjusted earnings per share  the same stands at  5 01  suggesting a decline of 5 1  from the year ago reported figure Key PicksSome better ranked stocks from the broader medical space are AmerisourceBergen Corporation   NYSE ABC    DENTSPLY SIRONA Inc    NASDAQ XRAY   and McKesson Corporation   NYSE MCK    each currently carrying a Zacks Rank  2  Buy   You can see  
AmerisourceBergen has a long term earnings growth rate of 7 9  DENTSPLY SIRONA has a long term earnings growth rate of 11 6  McKesson has a long term earnings growth rate of 6 9  
Free  Zacks  Single Best Stock Set to Double 
Today you are invited to download our just released Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all 
This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ",2019-09-30,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-retain-cardinal-health-stock-for-now-200469559,200469559
102913,324428,ABC,Why The Earnings Surprise Streak Could Continue For AmerisourceBergen  ABC ,opinion,"Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report  AmerisourceBergen  NYSE ABC   which belongs to the Zacks Medical   Dental Supplies industry  could be a great candidate to consider 
This prescription drug distributor has an established record of topping earnings estimates  especially when looking at the previous two reports  The company boasts an average surprise for the past two quarters of 7 81  
For the last reported quarter  AmerisourceBergen came out with earnings of  1 76 per share versus the Zacks Consensus Estimate of  1 63 per share  representing a surprise of 7 98   For the previous quarter  the company was expected to post earnings of  1 96 per share and it actually produced earnings of  2 11 per share  delivering a surprise of 7 65  
Price and EPS Surprise

Thanks in part to this history  there has been a favorable change in earnings estimates for AmerisourceBergen lately  In fact  the Zacks Earnings ESP  Expected Surprise Prediction  for the stock is positive  which is a great indicator of an earnings beat  particularly when combined with its solid Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
AmerisourceBergen has an Earnings ESP of  0 63  at the moment  suggesting that analysts have grown bullish on its near term earnings potential  When you combine this positive Earnings ESP with the stock s Zacks Rank  3  Hold   it shows that another beat is possibly around the corner  The company s next earnings report is expected to be released on November 7  2019 
When the Earnings ESP comes up negative  investors should note that this will reduce the predictive power of the metric  But  a negative value is not indicative of a stock s earnings miss 
Many companies end up beating the consensus EPS estimate  though this is not the only reason why their shares gain  Additionally  some stocks may remain stable even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-10-07,Zacks Investment Research,https://www.investing.com/analysis/why-the-earnings-surprise-streak-could-continue-for-amerisourcebergen-abc-200471539,200471539
102914,324429,ABC,What s In Store For Intuitive Surgical  ISRG  In Q3 Earnings ,opinion,Intuitive Surgical  Inc    NASDAQ ISRG   is expected to release third quarter 2019 results on Oct 17  after the closing bell  In the last reported quarter  the company delivered a positive earnings surprise of 14 04   Further  it has an average four quarter positive surprise of 4 13  Which Way Are Estimates Treading Currently  the Zacks Consensus Estimate for third quarter revenues is pegged at  1 06 billion  suggesting growth of 14 9  from the year ago reported number  The consensus estimate for earnings per share is pegged at  2 96 per share  indicating an improvement of 4 6  from the year ago reported figure Instruments   Accessories  A Key CatalystThe Instruments   Accessories segment is anticipated to see a solid third quarter  Notably  the segment  contributing 52 6  to total revenues  performed impressively in the last reported quarter as well  registering 21 5  growth year over year  Anticipated increase in da Vince procedure volumes and customer buying patterns are likely to get reflected in the segment s revenues in the to be reported quarter Further  the flagship   da Vinci surgical system   continues to be a revenue driver for the segment  In fact  we anticipate the company s da Vinci SP surgical system to benefit the company s performance in the soon to be reported quarter Reflective of these  the Zacks Consensus Estimate for Instruments   Accessories  third quarter revenues is pegged at  574 million  suggesting growth of 18 1  from the year ago quarter s reported figure Intuitive Surgical  Inc  Price and EPS Surprise    Other Factors at PlayRevenues from other two segments   Systems and Services   are expected to have positively impacted the third quarter courtesy of steady progress in the imaging and reality programs  In the last reported quarter  Systems contributed 31 3  to net sales while Services accounted for 16 1  For the quarter to be reported  the Zacks Consensus Estimate for Services stands at  179 million  indicating an improvement 11 9  from the year earlier quarter s reported figure  The same for Systems is pegged at  309 million  suggesting growth of 12 4  from the year ago quarter s reported number The company is likely to have witnessed growth in da Vinci procedures in the to be reported quarter on the back of probable procedure growth in the United States and outside of U S  markets  Moreover  general surgery in the United States and urology worldwide might contribute to the anticipated growth  In fact  Intuitive Surgical now forecasts 2019 procedure growth in the range of 16  to 17   compared with the previous 15  to 17  Moreover  the company s acquisition of Sch lly Fiberoptic s robotic endoscope business in July is likely to have improved da Vinci Surgical system through the addition of important aspects of da Vinci s visualization system  Notably  the buyout is anticipated to have strengthened Intuitive Surgical s supply chain and enhanced manufacturing capacity for imaging products  Thereby  the positive impacts of the acquisition are likely to reflect in the company s third quarter results However  cutthroat competition in the MedTech space continued to remain a headwind and might have weighed on its margins  which have been contracting over the last couple of quarters Earnings WhispersAccording to the Zacks model  a stock needs to have both   a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    for an earnings beat  However  this is not the case here as you will see below  You can see  Earnings ESP  Intuitive Surgical has an Earnings ESP of 0 00   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Intuitive Surgical carries a Zacks Rank  3 We caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revision Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter Edward Lifesciences Corporation   NYSE EW   has an Earnings ESP of  0 07  and a Zacks Rank  3 AmerisourceBergen Corporation   NYSE ABC   has an Earnings ESP of  0 55  and a Zacks Rank  3 Cardinal Health  Inc    NYSE CAH   has an Earnings ESP of  1 50  and a Zacks Rank  3 Breakout Biotech Stocks with Triple Digit Profit Potential The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119 and  164 in as little as 1 month  The stocks in this report could perform even better ,2019-10-13,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-intuitive-surgical-isrg-in-q3-earnings-200473188,200473188
102942,324457,ABC, AmerisourceBergen  Merck to Expand Blockchain Test Project for Tracking Drugs ,news,"US healthcare sector giants AmerisourceBergen  NYSE ABC  and Merck  NYSE MRK    Co intend to expand a blockchain pilot that was concluded in 2017  the Wall Street Journal   During the test  the companies tracked the ownership of medicines along the supply chain route  The upcoming trial is expected to include more drugs and healthcare devices and carry out more elaborate transactions  according to AmerisourceBergen CIO Dale Danilewitz 
A blockchain implementation is preferred in light of current federal laws  which require of healthcare companies to ensure the drugs reach the intended recipient 
Danilewitz said the test would focus on the verification process for drugs that a hospital or retailer returns to the company  If the history of the drugs is clean  they could be resold 

 We re making sure of the provenance of the product  guaranteeing it hasn t been tampered with all the way through the chain to the patient  Blockchain is such a natural fit for that kind of capability   he added 

Danilewitz revealed that Amerisource resells about 16 million product units each year  which is the equivalent of  3 billion in revenue  But if blockchain were to be implemented  that figure would go much higher  It is currently insignificant when measured against the company s total revenue  which was  153 1 billion last year 
Blockchain seems to be highly relevant given that the healthcare industry is facing new regulations  They will come into force in 2019 and aim to detect and remove fake  stolen  or contaminated drugs  Under the current Drug Supply Chain Security Act of 2013  companies have to adopt an electronic system to trace specific prescription medications from manufacturers to healthcare providers  distributors  retailers  and patients 
AmerisourceBergen s pilots are part of a broader initiative called MediLedger  on which we  last year  Due to regulatory pressures  the company teamed up with  Pfizer   NYSE PFE  and McKesson  NYSE MCK   among others  to explore the use of blockchain for tracking drugs 
The drug wholesale giant has applied blockchain solutions provided by SAP  On Thursday  we  that SAP had made its blockchain as a service solution available to all customers  AmerisourceBergen is also interested in the Hyperledger blockchain ",2018-06-08,Cryptovest,https://www.investing.com/news/cryptocurrency-news/amerisourcebergen-merck-to-expand-blockchain-test-project-for-tracking-drugs-1485728,1485728
102943,324458,ABC,Kentucky sues Walgreens  cites  alarming  rate of dispensing opioids,news,"By Nate Raymond  Reuters    Kentucky s attorney general on Thursday sued Walgreens Boots Alliance Inc  O WBA   accusing the company of playing a dual role in propagating an opioid epidemic in the state as both a pharmacy chain and wholesale drug distributor  The lawsuit by Kentucky Attorney General Andy Beshear was his sixth to date seeking to hold corporations like drug manufacturers and distributors responsible for their roles in the drug abuse crisis  The lawsuit  filed in state circuit court in Boone County  said Walgreens filled massive opioid orders in both unusually large sizes and great frequencies  In its role as a distributor that shipped drugs  the company failed to report suspicious orders to authorities  At the store level  Walgreens dispensed opioids at  such an alarming rate and volume that there could be no legitimate medical purpose associated to their use   according to the complaint  The only possible explanation for the large quantities of opioids dispensed from its Kentucky stores was that some of the drugs were distributed to addicts and abused or diverted for illegal uses  the complaint said   While Walgreens  slogan was  at the corner of happy and healthy   they have significantly harmed the health of our families in fueling the opioid epidemic   Beshear said in a statement  The lawsuit alleged that because Walgreens allowed for the proliferation of dangerous opioids into Kentucky  the state s citizens suffered from drug addiction  overdoses and death  The lawsuit seeks damages and penalties as well as an injunction  Deerfield  Illinois based Walgreens declined to comment  Opioids were involved in more than 42 000 overdose deaths in 2016  according to the U S  Centers for Disease Control and Prevention  Kentucky had 1 404 overdose deaths in 2016  the lawsuit said  The state had the third highest drug overdose rate in 2015 behind West Virginia and New Hampshire  according to Beshear s complaint  States  counties and cities have filed hundreds of lawsuits  accusing drugmakers of pushing addictive painkillers through deceptive marketing  and accused wholesale distributors of failing to report suspicious drug orders  
Beshear is pursuing similar cases against drug distributors AmerisourceBergen Corp  N ABC    Cardinal Health  Inc  N CAH  and McKesson Corp  N MCK  as well as drugmakers Johnson   Johnson  N JNJ  and Endo International Plc  O ENDP  ",2018-06-14,Reuters,https://www.investing.com/news/stock-market-news/kentucky-sues-walgreens-says-it-has-role-in-opioid-epidemic-1493357,1493357
102944,324459,ABC,Amazon just bought a tiny startup most people have never heard of and it s scaring the heck out of pharmacy shareholders,news,Amazon  NASDAQ AMZN  said it will buy online pharmacy PillPack  marking its latest push into the healthcare industry  The announcement reverberated through the entire supply chain  with the stocks of pharmacies and drug wholesalers getting hit hard  This is just the most recent example of Amazon s ability to disrupt an entire industry with a single corporate action   announced on Thursday that it has signed an agreement to acquire PillPack  an online pharmacy  PillPack s business is built around customers who take multiple daily prescriptions  It offers medications in pre sorted dose packaging  coordinates refills  and handles shipments  The deal   for which terms were not immediately disclosed   marks Amazon s latest push into the healthcare industry  In January  the company  with  and  to reduce healthcare costs for US workers   PillPack s visionary team has a combination of deep pharmacy experience and a focus on technology   Jeff Wilke  Amazon s CEO of worldwide consumer said in a    PillPack is meaningfully improving its customers  lives  and we want to help them continue making it easy for people to save time  simplify their lives  and feel healthier   Pharmacy stocks in the US market  on the deal announcement  most notably    8 1       3 1    and    9 2    The damage also spread throughout the entire pharmacy supply chain  with drug wholesalers seeing deep losses        and  all dropped more than 3  on the news  Amazon s ability to rock an entire industry Pharmacy shareholders will perhaps find solace in the fact that they re not the only industry to   It s a trend that s been playing out repeatedly over the past year  with grocery stores  athletic apparel retailers  and package delivery services among the afflicted groups  The reasoning is simple   Amazon has a ton of cash and an unparalleled logistical network  and when it looks poised to enter or expand its position in a market  traders get scared and bail out of existing holdings in other companies  And if Amazon s torrid stock performance in recent months is any indication  the company s shareholders love the deal activity  among other fundamental drivers  The firm s shares have spiked 435  since the beginning of 2015  more than 14 times the return for the benchmark  over the same period  This story is developing  Check back  for more updates ,2018-06-28,Business Insider,https://www.investing.com/news/stock-market-news/amazon-just-bought-a-tiny-startup-most-people-have-never-heard-of-and-it039s-scaring-the-heck-out-of-pharmacy-shareholders-1511136,1511136
102945,324460,ABC,Amazon to buy PillPack in potentially disruptive drug retail push,news,"By Ankur Banerjee and Bill Berkrot  Reuters    Amazon com Inc  NASDAQ AMZN  said on Thursday it would buy small online pharmacy PillPack  a move that will put the world s biggest online retailer in direct competition with drugstore chains  drug distributors and pharmacy benefit managers  The deal s potential to disrupt major players across the drug supply chain nationwide prompted a sell off in shares of possible rivals  while sending Amazon shares up 2 7 percent  PillPack supplies pre sorted prescription drugs and other services to people who take multiple medications  a growing market as the U S  population ages and requires treatment for multiple complex  chronic conditions  The value of the deal was not disclosed  Bloomberg reported it to be  1 billion  citing a person it said was familiar with the matter   Pharmacy chains and drug wholesalers lost around  14 billion in market value  while Amazon gained about  5 5 billion  Shares of CVS Health  NYSE CVS  were down 6 3 percent after falling as much as 10 percent  while Walgreen Boots Alliance was off nearly 10 percent  Shares of drug wholesalers McKesson Corp  NYSE MCK    Cardinal Health   NYSE CAH  and AmerisourceBergen  NYSE ABC  also fell sharply  The news comes just a week after a joint venture of Amazon  Berkshire Hathaway  NYSE BRKa  Inc and JPMorgan Chase   Co  NYSE JPM  named a chief executive who will be tasked with significantly cutting healthcare costs  WARNING SHOT Although brick and mortar stores might feel the effects of Amazon s competition  the biggest battles will likely be fought by mail order pharmacies  which generally serve patients with chronic conditions such as diabetes and heart disease that may require drugs to control blood pressure  cholesterol and other problems   PillPack has tens of thousands of customers across the country  will do over  100 million in revenue this year  and has launched PharmacyOS     designed specifically for customers with complex medication regimens   company spokeswoman Jacquelyn Miller said in an email   Amazon s acquisition of PillPack is a warning shot in what is about to become a major battle within the pharmacy space   said Neil Saunders  managing director of GlobalData Retail  Pharmacy benefit managers  PBMs   such as CVS and Express Scripts  which negotiate prescription drug pricing for employers and health plans  also run large mail order pharmacies  offering incentives to patients to fill their prescriptions with them  Doctors  insurers and PBMs have long said patients not properly taking their medicines is one of the main reasons for increased healthcare costs  leading to hospitalizations and more severe health issues  Companies like PillPack and Express Scripts that offer care management services to improve patient compliance are seen as increasingly important in helping control rising costs  With Amazon s announcement Mizuho analyst Ann Hynes  in a note  said pending health insurer PBM mergers of  Aetna Inc   NYSE AET  with CVS and  Cigna Corp   NYSE CI  with Express Scripts  are even more critical now    NOT WORRIED Walgreen CEO Stefano Pessina  on a conference call after reporting quarterly results  said he was  not particularly worried  about the PillPack deal   The pharmacy world is much more complex than just delivering certain pills or certain packages   Pessina said  That said  Pessina added   We know that we have to change the level of our services to the customers  and we are working quite hard on that direction   Some analysts played down the immediate threat  Morningstar analyst Vishnu Lekraj said he did not believe the deal would make Amazon  a major disruptor  in the near term   I believe they bought this to learn about the market and to determine if they are able to make larger investments   he said  Cantor Fitzgerald analyst Steven Halper noted that PBMs typically require health plan members to use their own mail order pharmacies   Even if PillPack is a network provider today  it does not mean it will be a network provider in the future  especially if Amazon has designs of significantly ramping its prescription volume   he said  Express Scripts dropped PillPack from its network in April 2016  alleging that it had misrepresented itself as a retail pharmacy  The two reached an agreement a month later  PillPack holds pharmacy licenses in all 50 states  It is an in network pharmacy for some PBMs and for major Medicare Part D plans  a federal drug benefit to help Medicare beneficiaries pay for self administered prescription medicines  PillPack had attracted interest from Walmart  NYSE WMT  Inc  which was looking to buy it for less than  1 billion  CNBC  in April  The deal is expected to close during the second half of 2018  
To view a graphic on Amazon disrupts the health and pharmacy space  click  ",2018-06-28,Reuters,https://www.investing.com/news/stock-market-news/amazon-to-acquire-online-pharmacy-pillpack-1510964,1510964
102946,324461,ABC,Trump administration proposes altering rule on drug rebates,news," Reuters    The Trump administration has proposed a rule that would scale back protections currently in place that allow rebates between drug manufacturers and insurers and pharmacy benefits managers  according to the Office of Management and Budget  OMB  website  Bloomberg first reported the existence of the proposed rule  which comes as the administration works to implement a wide ranging plan to lower prescription medicine prices  The U S  Department of Health and Human Services on Wednesday night sent the proposed rule to the OMB   Details of the proposed rule have not yet been made public  but its title on the OMB site refers to removing the safe harbor protection for rebates from the anti kickback law  The move is the first concrete sign that the Trump administration has started to review the legal status of these rebates since Food and Drug Administration Commissioner Scott Gottlieb raised the idea early this year that they should not be exempted from anti kickback law   The anti kickback law makes it illegal to pay an incentive for drugs or services that Medicare  Medicaid or other federal healthcare programs cover   Shares of drug wholesalers such as AmerisourceBergen Corp  N ABC  and McKesson Corp  N MCK   and pharmacy benefit managers  including CVS Health Corp  N CVS  and Express Scripts  O ESRX   fell slightly on Thursday on the move   The administration has placed blame on  middlemen  such as pharmacy benefits managers   which administer drug benefits for employers and health plans   and health insurers for driving up drug prices by demanding hefty rebates in exchange for the broadest access to patients  Health and Human Services Secretary Alex Azar and Gottlieb have questioned whether rebates provided by drug manufacturers should remain protected by federal law   Health and Human Services and OMB did not immediately respond to requests for comment  U S  President Donald Trump made lowering prescription drug prices a top priority during his 2016 presidential campaign  In May  his administration unveiled a drug pricing blueprint that included broad proposals for lowering prices that largely spared pharmaceutical manufacturers and instead went after pharmacy benefits managers  Pharmaceutical stocks rose after the blueprint s release   JP Morgan analyst Lisa Gill said Wall Street overreacted to the proposal submitted on Wednesday because rebates are only one component of pharmacy benefits managers  profit streams  
 If there are any changes around rebates they can adjust other aspects of the pricing model to ensure they are being paid fairly for the value they are adding   Gill wrote ",2018-07-19,Reuters,https://www.investing.com/news/stock-market-news/trump-administration-proposes-altering-rule-on-drug-rebates-1537304,1537304
102947,324462,ABC,Pharma s middlemen see shares suffer as challenges grow,news,By Lewis Krauskopf NEW YORK  Reuters    Uncertainty over potential actions to reduce prescription drug costs and competitive threats have taken a toll this year on shares of companies in the U S  pharmaceutical supply chain  They get their chance to change investor sentiment with quarterly earnings reports in the coming days  Prescription drug wholesalers  drug store chains and pharmacy benefit managers generally have seen their stock prices tumble this year  even as the overall S P 500 healthcare sector  SPXHC  has gained 6 percent  Six S P 500 stocks   CVS Health Corp  N CVS   Walgreens Boots Alliance Inc  O WBA   AmerisourceBergen Corp  N ABC   McKesson Corp  N MCK    Cardinal Health  Inc  N CAH  and Express Scripts Holding Co  O ESRX    collectively recently traded a third below their average valuation of the past five years  based on price to earnings estimates  according to Thomson Reuters Datastream    It s the uncertainty related to the business model itself that is causing the steep discount in valuations   said Jefferies analyst Brian Tanquilut   Fears the U S  government will take actions to rein in prescription drug prices  an issue trumpeted by U S  President Donald Trump  have cast a cloud over the stocks  Just last week  the shares were rattled as the Trump administration proposed a rule to scale back protections that allow rebates between drug manufacturers and insurers and pharmacy benefits managers  among the industry s so called middlemen  Amazon s  O AMZN  designs on health care  in particular its planned acquisition of online pharmacy PillPack  also are pressuring the stocks  as are moves by drugmakers such as  Pfizer  Inc  N PFE  and Merck   Co  N MRK  to cut some drug prices or roll back increases   This space is incredibly difficult to analyze and we can t in good conscience recommend fresh investment  despite low valuations   Eric Coldwell  an analyst at Robert W  Baird  said in a research note last week  Coldwell downgraded his ratings to  neutral  on shares of McKesson  Amerisource and Express Scripts  For the graphic  Prescription needed  U S  pharma supply stocks in 2018   click    McKesson  which reports results on Thursday with other companies following in next two weeks  has had its shares fall about 15 percent this year  Shares of rival drug wholesalers  Amerisource and Cardinal  have fallen nearly 9 percent and 20 percent  respectively  Drug store chains CVS and Walgreens have dropped about 9 5 percent each  CVS is also a large pharmacy benefit manager  PBM   Express Scripts shares have climbed more than 6 percent this year  The PBM s stock price has benefited from the company s March agreement to be bought by insurer  Cigna Corp   N CI   Even so  the stock recently traded at only 8 3 times earnings estimates for next 12 months  a discount to its five year average of 12 times  The cheaper valuations are drawing the attention of some investors who believe the selling appears overdone   Jeff Jonas  a portfolio manager who focuses on healthcare for Gabelli   Co  has been buying shares of Amerisource   The wholesalers in particular are always going to have a role to play   he said   We have just had too many issues of counterfeit or tampered drugs over the years   Jonas said   So I think having these well monitored  well controlled supply chains is still pretty important  ,2018-07-25,Reuters,https://www.investing.com/news/stock-market-news/pharmas-middlemen-see-shares-suffer-as-challenges-grow-1544881,1544881
102948,324463,ABC,Drug distributors maintain strength,news,Brushing off the market s sour mood  AmerisourceBergen  ABC  1 8     Cardinal Health   CAH  1 8   and McKesson  MCK  1 3   are all up and continue to show bullish chart action ABC should report fiscal Q4 and fiscal 2018 results on or about November 6 before the open  Consensus views for the quarter and year are EPS of  1 44 on revenues of  43 4B and EPS of  6 48 on revenues of  168 0B  respectively CAH should report fiscal Q1 results about the same time  Consensus view is EPS of  1 09 on revenues of  33 7B MCK should report fiscal Q2 results on October 25 before the open  Consensus view is EPS of  3 30 on revenues of  53 7B Now read ,2018-10-10,Seeking Alpha,https://www.investing.com/news/stock-market-news/drug-distributors-maintain-strength-1639190,1639190
102955,324470,ABC,Is AmerisourceBergen  ABC  Stock Undervalued Right Now ,opinion,"Here at Zacks  we focus on our proven ranking system  which places an emphasis on earnings estimates and estimate revisions  to find winning stocks  But we also understand that investors develop their own strategies  so we are constantly looking at the latest trends in value  growth  and momentum to find strong companies for our readers 
Looking at the history of these trends  perhaps none is more beloved than value investing  This strategy simply looks to identify companies that are being undervalued by the broader market  Value investors use a variety of methods  including tried and true valuation metrics  to find these stocks 
In addition to the Zacks Rank  investors looking for stocks with specific traits can utilize our Style Scores system  Of course  value investors will be most interested in the system s  Value  category  Stocks with  A  grades for Value and high Zacks Ranks are among the best value stocks available at any given moment 
One stock to keep an eye on is AmerisourceBergen  NYSE ABC   ABC is currently holding a Zacks Rank of  2  Buy  and a Value grade of A  The stock is trading with P E ratio of 12 27 right now  For comparison  its industry sports an average P E of 15 77  Over the last 12 months  ABC s Forward P E has been as high as 14 32 and as low as 10 10  with a median of 11 84 
ABC is also sporting a PEG ratio of 1 55  This figure is similar to the commonly used P E ratio  with the PEG ratio also factoring in a company s expected earnings growth rate  ABC s industry has an average PEG of 1 61 right now  Within the past year  ABC s PEG has been as high as 1 66 and as low as 1 10  with a median of 1 32 
Finally  we should also recognize that ABC has a P CF ratio of 12 50  This data point considers a firm s operating cash flow and is frequently used to find companies that are undervalued when considering their solid cash outlook  This company s current P CF looks solid when compared to its industry s average P CF of 14 90  Over the past year  ABC s P CF has been as high as 12 68 and as low as 6 91  with a median of 10 29 
These are just a handful of the figures considered in AmerisourceBergen s great Value grade  Still  they help show that the stock is likely being undervalued at the moment  Add this to the strength of its earnings outlook  and we can clearly see that ABC is an impressive value stock right now ",2019-08-06,Zacks Investment Research,https://www.investing.com/analysis/is-amerisourcebergen-abc-stock-undervalued-right-now-200452207,200452207
102956,324471,ABC,5 Stocks That Brokers Currently Love,opinion,Lack of proper guidance may lead an investor to make wrong choices while designing their portfolio  The addition of random stocks to one s portfolio can adversely impact returns  thereby ruining the very objective of investing Why Broker Advice is a MustThe opinion of brokers is highly valued by investors as they have a clear insight into the nitty gritty of the investment world  Brokers thoroughly scrutinize the publicly available financial documents apart from attending company conference calls and other presentations  Of the three types of brokers analysts  sell side  buy side and independent  present in the investment world  sell side analysts are most common  Various brokerage firms employ them to provide unbiased opinion to investors after thorough research  Buy side analysts are employed by hedge funds  mutual funds etc  while the independent ones simply sell their reports to investors Brokers revise their earnings estimates after carefully examining the pros and cons of an event for the concerned stock  Estimates can move north for a number of reasons   favorable earnings performance  a bullish guidance  product launch or any favorable macro scenario   On the contrary  lackluster earnings often result in stock price depreciation  Investors tend to be guided by the direction of estimate revisions and stock price while formulating their investment strategy The above writeup clearly demonstrates the utility of broker guidance for investors while deciding their course of action  buy  sell or hold  on a particular stock  To take care of the earnings performance  we have designed a screen based on improving analyst recommendation and upward estimate revisions over the last four weeks What About Revenues While we have talked about the bottom line in detail  the top line  revenue portion  cannot be ignored  Actually  according to many market watchers a revenue beat is more creditable for a company than a mere earnings outperformance  Therefore  we have included in our screen the price sales ratio that serves as a strong complementary valuation metric Screening Criteria   Up  Down Rating   Total  4 weeks   Top  75  This gives the list of top 75 companies that have witnessed net upgrades over the last 4 weeks   change in Q  1  est   4 weeks    Top  10  This gives the top 10 stocks that have witnessed earnings estimate revisions over the past 4 weeks for the upcoming quarter To ensure that the strategy is a winning one  covering all bases  we have added the following screening parameters Price to Sales   Bot 10  The lower the ratio the better  companies meeting this criteria are in bottom 10  of our universe of over 7 700 stocks with respect to this ratio Price greater than 5  A stock trading below  5 will not likely create significant interest for most investors Average Daily Volume greater than 100 000 shares over the last 20 trading days  Volume has to be significant to ensure that these are easily traded Market value    mil    Top  3000  This gives us stocks that are the top 3000 if one judges by market  Com  This takes out the ADR and Canadian stocks Here are five of the 10 stocks that made it through the screen Diebold Nixdorf   NYSE DBD   is a provider of connected commerce solutions to financial institutions  This Zacks Rank  1  Strong Buy  Ohio based company provides automatic teller machines  financial and point of sale services  The Zacks Consensus Estimate for the current quarter has increased 44 4  over the past 30 days  You can see Headquartered in Woonsocket  RI  CVS Health   NYSE CVS   is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care  This Zacks Rank  2  Buy  company has an impressive earnings surprise history  having outperformed the Zacks Consensus Estimate in each of the trailing four quarters  The average beat was 5 9  AmerisourceBergen Corporation   NYSE ABC   is one of the world s largest pharmaceutical services companies  This Zacks Rank  2 company focuses on providing drug distribution and related services to reduce health care costs and improve patient outcomes  The company has a long term  three to five years  expected growth rate of 14 3   higher than its  s 9 6  AutoNation   NYSE AN    through its subsidiaries  operates as an automotive retailer in the United States  The company also offers vehicle maintenance and repair services  vehicle parts  extended service contracts and vehicle protection products  This Zacks Rank  2 stock has seen the Zacks Consensus Estimate for current quarter earnings being revised upward to the tune of 2 7  over the past 30 days Spokane  WA based Clearwater Paper   NYSE CLW   produces and sells private label tissue and bleached paperboard products in the United States and internationally  Over the past 30 days  the Zacks Consensus Estimate for current quarter earnings per share has remained unchanged at 15 cents  The stock currently has a Zacks Rank  3  Hold   The company has a long term  three to five years  expected growth rate of 5  You can get the rest of the stocks on this list by signing up now for your 2 week free trial to the Research Wizard and start using this screen in your own trading  Further  you can also create your own strategies and test them first before taking the investment plunge The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material Disclosure  Performance information for Zacks  portfolios and strategies are available at   ,2019-08-12,Zacks Investment Research,https://www.investing.com/analysis/5-stocks-that-brokers-currently-love-200454691,200454691
102957,324472,ABC,Zacks com Featured Highlights Include  Diebold Nixdorf  CVS Health  AmerisourceBergen  AutoNation And Clearwater Paper,opinion,For Immediate ReleaseChicago  IL   August 14  2019   Stocks in this week s article are Diebold Nixdorf   NYSE DBD    CVS Health   NYSE CVS    AmerisourceBergen Corporation   NYSE ABC    AutoNation   NYSE AN   and Clearwater Paper   NYSE CLW   5 Stocks That Brokers Currently LoveLack of proper guidance may lead an investor to make wrong choices while designing their portfolio  The addition of random stocks to one s portfolio can adversely impact returns  thereby ruining the very objective of investing Why Broker Advice is a MustThe opinion of brokers is highly valued by investors as they have a clear insight into the nitty gritty of the investment world  Brokers thoroughly scrutinize the publicly available financial documents apart from attending company conference calls and other presentations  Of the three types of brokers analysts  sell side  buy side and independent  present in the investment world  sell side analysts are most common  Various brokerage firms employ them to provide unbiased opinion to investors after thorough research  Buy side analysts are employed by hedge funds  mutual funds etc  while the independent ones simply sell their reports to investors Brokers revise their earnings estimates after carefully examining the pros and cons of an event for the concerned stock  Estimates can move north for a number of reasons   favorable earnings performance  a bullish guidance  product launch or any favorable macro scenario   On the contrary  lackluster earnings often result in stock price depreciation  Investors tend to be guided by the direction of estimate revisions and stock price while formulating their investment strategy The above write up clearly demonstrates the utility of broker guidance for investors while deciding their course of action  buy  sell or hold  on a particular stock  To take care of the earnings performance  we have designed a screen based on improving analyst recommendation and upward estimate revisions over the last four weeks What About Revenues While we have talked about the bottom line in detail  the top line  revenue portion  cannot be ignored  Actually  according to many market watchers a revenue beat is more creditable for a company than a mere earnings outperformance  Therefore  we have included in our screen the price sales ratio that serves as a strong complementary valuation metric For the rest of this Screen of the Week article please visit Zacks com at Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material About Screen of the WeekZacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine   But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has more than doubled the market from 1988 through 2016  Its average gain has been a stellar  25  per year  Follow us on Twitter   Join us on Facebook  NASDAQ FB    Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Contact  Jim GiaquintoCompany  Zacks comPhone  312 265 9268Email  Visit  Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer   Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ,2019-08-14,Zacks Investment Research,https://www.investing.com/analysis/zackscom-featured-highlights-include-diebold-nixdorf-cvs-health-amerisourcebergen-autonation-and-clearwater-paper-200455003,200455003
102958,324473,ABC,Zacks com Featured Highlights Include  CVS Health  Asbury Automotive  Anixter International  Cincinnati Bell And AmerisourceBergen,opinion,For Immediate ReleaseChicago  IL  August 30  2019   Stocks in this week s article are CVS Health   NYSE CVS    Asbury Automotive Group   NYSE ABG    Anixter International   NYSE AXE    Cincinnati Bell   NYSE CBB   and AmerisourceBergen   NYSE ABC   Recent Broker Rating Upgrades Add Lustre to These 5 StocksInvestors  while putting their hard earned money into a stock  obviously expect handsome returns  However  in view of the uncertainties associated with the investment world and the huge number of stocks flooding the market  the task of designing a winning portfolio becomes daunting  particularly in the absence of proper know how expertise In fact  lack of proper guidance often causes one to falter in life  This is true for the investing world as well  Moreover  with time at a premium these days  it is next to impossible for investors to keep track of market movements to identify opportune moment s  for buying or offloading a particular stock to maximize returns  Therefore  guidance from proper channels is a must Time for Some Broker Advice The experts in the investing world are brokers  Generally  three types of brokers  sell side  buy side and independent  are present in the investment world  with sell side analysts being the most common  They are employed by various brokerage firms to provide unbiased opinion to investors on the stocks under their coverage after thorough research  Buy side analysts are employed by hedge funds  mutual funds etc  while the independent ones simply sell their reports to investors All types of brokers indulge in thorough research of the stocks under their coverage  They have access to much detailed information on a company  Toward this end  they attend company conference calls presentations and scrutinize every detail available publicly before advising investors  Naturally  broker advice acts as an invaluable guide for investors in their bid to garner the maximum from their portfolios Direction of Earnings Estimates  An Invaluable Guide Since brokers meticulously follow the stocks in their coverage  they revise their earnings estimates after carefully examining the pros and cons of an event for the concerned company  The estimate revisions serve as an important pointer regarding the price of a stock For example  an earnings outperformance by a company generally leads to upward estimate revisions with prices moving north  Similarly  lackluster earnings often lead to stock price depreciation  Investors tend to be guided by the direction of estimate revisions and stock price while formulating their investment strategy Making the Most of Broker GuidanceThe above write up clearly suggests that by following broker actions  one can arrive at a winning portfolio of stocks  Keeping this in mind  we have designed a screen to shortlist stocks based on improving analyst recommendation and upward revisions in earnings estimates over the last four weeks Also  since the price sales ratio is a strong complementary valuation metric in the presence of analyst information  it has been included  The abovementioned ratio takes care of the company s top line  making the strategy effective For the rest of this Screen of the Week article please visit Zacks com at Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material About Screen of the WeekZacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine   But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has more than doubled the market from 1988 through 2016  Its average gain has been a stellar  25  per year  Follow us on Twitter   Join us on Facebook  NASDAQ FB    Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Contact  Jim GiaquintoCompany  Zacks comPhone  312 265 9268Email  Visit  Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer   Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ,2019-08-29,Zacks Investment Research,https://www.investing.com/analysis/zackscom-featured-highlights-include-cvs-health-asbury-automotive-anixter-international-cincinnati-bell-and-amerisourcebergen-200460353,200460353
102959,324474,ABC,AmerisourceBergen  ABC  Down 10 3  Since Last Earnings Report  Can It Rebound ,opinion,"It has been about a month since the last earnings report for AmerisourceBergen  NYSE ABC   Shares have lost about 10 3  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is AmerisourceBergen due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  AmerisourceBergen Q3 Earnings   Revenues Top EstimatesAmerisourceBergen delivered third quarter fiscal 2019 adjusted earnings per share  EPS  of  1 76 surpassing the Zacks Consensus Estimate of  1 63 by 7 9   The figure also improved 14 3  year over year The better than expected bottom line performance can be attributed to increase in adjusted operating income  lower share count and reduced net interest expense Revenues improved 4 9  to  45 24 billion in the reported quarter  Moreover  the figure beat the Zacks Consensus Estimate by 0 01  Segmental AnalysisPharmaceutical Distribution SegmentRevenues at this segment totaled  43 53 billion  improved 4 7  on a year over year basis  Overall market growth  consistent robust specialty product sales and increase in volume related to growth of some of its largest customers contributed to the improvement Segmental operating income was  411 7 million  up 4 9  year over year  Increase in gross profit drove the upside  However  an increase in operating expenses partially offset the uptick Other SegmentThis segment includes AmerisourceBergen Consulting Services  ABCS   World Courier and MWI Veterinary Supply Revenues at this segment came in at  1 73 billion  up 8 6  year over year  This upside was driven by ABCS s growth in Canadian operations and MWI Operating income in the segment was  95 1 million in the quarter  up 15 6  year over year primarily on the back of the results at MWI Margin AnalysisIn the quarter under review  AmerisourceBergen reported adjusted gross profit of  1 2 billion  up 4 9  on a year over year basis  As a percentage of revenues  adjusted gross margin was 2 7  in the quarter  which remained flat year over year AmerisourceBergen reported adjusted operating income of  506 7 million  up 6 8  year over year  As a percentage of revenues  adjusted operating income was 1 1  in the quarter  up 2 basis points year over year Guidance RevisedAdjusted EPS is now estimated in the range of  7 00  7 10  up from the previously guided range of  6 70  6 90   The Zacks Consensus Estimate is currently pegged at  6 86  which is within the guided range Adjusted operating income is projected to grow in the range of 3 4   up from low single digit percent range  Operating income at Pharmaceutical Distribution Services segment is expected to grow in the band of 2 3   down from low single digit percent range  Further  the company anticipates weighted average diluted shares to be about 212 million  down from the previous estimate of around 214 million Notably  per management  all the other previously announced aspects of the company s fiscal year 2019 financial guidance and assumptions remain intact 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in estimates review 
VGM Scores
Currently  AmerisourceBergen has a great Growth Score of A  a grade with the same score on the momentum front  Following the exact same course  the stock was allocated a grade of A on the value side  putting it in the top 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been trending upward for the stock  and the magnitude of these revisions looks promising  It comes with little surprise AmerisourceBergen has a Zacks Rank  2  Buy   We expect an above average return from the stock in the next few months ",2019-08-30,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-abc-down-103-since-last-earnings-report-can-it-rebound-200460465,200460465
102994,324509,ABC,U S  seeks time to consider joining opioid litigation,news,By Nate Raymond  Reuters    The U S  Justice Department has asked a federal judge overseeing hundreds of lawsuits against opioid manufacturers and distributors to give it 30 days to decide whether to participate in the litigation  The department made the request in papers filed in federal court in Cleveland late on Thursday after U S  President Donald Trump earlier in the day called for a federal lawsuit against companies over their roles in the opioid epidemic  The Justice Department asked U S  District Judge Dan Polster to give it time to evaluate participating in the litigation  citing the  substantial costs that the federal government has borne as a result of the opioid epidemic   It cited estimates made by the White House Council of Economic Advisers in November that opioid abuse cost the U S  economy as much as  504 billion in 2015   The economic burden from the opioid epidemic includes considerable costs associated with the medical treatment of opioid users   the Justice Department said  As just one example of the costs federal agencies have incurred for treatment  the U S  Defense Department s costs for care related to opioid use and dependence were  82 million in 2017  the Justice Department said  According to the Centers for Disease Control and Prevention  42 000 people died from opioid overdoses in 2016  the last year with publicly available data   Thursday s filing came after U S  Attorney Jeff Sessions on Tuesday announced the department would file a statement of interest in cases consolidated before Polster  saying the federal government would seek reimbursement for the cost of the epidemic  The judge is overseeing at least 355 lawsuits filed by cities  counties and others against opioid manufacturers and distributors generally seeking to recover the costs they had incurred grappling with the public health crisis  Polster has been pushing for a quick  global settlement in the litigation  and has invited state attorneys general who have cases in state courts or who are conducting a multistate probe of the companies to participate in those talks  The lawsuits have generally accused the drugmakers of deceptively marketing opioids and allege distributors ignored red flags indicating the painkillers were being diverted for improper uses  The defendants include opioid manufacturers Purdue Pharma LP  Johnson   Johnson  N JNJ   Teva Pharmaceutical  NYSE TEVA  Industries Ltd  TA TEVA   Endo International PLC  O ENDP  and Allergan PLC  N AGN  and drug distributors AmerisourceBergen Corp  N ABC    Cardinal Health  Inc  N CAH  and McKesson Corp  N MCK   The first settlement hearing was held in January  A second one is expected on Tuesday ,2018-03-02,Reuters,https://www.investing.com/news/stock-market-news/us-seeks-time-to-consider-joining-opioid-litigation-1322366,1322366
102995,324510,ABC,Walgreens Boots declares  0 40 dividend,news,Walgreens Boots  NASDAQ WBA  declares  0 40 share quarterly dividend  in line with previous Forward yield 2 51 Payable June 12  for shareholders of record May 18  ex div May 17 Now read ,2018-04-11,Seeking Alpha,https://www.investing.com/news/stock-market-news/walgreens-boots-declares-040-dividend-1389005,1389005
102996,324511,ABC,Drug suppliers  shares rise as looming Amazon threat appears to ease,news,"By Manas Mishra  Reuters    Shares of U S  drug suppliers rose on Monday after a report that Amazon com Inc had dropped plans to sell drugs to hospitals  in a boost to a pharmaceutical supply chain rattled by the looming threat of competition from the online retailer  Stocks of drug distributors McKesson  N MCK   AmerisourceBergen  N ABC  and  Cardinal Health   N CAH  rose 2 to 3 percent  while drugstore chains Walgreens Boots Alliance  O WBA  and CVS Health  N CVS  each advanced about 5 percent  Healthcare investors expect Amazon  O AMZN  will become a major force in the industry  fueled by recent media reports that the Seattle based company was considering entering the pharmacy business  CNBC  which reported Amazon s plans on Monday  said the change comes partly because the e commerce company had not been able to convince big hospitals to change their traditional purchasing process  The company  through its Amazon Business unit  will instead focus on selling less sensitive medical supplies to hospitals and smaller clinics  CNBC said  citing people familiar with the matter  Amazon told Reuters it does not comment on rumors or speculation   After months of hype and fear it appears now that Amazon s entry into the drug distribution space has been indefinitely delayed   said Evercore ISI analyst Ross Muken  Amazon is likely to remain focused on selling dental and medical products  he added  The presence of established drug suppliers  along with difficulties in distributing highly regulated treatments  likely deterred the technology giant from entering the industry  analysts said   Even with Amazon s large war chest  it is still a difficult prospect given the dynamics of the whole pharmaceutical market   Morningstar analyst Vishnu Lekhraj said  
In January  Amazon   Berkshire Hathaway Inc   N BRKa  and JPMorgan Chase   Co  N JPM  unveiled plans to form a company to cut healthcare costs for hundreds of thousands of employees ",2018-04-16,Reuters,https://www.investing.com/news/stock-market-news/drug-suppliers-shares-rise-as-looming-amazon-threat-appears-to-ease-1397035,1397035
102997,324512,ABC,Kentucky sues J J over opioid marketing,news,Reuters reports  tweets  that the Kentucky AG has filed suit against Johnson   Johnson  JNJ  2 6   over alleged deceptive opioid marketing The company is not the first  Kentucky sued the three major drug wholesalers  McKesson  NYSE MCK   AmerisourceBergen  NYSE ABC  and  Cardinal Health   NYSE CAH   last year over their role in the opioid crisis in the state Now read ,2018-04-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/kentucky-sues-jj-over-opioid-marketing-1401253,1401253
102998,324513,ABC,Kentucky accuses J J of contributing to opioid epidemic,news," Reuters    Kentucky s attorney general on Wednesday sued Johnson   Johnson  N JNJ   accusing the pharmaceutical manufacturer of devising a deceptive marketing scheme that mischaracterized the risk of opioid abuse and addiction  The lawsuit by Kentucky Attorney General Andy Beshear was his fifth to date seeking to hold a drug manufacturer or distributor responsible for its role in the national opioid epidemic  The lawsuit  filed in McCracken Circuit Court  accused J J and its Janssen Pharmaceuticals unit of misrepresenting that its opioid medications were safer than alternatives and were  rarely addictive  when used for chronic pain  Those opioids included Duragesic  which before 2009 accounted for at least  1 billion in annual sales  and Nucynta and Nucynta ER  the lawsuit said  Janssen sold the rights to Nucynta to another drugmaker in 2015  The lawsuit seeks penalties and compensatory and punitive damages   Janssen has profited from their illegal conduct  and my office is taking action to make sure they pay for ravaging our communities and destroying our families just to make a profit   Beshear said in a statement  J J in a statement said that it marketed and promoted opioids appropriately and that its products  labels provided information about their risks and benefits  Opioids were involved in more than 42 000 overdose deaths in 2016  according to the U S  Centers for Disease Control and Prevention  Hundreds of lawsuits by states  counties and cities have accused drugmakers of pushing addictive pain killers through deceptive marketing and wholesale distributors of failing to report suspicious drug orders  
Eight other states have sued J J  Beshear is also pursuing similar cases against drug distributors AmerisourceBergen Corp  N ABC    Cardinal Health   N CAH  and McKesson Corp  N MCK  and drugmaker Endo International Plc  O ENDP  ",2018-04-18,Reuters,https://www.investing.com/news/stock-market-news/kentucky-accuses-jj-of-contributing-to-opioid-epidemic-1401341,1401341
102999,324514,ABC, Consensus 2018 Sees over 8 000 Attendees vs Expected 4 000 ,news,"Consensus 2018 is by far the most popular blockchain event this month  So popular  in fact  that the organizers have to deal with double the number of attendees initially anticipated  according to Ronnie Moas  who runs market research company Standpoint 
The blockchain and cryptocurrency conference is held at New York Hilton Midtown hotel from May 14 to May 16  The organizers had been expecting over 4 000 attendees this year  up from about 2 700 at the 2017 event  However  Moas reports that more than 8 000 people are attending  while Digital Currency Group CEO Barry Silbert estimates the number at minimum 8 500 
Moas was apparently disappointed with the large number of participants  saying in a tweet it felt like New York s Grand Central Station during rush hour  A sports arena may have been a better location than a convention center  he concluded 


 It is a bit chaotic in here  I think they sold too many tickets   he  CNBC 

In an earlier tweet  Ronnie complained about computers being down  causing people to wait in long queues 

Moas is not the only one with gripes  A CNBC reporter had to wait one hour to get her entrance badge  the news portal writes  Jeff Denton of AmerisourceBergen  NYSE ABC   who is also an attendee  said 

 I ve never seen anything like this for registration  I ve been on line for an hour  

However  these inconveniences did not stop people from flocking to the event  With the average ticket price being  2 000  the organizers have generated at least  17 million from ticket sales 
CoinDesk  which was responsible for organizing the event  declined to comment on the revenue figures  However  the company s director of marketing Jacob Donnelly came up with an apology for the inconveniences 

 Whilst we apologize for any delays  Consensus 2018 has received overwhelming interest and is the largest blockchain focused event ever held in the United States  We are working to reduce the wait time  

Many blockchain and crypto stars were booked as speakers at the event  including Emmanuel Aidoo  head of blockchain and cryptocurrency strategy at  Credit Suisse   SIX CSGN   Jeremy Allaire  CEO of Circle  former JPMorgan  NYSE JPM  blockchain strategy chief   Brian Behlendorf  executive director at Hyperledger  and ConsenSys executive director Vanessa Grellet 
Ethereum co founder Vitalik Buterin refused to participate or support the event  saying the ticket prices were too high and CoinDesk s use of off the record quotes was wrong 

 I refuse to personally contribute to that level of rent seeking  ",2018-05-16,Cryptovest,https://www.investing.com/news/cryptocurrency-news/consensus-2018-sees-over-8000-attendees-vs-expected-4000-1449375,1449375
103006,324521,ABC,Recent Analyst Upgrades Add Shine To These 5 Stocks,opinion,The Q2 earnings season is in full swing  Despite headwinds like the Sino U S  trade tensions  the current reporting cycle has seen a healthy proportion of companies reporting better than expected earnings Generally  an earnings beat by a company leads to appreciation in its stock price  Given this backdrop  investors would like to add outperformers to their respective portfolios for healthy returns However  the task is far from easy with a plethora of companies present in the market  Moreover  the complexities associated with the stock market makes it even more difficult for individual investors to select outperformers in their portfolios in the absence of proper guidance Broker Advice   An Invaluable GuideThe requisite guidance to design a winning portfolio comes from brokers  Brokers invest a lot of time in researching stocks under their coverage  Such investment specialists attend conference calls  company presentations and also interact with management Brokers revise their earnings estimates after carefully examining the pros and cons of an event for the concerned stock  Naturally  their stock related actions  upgrade or downgrade  serve as an invaluable guide as far as fixing target price of stock s  is concerned  Therefore  it is prudent for investors to pay heed to broker advice in order to design a winning portfolioOut of the three types of brokers  sell side  buy side and independent   sell side analysts are the most common  They are employed by various brokerage firms to provide unbiased opinion on stocks  Meanwhile  buy side analysts are employed by hedge funds  mutual funds and others while independent analysts directly sell their reports to investors Making the Most of Broker OpinionsBy following broker actions  one can arrive at a winning portfolio of stocks  Keeping this in mind  we have designed a screen to shortlist stocks based on improving analyst recommendation and upward earnings estimate revisions over the last four weeks  Also  since the price sales ratio is a strong complementary valuation metric in the presence of analyst information  it has been included  The price sales ratio takes care of the company s top line  making the strategy foolproof Screening Criteria   Up  Down Rating   Total  4 weeks   Top  75 This gives the list of top 75 companies that have witnessed net upgrades over the last 4 weeks    change in Q  1  est   4 weeks    Top  10 This gives the top 10 stocks that have witnessed earnings estimate revisions over the past 4 weeks for the upcoming quarter  We have also added the following screening parameters to ensure that the strategy is a winning one Price to Sales   Bot 10  The lower the ratio the better  companies meeting this criteria are in bottom 10  of our universe of over 7 700 stocks with respect to this ratio  Price greater than 5  as a stock trading below  5 will not likely create significant interest for most of the investors  Average Daily Volume greater than 100 000 shares over the last 20 trading days Volume has to be significant to ensure that these are easily traded  Market value    mil    Top  3000  This gives us stocks that are the top 3000 in terms of market capitalization  Com ADR Canadian  Com  This takes out the ADR and Canadian stocks  Here are five of the 10 stocks that made it through the screen Headquartered in Dublin  OH  Cardinal Health   NYSE CAH   is a nation wide drug distributor and provider of services to pharmacies  healthcare providers and manufacturers  The company  carrying a Zacks Rank  3  Hold   has an impressive track with respect to earnings per share  having outshined the Zacks Consensus Estimate in each of the trailing four quarters  The average beat is 15  Builders FirstSource   NASDAQ BLDR   is a leading supplier and manufacturer of structural and related building products for residential new construction in the United States  This Zacks Rank  1  Strong Buy  stock has seen the Zacks Consensus Estimate for current year earnings being revised upward to the tune of 3 3  over the past 60 days  You can see  AmerisourceBergen Corporation   NYSE ABC    based in Chesterbrook  PA  is one of the world s largest pharmaceutical services companies  The company focuses on providing drug distribution and related services in a bid to reduce health care costs and improve patient outcomes   This Zacks Rank  3 stock has an expected earnings per share growth rate of 7 7  for three to five years AutoNation   NYSE AN    through its subsidiaries  operates as an automotive retailer in the United States  The company also offers vehicle maintenance and repair services  vehicle parts  extended service contracts and vehicle protection products  This Zacks Rank  2  Buy  stock has seen the Zacks Consensus Estimate for current year earnings being revised upward to the tune of 1 8  over the past 60 days Party City Holdco   NYSE PRTY    This Zacks Rank  3 company s activities include designing  manufacturing and distributing party goods like paper and plastic tableware  The company  based in Elmsford  NY  has an expected earnings per share growth rate  three to five years  of 14 9  that compares favorably with the  s comparable figure of 9 9  You can get the rest of the stocks on this list by signing up now for your 2 week free trial to the Research Wizard and start using this screen in your own trading  Further  you can also create your own strategies and test them first before taking the investment plunge The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material Disclosure  Performance information for Zacks  portfolios and strategies are available at   ,2019-07-29,Zacks Investment Research,https://www.investing.com/analysis/recent-analyst-upgrades-add-shine-to-these-5-stocks-200446373,200446373
103007,324522,ABC,Zacks com Featured Highlights Include  Cardinal Health  Builders FirstSource  AmerisourceBergen  AutoNation And Party City,opinion,For Immediate ReleaseChicago  IL   July 30  2019   Stocks in this week s article are Cardinal Health   NYSE CAH    Builders FirstSource   NASDAQ BLDR    AmerisourceBergen Corp    NYSE ABC    AutoNation   NYSE AN   and Party City Holdco   NYSE PRTY   Recent Analyst Upgrades Add Shine to These 5 StocksThe Q2 earnings season is in full swing  Despite headwinds like the Sino U S  trade tensions  the current reporting cycle has seen a healthy proportion of companies reporting better than expected earnings Generally  an earnings beat by a company leads to appreciation in its stock price  Given this backdrop  investors would like to add outperformers to their respective portfolios for healthy returns However  the task is far from easy with a plethora of companies present in the market  Moreover  the complexities associated with the stock market makes it even more difficult for individual investors to select outperformers in their portfolios in the absence of proper guidance Broker Advice   An Invaluable GuideThe requisite guidance to design a winning portfolio comes from brokers  Brokers invest a lot of time in researching stocks under their coverage  Such investment specialists attend conference calls  company presentations and also interact with management Brokers revise their earnings estimates after carefully examining the pros and cons of an event for the concerned stock  Naturally  their stock related actions  upgrade or downgrade  serve as an invaluable guide as far as fixing target price of stock s  is concerned  Therefore  it is prudent for investors to pay heed to broker advice in order to design a winning portfolioOut of the three types of brokers  sell side  buy side and independent   sell side analysts are the most common  They are employed by various brokerage firms to provide unbiased opinion on stocks  Meanwhile  buy side analysts are employed by hedge funds  mutual funds and others while independent analysts directly sell their reports to investors Making the Most of Broker OpinionsBy following broker actions  one can arrive at a winning portfolio of stocks  Keeping this in mind  we have designed a screen to shortlist stocks based on improving analyst recommendation and upward earnings estimate revisions over the last four weeks  Also  since the price sales ratio is a strong complementary valuation metric in the presence of analyst information  it has been included  The price sales ratio takes care of the company s top line  making the strategy foolproof For the rest of this Screen of the Week article please visit Zacks com at Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material About Screen of the WeekZacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine   But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has more than doubled the market from 1988 through 2016  Its average gain has been a stellar  25  per year  Follow us on Twitter   Join us on Facebook  NASDAQ FB    Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Contact  Jim GiaquintoCompany  Zacks comPhone  312 265 9268Email  Visit  Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer   Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-07-29,Zacks Investment Research,https://www.investing.com/analysis/zackscom-featured-highlights-include-cardinal-health-builders-firstsource-amerisourcebergen-autonation-and-party-city-200447414,200447414
103008,324523,ABC,Etsy  ETSY  To Report Q2 Earnings  What s In The Offing ,opinion,"Etsy  Inc    NASDAQ ETSY   is slated to report second quarter 2019 results on Aug 1 Notably  the company has surpassed the Zacks Consensus Estimate in three of the trailing four quarters  with an average positive surprise of 49 92  Past Quarter PerformanceIn the first quarter  Etsy s delivered a positive earnings surprise of 71 43   In fact  the company s earnings of 24 cents was higher than prior year quarter figure of 10 cents  However  the figure was lower than 32 cents reported in the previous quarter Revenues advanced 40 1  year over year to  169 3 million and outpaced the Zacks Consensus Estimate of  169 million  The top line was driven by accelerating Marketplace and Services revenues   However  the figure declined 15 3  sequentially For the second quarter  the Zacks Consensus Estimate for earnings and revenues is pegged at 14 cents per share and  182 57 million  respectively Let s see how things are shaping up for this announcement Etsy  Inc  Price and EPS Surprise   Factors to Consider
The company s strong efforts toward proper execution of its key growth initiatives   search and discovery  customer liability  marketing  seller tools and services  is likely to benefit second quarter results  Moreover  Search and discovery continues to act as the key catalyst Further  strengthening ecosystem on Etsy s platform for both sellers and buyers is likely to expand its addressable market size in the to be reported quarter  Furthermore  its growing focus toward expansion in U S  marketplace remains a positive Additionally  recommendations available on the company s listing and landing pages that reflect purchasing patterns  taste and preferences of buyers are expected to aid the conversion rate in the to be reported quarter Further  advancements in Etsy s conversation tool have made interaction between buyers and sellers easier  The tool enables buyers to message sellers directly from shop and listing pages  while aiding the sellers to respond quickly  Consequently  this tool is a key catalyst and likely to aid the to be reported quarter s results The company is also leveraging TV  cable and digital video channels to expand audience reach  which is likely to drive growth in its marketplace in the quarter under review Additionally  Etsy s progression with cloud migration remains a positive  Moreover  it has started addressing search traffic via Google  NASDAQ GOOGL  Cloud  which is a tailwind  All these strong endeavors are likely to drive the company s top line in the to be reported quarter However  increasing cloud spending is a matter of concern  Further  the company s creative campaigns are likely to hike its marketing expenses in the quarter under review What Our Model SaysAccording to the Zacks model  a company with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has good chance of beating estimates if it also has a positive   The Sell rated stocks  Zacks Rank  4 or 5  are best avoided  You can uncover the best stocks to buy or sell before they re reported with our  Etsy has a Zacks Rank  3 and an Earnings ESP of 0 00   which makes the surprise prediction difficult Stocks That Warrant a LookHere are a couple of stocks you may consider  as our proven model shows that these have the right combination of elements to post an earnings beat this quarter Clearway Energy   NYSE CWEN   has an Earnings ESP of  15 00  and a Zacks Rank  1  You can see AmerisourceBergen Corporation   NYSE ABC   has an Earnings ESP of  0 82  and a Zacks Rank  3 Ciena   NYSE CIEN   has an Earnings ESP of  5 26  and a Zacks Rank  2 Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-07-29,Zacks Investment Research,https://www.investing.com/analysis/etsy-etsy-to-report-q2-earnings-whats-in-the-offing-200447269,200447269
103009,324524,ABC,AmerisourceBergen  ABC  Q3 Earnings   Revenues Top Estimates,opinion,"AmerisourceBergen Corporation   NYSE ABC   delivered third quarter fiscal 2019 adjusted earnings per share  EPS  of  1 76 surpassing the Zacks Consensus Estimate of  1 63 by 7 9   The figure also improved 14 3  year over year The better than expected bottom line performance can be attributed to increase in adjusted operating income  lower share count and reduced net interest expense Revenues improved 4 9  to  45 24 billion in the reported quarter  Moreover  the figure beat the Zacks Consensus Estimate by 0 01  Segmental AnalysisPharmaceutical Distribution SegmentRevenues at this segment totaled  43 53 billion  improved 4 7  on a year over year basis  Overall market growth  consistent robust specialty product sales and increase in volume related to growth of some of its largest customers contributed to the improvement Segmental operating income was  411 7 million  up 4 9  year over year  Increase in gross profit drove the upside  However  an increase in operating expenses partially offset the uptick Other SegmentThis segment includes AmerisourceBergen Consulting Services  ABCS   World Courier and MWI Veterinary Supply Revenues at this segment came in at  1 73 billion  up 8 6  year over year  This upside was driven by ABCS s growth in Canadian operations and MWI Operating income in the segment was  95 1 million in the quarter  up 15 6  year over year primarily on the back of the results at MWI Margin AnalysisIn the quarter under review  AmerisourceBergen reported adjusted gross profit of  1 2 billion  up 4 9  on a year over year basis  As a percentage of revenues  adjusted gross margin was 2 7  in the quarter  which remained flat year over year AmerisourceBergen reported adjusted operating income of  506 7 million  up 6 8  year over year  As a percentage of revenues  adjusted operating income was 1 1  in the quarter  up 2 basis points year over year Guidance RevisedAdjusted EPS is now estimated in the range of  7 00  7 10  up from the previously guided range of  6 70  6 90   The Zacks Consensus Estimate is currently pegged at  6 86  which is within the guided range Adjusted operating income is projected to grow in the range of 3 4   up from low single digit percent range  Operating income at Pharmaceutical Distribution Services segment is expected to grow in the band of 2 3   down from low single digit percent range  Further  the company anticipates weighted average diluted shares to be about 212 million  down from the previous estimate of around 214 million Notably  per management  all the other previously announced aspects of the company s fiscal year 2019 financial guidance and assumptions remain intact Bottom LineAmerisourceBergen exited the fiscal third quarter on a strong note  wherein both the bottom and the top line beat the consensus mark  The company continues to gain from its Pharmaceutical segment and World Courier business  which have been generating huge profits since quite some time  Its specialty distribution business also continues to contribute significantly to the top line  Additionally  the company s Global Commercialization Services and Animal Health unit witnessed a strong third quarter  A raised EPS guidance for 2019 instills investors  optimism in the stock These apart  the company entered into a long term strategic relationship with OneOncology   a national partnership of community oncologists in the United States  Additionally  Innomar Strategies  the Canadian operations business unit of the company  added Chronically Simple to its digital solutions portfolio  Notably  Chronically Simple is a secure web based service and mobile application that has been developed to meet the complex needs of patients with chronic illnesses and ongoing health challenges  We believe these developments to have impacted the company s results Meanwhile  sluggish performances by the company s PharMEDium and Lash units have been a headwind over the last couple of quarters  The company faces other headwinds like conversion of branded drugs and lower price generics  Cutthroat competition in the MedTech space adds to woes Zacks RankCurrently  AmerisourceBergen carries a Zacks Rank  3  Hold   Earnings of Other MedTech Majors at a GlanceSome better ranked stocks which posted solid results this earning season are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Stryker delivered third quarter 2019 adjusted earnings per share of  1 98  beating the Zacks Consensus Estimate by 2 6   Revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4   The company carries a Zacks Rank of 2  Buy   You can see  
Baxter delivered third quarter 2019 adjusted earnings of 89 cents per share  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Revenues of  2 84 billion outpaced the Zacks Consensus Estimate of  2 79 billion by 1 9   The company carries a Zacks Rank  2 Intuitive Surgical reported third quarter 2019 adjusted earnings per share of  3 25  which beat the Zacks Consensus Estimate of  2 85  Revenues were  1 1 billion  surpassing the Zacks Consensus Estimate of  1 03 billion  The company sports a Zacks Rank  1 
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-07-31,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-abc-q3-earnings--revenues-top-estimates-200449264,200449264
103010,324525,ABC,Match Group  MTCH  To Report Q2 Earnings  What s In Store ,opinion,Match Group  Inc    NASDAQ MTCH   is set to report second quarter 2019 results on Aug 6  Notably  the company surpassed the Zacks Consensus Estimate for earnings in the trailing four quarters  with an average positive earnings surprise of 20 2  Past Quarter PerformanceMatch Group had delivered first quarter 2019 adjusted earnings of 49 cents per share  which surpassed the Zacks Consensus Estimate of 33 cents Revenues of  464 6 million beat the Zacks Consensus Estimate of  464 million and improved 14  year over year  Excluding the effect of Foreign Exchange  the top line was up 18  year over year What to Expect in Q2Match Group anticipates second quarter 2019 revenues between  480 million and  490 million  Tinder remains the key catalystThe Zacks Consensus Estimate for second quarter earnings is pegged at 45 cents per share  unchanged for the last 30 days  The figure indicates growth of 9 8  from the year ago reported figure  The Zacks Consensus Estimate for revenues stands at  488 6 million  suggesting an improvement of 16  from the year ago quarter Match Group s stock has gained 97 9  in a year  against the  s decline of 16 6  Let s see how things are shaping up prior to this announcement Factors at PlayMatch Group is benefiting from increasing subscriber addition in the form of membership subscriptions  Total average subscribers in the first quarter came in at 8 6 million  surging 16  from the year ago quarter  The Zacks Consensus Estimate is pegged at approximately 9 million for the second quarter  indicating an improvement of approximately 16 9  year over year Strong product portfolio comprising Tinder  Match com  Meetic  PlentyOfFish and OkCupid are expected to aid Match Group s top line in the to be reported quarter  Tinder has been the key catalyst behind the company s year over year revenue growth  Direct revenues from Tinder grew 38  year over year in the last reported quarter  Tinder s average subscribers surged 36  year over year and came in at 4 7 million  The momentum is anticipated to aid the upcoming quarterly results Further  Match Group is leaving no stone unturned to capitalize on opportunities in India  The country is currently experiencing demographic dividend  wherein majority of the population is below 35 years of age  A burgeoning well educated middle class  increasing spending power and rapid adoption of smartphones are enhancing the company s business prospects in th country In the first quarter  management noted that with initial levels of investment in India  OkCupid downloads soared 600  year over year in first quarter  Tinder and OkCupid dating apps are becoming increasingly popular among single millennials in the country  Management notes that migration of youngsters to bigger cities and lessening allegiance to arranged marriage are favoring growth prospects in India  This in turn is likely to aid the to be reported quarter s results Growing Internet penetration in overall South east Asia and impending launch of Tinder Lite are expected to be tailwinds What the Zacks Model UnveilsAccording to the Zacks model  a company with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has a good chance of beating estimates if it also has a positive   The Sell rated stocks  Zacks Rank  4 or 5  are best avoided Match Grouphas a Zacks Rank  4  Sell  and an Earnings ESP of 0 00   You can uncover the best stocks to buy or sell before they re reported with our  Stocks to ConsiderHere are some stocks which you may consider as our model shows that these have the right combination of elements to post an earnings beat in its upcoming release Lockheed Martin Corporation   NYSE LMT   has an Earnings ESP of  0 90  and a Zacks Rank  2  You can see  AmerisourceBergen Corporation   NYSE ABC   has an Earnings ESP of  0 82  and a Zacks Rank  3 SeaWorld Entertainment   NYSE SEAS   has an Earnings ESP of  11 01  and a Zacks Rank  3 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-07-31,Zacks Investment Research,https://www.investing.com/analysis/match-group-mtch-to-report-q2-earnings-whats-in-store-200449250,200449250
103011,324526,ABC,AmerisourceBergen  ABC  Tops Q3 Earnings And Revenue Estimates,opinion,"AmerisourceBergen  NYSE ABC  came out with quarterly earnings of  1 76 per share  beating the Zacks Consensus Estimate of  1 63 per share  This compares to earnings of  1 54 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 7 98   A quarter ago  it was expected that this prescription drug distributor would post earnings of  1 96 per share when it actually produced earnings of  2 11  delivering a surprise of 7 65  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
AmerisourceBergen  which belongs to the Zacks Medical   Dental Supplies industry  posted revenues of  45 24 billion for the quarter ended June 2019  surpassing the Zacks Consensus Estimate by 0 01   This compares to year ago revenues of  43 14 billion  The company has topped consensus revenue estimates two times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
AmerisourceBergen shares have added about 17 1  since the beginning of the year versus the S P 500 s gain of 18 9  
What s Next for AmerisourceBergen 
While AmerisourceBergen has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for AmerisourceBergen was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 51 on  45 31 billion in revenues for the coming quarter and  6 86 on  178 58 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Dental Supplies is currently in the top 39  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-08-01,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-abc-tops-q3-earnings-and-revenue-estimates-200448931,200448931
103044,324559,ABC,New York City sues drug companies over opioid epidemic,news,"By Jonathan Stempel and Nate Raymond NEW YORK  Reuters    New York City on Tuesday sued eight companies that make or distribute prescription opioids  blaming them for fuelling a deadly epidemic afflicting the most populous U S  city  Mayor Bill de Blasio said the lawsuit sought  500 million of damages to help fight the crisis  which kills more people in the city annually than homicides and car accidents combined  including more than 1 100 from opioid induced overdoses in 2016   Big Pharma helped to fuel this epidemic by deceptively peddling these dangerous drugs and hooking millions of Americans in exchange for profit   de Blasio said in a statement  The defendants include manufacturers Allergan Plc  N AGN   Endo International Plc  O ENDP   Johnson   Johnson  N JNJ   Purdue Pharma LP and Teva Pharmaceutical  NYSE TEVA  Industries Ltd  TA TEVA   and distributors AmerisourceBergen Corp  N ABC    Cardinal Health  Inc  N CAH  and McKesson Corp  N MCK   All were accused in the city s complaint of creating a public nuisance  and the distributors were accused of negligence  Allergan  Endo  J J  Purdue  Teva  AmerisourceBergen and McKesson in separate statements emphasized the importance of using opioids safely  Endo  J J and Purdue also denied the city s allegations  while McKesson declined to comment on the lawsuit  Cardinal Health did not immediately respond to requests for comment  New York City  whose population is about 8 54 million  joined a long list of U S  states and municipalities to sue drug companies over opioid abuse  which U S  President Donald Trump has called a national public health emergency  Opioids  including prescription painkillers and heroin  played a role in 42 249 U S  deaths in 2016  up 28 percent from 2015 and 47 percent from 2014  according to the U S  Centers for Disease Control and Prevention  In its complaint filed in state court in Manhattan  New York accused manufacturers of having for two decades misled consumers into believing that prescription opioids were safe to treat chronic non cancer pain  with minimal risk of addiction  The city also said distributors fueled abuse through oversupply  including a failure to identify suspicious orders and report them to authorities  contributing to an illegal secondary market  Prescription opioids  such as Purdue s OxyContin and Endo s Percocet  are regulated as controlled substances  New York City said roughly 2 5 million to 2 7 million opioid prescriptions were filled there each year from 2014 to 2016  
The case is City of New York v Purdue Pharma LP et al  New York State Supreme Court  New York County  No  450133 2018 ",2018-01-23,Reuters,https://www.investing.com/news/stock-market-news/new-york-city-sues-drug-companies-over-opioid-epidemic-1140930,1140930
103045,324560,ABC,Height weighs in on Amazon Berkshire JPMorgan healthcare venture,news,Height Securities  Andrea Harris says managed care firms are not the ones in the crosshairs of Amazon  NASDAQ AMZN   Berkshire Hathaway  NYSE BRKa  and JPMorgan  NYSE JPM  s planned venture into healthcare  The margins are too thin and setting up a care network is expensive and difficult The companies at greater risk are drug makers  wholesalers  pharmacy benefit managers  PBMs  and specialty pharmacies since this is where scale and efficiencies can make the biggest impact  Ms  Harris says if Amazon acquires Express Scripts  NASDAQ ESRX   the only remaining large cap PBM remaining  it would be in a strong position to drive down prices Related tickers   NYSE GRX  NYSE THW  NYSE BME  NYSEARCA IXJ  NYSEARCA XLV  NYSEARCA PJP  NYSEARCA IHE  NASDAQ IBB  NYSEARCA XBI  NYSE ABC  NYSE MCK  NYSE CAH  NYSE CVS  NYSE UNH  NYSE CNC  NYSE ANTM  NYSE AET  NYSE CI  NYSE MOH  NYSE JNJ  NYSE ABBV  NYSE AGN  NYSE AZN  NYSE BMY  NYSE LLY  NYSE GSK  NYSE MRK  NYSE PFE  NYSE NVS  NYSE VRX Now read ,2018-01-30,Seeking Alpha,https://www.investing.com/news/stock-market-news/height-weighs-in-on-amazonberkshirejpmorgan-healthcare-venture-1171022,1171022
103046,324561,ABC,Amazon  Berkshire  JPMorgan partner to cut  healthcare costs,news,"By Caroline Humer and Ankur Banerjee  Reuters    Amazon com Inc  NASDAQ AMZN   Berkshire Hathaway  NYSE BRKa  and JPMorgan Chase   Co  NYSE JPM  will form a healthcare company aimed at cutting costs for their U S  employees  they said on Tuesday  sending shares in the broad healthcare sector sharply lower  The company will not aim to make a profit and initially focus on technology to provide what they called  simplified  high quality and transparent healthcare  for their more than 500 000 U S  employees   The ballooning costs of healthcare act as a hungry tapeworm on the American economy   said Berkshire Hathaway Chairman and Chief Executive Officer Warren Buffett   Our group does not come to this problem with answers  But we also do not accept it as inevitable   The announcement comes as investors in the healthcare sector worry that technology and retailing behemoth Amazon could become a healthcare competitor and eat away at sector profits  just as it has done in retailing  Amazon has been looking at the pharmacy business and pharmacy distribution  according to numerous media reports and Wall Street analysts  It is unclear if the company has plans beyond this initiative  U S  healthcare spending increases each year faster than inflation  and in 2017 accounted for 18 percent of the U S  economy  Corporations  which sponsor healthcare plans for more than 160 million Americans  and the U S  government are trying to cut those costs  Prices have risen under former Democratic President Barack Obama s 2010 Affordable Care Act  which overhauled health insurance and expanded the Medicaid government program for the poor  Republican President Donald Trump has rolled back the mandate that required all Americans to have health insurance or pay a fine  cut subsidies for low income people and promised new  cheaper insurance  By teaming up with JPMorgan  the biggest U S  bank  and Berkshire  the third largest public company in the world  Amazon appears to be taking a big step in shaking up the health industry    Investors have continually asked what unexpected development might spoil the strong investor sentiment towards managed care  Unfortunately  this seems tailor made to fit the bill   BMO Capital Markets analyst Matt Borsch said in a research note  INSURERS FALL Health insurers that provide benefit management or health plans to the three companies could be among the hardest hit  JPMorgan uses UnitedHealth Group Inc  NYSE UNH  and  Cigna Corp   NYSE CI  for health benefits for its global workforce  according to ISI Evercore analyst Ross Muken  Neither company was immediately available for comment  Amazon uses Premera Blue Cross  part of the Blue Cross Blue Shield network  according to Muken  Express Scripts  the pharmacy benefits manager  has disclosed it manages pharmacy benefits for Amazon  Shares in UnitedHealth  Cigna Corp and health insurer Anthem Inc fell 4 percent to 7 percent   Drugstore operators CVS Health Corp  NYSE CVS  and Walgreen Boots Alliance as well Express Scripts all dropped between 4 percent to 8 percent   Drug distributors  Cardinal Health   NYSE CAH   AmerisourceBergen  NYSE ABC  and McKesson  NYSE MCK  were off 2 percent to 4 percent   The plan  currently in the early stages  will be spearheaded by Berkshire investment officer Todd Combs  JPMorgan managing director Marvelle Berchtold and Amazon senior vice president Beth Galetti  Wall Street saw the move as a positive for Amazon though its shares fell 0 5 percent  Much of Amazon s value is from its owning and interpreting massive amounts of data  according to ISI Evercore  
 Though it is unclear how the data of this venture will be shared utilized  it is not inconceivable that Amazon could potentially leverage it longer term to better navigate the complexities of the healthcare market   the note said ",2018-01-30,Reuters,https://www.investing.com/news/stock-market-news/amazon-berkshire-jpm-to-partner-on-cheaper-healthcare-for-staff-1169520,1169520
103047,324562,ABC,Big biopharma firms poised to end session in the red after Trump comments on high prices,news,Large cap biopharma companies continue to be under pressure as the close nears  In last night s State of the Union address  President Trump stated that cutting drug prices is a  top priority  Drug wholesalers are down as well Selected tickers   JNJ  2 5   ABBV  2 6   AGN  1 9   AZN  1 7   BMY  2   LLY  4 6   GSK  1 3   MRK  1 9   PFE  1 7   NVS  1 6   NVO  2   SHPG  2 8   VRX  0 4   TEVA  1 1   BIIB  1 2   AMGN  2 6   VRTX  0 1   CELG  SNY  1 7   REGN  3 4   ABC  2 4   MCK  1 4   CAH  2 7  Now read ,2018-01-31,Seeking Alpha,https://www.investing.com/news/stock-market-news/big-biopharma-firms-poised-to-end-session-in-the-red-after-trump-comments-on-high-prices-1178432,1178432
103048,324563,ABC,Walgreens bid for AmerisourceBergen would be a head scratcher  analysts,news,"By Ankur Banerjee  Reuters    Walgreens  potential move to buy a drug distributor in which it already has a 26 percent stake has some analysts questioning the logic and wondering if it would be enough to compete in an evolving U S  healthcare sector  Analysts said any deal would not be a surprise  but might cost Walgreens opportunities down the line as the company tries to keep pace with rival CVS Health Corp  NYSE CVS   which is set to buy health insurer  Aetna Inc   NYSE AET   and an impending threat from Amazon com  NASDAQ AMZN   Walgreens Boots Alliance  NASDAQ WBA  Inc  the largest U S  drugstore operator  has made a takeover approach to AmerisourceBergen  NYSE ABC  Corp  the Wall Street Journal reported on Monday  but said the talks were in early stages  AmerisourceBergen shares were up 12 percent in early trading  while Walgreens shares were up 1 4 percent  Shares of drug distributors Mckesson Corp and  Cardinal Health   NYSE CAH  were lower    This purported deal wouldn t be shocking     but we re currently struggling to see the strategic allure of the combination for Walgreens   Baird analyst Eric Coldwell said in a note   The two companies are already closely allied  having struck a 10 year deal in 2013 for AmerisourceBergen to buy drugs for Walgreens  which subsequently acquired 26 percent of the distributor  The rationale for such a deal is a bit of a head scratcher as Walgreens and AmerisourceBergen already have a joint venture that affords both the strategic value that combining would provide  Jefferies analyst Brian Tanquilut said  The news comes as the U S  healthcare landscape remains in a state of flux  with changes to the U S  Affordable Care Act escalating drug prices and Amazon s possible entry  Walgreens has highlighted that it tends to prefer partnerships  which analysts say could eventually turn into acquisitions  A deal  however  would give Walgreens a bigger presence in the specialty pharmacy space  where it does not have adequate exposure  setting it up to compete better against CVS and pharmacy benefit manager Express Scripts Holding Co  
 As the broader healthcare sector focuses more on moving specialty drug administration out of facility based  hospital physician s office  settings  gaining a strong foothold in specialty through ABC could be a valuable strategic move   Tanquilut said ",2018-02-13,Reuters,https://www.investing.com/news/stock-market-news/walgreens-bid-for-amerisourcebergen-would-be-a-headscratcher-analysts-1237873,1237873
103049,324564,ABC,Albertsons to buy Rite Aid as Amazon threat looms,news,"By Siddharth Cavale  Reuters    U S  grocer Albertsons Cos Inc said it would buy drug store chain  Rite Aid Corp   N RAD  to create a company with  83 billion in annual revenue  giving it more clout to compete with bigger chains in an industry fearing the entry of Amazon Com  O AMZN   The deal is the latest in a wave of consolidation in the drug retailing sector  which is looking to cut costs amid weak reimbursement rates and lower generic drug prices  At the same time  Amazon s foray is widely expected to disrupt the industry  prompting drug chains to beef up their businesses  Backed by private equity firm Cerberus Capital Management  Albertsons hopes the deal will help it become a formidable competitor to CVS Corp  N CVS  and Walgreens  O WBA   and give its private equity owners a way to exit their decade long investment in the grocer  Cerberus first took a stake in Albertsons in 2006 and scaled it through acquisitions including that of Safeway in 2014  It planned to sell its stake through an IPO in 2017  but dropped the plans after Amazon bought grocer Whole Foods Market  NASDAQ WFM  in May   The new company will have an expanded footprint and be ranked first or second in 66 percent of the top metropolitan areas in the United States and will be ranked first or second in 70 percent of pharmacy locations   Albertsons and Rite Aid said in a joint statement on Tuesday  Albertsons owns about 2 300 supermarket stores mainly on the east and west coasts of the United States and also operates about 1 800 pharmacies  Rite Aid owns about 2 569 drug stores  after it sold 1 932 pharmacies to Walgreens for  4 38 billion  Albertsons said it would convert its existing pharmacies to Rite Aid stores and let existing Rite Aid outlets operate as stand alone pharmacies  Together  the combined company will operate about 4 350 pharmacy counters and 320 clinics across 38 states and Washington  Within three years the combined company is expected to deliver annual run rate cost savings of  375 million  with more than 60 percent within the first two years  the companies said  The combined company is expected to generate pre tax earnings of about  3 7 billion within three years  they said  Rite Aid s shares  which initially surged by as much as 25 percent premarket on Tuesday  were trading up 2 3 percent at  2 18 in afternoon trading  TOUGH MARKET The deal follows Amazon com Inc s  O AMZN  move to team up with  Berkshire Hathaway Inc   N BRKa  and JPMorgan Chase   Co  N JPM  to form a not for profit company to provide health care for their employees  challenging the existing U S  healthcare system  The threat of Amazon making further inroads has jolted U S  drug store chains into action after several years of declines in traffic and sales at front end stores  Larger rival CVS Health Corp  N CVS  reached a  69 billion deal to buy insurer  Aetna Inc   N AET  last month  while Walgreens is also reported to have made a takeover approach for drug distributor AmerisourceBergen Corp  N ABC    Drug retailing has had its own challenges with reimbursement pressure and weak front end sales as evidenced in Rite Aid s weak profits over the last couple of years   said Mickey Chadha  a vice president with credit ratings agency Moody s   Competing with much larger and more diversified drug retailers like CVS and Walgreens will be a formidable challenge   he said  Based on the enterprise value of both Albertsons and Rite Aid  the combined company is valued at  24 billion  an Albertsons Companies  spokeswoman told Reuters  Rite Aid shareholders can elect to get either one Albertsons common share plus about  1 83 in cash  or 1 079 Albertsons common shares for every 10 shares they hold  Shareholders of Rite Aid  which had a market cap of  2 33 billion at midday Tuesday  will own between 28 percent and 29 6 percent of the combined company  while Albertsons  shareholders will own the rest based on the elections  the companies said   
Depending on whether Rite Aid shareholders choose to be paid in cash and Albertsons stock or only stock  the deal values Rite Aid at between  1 30 and  2 65 per share  Evercore ISI analyst Ross Muken said ",2018-02-20,Reuters,https://www.investing.com/news/stock-market-news/albertsons-will-buy-chunk-of-rite-aid-that-isnt-going-to-walgreens-wsj-1277149,1277149
103057,324572,ABC,DaVita  DVA  Announces Preliminary Q2 Results  View Upbeat,opinion,"DaVita Inc    NYSE DVA   recently announced preliminary results for second quarter 2019  with operating income projected within  460  465 million The company is scheduled to release full financial results on Aug 1  after market close Investors CheerFollowing the announcement  shares of this Zacks Rank  3  Hold  company jumped 4 9  to  58 80 at close Notably  DaVita s impressive guidance for 2019 has boosted investors  optimism in the stock  The company now expects adjusted operating income between  1 64 billion and  1 70 billion  This reflects a significant increase from the earlier projected range of  1 54 billion to  1 64 billion Per management  the substantially raised view is a result of the company s higher profit expectation from calcimimetics Quarter HighlightsDaVita expects calcimimetics to have contributed nearly  40 million to its operating income in the second quarter Additionally  the company s U S  dialysis and related lab services segment is anticipated to have significantly driven the top line Hence  the company now expects non acquired treatment growth of 2 1   with 7 520 587 treatments in the second quarter  Revenue per treatment is expected at  350  an increase of approximately  1 60 year over year For the second quarter  DaVita projects reduced per treatment costs of  9 from the year ago figure  Per management  this is likely to be driven by reduced calcimimetics expenses and reduced labor and benefit expenses due to strong productivity Notably  the recent divestment of the DaVita Medical Group unit to Optum has helped the company focus more on its core Kidney Care business  thereby fortifying its foothold in the global renal care market DaVita Inc  Price and Consensus
    Price PerformanceWe believe positive performances such as these will boost DaVita s shares which have slipped 17  in a year  compared with the  s 19 4  decline Key PicksSome better ranked stocks in the broader medical space are DENTSPLY SIRONA   NASDAQ XRAY    AmerisourceBergen Corporation   NYSE ABC   and Stryker Corporation   NYSE SYK    While DENTSPLY SIRONA sports a Zacks Rank  1  Strong Buy   AmerisourceBergen and Stryker carry a Zacks Rank  2  Buy   You can see  The Zacks Consensus Estimate for DENTSPLY SIRONA s second quarter 2019 revenues is pegged at  1 03 billion   The same for adjusted earnings per share stands at 62 cents  indicating an increase of 3 3  from the year ago reported figure The Zacks Consensus Estimate for AmerisourceBergen s third quarter fiscal 2019 revenues is pegged at  45 2 billion  suggesting 4 8  growth from the prior year reported figure  The same for adjusted earnings per share stands at  1 63  implying a 5 8  improvement from the year ago reported number The Zacks Consensus Estimate for Stryker s second quarter 2019 revenues is pegged at  3 6 billion  indicating an 8 5  rise from the year ago reported figure   The same for adjusted earnings per share stands at  1 94  suggesting 10 2  growth from the year earlier quarter s reported figure Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-07-23,Zacks Investment Research,https://www.investing.com/analysis/davita-dva-announces-preliminary-q2-results-view-upbeat-200443107,200443107
103058,324573,ABC,AmerisourceBergen  ABC  Earnings Expected To Grow  Should You Buy ,opinion,"The market expects AmerisourceBergen  NYSE ABC  to deliver a year over year increase in earnings on higher revenues when it reports results for the quarter ended June 2019  This widely known consensus outlook is important in assessing the company s earnings picture  but a powerful factor that might influence its near term stock price is how the actual results compare to these estimates 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on August 1  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This prescription drug distributor is expected to post quarterly earnings of  1 63 per share in its upcoming report  which represents a year over year change of  5 8  
Revenues are expected to be  45 19 billion  up 4 8  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 1 1  higher over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for AmerisourceBergen 
For AmerisourceBergen  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  0 82  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination indicates that AmerisourceBergen will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that AmerisourceBergen would post earnings of  1 96 per share when it actually produced earnings of  2 11  delivering a surprise of  7 65  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
AmerisourceBergen appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-07-24,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-abc-earnings-expected-to-grow-should-you-buy-200445011,200445011
103087,324602,ABC,Amazon the real impetus behind CVS Aetna deal talks  reports say,news,The threat of Amazon  NASDAQ AMZN  is the real reason behind CVS Health s  NYSE CVS  reported  66B offer for Aetna  NYSE AET   as the prospect of AMZN s entry into the healthcare industry begins to roil drugstore chains  drug distributors and  pharmacy benefit managers  An acquisition of a major insurer was among a dozen or so strategies CVS s management team recently presented to directors  WSJ reports  The day s turmoil began earlier when the St  Louis Post Dispatch reported that AMZN had obtained wholesale pharmacy licenses in at least a dozen states  which sent the likes of McKesson  NYSE MCK   AmerisourceBergen  NYSE ABC  and  Cardinal Health   NYSE CAH  sharply lower  Drug industry execs say AMZN could use its online reach and logistical strength to threaten companies that ship and sell medicines to consumers and cut pricing deals with drug makers  AET still closed more than 10  below the reported   200 share offer price  a sign that investors have some doubts that the CVS deal will close successfully  but  given the state of affairs in the drug business  the real risk for CVS shareholders might be standing pat   writes Heard On The Street s Charley Grant  Now read ,2017-10-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/amazon-the-real-impetus-behind-cvsaetna-deal-talks-reports-say-548929,548929
103088,324603,ABC,Investor group presses U S  drug companies on opioid controls,news,"By Ross Kerber BOSTON  Reuters    U S  shareholder activists are addressing a soaring death toll from opioid drug abuse  asking companies that make and distribute the painkillers to review the risks their businesses could face from their role in the sector  Leaders of a 30 fund group that includes state pension officials and religious and labor organizations plan to reveal on Monday they have begun filing shareholder resolutions at 10 companies  including distributors AmerisourceBergen Corp  N ABC  and  Cardinal Health  Inc  N CAH  and manufacturers Johnson   Johnson  N JNJ  and Insys Therapeutics  O INSY   In resolutions aimed at annual shareholder meetings to be held in 2018 and in letters to the companies  activists are urging independent directors to review and report on how the boards are managing the legal  financial and reputational risks their enterprises face from their involvement with opioids  They also seek corporate governance reforms such as allowing more grounds to claw back pay from executives who inappropriately promote the drugs  or creating independent board chairs to provide better oversight  Representatives of Cardinal and Insys did not immediately respond to requests for comment  Johnson   Johnson spokesman Ernie Knewitz said the company was preparing a response to the investors  and that the company had acted responsibly    Opioid abuse is a serious public health issue that must be addressed  and doing so will require collaboration among many stakeholders  and our company is committed to working with federal  state and local officials to help find meaningful solutions   he said in an emailed statement  In a statement emailed by AmerisourceBergen spokeswoman Keri Mattox  the company said it  welcomes a productive dialogue with all shareholders  The issue of opioid abuse is a complex one that spans the full healthcare spectrum  including manufacturers  wholesalers  insurers  prescribers  pharmacists and regulatory and enforcement agencies   The statement said the company worked closely with officials  to combat drug diversion while supporting appropriate access to medications    At an annual meeting on Nov  8  Cardinal Health will face a resolution calling for an independent board chair in order to improve oversight   These considerations are especially critical at Cardinal given the potential reputational  legal and regulatory risks Cardinal faces over its role in the nation s opioid epidemic  including its history of compliance challenges concerning the distribution of controlled substances   the resolution s sponsors  including the International Brotherhood of Teamsters  said in a supporting statement  The statement cited Cardinal s payment of tens of millions of dollar to settle various federal and state charges related to opioids  In a securities filing  Cardinal calls the change unnecessary  noting it already has an independent lead director and  state of the art controls  over its pain medications  Officials at all levels of government in the United States are struggling to respond to a surge in deaths from opioid abuse  which hit 33 000 in 2015  the last year for which there is complete federal data   In many cases patients prescribed opioid painkillers become addicted to them and then move on to acquiring the drugs illegally  or turn to heroin or fentanyl  a highly potent synthetic opiate  U S  President Donald Trump on Thursday declared the opioid epidemic a national public health emergency  State attorneys general have also taken on opioid manufacturers  with lawsuits charging that deceptive marketing practices helped fuel an epidemic of abuse  Federal prosecutors on Thursday charged the founder of Insys  John Kapoor  with participating in a scheme to bribe doctors to prescribe a particularly potent opioid  A lawyer for Kapoor said in a statement that Kapoor is innocent and will fight the charges  Shareholder activists said healthcare providers may have underestimated how addictive the drugs were  but said the crisis points to a need for stronger oversight within drugmakers  
 We believe these companies have played an important role in this epidemic   said Donna Meyer  director of shareholder advocacy for Mercy Investment Services  an investment fund for Roman Catholic nuns  It is leading the resolutions push  along with the UAW Retiree Medical Benefits Trust  which oversees benefits for about 700 000 retirees of the United Auto Workers ",2017-10-30,Reuters,https://www.investing.com/news/stock-market-news/investor-group-presses-us-drug-companies-on-opioid-controls-760181,760181
103089,324604,ABC,Analyst action   healthcare,news,OrthoPediatrics   Pending KIDS  initiated with Buy rating and  23  11  upside  by Stifel  Initiated at Outperform by William Blair  Rigel Pharmaceuticals   NASDAQ RIGL  initiated with Buy rating and  7  80  upside  price target by H C  Wainwright SpringBank Pharmaceuticals  NASDAQ SBPH  initiated with Buy rating and  30  91  upside  by B  Riley FBR Bluebird bio  NASDAQ BLUE  downgraded to In line  Neutral  by Evercore ISI Tetraphase Pharmaceuticals  NASDAQ TTPH  price target raised to  17 from  15 by H C  Wainwright Five Prime Therapeutics  NASDAQ FPRX  price target raised to  50 from  41 by RBC Capital Markets VBL Therapeutics  NASDAQ VBLT  price target raised to  25 from  20 by Chardan Capital Markets AmerisourceBergen  NYSE ABC  price target lowered to  86 from  93 citing near term sentiment toward the group and risk associated with a potential entry by Amazon  NASDAQ AMZN  Obalon Therapeutics  NASDAQ OBLN  price target lowered to  15 from  20 by BTIG Research HCA price target lowered to  81 from  87 by  Citigroup   NYSE C  Teva Pharmaceutical Industries  NYSE TEVA  price target lowered to  14 from  20 by Susquehanna Source  BloombergNow read ,2017-11-06,Seeking Alpha,https://www.investing.com/news/stock-market-news/analyst-action--healthcare-764474,764474
103090,324605,ABC,Amazon has range of options to invade pharmacy business   Bloomberg,news,Online 8 000 lb  gorilla Amazon  AMZN  0 1   can make life miserable for prescription drug sellers in a variety of ways according to Bloomberg At the top of list is leveraging its massive logistics operation to launch a mail based drug delivery business  Prime membership  where customers pay an annual fee of  99 for unlimited qualified shipments  would be yet another way for Amazon to build customer loyalty among retail prescription drug buyers  Prime Now  with its two hour delivery  already includes convenience items found in drug stores  It would also be in position to improve the consumer experience using Alexa to shop for medicines online or on mobile devices Use its buying power to offer customers inexpensive generics  like Walmart  NYSE WMT   but with the added convenience of online ordering  It could make deals with insurers who do not have a large presence in mail drug delivery such as Humana  HUM  0 3    Cigna  CI  0 3   and even UnitedHealth Group  UNH  0 1   Leverage the physical presence of Whole Foods to set up pharmacies or pick up points in addition to mail delivery  It could also partner with local independent pharmacies by allowing patients to order medicines online for pick up at the stores Buy a drug distributor or pharmacy benefit manager like Express Scripts  ESRX  0 6   which already operates a large mail order business  A downside  though  would be the potential exclusion from competitors Launch a startup  Amazon already owns wholesale distribution licenses in at least 13 states and could build a pharmacy operation from scratch which would enable it to restructure the drug supply chain Related tickers   ABC  0 1   WBA  3 1   CVS  3 3   CAH  0 3   MCK  1   AET  0 4  Now read ,2017-11-07,Seeking Alpha,https://www.investing.com/news/stock-market-news/amazon-has-range-of-options-to-invade-pharmacy-business--bloomberg-839662,839662
103091,324606,ABC,Amazon cancels drug wholesaler license application in Maine,news,RBC reports that Amazon  AMZN  0 7   has canceled its pharmaceutical wholesaler application in Maine  Pundits and analysts say the action implies that the online juggernaut will not enter prescription drug distribution in the near term  opting instead for selling medical supplies  an activity that does not require a license in Maine If  indeed  Amazon defers on the pharma side  RBC says it will be a positive for pharmacy operators and drug suppliers Amazon has similar licenses in 15 states Related tickers   WBA  2   CVS  1 2   RAD  6 4   ABC  1 5   MCK  1 6   CAH  1 1  Now read ,2017-12-05,Seeking Alpha,https://www.investing.com/news/stock-market-news/amazon-cancels-drug-wholesaler-license-application-in-maine-956889,956889
103092,324607,ABC,Delaware sues opioid manufacturers  distributors over epidemic,news,"By Nate Raymond  Reuters    Delaware on Friday became the latest state to file a lawsuit accusing corporations of helping fuel the national opioid epidemic  suing a wide range of companies involved in making  distributing and selling prescription painkillers  The lawsuit  filed by Delaware Attorney General Matt Denn in a state court  targeted drugmakers Purdue Pharma LP and Endo International Plc  O ENDP  along with several wholesale drug distributors and the retailers CVS Health Corp  N CVS  and Walgreens Boots Alliance Inc  O WBA   The lawsuit accused Purdue and Endo of engaging in a massive marketing campaign aimed at concealing the risks of using opioids to treat chronic pain in order to overcome a medical consensus that using the drugs for that purpose was unsafe  Distributors including McKesson Corp  N MCK    Cardinal Health  Inc  N CAH  and AmerisourceBergen Corp  N ABC  along with the two retailers ignored red flags indicating that opioids were being diverted for illicit uses  according to the lawsuit   The failure of these corporate defendants to meet their legal obligations has had a devastating impact on Delawareans   Denn said in a statement  Purdue  which produces OxyContin  and Endo  which last year withdrew Opana ER from the market  in separate statements said they denied the allegations but are concerned about opioid abuse  AmerisourceBergen said it was dedicated to doing its part to mitigate the diversion of drugs  Cardinal Health said it would defend itself in court  Other defendants in the lawsuit included Anda  a distributor owned by Teva Pharmaceutical  NYSE TEVA  Industries Ltd  TA TEVA   Representatives for Anda and the other companies did not immediately respond to requests for comment  Opioids were involved in over 42 000 overdose deaths in 2016  according to the U S  Centers for Disease Control and Prevention   A wave of lawsuits by states  counties and cities have accused drugmakers of pushing addictive painkillers through deceptive marketing and wholesale distributors of failing to report suspicious drug orders   A group of state attorneys general have been conducting a multistate investigation into whether companies that manufacture and distribute prescription opioids engaged in unlawful practices   Increasingly  some attorneys general have decided to file lawsuits outside of the probe alone against the companies under scrutiny  At least 14 other states are pursuing opioid related lawsuits against one or more the companies Delaware sued  
A federal judge in Ohio overseeing more than 200 lawsuits by cities  counties and others over the opioid epidemic recently reached out to some state attorneys general about meeting as he pushes for a quick settlement of the litigation ",2018-01-19,Reuters,https://www.investing.com/news/stock-market-news/delaware-sues-opioid-manufacturers-distributors-over-epidemic-1127587,1127587
103100,324615,ABC,Intuitive Surgical  ISRG  Q2 Earnings Beat  Guidance Narrowed,opinion,"Intuitive Surgical  Inc    NASDAQ ISRG   reported adjusted earnings per share  EPS  of  3 25 in the second quarter of 2019  ahead of the Zacks Consensus Estimate of  2 85  Adjusted EPS improved 17 8  year over year The Zacks Rank  3  Hold  company recorded revenues of  1 1 billion which improved 20 9  from the prior year quarter  The figure also outpaced the Zacks Consensus Estimate of  1 03 billion Per management  higher second quarter revenues were driven by increased procedures and system placements Segment DetailsInstruments   AccessoriesRevenues at the segment came in at  578 5 million  reflecting a year over year increase of 21 5  on 17  growth in da Vinci procedure volumes SystemsIn the reported quarter  System revenues increased 23 9  year over year to  343 8 million  Notably  the company shipped 273 da Vinci Surgical Systems in the quarter ServicesServices revenues came in at  176 6 million  up 13 4  from the year ago quarter Intuitive Surgical  Inc  Price  Consensus and EPS Surprise
    International Sales UpOutside the United States  revenues totaled  314 million  up 19  on a year over year basis  The improvement can be attributed to higher instruments and accessory revenues  driven by procedure growth and customer buying patterns Outside the United States  Intuitive Surgical placed 80 systems in the second quarter compared with 82 in the second quarter of 2018  Of these  30 were in Europe  24 in Japan  and eight in China MarginsAdjusted gross profit in the reported quarter was  783 7 million  up 21 2  year over year  As a percentage of revenues  gross margin in the quarter was 71 3   up 20 basis points  bps  Adjusted operating income totaled  455 3 million  up 17 1  year over year  As a percentage of revenues  operating margin in the quarter was 41 4   down 130 bps 2019 OutlookIntuitive Surgical now forecasts 2019 procedure growth in the range of 16  to 17   compared with the previous 15  to 17  Full year gross profit is expected within 70 71  of net revenues Wrapping UpIntuitive Surgical ended the second quarter on a solid note  The flagship da Vinci procedures recorded solid growth in the quarter which drove the core Instrument   Accessories arm  In fact  management continues to expect strong procedure growth in 2019  The company looks to accelerate its business in China  which saw a solid second quarter as well  Overall international sales also surged in the quarter  Management is optimistic about the recent approvals of the Ion endoluminal system  IRIS augmented reality product and the da Vinci SP Surgical System  Expansion in gross margin is an added positive On the flip side  contraction in operating margin is worrisome  Additionally  the da Vinci system is in the early stages of adoption in some of the markets outside the United States which is likely to impede placements  Intense competition in the global MedTech space is concerning as well Key PicksSome better ranked stocks in the broader medical space are DENTSPLY SIRONA   NASDAQ XRAY    AmerisourceBergen Corporation   NYSE ABC   and Stryker Corporation   NYSE SYK    While DENTSPLY SIRONA sports a Zacks Rank  1  Strong Buy   AmerisourceBergen and Stryker carry a Zacks Rank  2  Buy   You can see  The Zacks Consensus Estimate for DENTSPLY SIRONA s second quarter 2019 revenues is pegged at  1 03 billion   The same for adjusted EPS stands at 62 cents  indicating an increase of 3 3  from the year ago reported figure The Zacks Consensus Estimate for AmerisourceBergen s third quarter fiscal 2019 revenues is pegged at  45 3 billion  suggesting 4 9  growth from the prior year reported figure  The same for adjusted EPS stands at  1 64  implying a 6 5  improvement from the year ago reported number The Zacks Consensus Estimate for Stryker s second quarter 2019 revenues is pegged at  3 6 billion  indicating an 8 5  rise from the year ago reported figure   The same for adjusted EPS stands at  1 94  suggesting 10 23  growth from the year earlier quarter s reported figure Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-07-19,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-isrg-q2-earnings-beat-guidance-narrowed-200441891,200441891
103101,324616,ABC,Top Ranked Growth Stocks To Buy For July 22nd,opinion,Here are four stocks with buy ranks and strong growth characteristics for investors to consider today  July 22nd eBay Inc  NASDAQ EBAY    EBAY   This commerce platforms operator  which carries a Zacks Rank  2  Buy   has witnessed the Zacks Consensus Estimate for its current year earnings increasing 1 1  over the last 60 days eBay Inc  Price and Consensus   eBay has a PEG ratio of 1 57 compared with 2 21 for the industry  The company possesses a  of B eBay Inc  PEG Ratio  TTM    Merck   Co   Inc   MRK  This healthcare solutions provider  which carries a Zacks Rank  2  has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0 4  over the last 60 days Merck   Co   Inc  Price and Consensus   Merck has a PEG ratio of 1 73  compared with 1 92 for the industry  The company possesses a Growth Score of B Merck   Co   Inc  PEG Ratio  TTM    Magellan Health  Inc   MGLN   This healthcare management services provider  which carries a Zacks Rank  2  has witnessed the Zacks Consensus Estimate for its current year earnings increasing 2  over the last 60 days Magellan Health  Inc  Price and Consensus   Magellan Health has a PEG ratio of 0 73  compared with 1 35 for the industry  The company possesses a Growth Score of A Magellan Health  Inc  PEG Ratio  TTM    AmerisourceBergen  NYSE ABC  Corporation  ABC   This pharmaceutical products distributor  which carries a Zacks Rank  2  has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0 4  over the last 60 days AmerisourceBergen Corporation Price and Consensus   AmerisourceBergen has a PEG ratio of 1 67  compared with 1 75 for the industry  The company possesses a Growth Score of A AmerisourceBergen Corporation PEG Ratio  TTM    See the  Learn more about the  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-07-21,Zacks Investment Research,https://www.investing.com/analysis/top-ranked-growth-stocks-to-buy-for-july-22nd-200442767,200442767
103138,324653,ABC,U S  Senator expands opioid probe to distributors  drugmakers,news," Reuters    U S  Democratic Senator Claire McCaskill on Thursday expanded an investigation into the causes of the opioid crisis plaguing the country  seeking information from four more drugmakers and three drug distributors  The top ranking Democrat on the Senate Homeland Security and Governmental Affairs Committee is focusing on the distribution of opioids and the efforts companies made to report and investigate the diversion of drugs for illicit use  The investigation comes at a time when lawmakers and regulators take steps to combat the epidemic of opioid addiction  with 91 Americans dying everyday as a result of overdose  according to the U S  Centers for Disease Control and Prevention   McCaskill requested for documents and information from opioid manufacturers  Mallinckrodt   NYSE MNK  Plc  Endo International Plc  Teva Pharmaceutical  NYSE TEVA  and Allergan  NYSE AGN  Plc  In March  McCaskill asked Johnson   Johnson  NYSE JNJ   Mylan  NASDAQ MYL  NV  Purdue Pharma  Insys Therapeutics Inc and Depomed Inc for internal estimates of the risk of abuse  addiction and overdose of opioids  The senator also sent a request to McKesson Corp  NYSE MCK   AmerisourceBergen  NYSE ABC  Corp and  Cardinal Health  Inc  NYSE CAH   focusing on their distribution of opioid products   McCaskill also requested for information on compensation provided that is in any way derived from revenue or profitability targets for sales of opioid products   We appreciate Senator McCaskill s inquiry and look forward to thoughtfully answering her questions   a McKesson spokeswoman said in an email  adding that there was no link between the sale of controlled substances and incentive compensation for the company s executives   AmerisourceBergen said it would respond to the letter from the Senator  adding it provides daily reports to the regulators about the quantity  type and receiving pharmacy of every single order of controlled substances it distributes  Endo said it received the letter and would provide the Senator with the requested information  Allergan said it is working with the Senator s office to provide the requested information  The company also said its two branded opioid products   Norco and Kadian   account for 0 1 percent or less of all opioids prescribed in the United States  Israel based Teva in an email said it is committed to the  appropriate use of opioids and responsible pain management   Mallinckrodt confirmed receipt of Senator McCaskill s request for information  adding it has previously met with and provided information to her staff and would continue working with her office  The company noted it manufactures  only generic and non promoted branded opioids   
Cardinal Health declined to comment ",2017-07-27,Reuters,"https://www.investing.com/news/politics-news/senator-mccaskill-expands-opioid-probe-to-distributors,-drugmakers-511209",511209
103139,324654,ABC,Wal Mart  Walgreens  CVS turn up the heat on generic drugmaker deals,news,"By Deena Beasley  Reuters    The largest U S  retail pharmacies  including Wal Mart Stores Inc  NYSE WMT  and Walgreens Boots Alliance  NASDAQ WBA  Inc  are wielding more leverage when buying generic drugs  accelerating a decline in prices likely to affect drug companies for some time  industry experts said on Thursday  That pressure is exacerbated by efforts from U S  health regulators to speed approval of copycat drugs  industry sources said  The extent of the shift became clearer this week  when wholesale drug distributors  Cardinal Health  Inc  NYSE CAH  and AmerisourceBergen  NYSE ABC  Corp  as well as top global generic drugmaker Teva Pharmaceutical Industries  NYSE TEVA  Ltd  warned of generic price declines of as much as 9 percent through the end of the year   The news prompted a sell off in shares of generic manufacturers and distributors  On Thursday  Teva fell 24 percent  while rival Mylan  NASDAQ MYL  NV dropped 6 percent and AmerisourceBergen fell 10 percent  Drugmakers  Perrigo Co   NYSE PRGO  Plc and Endo International Plc fell 5 percent and 6 percent  respectively  Since Thursday  Cardinal Health has dropped 10 percent  Walgreens formed a drug buying partnership with AmerisourceBergen in 2013  and earlier this year partnered with pharmacy benefit manager Express Scripts Holdings Co  Retailer CVS Health Corp  NYSE CVS  has tied up with Cardinal Health and  more recently  Wal Mart has joined with McKesson Corp  NYSE MCK  to source generic drugs  Industry analysts said the alliances took some time to become effective  but their power over negotiations is becoming clear   There s no question those guys are getting much better pricing and really squeezing the manufacturers on margins   said Gabelli   Co portfolio manager Jeff Jonas   It s going to be a tough space for some time     they are just going to keep playing the manufacturers off against each other   Express Scripts  in an emailed statement  said its partnership with Walgreens  helps enhance our ability to further drive down the cost of generics     Scale matters and when you can negotiate on behalf of 83 million people   The alliances appear to benefit the retail pharmacies more than their partner wholesalers  whose revenue depends on a cut of the prices of the generic drugs they distribute   Those distributors operate on a maybe 2 percent profit margin  so when your revenue drops  your 2 percent margin becomes a smaller dollar amount   Jonas said   I think that maybe they underestimated how big of an impact that would be when they joined these groups   Teva said it is awaiting the result of bids for a supply contract with Wal Mart and McKesson  and that it now expects prices to fall by a rate in the high single digits through the remainder of the year  In May  Teva said its outlook for price erosion had worsened to 7 percent from 5 percent  AmerisourceBergen sees generic drug price erosion at the high end of the 7 percent to 9 percent range it had previously forecast    It is not at all clear whether the pricing environment will materially improve next year either   Jefferies analyst David Steinberg said in a note to clients  Generic drugmakers have also come under greater scrutiny from U S  consumers  lawmakers and regulators after a series of steep price hikes for drugs long on the market in recent years  The U S  Food and Drug Administration began in 2015 to clear a backlog of applications to bring additional competing generic drugs to market and lower prices  a mission endorsed by its new Commissioner Scott Gottlieb  
 There are good reasons to think the changes we are seeing are structural    Wells Fargo   NYSE WFC  analyst David Maris wrote on Thursday  citing  larger retailing and wholesaling groups  a more efficient FDA  slowing generic drug penetration rates  ",2017-08-03,Reuters,https://www.investing.com/news/stock-market-news/walmart-walgreens-cvs-turn-up-the-heat-on-generic-drugmaker-deals-514549,514549
103140,324655,ABC,Premarket analyst action   healthcare,news,Ultragenyx   NASDAQ RARE  upgraded to Outperform by Wedbush Agile Therapeutics  NASDAQ AGRX  price target raised to  10  186  upside  by RBC Capital Markets citing pending FDA action date on contraceptive patch Twirla by year end  Takeover possible if approved  Opko Health   NYSEMKT OPK  downgraded to Neutral by JPMorgan  NYSE JPM  McKesson  NYSE MCK  downgraded to Equal Weight by  Morgan Stanley   NYSE MS  AmerisourceBergen  NYSE ABC  downgraded to Equal Weight by Morgan Stanley  Applied Genetic  Technologies  NASDAQ AGTC  price target lowered to  12  196  upside  from  15 by Stifel after Q4 results Now read ,2017-09-14,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action--healthcare-528780,528780
103141,324656,ABC,Premarket analyst action   healthcare new coverage,news,CVS Health  NYSE CVS  initiated with Outperform rating and  95  14  upside  price target by RBC Capital Markets saying the company is at an inflection point in its life cycle and should merge with a managed care organization Charles River Laboratories  NYSE CRL  initiated with Sector Perform rating with a  110  3  upside  price target by RBC Capital Markets citing valuation AmerisourceBergen  NYSE ABC  initiated with Sector Perform rating and  87  7  upside  price target by RBC citing the need for more clarity that generic drug pricing has bottomed Allscripts  NASDAQ MDRX  initiated with Outperform rating and  17  24  upside  price target by RBC citing positive business execution  positioning for next generation HCIT solutions and accretion from EIS acquisition Mirati Therapeutics  NASDAQ MRTX  initiated with Outperform rating by Oppenheimer Express Scripts  NASDAQ ESRX  initiated with Sector Perform rating and  68  10  upside  price target by RBC citing the transition of Anthem s business and valuation Walgreens Boots Alliance  NASDAQ WBA  initiated with Outperform rating and  96  16  upside  price target by RBC citing improved execution  volume growth and accelerating EPS  Cardinal Health   NYSE CAH  initiated with Sector Perform rating and  72  7  upside  price target by RBC citing the need for more clarity that generic drug pricing has bottomed  athenahealth   NASDAQ ATHN  initiated with Sector Perform rating and  153  20  upside  price target by RBC citing valuation  Athenex   NASDAQ ATNX  initiated with Buy rating and  36 price target by Laidlaw Patterson Companies  NASDAQ PDCO  initiated with Sector Perform rating and  42  11  upside  price target by RBC citing the need for improved execution and valuation McKesson  NYSE MCK  initiated with Sector Perform rating and  168  14  upside  price target by RBC citing valuation and issues relating to drug pricing  Henry Schein   NASDAQ HSIC  initiated with Sector Perform rating and  91  12  upside  price target by RBC citing valuation Source  BloombergNow read ,2017-09-19,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action--healthcare-new-coverage-530365,530365
103142,324657,ABC,Premarket analyst action   healthcare,news,Abeona Therapeutics  NASDAQ ABEO  initiated with Buy rating and  32  83  upside  price target by Citigroup  NYSE C  MannKind  NASDAQ MNKD  initiated with Buy rating and  7  31  upside  price target by H C  Wainwright Strongbridge Biopharma  NASDAQ SBBP  reiterated with Buy rating and  15  152  upside  price target by Stifel citing bullish prospects for Keveyis and Recorlev AmerisourceBergen  NYSE ABC  and McKesson  NYSE MCK  upgraded to Outperform by Cowen and Company Quest Diagnostics  NYSE DGX  removed from Conviction List at Goldman Sachs  NYSE GS  Eli Lilly  NYSE LLY  downgraded to Neutral by Credit Suisse  SIX CSGN  after Verzenio flop in lung cancer Now read ,2017-10-10,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action--healthcare-539268,539268
103143,324658,ABC,Trump declares opioid emergency,news,Calling opioid abuse the worst drug crisis in U S  or world history  the president declares a national public health emergency  Drug overdoses  he says  are  by far  the top cause of unintentional death  he says  and the government will consider lawsuits against  bad actors  Headed lower  AmerisourceBergen  ABC  4 8     Cardinal Health   CAH  0 6    McKesson  MCK  1 1  Insys  NASDAQ INSY  now down 20  Others on the move  CVS  CVS  5 1    Walgreens  WBA  4 1    Rite Aid  RAD  5 9  Previously  Insys down 10  after founder Kapoor arrested on racketeering charges  Oct  26 Now read ,2017-10-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/trump-declares-opioid-emergency-548698,548698
103151,324666,ABC,Zacks com Featured Highlights Include  Oracle  AngloGold Ashanti  AmerisourceBergen  Ford Motor And CACI International,opinion,For Immediate ReleaseChicago  IL   July 16  2019   Stocks in this week s article are Oracle Corp    NYSE ORCL    AngloGold Ashanti Ltd    NYSE AU    AmerisourceBergen Corp    NYSE ABC    Ford Motor Co    NYSE F   and CACI International Inc    NYSE CACI   5 Discounted PEG Stocks Suitable for Value InvestorsWhile searching for a suitable investment option  value investors with varied risk appetite are unlikely to consider price earnings to growth  PEG  ratio among a number of other popular metrics like price earnings  P E   price sales  P S  or price book value  P B  This is because they often find this ratio complicated  considering the limitations in calculating the future earnings growth potential of a stock  Yardsticks such as dividend yield  P E or P B are most commonly used to single out stocks trading at a discount However  these ratios  while not taking into account the future growth potential of a stock  may end up convincing us to invest in stocks that are at a discount just because of their poor show  This may often lead to  value traps    a situation when these value picks start to underperform over the long run as the temporary problems  which once pulled down the share price  turn out to be persistent In such a case  even if you buy a stock at less than its fair value  you might still end up paying more  And here comes the importance of this not so popular but crucial value investing metric  the PEG ratio The PEG ratio is defined as   Price  Earnings  Earnings Growth RateA low PEG ratio is always better for value investors While P E alone fails to identify a true value stock  PEG helps to find the intrinsic value of a stock There are some drawbacks to using the PEG ratio though  It doesn t consider the very common situation of changing growth rates such as the forecast of the first three years at a very high growth rate  followed by a sustainable but lower growth rate in the long term Hence  PEG based investing can turn out to be even more rewarding if some other relevant parameters are also taken into consideration For the rest of this Screen of the Week article please visit Zacks com at Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material About Screen of the WeekZacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine   But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has more than doubled the market from 1988 through 2016  Its average gain has been a stellar  25  per year  Follow us on Twitter   Join us on Facebook  NASDAQ FB    Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Contact  Jim GiaquintoCompany  Zacks comPhone  312 265 9268Email  Visit  Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer   Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ,2019-07-15,Zacks Investment Research,https://www.investing.com/analysis/zackscom-featured-highlights-include-oracle-anglogold-ashanti-amerisourcebergen-ford-motor-and-caci-international-200440136,200440136
103152,324667,ABC,What s In The Offing For Cadence  CDNS  In Q2 Earnings ,opinion,Cadence Design Systems Inc    NASDAQ CDNS   is slated to report second quarter 2019 results on Jul 22 Notably  the company has surpassed the Zacks Consensus Estimate in the trailing four quarters  with a positive earnings surprise of 12 1  Past Quarter PerformanceCadence delivered first quarter 2019 non GAAP earnings of 54 cents per share  surpassing the Zacks Consensus Estimate by 4 cents  The figure surged 35  from the year ago quarter Revenues of  576 7 million outpaced the Zacks Consensus Estimate of  560 million and improved 11 5  on a year over year basis What to Expect in Q2 For second quarter 2019  Cadence expects total revenues in the range of  575  585 million  Management guided non GAAP earnings in the range of 52 54 cents per share The Zacks Consensus Estimate for second quarter earnings is pegged at 53 cents  unchanged over the last 30 days  This indicates an improvement of about 17 8  from year ago reported figure  The Zacks Consensus Estimate for quarterly sales stands at  579 1 million  suggesting growth of 11 7  from the prior year quarter Notably  Cadence stock has returned 64 1  in past year  substantially outperforming the  s rally of 26 7  Let s see how things are shaping up prior to this announcement Factors Likely to Influence Q2 ResultsRobust adoption of Cadence s digital and signoff  custom and analog  IP solutions and expanding customer base are expected to influence second quarter results Cadence is evolving its silicon based design strategy with an aim to meet complex computing demands of 5G and AI applications  In fact  the company has carved a new System Analysis Group to focus exclusively on system analysis and design  Increasing investments on emerging trends like 5G  IoT  AR VR and autonomous vehicle sub systems are expected to aid its upcoming quarterly results Increasing digital transformation across aerospace  automotive and medical domains is fueling demand for robust computational software and developer tools  which is likely to enhance the company s prospects and drive the to be reported quarter s results Moreover  Cadence is focusing on providing end to end solutions  which rapidly reduces the time required to introduce a semiconductor product in the market  In this regard  the company s frequent product launches and enhancements are expected to act as a tailwind in the to be reported quarter Cadence recently unveiled CloudBurst Platform  which offers access to the company s design tools in hybrid cloud infrastructure  It was recently utilized by Barefoot Networks  It also introduced Verification IP  VIP   which is compliant with DisplayPort 2 0 standard  Furthermore  the company recently rolled out Clarity 3D Solver  marking its foray into the 3D modeling software market  The fact that Clarity 3D Solver can be integrated with Cadence s implementation platforms to enhance performance provides leverage to its 3D modeling goals Moreover  Cadence s association with Northrop Grumman  NYSE NOC   which is utilizing the company s IP and EDA solutions  is noteworthy  We believe the deal will aid the company enhance presence in aerospace and defense end market Cadence is anticipated to benefit considerably from latest customer wins and product roll outs in strategic growth markets  consequently  favoring its top line in the upcoming quarterly results Further  increasing popularity of the company s innovative cloud ready solutions and strong demand for growing hardware capacity is fueling adoption of Palladium Z1  Cadence recently announced that Innovium has implemented the Palladium Z1 platform and the Protium S1 to accelerate development of its Ethernet switch  Further  NVIDIA  NASDAQ NVDA  recently selected the company s Protium X1 platform to speed up development of its high capacity GPUs We believe traction witnessed by Xcelium Parallel Simulator  Protium X1 and Palladium Z1 will bolster the top line in the to be reported quarter What the Zacks Model UnveilsAccording to the Zacks model  a company with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has a good chance of beating estimates if it also has a positive   The Sell rated stocks  Zacks Rank  4 or 5  are best avoided Cadence has a Zacks Rank  3 and an Earnings ESP of 0 00   You can uncover the best stocks to buy or sell before they re reported with our  Stocks to ConsiderHere are some stocks which you may consider as our model shows that these have the right combination of elements to post an earnings beat in its upcoming release Lockheed Martin Corporation   NYSE LMT   has an Earnings ESP of  0 14  and a Zacks Rank  1  You can see  AmerisourceBergen Corporation   NYSE ABC   has an Earnings ESP of  0 92  and a Zacks Rank  2 PayPal Holdings  Inc    NASDAQ PYPL   has an Earnings ESP of  14 38  and a Zacks Rank  3 Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-07-17,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-offing-for-cadence-cdns-in-q2-earnings-200440636,200440636
103153,324668,ABC,What s In Store For Citrix Systems  CTXS  In Q2 Earnings ,opinion,"Citrix Systems  Inc    NASDAQ CTXS   is slated to report second quarter 2019 results on Jul 24 Notably  the company has surpassed the Zacks Consensus Estimate in the trailing four quarters  with a positive earnings surprise of 8 1  Citrix Systems  Inc  Price  Consensus and EPS Surprise
    Past Quarter PerformanceCitrix delivered first quarter 2019 non GAAP earnings of  1 27 per share  beating the Zacks Consensus Estimate of  1 17 per share  However  the figure decreased by 2 cents from the year ago quarter Revenues rose 3  from the year ago quarter to  719 1 million and comfortably surpassed the Zacks Consensus Estimate of  712 million What to Expect in Q2 For second quarter 2019  Citrix anticipates revenues between  765 million and  775 million   Moreover  non GAAP earnings are expected in the range of  1 30  1 35 per share The Zacks Consensus Estimate for second quarter earnings is pegged at  1 33 per share  unchanged over the last 30 days  This indicates an improvement of about 3 9  from year ago reported figure  The Zacks Consensus Estimate for quarterly sales stands at  771 6 million  suggesting growth of 3 9  from the prior year quarter Let s see how things are shaping up prior to this announcement Factors Likely to Influence Q2 ResultsAs Citrix prioritizes transition to the cloud  it is witnessing a higher mix of product bookings that are subscription based  During the last reported quarter  SaaS revenue was up 43  year over year  Notably  SaaS revenues are the most significant part of subscription transition Subscription revenues came in at  142 million in the last reported quarter  up 37  year over year  With an aim to capitalize on this growth  the company is making every effort to enhance subscription offerings with new capabilities which is expected to favor second quarter results The Zacks Consensus Estimate for Subscription revenues is pegged at  153 million Moreover  solid adoption of unified workspace solutions and hybrid cloud offerings hold promise  Furthermore  traction witnessed by ShareFile deserves a special mention  We believe the momentum is likely to persist as evident from deal wins in the second quarter Citrix recently announced that it intends to expand its intelligent digital workspace workspace solutions to Google  NASDAQ GOOGL  Cloud  In doing so  Citrix will aid companies to efficiently deliver apps to Google devices and operating systems  thereby creating a digital work experience to drive productivity and innovation  Notably  in the last reported quarter  management stated that 62  of new product bookings in Workspace services were subscription based Additionally  acquisition of Cedexis has enabled the company to gain traffic management capabilities  With the enhanced engagement features  the company is well poised to gain new enterprise customers in the to be reported quarter In the quarter under review  the company introduced innovations to Citrix digital workspace solution with more security capabilities  This is likely to lead to new customer additions  consequently generating incremental revenues  favoring the top line in the upcoming quarterly results We believe synergies from buyouts  strategic alliances and addition of innovative capabilities are likely to act as tailwinds for the to be reported quarter s results What the Zacks Model UnveilsAccording to the Zacks model  a company with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has a good chance of beating estimates if it also has a positive   The Sell rated stocks  Zacks Rank  4 or 5  are best avoided Citrixhas a Zacks Rank  3 and an Earnings ESP of 0 00   You can uncover the best stocks to buy or sell before they re reported with our  Stocks to ConsiderHere are some stocks which you may consider as our model shows that these have the right combination of elements to post an earnings beat in its upcoming release Lockheed Martin Corporation   NYSE LMT   has an Earnings ESP of  0 14  and a Zacks Rank  1  You can see  AmerisourceBergen Corporation   NYSE ABC   has an Earnings ESP of  0 67  and a Zacks Rank  2 PayPal Holdings  Inc    NASDAQ PYPL   has an Earnings ESP of  14 38  and a Zacks Rank  2 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-07-18,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-citrix-systems-ctxs-in-q2-earnings-200442051,200442051
103183,324698,ABC,Walgreens deal offers no lasting relief to Rite Aid,news,"By Siddharth Cavale  Reuters    A slimmed down  Rite Aid Corp   N RAD  could lose much of its bargaining heft with insurers and makers of branded drugs at a time when it is trying to turn around its flagging pharmacy business  analysts said  Rite Aid said on Thursday it would sell nearly half its U S  stores to larger rival Walgreens Boots Alliance Inc  O WBA  after the drugstore operators agreed to scrap a whole sale merger  Wall Street showed its displeasure at the new deal  pushing Rite Aid s shares down 30 percent to a near four year low after the announcement  The stock added to its losses  falling 7 percent on Friday  Rite Aid has been struggling with eroding profits in its pharmacy business  which sells prescription drugs  as increases in branded drug prices have slowed while reimbursement pressure for generics has intensified   I think Rite Aid is going to struggle to remain relevant in the pharmacy industry   said Adam Fein  president at Pembroke Consulting  which tracks the drug distribution industry   The pharmacy industry has become hyper competitive and it favors either large teams or nimble independents  and Rite Aid is buck in the middle and doesn t have geographic scale anywhere  except in the North East and the West Coast   But it s not all bad news for the company  Under the new deal  Rite Aid will gain access to Walgreen s centralized sourcing system  allowing it to procure generic drugs at low costs for 10 years and giving its pharmacy margins a much needed boost  Walgreens  the No  1 drugstore chain in the country  has a sourcing contract with AmerisourceBergen Corp  N ABC   the second largest U S  drug distributor  giving the alliance bargaining clout against drugmakers   We estimate more favorable generic procuring costs could provide 3 5 percent of saving on RAD s total generic spend   Cowen   Co analyst Charles Rhyee said in a research note  LEANER AND MEANER  Still  being left with only half its stores will be punishing on economies of scale for Rite Aid  which is already struggling to turn a profit  said Neil Saunders  managing director of market research firm GlobalData Retail  Rite Aid on Thursday posted a much bigger quarterly loss  mainly because of a drop in same store sales due to low reimbursement rates  This was the company s third loss in the past five quarters  EBITDA margins for the company fell to an average of 3 4 percent in fiscal 2017 ended March 31  from 4 8 percent in 2013  In contrast  Walgreens  EBITDA margins have averaged 7 3 percent on average for first three quarters of fiscal 2017  which ends in August  from 6 9 percent for the whole of 2013  Rite Aid  however  said the deal would make it a smaller but stronger company  helping it address pharmacy margin challenges and significantly cut its debt   over  7 billion at the end of fiscal 2017  Selling roughly half its stores will leave Rite Aid more reliant on its pharmacy benefit management business  which maintains formularies  or preferred drugs lists  negotiates rebates with drugmakers  and processes prescription drug claims   We think this will benefit RAD from a valuation perspective as we estimate that PBMs trade at a premium to drug retailers  by about a couple of turns in our view   Cowen   Co analyst Charles Rhyee said in a research note  
The smaller company could also be an attractive buyout target for a private equity firm or a rival such as Fred s Inc  O FRED   which was to buy some assets that would have been divested under the previously planned Walgreens Rite Aid merger  analysts said ",2017-06-30,Reuters,https://www.investing.com/news/stock-market-news/walgreens-deal-offers-no-lasting-relief-to-rite-aid-501048,501048
103187,324702,ABC,Top Ranked Momentum Stocks To Buy For July 8th,opinion,"Here are four stocks with buy rank and strong momentum characteristics for investors to consider today  July 8th AmerisourceBergen  NYSE ABC  Corporation  ABC   This distributor of pharmaceutical products has a Zacks Rank  2  Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0 3  over the last 60 days AmerisourceBergen Corporation Price and Consensus   AmerisourceBergen s shares gained 3 8  over the last one month more than S P 500 s rise of 3 6   The company possesses a  of A 
AmerisourceBergen Corporation Price   Arch Capital Group Ltd   ACGL   This provider of property  casualty  and mortgage insurance and reinsurance products has a Zacks Rank  2  Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 2 7  over the last 60 days 
Arch Capital Group Ltd  Price and Consensus   Arch Capital s shares gained 7 2  over the last one month  The company possesses a Momentum Score of B 
Arch Capital Group Ltd  Price   Adamas Pharmaceuticals  Inc   ADMS   This developer of medicines for patients suffering from chronic neurologic disorders has a Zacks Rank  2  Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 6 5  over the last 60 days 
Adamas Pharmaceuticals  Inc  Price and Consensus   Adamas  shares gained 30 5  over the last one month  The company possesses a Momentum Score of B 
Adamas Pharmaceuticals  Inc  Price   AerCap Holdings N V   AER   This aircraft leasing company has a Zacks Rank  2  Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 1 5  over the last 60 days 
Aercap Holdings N V  Price and Consensus   AerCap s shares gained 6 9  over the last one month  The company possesses a Momentum Score of B 
Aercap Holdings N V  Price   See the 
Learn more about the  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-07-07,Zacks Investment Research,https://www.investing.com/analysis/top-ranked-momentum-stocks-to-buy-for-july-8th-200437744,200437744
103188,324703,ABC,ABC Or ALGN  Which Is The Better Value Stock Right Now ,opinion,"Investors interested in Medical   Dental Supplies stocks are likely familiar with AmerisourceBergen  NYSE ABC  and Align Technology  ALGN   But which of these two stocks offers value investors a better bang for their buck right now  We ll need to take a closer look 
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system  The Zacks Rank favors stocks with strong earnings estimate revision trends  and our Style Scores highlight companies with specific traits 
Currently  AmerisourceBergen has a Zacks Rank of  2  Buy   while Align Technology has a Zacks Rank of  3  Hold   This means that ABC s earnings estimate revision activity has been more impressive  so investors should feel comfortable with its improving analyst outlook  But this is only part of the picture for value investors 
Value investors analyze a variety of traditional  tried and true metrics to help find companies that they believe are undervalued at their current share price levels 
The Style Score Value grade factors in a variety of key fundamental metrics  including the popular P E ratio  P S ratio  earnings yield  cash flow per share  and a number of other key stats that are commonly used by value investors 
ABC currently has a forward P E ratio of 12 88  while ALGN has a forward P E of 50 13  We also note that ABC has a PEG ratio of 1 70  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  ALGN currently has a PEG ratio of 2 14 
Another notable valuation metric for ABC is its P B ratio of 6 10  The P B ratio pits a stock s market value against its book value  which is defined as total assets minus total liabilities  For comparison  ALGN has a P B of 17 55 
These are just a few of the metrics contributing to ABC s Value grade of A and ALGN s Value grade of D 
ABC sticks out from ALGN in both our Zacks Rank and Style Scores models  so value investors will likely feel that ABC is the better option right now ",2019-07-09,Zacks Investment Research,https://www.investing.com/analysis/abc-or-algn-which-is-the-better-value-stock-right-now-200438498,200438498
103189,324704,ABC,Can Instruments Drive Intuitive Surgical  ISRG  Q2 Earnings ,opinion,Intuitive Surgical  Inc    NASDAQ ISRG   is slated to release its second quarter 2019 results soon  after market close  The company expects steady growth in the Instruments and Accessories segment in the quarter to be reported  Revenues from other segments are likely to bolster the quarterly results Notably  the company has outpaced the Zacks Consensus Estimate in two of the trailing four quarters  the average beat being 3 44  Which Way Are Estimates Treading The Zacks Consensus Estimate for second quarter revenues is pinned at  1 03 billion  indicating 12 8  growth from the year earlier quarter s reported figure  The same for earnings is pegged at  2 84  implying a 2 9  increase from the prior year quarter s reported number Intuitive Surgical  Inc  Price and EPS Surprise   Let s delve deeper Instruments   Accessories   A Key CatalystThe Instruments and Accessories segment is expected to see a solid second quarter  Not to forget  the segment  contributing 56 7  to total revenues  performed impressively in the last reported quarter as well  registering 20  growth year over year Markedly  the flagship   da Vinci surgical system   continues to be a revenue driver for the segment  In fact  the unit s 60 millimeter stapler has been launched recently and is being used in abdominal surgeries  Intuitive Surgical s second generation 45 millimeter stapler has also received 510 k  clearance in recent times  expanding the customer base for the segment s offerings  Additionally  a third generation vessel sealer has been launched that is likely to benefit the company in the second quarter Reflective of these  the Zacks Consensus Estimate for Instruments   Accessories  second quarter revenues is pegged at  570 million  suggesting 19 7  growth from the year ago quarter s reported figure Other Factors at PlayRevenues from other two segments   Systems and Services   are also expected to boost second quarter results on steady progress in the imaging and reality programs In the last reported quarter  Systems contributed 25 4  to net sales while Services accounted for 17 9  For the quarter to be reported  the Zacks Consensus Estimate for Services stands at  175 million  indicating 12 2  improvement from the year earlier quarter s reported figure  The same for Systems is pinned at  275 million  implying a mere decline by 0 7  from the year ago quarter s reported number These apart  Intuitive Surgical is focusing on delivering insights to customers in its cloud computing and informatics efforts  In fact  the company recently received the FDA clearance for its Auris augmented reality product  which is expected to be clinically used for the first time in 2019 Management at Intuitive Surgical sees more consistent and higher investments in this space in the near term Meanwhile  cutthroat competition in the MedTech space remains a headwind as it might weigh on the company s margins  which have been contracting over the last couple of quarters Earnings WhispersAccording to the Zacks model  a stock needs to have both   a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    for an earnings beat  However  this is not the case here as you will see below  You can see  Earnings ESP  Intuitive Surgical has an Earnings ESP of 0 00   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Intuitive Surgical carries a Zacks Rank  3 We caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revision Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter AmerisourceBergen   NYSE ABC   has an Earnings ESP of  1 14  and a Zacks Rank  2 DENTSPLY SIRONA   NASDAQ XRAY   has an Earnings ESP of  6 95  and a Zacks Rank  2 McKesson Corporation   NYSE MCK   has an Earnings ESP of  2 20  and a Zacks Rank  3 The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-07-11,Zacks Investment Research,https://www.investing.com/analysis/can-instruments-drive-intuitive-surgical-isrg-q2-earnings-200439283,200439283
103190,324705,ABC,5 Discounted PEG Stocks Suitable For Value Investors,opinion,While searching for a suitable investment option  value investors with varied risk appetite are unlikely to consider price earnings to growth  PEG  ratio among a number of other popular metrics like price earnings  P E   price sales  P S  or price book value  P B  This is because they often find this ratio complicated  considering the limitations in calculating the future earnings growth potential of a stock  Yardsticks such as dividend yield  P E or P B are most commonly used to single out stocks trading at a discount However  these ratios  while not taking into account the future growth potential of a stock  may end up convincing us to invest in stocks that are at a discount just because of their poor show  This may often lead to  value traps    a situation when these value picks start to underperform over the long run as the temporary problems  which once pulled down the share price  turn out to be persistent In such a case  even if you buy a stock at less than its fair value  you might still end up paying more  And here comes the importance of this not so popular but crucial value investing metric  the PEG ratio The PEG ratio is defined as   Price  Earnings  Earnings Growth RateA low PEG ratio is always better for value investors While P E alone fails to identify a true value stock  PEG helps to find the intrinsic value of a stock There are some drawbacks to using the PEG ratio though  It doesn t consider the very common situation of changing growth rates such as the forecast of the first three years at a very high growth rate  followed by a sustainable but lower growth rate in the long term Hence  PEG based investing can turn out to be even more rewarding if some other relevant parameters are also taken into consideration Here are some of the screening criteria for a winning strategy PEG Ratio less than X Industry MedianP E Ratio  using F1  less than X Industry Median  for more accurate valuation purpose Zacks Rank of 1  Strong Buy  or 2  Buy   Whether good market conditions or bad  stocks with a Zacks Rank  1 or 2 have a proven history of success  Market Capitalization greater than  1 Billion  This helps us to focus on companies that have strong liquidity  Average 20 Day Volume greater than 50 000  A substantial trading volume ensures that the stock is easily tradable  Percentage Change F1 Earnings Estimate Revisions  4 Weeks  greater than 5   Upward estimate revisions add to the optimism  suggesting further bullishness  Value Score of less than or equal to B  Our research shows that stocks with a Style Score of A or B when combined with a Zacks Rank  1  2 or 3  Hold  offer the best upside potential  Here are five of the 20 stocks that qualified the screening Oracle Corporation   NYSE ORCL    It is one of the largest enterprise grade database  middleware and application software providers  Oracle has expanded its cloud computing operations over the last couple of years  The company offers cloud solutions and services that can be used to build and manage various cloud deployment models  The company has an impressive long term expected growth rate of 9 8   The stock carries a Zacks Rank  2 and has a Value Score of B  You can see  AngloGold Ashanti Limited   NYSE AU    It operates as a gold mining company  It also produces silver  uranium and sulphuric acid and d re bars  Apart from a discounted PEG and P E  the stock has a Value Score of A and holds a Zacks Rank  2  The company also has an impressive long term expected growth rate of 33  AmerisourceBergen Corporation   NYSE ABC    It is one of the world s largest pharmaceutical services companies  which focuses on providing drug distribution and related services to reduce health care costs and improve patient outcomes  Apart from a discounted PEG and P E  the stock holds a Zacks Rank  2 and has a Value Score of A Ford Motor Company   NYSE F    This is an automotive  financial services and mobility company with operations in the United States and across the world  The company currently holds a Zacks Rank  1 and has a Value Score of A  The company also has an impressive expected five year growth rate of 7 3  CACI International Inc   NYSE CACI    Based in Arlington  VA  CACI International delivers IT applications and infrastructure to improve communications and secure the integrity of information systems and networks  enhance data collection and analysis  and increase efficiency and mission effectiveness  The company holds a Zacks Rank  2 and has a Value Score of A  The stock also has an impressive earnings growth rate of 10  for the next five years Get the rest of the stocks on the list and start putting this and other ideas to the test  It can all be done with the Research Wizard stock picking and backtesting software The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  Disclosure  Performance information for Zacks  portfolios and strategies are available at   ,2019-07-14,Zacks Investment Research,https://www.investing.com/analysis/5-discounted-peg-stocks-suitable-for-value-investors-200439844,200439844
103191,324706,ABC,Can AmerisourceBergen  ABC  Keep The Earnings Surprise Streak Alive ,opinion,"Have you been searching for a stock that might be well positioned to maintain its earnings beat streak in its upcoming report  It is worth considering AmerisourceBergen  NYSE ABC   which belongs to the Zacks Medical   Dental Supplies industry 
This prescription drug distributor has seen a nice streak of beating earnings estimates  especially when looking at the previous two reports  The average surprise for the last two quarters was 7 16  
For the last reported quarter  AmerisourceBergen came out with earnings of  2 11 per share versus the Zacks Consensus Estimate of  1 96 per share  representing a surprise of 7 65   For the previous quarter  the company was expected to post earnings of  1 50 per share and it actually produced earnings of  1 60 per share  delivering a surprise of 6 67  
Price and EPS Surprise

For AmerisourceBergen  estimates have been trending higher  thanks in part to this earnings surprise history  And when you look at the stock s positive Zacks Earnings ESP  Expected Surprise Prediction   it s a great indicator of a future earnings beat  especially when combined with its solid Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
AmerisourceBergen currently has an Earnings ESP of  0 92   which suggests that analysts have recently become bullish on the company s earnings prospects  This positive Earnings ESP when combined with the stock s Zacks Rank  2  Buy  indicates that another beat is possibly around the corner  We expect the company s next earnings report to be released on August 1  2019 
When the Earnings ESP comes up negative  investors should note that this will reduce the predictive power of the metric  But  a negative value is not indicative of a stock s earnings miss 
Many companies end up beating the consensus EPS estimate  but that may not be the sole basis for their stocks moving higher  On the other hand  some stocks may hold their ground even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-07-14,Zacks Investment Research,https://www.investing.com/analysis/can-amerisourcebergen-abc-keep-the-earnings-surprise-streak-alive-200439832,200439832
103223,324738,ABC,5 Excellent Value Stocks To Grab On Discounted PEG,opinion,While searching for a suitable investment option  value investors with varied risk appetite are unlikely to consider price earnings to growth  PEG  ratio among a number of other popular metrics like price earnings  P E   price sales  P S  or price book value  P B  This is because they often find this ratio complicated  considering the limitations in calculating the future earnings growth potential of a stock  Yardsticks such as dividend yield  P E or P B are most commonly used to single out stocks trading at a discount However  these ratios  while not taking into account the future growth potential of a stock  may end up convincing us to invest in stocks that are at a discount just because of their poor show  This may often lead to  value traps    a situation when these value picks start to underperform over the long run as the temporary problems  which once pulled down the share price  turn out to be persistent In such a case  even if you buy a stock at less than its fair value  you might still end up paying more  And here comes the importance of this not so popular but crucial value investing metric  the PEG ratio The PEG ratio is defined as   Price  Earnings  Earnings Growth RateA low PEG ratio is always better for value investors While P E alone fails to identify a true value stock  PEG helps to find the intrinsic value of a stock There are some drawbacks to using the PEG ratio though  It doesn t consider the very common situation of changing growth rates such as the forecast of the first three years at a very high growth rate  followed by a sustainable but lower growth rate in the long term Hence  PEG based investing can turn out to be even more rewarding if some other relevant parameters are also taken into consideration Here are some of the screening criteria for a winning strategy PEG Ratio less than X Industry MedianP E Ratio  using F1  less than X Industry Median  for more accurate valuation purpose Zacks Rank of 1  Strong Buy  or 2  Buy   Whether good market conditions or bad  stocks with a Zacks Rank  1 or 2 have a proven history of success  Market Capitalization greater than  1 Billion  This helps us to focus on companies that have strong liquidity  Average 20 Day Volume greater than 50 000  A substantial trading volume ensures that the stock is easily tradable  Percentage Change F1 Earnings Estimate Revisions  4 Weeks  greater than 5   Upward estimate revisions add to the optimism  suggesting further bullishness  Value Score of less than or equal to B  Our research shows that stocks with a Style Score of A or B when combined with a Zacks Rank  1  2 or 3  Hold  offer the best upside potential  Here are five of the 15 stocks that qualified the screening Tyson Foods  Inc    NYSE TSN    It is one of the world s leading food companies and a recognized leader in protein  The company has a broad portfolio of products and brands like Tyson  Jimmy Dean  Hillshire Farm  Ball Park  Wright  Aidells  ibp and State Fair  The company has an impressive long term historical growth rate of 20 8   The stock currently has a Value Score of A and a Zacks Rank  2  You can see  Asbury Automotive Group  Inc    NYSE ABG    This company is one of the largest automotive retailers in the United States  Asbury currently operates 87 dealerships  consisting of 106 franchises  representing 30 domestic and foreign brands of vehicles  The stock currently sports a Zacks Rank  1 and has a Value Score of 2  The company also has an impressive long term historical growth rate of 18 8  AmerisourceBergen Corporation   NYSE ABC    It is one of the world s largest pharmaceutical services companies  which focuses on providing drug distribution and related services to reduce health care costs and improve patient outcomes  Apart from a discounted PEG and P E  the stock holds a Zacks Rank  2 and has a Value Score of A Ford Motor Company   NYSE F    This is an automotive  financial services and mobility company with operations in the United States and across the world  The company currently holds a Zacks Rank  2 and has a Value Score of B  The company also has an impressive expected five year growth rate of 9  CACI International Inc   NYSE CACI    Based in Arlington  VA  CACI International delivers IT applications and infrastructure to improve communications and secure the integrity of information systems and networks  enhance data collection and analysis  and increase efficiency and mission effectiveness  The company holds a Zacks Rank  2 and has a Value Score of A  The stock also has an impressive earnings growth rate of 10  for the next five years Get the rest of the stocks on the list and start putting this and other ideas to the test  It can all be done with the Research Wizard stock picking and backtesting software The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  Disclosure  Performance information for Zacks  portfolios and strategies are available at   ,2019-05-08,Zacks Investment Research,https://www.investing.com/analysis/5-excellent-value-stocks-to-grab-on-discounted-peg-200419652,200419652
103224,324739,ABC,AmerisourceBergen  ABC  Moves To Buy  Rationale Behind The Upgrade,opinion,"AmerisourceBergen  NYSE ABC  could be a solid choice for investors given its recent upgrade to a Zacks Rank  2  Buy   This rating change essentially reflects an upward trend in earnings estimates    one of the most powerful forces impacting stock prices 
The Zacks rating relies solely on a company s changing earnings picture  It tracks EPS estimates for the current and following years from the sell side analysts covering the stock through a consensus measure    the Zacks Consensus Estimate 
Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts  since these are mostly driven by subjective factors that are hard to see and measure in real time  In these situations  the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near term stock price movements 
As such  the Zacks rating upgrade for AmerisourceBergen is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price 
Most Powerful Force Impacting Stock Prices
The change in a company s future earnings potential  as reflected in earnings estimate revisions  has proven to be strongly correlated with the near term price movement of its stock  That s partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company s shares  An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock  and institutional investors typically buy or sell it  Their transaction of large amounts of shares then leads to price movement for the stock 
Fundamentally speaking  rising earnings estimates and the consequent rating upgrade for AmerisourceBergen imply an improvement in the company s underlying business  Investors should show their appreciation for this improving business trend by pushing the stock higher 
Harnessing the Power of Earnings Estimate Revisions
As empirical research shows a strong correlation between trends in earnings estimate revisions and near term stock movements  tracking such revisions for making an investment decision could be truly rewarding  Here is where the tried and tested Zacks Rank stock rating system plays an important role  as it effectively harnesses the power of earnings estimate revisions 
The Zacks Rank stock rating system  which uses four factors related to earnings estimates to classify stocks into five groups  ranging from Zacks Rank  1  Strong Buy  to Zacks Rank  5  Strong Sell   has an impressive externally audited track record  with Zacks Rank  1 stocks generating an average annual return of  25  since 1988  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here      
Earnings Estimate Revisions for AmerisourceBergen
For the fiscal year ending September 2019  this prescription drug distributor is expected to earn  6 81 per share  which is a change of 4 9  from the year ago reported number 
Analysts have been steadily raising their estimates for AmerisourceBergen  Over the past three months  the Zacks Consensus Estimate for the company has increased 0 9  
Bottom Line
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations  the Zacks rating system maintains an equal proportion of  buy  and  sell  ratings for its entire universe of more than 4000 stocks at any point in time  Irrespective of market conditions  only the top 5  of the Zacks covered stocks get a  Strong Buy  rating and the next 15  get a  Buy  rating  So  the placement of a stock in the top 20  of the Zacks covered stocks indicates its superior earnings estimate revision feature  making it a solid candidate for producing market beating returns in the near term 
You can learn more about the Zacks Rank here    
The upgrade of AmerisourceBergen to a Zacks Rank  2 positions it in the top 20  of the Zacks covered stocks in terms of estimate revisions  implying that the stock might move higher in the near term ",2019-05-13,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-abc-moves-to-buy-rationale-behind-the-upgrade-200421282,200421282
103225,324740,ABC,AmerisourceBergen High Quality Dividend With Compelling Valuation ,opinion,"Introduction
This is the first in a continuing series where I identify and present dividend growth stocks for an above average long term total return objective  Throughout this series  I will be illustrating that there are several prudent sources of long term return and there is also luck or chance  Personally  I suggest that investors strive to build their portfolios based on prudent fundamental realities and not simply invest with the hope that your stocks will rise 
The primary prudent sources of total return that I am alluding to are first and foremost sound fundamental valuation   although attractive undervaluation is even more desirable  The second primary source would be growth defined as the potential long term rate of change of earnings and or cash flow growth and dividend growth  When you invest at sound valuation  you position yourself to participate in the growth that the business generates on your behalf 
If you can identify attractive undervaluation  you can expect a secondary source and a potential kicker to total return that I like to call natural leverage  Simply stated  in addition to the operating growth and dividend growth that the company achieves  you are also positioned to get P E ratio expansion  To clarify  you initially invest in a smaller level of earnings at a lower P E ratio where the company over time delivers a higher level of future earnings that the market capitalizes at a higher P E ratio  I metaphorically refer to this as a double double  In the future  you get double the earnings that are valued at double the P E ratio  Of course  the math does not always work out so perfectly  but I hope you get the point 
Furthermore  I will be presenting stocks that I believe offer the potential for significantly above average total return  Stated more clearly  I will be looking for dividend growth stocks that I believe can provide double digit total returns including a growing dividend income stream  But perhaps most importantly  because of the focus on attractive valuation  I believe these future returns can be generated at greatly mitigated  lower  levels of long term risk 
Moreover  it s important to distinguish between long term results versus short term results  Intelligent value investors understand that investing in unpopular securities is where value is most often found  This is especially true when you are in a bull market like we have been in for the last several years 
Consequently  there are typically reasons why a stock s valuation is low  The trick is in determining whether those reasons are valid  permanent or temporary  Nevertheless  the intelligent value investor understands that unpopular stocks can remain unpopular for some time  and therefore provide below average short term results  On the other hand  unpopular stocks that are erroneously valued can provide exceptional long term returns based on the sources of long term return described above 
AmerisourceBergen ABC   Prudent Investment Interesting Speculation
AmerisourceBergen  NYSE ABC  could well be the epitome of a near perfect dividend growth stock  It has a long history of consistent above average earnings growth  and it has increased its dividend for 14 consecutive years at an average rate exceeding 30  per annum  Therefore  even though its current dividend yield is slightly below the market average  its growth yield  yield on cost  potential is significantly above average 
Additionally  the company has a solid investment grade A  credit rating and modest debt to capital of 57   Although the company is not expected to grow at its historical double digit rates  it is expected to continue growing at the above average rate of 7 to 9   Nevertheless  trading at a blended P E ratio below 12 makes this medical distributor a compelling long term investment based on significant undervaluation alone  Consequently  AmerisourceBergen looks like an attractive dividend growth stock especially for those seeking an above average long term total return 
On the other hand  in addition to the company s apparent long term attractiveness  it also appears to be a compelling short term speculation  Walgreens Boots Alliance  NASDAQ WBA  already owns a 27  stake in this premier drug wholesaler and medical distributor  Moreover  according to Raymond James analyst John Ransom  it might also be a potential acquisition target  This seems plausible considering that competitor CVS has recently merged  acquired  with Aetna  NYSE AET  and the fact that Walgreens Boots Alliance has not engaged in any significant deals recently  Therefore  Walgreens Boots Alliance may have some incentive or need to catch up 
AmerisourceBergen Corp  Compelling Valuation
The following long term earnings and price correlated FAST Graph on AmerisourceBergen clearly illustrates that the company has not been available at such a compelling valuation since the throes of the Great Recession  This is somewhat understandable considering that healthcare  in general  is a current political football  However  I believe that investors should also consider that the current political risk is also already priced in  In other words  the current low valuations on healthcare stocks  in general  appear too attractive to ignore despite the political risks 

As I have stated many times in the past  I never consider investing in a stock before calculating a specific rate of return expectation  I call this running the numbers out to their logical conclusion  In the case of AmerisourceBergen  if the company did grow earnings at the consensus rate of 7 9  and its P E ratio expanded from the current 12 to a more rational P E ratio of 15  its total annualized rate of return out to fiscal year end 2021 would be slightly over 20   In other words  the current political risk is already baked into the valuation  price  

As the Wall Street Journal suggested in an article by Charley Grant on May 20 titled   Everyone Hates Health Care stocks  Buy Them Anyway   The article s byline stated   relatively attractive valuation and defensive properties could make this sector shine   I consider this sound advice especially when you understand that these healthcare stocks do not really need to grow very much to generate strong future returns  The point is that even a no growth business is worth a reasonable multiple of earnings and cash flows  typically in the neighborhood of 14 to 16 times earnings  Consequently  today s low valuations have already priced in the risk and suggest that high quality healthcare stocks are attractive 
To illustrate how an undervalued stock doesn t have to grow in order to be a good investment  I present the following  Custom  forecasting calculator where I have overridden the consensus estimates  The following Custom forecast calculator illustrates the return potential on AmerisourceBergen assuming the company only grows at 1   significantly below consensus  and trades at a rational 15 P E ratio  Even under that draconian scenario  AmerisourceBergen could still potentially generate double digit returns over the next couple of years  As I often say  valuation matters  and it matters a lot  But perhaps more importantly  low valuation can mitigate a great deal of risk 

How Reliable are Consensus Estimates on AmerisourceBergen 
As I often state  as investors we can only invest in the future and not the past  However  it also logically follows that it is implicit upon us to base our decisions on a prudent and reliable forecast of what the future might bring  Consequently  I believe it makes sense to start by reviewing the consensus estimates of the leading analysts following the company  However  it is also important to realize that consensus analyst estimates are quite often derived and aligned with company guidance  The following slide from AmerisourceBergen s recent earnings report provides their fiscal 2019  ending in September  guidance for adjusted diluted earnings of  6 70 to  6 90  The reader should note that this guidance is consistent with the consensus estimates of 18 analysts presented in the forecasting calculator above 

Furthermore  the following Analyst Scorecard illustrates that leading analysts have an excellent track record of forecasting AmerisourceBergen s earnings in advance  As seen in the following screenshots  analysts have been extremely accurate with their forecasts when they have been made exactly one year or two years in advance of the actual financial reports  Consequently  this provides me some confidence that consensus estimates are a reliable starting point towards providing a reasonable future earnings expectation on this blue chip dividend growth stock  Therefore  I am enthusiastically motivated to continue conducting a comprehensive research and due diligence process on AmerisourceBergen because I believe the potential is worth my while 


Amerisourcebergen  Thesis for Growth And Success
According to MorningStar   Business Strategy and Outlook by Soo Romanoff  Updated Apr 08  2019 
AmerisourceBergen has developed a pharmaceutical platform addressing the comprehensive sourcing and distribution needs of manufacturers and providers  With 20 000 employees and an electronic inventory platform  the company is equipped to ship more than 3 million products a day worldwide  The global scale and sheer pharmaceutical volumes enable the company to negotiate competitive prices  and it can efficiently provide access to a vast portfolio of drugs  The core business  roughly 96  of revenue  is focused on pharmaceutical distribution  and the balance of revenue is attributable to acquired businesses  AmerisourceBergen handles roughly a third of the drugs sold in the United States and has created an extensive footprint into physician administered products  with key anchor customers within communities  Further  the company operates efficiently in a highly regulated environment  which provides some insulation  
Furthermore  I believe that regardless of whatever happens to healthcare delivery politically in the future  that AmerisourceBergen will still be positioned as a viable long term business 
AmerisourceBergen s confidence in their future growth was presented in their most recent earnings report as follows 

FAST Graphs Fundamentals Analyzer Out Loud Video  AmerisourceBergen
In the following analyze out loud video I m going to run AmerisourceBergen by the numbers looking at numerous cash flow and earnings metrics  In addition to looking at valuation  I will also be looking at dividend coverage and safety  There is more than one way to skin a cat  and certainly more than one way to value a business  However  no matter how you evaluate AmerisourceBergen  I believe the conclusion is the same  This is an extremely high quality dividend growth stock that is currently available at a very attractive valuation 


Summary and Conclusions 
I believe that AmerisourceBergen is an extremely high quality dividend growth stock that is currently an attractive total return investment based on low valuation and above average potential growth of earnings and dividends  Consequently  I also believe that the political risk associated with medical companies in general and AmerisourceBergen specifically is already priced in 
Furthermore  the possibility that Walgreens Boots Alliance may make a play for the remaining shares in the company they do not already own  provides an interesting and reasonable short term speculation  AmerisourceBergen is certainly cheap enough at current levels for Walgreens to make an offer above current valuation and still purchase the shares at a sensible valuation  However  I don t believe the acquisition needs to occur in order to make AmerisourceBergen an attractive long term dividend growth investment 
Finally  and as always  I suggest that investors conduct their own comprehensive research and due diligence  Caveat emptor 
Disclosure  Long ABC 
Disclaimer  The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients  Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted  The information in this document is believed to be accurate  but under no circumstances should a person act upon the information contained within  We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation ",2019-05-23,Chuck Carnevale,https://www.investing.com/analysis/invest-in-amerisourcebergen-for-its-growth-and-valuation--speculate-in-a-potentia-200424147,200424147
103226,324741,ABC,Dividend Growth Stocks  Cardinal Health  CVS  McKesson  Walgreens ,opinion,"Introduction
This is a follow up to my first article in a continuing series where I will be identifying and presenting dividend growth stocks for an above average long term total return objective  My first article in this series covered AmerisourceBergen  NYSE ABC   a leading medical distributor that I presented as significantly undervalued  However  I offer this follow up to illustrate that the entire sector and subsector is currently out of favor and undervalued  Consequently  this represents a case that is more sector related than company specific 
Most importantly  the primary issues causing concern throughout this sector are politically related  There are also concerns about lawsuits related to the opium epidemic  However  these issues are based on fears about things that might happen but have not yet happened  Consequently  the future fundamentals for each of these companies are currently expected to remain positive going forward  As a result  and based on those fundamental future expectations  the stocks would be considered extremely cheap offering above average upside  Therefore  as long as earnings do in fact continue to manifest  that would be a true statement 
On the other hand  if the future does bring significant health care reform to include limits and restrictions on pharmaceutical prices  the future earnings and cash flows of these companies could change negatively  Therefore  prospective investors should be aware of these risks but at the same time recognize that these risks may already be priced in  Nevertheless  it s up to each individual investor to decide for themselves whether they are willing to take that risk or not 
Sources of Long Term Return
Throughout this series  I will be illustrating that there are several prudent sources of long term return and there is also luck or chance  Personally  I suggest that investors strive to build their portfolios based on prudent fundamental realities and not simply invest with the hope that your stocks will rise 
The primary prudent sources of total return that I am alluding to are  first and foremost  sound fundamental valuation   although attractive undervaluation is even more desirable  The second primary source would be growth defined as the potential long term rate of change of earnings and or cash flow growth and dividend growth  When you invest at sound valuation  you position yourself to participate in the growth that the business generates on your behalf 
If you can identify attractive undervaluation  you can expect a secondary source and a potential kicker to total return that I like to call natural leverage  Simply stated  in addition to the operating growth and dividend growth that the company achieves  you are also positioned to get P E ratio expansion  To clarify  you initially invest in a smaller level of earnings at a lower P E ratio where the company  over time  delivers a higher level of future earnings that the market capitalizes at a higher P E ratio  I metaphorically refer to this as a double double  In the future  you get double the earnings that are valued at double the P E ratio  Of course  the math does not always work out so perfectly  but I hope you get the point 
Furthermore  I will be presenting stocks that I believe offer the potential for significantly above average total return  Stated more clearly  I will be looking for dividend growth stocks that I believe can provide double digit total returns  including a growing dividend income stream  But perhaps most importantly  because of the focus on attractive valuation  I believe these future returns can be generated at greatly mitigated  lower  levels of long term risk 
Moreover  it s important to distinguish between long term results versus short term results  Intelligent value investors understand that investing in unpopular securities is where value is most often found  This is especially true when you are in a bull market like we have been in for the last several years 
Consequently  there are typically reasons why a stock s valuation is low  The trick is in determining whether those reasons are valid  permanent or temporary  Nevertheless  the intelligent value investor understands that unpopular stocks can remain unpopular for some time  and therefore provide below average short term results  On the other hand  unpopular stocks that are erroneously valued can provide exceptional long term returns based on the sources of long term return described above  But most importantly  if the stocks in question are truly undervalued  then the exceptional long term returns are also achieved at significantly mitigated levels of risk  Low risk and high return equals investor nirvana 
Medical Distributors and Drugstore Chains  Low Multiples of Earnings And Cash Flows
The following summary illustrates the low multiples of earnings and cash flows that these medical distributors and drugstore chains can currently be purchased at  Additionally  note that these low multiples translate into high levels of earnings and cash flow yields  the inverse of P E ratios and price to cash flow ratios  

FAST Graphs Screenshots of the 4 Research Candidates with Performance Calculation Estimates
The following long term earnings and price correlated FAST Graphs tell several important stories about each of the four medical distributors and or drug chains  First notice the long term relationship and high correlation between the companies  adjusted operating earnings  the orange line on the graph  and its monthly closing stock price  the black line on the graph   Price follows earnings  and when it gets disconnected  it inevitably reverts to the mean  Consequently  long term historical evidence suggests that as long as the orange earnings line continues to advance as forecast  that stock price should logically revert to the mean  Utilizing the calculator function  I provided the estimated total annualized rate of return  Tot Ann ROR  on each of the companies   Note  that these returns are a result of the sources of long term return discussed above  
Cardinal Health Inc  NYSE CAH 

CVS Health Corp  NYSE CVS 

McKesson Corp  NYSE MCK 

Walgreens Boots Alliance  NASDAQ WBA 

FAST Graphs Analyze Out Loud Video 


Summary and Conclusions
My primary purpose for presenting this follow up article to my AmerisourceBergen article is to illustrate that the undervaluation found in these subsectors are industry related  In other words  the concerns relate to issues affecting the entire sector and not specifically related to each of the individual research candidates 
However  and I consider this critically important  the rate of return forecasts presented on the screenshots and in the video are rational and highly likely as long as the earnings  the orange line on the graphs  manifest within reason according to the estimates  The orange line on each of the graphs represents a fair value 15 P E ratio  Clearly  the long term evidence supports the reality that whenever the price deviates from that valuation it inevitably reverts to the mean  and typically very quickly  Consequently  these research candidates do provide extremely attractive long term rates of return for the prudent value investor  However  continuous monitoring of the political and legal climate threatening these companies is imperative  Caveat emptor 
Disclosure  Long CAH CVS MCK WBA 
Disclaimer  The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients  Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted  The information in this document is believed to be accurate  but under no circumstances should a person act upon the information contained within  We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation ",2019-05-30,Chuck Carnevale,https://www.investing.com/analysis/mckesson-corp-walgreens-boots-alliance-cardinal-health-corp-cvs-health-corp-200426386,200426386
103227,324742,ABC,AmerisourceBergen  ABC  Up 1 6  Since Last Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for AmerisourceBergen  NYSE ABC   Shares have added about 1 6  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is AmerisourceBergen due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  AmerisourceBergen Q2 Earnings Beat  Revenues MissAmerisourceBergen Corporation delivered second quarter fiscal 2019 adjusted earnings per share  EPS  of  2 11 surpassing the Zacks Consensus Estimate of  1 96 by 7 7   maintaining its streak of positive earnings surprises  The figure also improved 8 8  year over year The better than expected bottom line performance can be attributed to increase in adjusted operating income and lower share count Revenues improved 5 6  to  43 32 billion in the reported quarter  However  the figure missed the Zacks Consensus Estimate of  43 58 billion by 0 6  Segmental AnalysisPharmaceutical Distribution SegmentRevenues at this segment totaled  41 68 billion  increasing 5 6  on a year over year basis  Overall market growth  consistent robust specialty product sales and increase in some of its largest customers contributed to the improvement Segmental operating income was  517 million  up 5 7  year over year  Increase in gross profit drove the upside  However  an increase in operating expenses partially offset the uptick Other SegmentThis segment includes AmerisourceBergen Consulting Services   ABCS    World Courier and MWI Veterinary Supply Revenues at this segment came in at  1 67 billion  up 4 5  year over year  This upside was driven by ABCS s growth in Canadian operations  World Courier business and MWI Operating income in the segment was  99 9 million in the quarter  up 2 9  year over year  Higher operating income at the company s Canadian operations and World Courier business led to the improvement Margin AnalysisIn the quarter under review  AmerisourceBergen registered adjusted gross profit of  1 3 billion  up 3 2  on a year over year basis  As a percentage of revenues  adjusted gross margin was 3  in the quarter  down 7 basis points year over year AmerisourceBergen registered adjusted operating income of  616 7 million  up 5 2  year over year  As a percentage of revenues  adjusted operating income was 1 4  in the quarter  down 1 basis point year over year Guidance RevisedAdjusted EPS is now estimated in the range of  6 70  6 90  up from the previously guided range of  6 65  6 85   The Zacks Consensus Estimate is currently pegged at  6 75  which is within the guided range Further the company anticipates weighted average diluted shares to be about 214 million  down from the previous estimate of around 215 million It is important to note here that per management all the other previously announced aspects of the company s fiscal year 2019 financial guidance and assumptions remain intact 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates 
VGM Scores
At this time  AmerisourceBergen has a strong Growth Score of A  a grade with the same score on the momentum front  Following the exact same course  the stock was allocated a grade of A on the value side  putting it in the top quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been trending upward for the stock  and the magnitude of this revision looks promising  Notably  AmerisourceBergen has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-05-31,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-abc-up-16-since-last-earnings-report-can-it-continue-200427398,200427398
103228,324743,ABC,Are Investors Undervaluing AmerisourceBergen  ABC  Right Now ,opinion,"While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks  we also know that investors tend to develop their own individual strategies  With this in mind  we are always looking at value  growth  and momentum trends to discover great companies 
Of these  perhaps no stock market trend is more popular than value investing  which is a strategy that has proven to be successful in all sorts of market environments  Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued  leaving room for profits 
In addition to the Zacks Rank  investors looking for stocks with specific traits can utilize our Style Scores system  Of course  value investors will be most interested in the system s  Value  category  Stocks with  A  grades for Value and high Zacks Ranks are among the best value stocks available at any given moment 
AmerisourceBergen  NYSE ABC  is a stock many investors are watching right now  ABC is currently holding a Zacks Rank of  2  Buy  and a Value grade of A  The stock is trading with a P E ratio of 11 21  which compares to its industry s average of 15 97  Over the past year  ABC s Forward P E has been as high as 14 32 and as low as 10 10  with a median of 11 95 
ABC is also sporting a PEG ratio of 1 48  This popular figure is similar to the widely used P E ratio  but the PEG ratio also considers a company s expected EPS growth rate  ABC s PEG compares to its industry s average PEG of 1 67  Within the past year  ABC s PEG has been as high as 1 55 and as low as 1 10  with a median of 1 28 
Finally  investors should note that ABC has a P CF ratio of 11 13  This metric takes into account a company s operating cash flow and can be used to find stocks that are undervalued based on their solid cash outlook  ABC s current P CF looks attractive when compared to its industry s average P CF of 14 94  Over the past year  ABC s P CF has been as high as 16 07 and as low as 6 91  with a median of 10 29 
These are just a handful of the figures considered in AmerisourceBergen s great Value grade  Still  they help show that the stock is likely being undervalued at the moment  Add this to the strength of its earnings outlook  and we can clearly see that ABC is an impressive value stock right now ",2019-06-04,Zacks Investment Research,https://www.investing.com/analysis/are-investors-undervaluing-amerisourcebergen-abc-right-now-200428739,200428739
103229,324744,ABC,ABC Vs  ALGN  Which Stock Is The Better Value Option ,opinion,"Investors looking for stocks in the Medical   Dental Supplies sector might want to consider either AmerisourceBergen  NYSE ABC  or Align Technology  ALGN   But which of these two companies is the best option for those looking for undervalued stocks  Let s take a closer look 
Everyone has their own methods for finding great value opportunities  but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank  The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions  while our Style Scores work to identify stocks with specific traits 
Right now  both AmerisourceBergen and Align Technology are sporting a Zacks Rank of   2  Buy   Investors should feel comfortable knowing that both of these stocks have an improving earnings outlook since the Zacks Rank favors companies that have witnessed positive analyst estimate revisions  However  value investors will care about much more than just this 
Value investors analyze a variety of traditional  tried and true metrics to help find companies that they believe are undervalued at their current share price levels 
Our Value category grades stocks based on a number of key metrics  including the tried and true P E ratio  the P S ratio  earnings yield  and cash flow per share  as well as a variety of other fundamentals that value investors frequently use 
ABC currently has a forward P E ratio of 12 38  while ALGN has a forward P E of 56 22  We also note that ABC has a PEG ratio of 1 64  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  ALGN currently has a PEG ratio of 2 40 
Another notable valuation metric for ABC is its P B ratio of 5 86  The P B ratio is used to compare a stock s market value with its book value  which is defined as total assets minus total liabilities  For comparison  ALGN has a P B of 19 68 
These are just a few of the metrics contributing to ABC s Value grade of A and ALGN s Value grade of D 
Both ABC and ALGN are impressive stocks with solid earnings outlooks  but based on these valuation figures  we feel that ABC is the superior value option right now ",2019-06-11,Zacks Investment Research,https://www.investing.com/analysis/abc-vs-algn-which-stock-is-the-better-value-option-200430987,200430987
103230,324745,ABC,6 Discounted PEG Stocks That Value Investors Love,opinion,Going by the Oracle  NYSE ORCL  of Omaha s success story  value investment is one of the most tempting strategies to bet on even amid uncertain market conditions  Per data provided by a Forbes article  shares of Berkshire Hathaway  NYSE BRKa   owned by Warren Buffett  increased 20  in 2016  boosting the Oracle of Omaha s personal fortune by  12 3 billion  more than any other billionaire in the U S   to  74 2 billion While searching for a suitable value investment option  investors are unlikely to consider price earnings to growth  PEG  ratio among a number of other popular value metrics like price earnings  P E   price sales  P S  or price book value  P B   This is because they often find this ratio complicated  considering the limitations in calculating the future earnings growth potential of a stock However  at a time when volatility strikes every second day  it is pointless to ponder on methods  which do not consider a stock s future growth rate while calculating its intrinsic merit  Yardsticks such as dividend yield  P E or P B are most commonly used to single out stocks trading at a discount However  these ratios  while not taking into account the future growth potential of a stock  may end up convincing us to invest in stocks that are at a discount just because of their poor show  This may often lead to  value traps    a situation when these value picks start to underperform over the long run as the temporary problems  which once drove the share price down  turn out to be persistent In such a case  even if you buy a stock at less than its fair value  you might still end up paying more  And here comes the importance of this not so popular but crucial value investing metric  the PEG ratio The PEG ratio is defined as  Price  Earnings  Earnings Growth RateA low PEG ratio is always better for value investors While P E alone fails to identify a true value stock  PEG helps to find the intrinsic value of a stock There are some drawbacks to using the PEG ratio though  It does not consider the very common situation of changing growth rates such as the forecast of the first three years at a very high growth rate followed by a sustainable but lower growth rate in the long term Hence  PEG based investing can turn out to be even more rewarding if some other relevant parameters are also taken into consideration Here are some of the screening criteria for a winning strategy PEG Ratio less than X Industry MedianP E Ratio  using F1  less than X Industry Median  for more accurate valuation purpose Zacks Rank of 1  Strong Buy  or 2  Buy   Whether good market conditions or bad  stocks with a Zacks Rank  1 or 2 have a proven history of success  Market Capitalization greater than  1 Billion  This helps us to focus on companies that have strong liquidity  Average 20 Day Volume greater than 50 000  A substantial trading volume ensures that the stock is easily tradable  Percentage Change F1 Earnings Estimate Revisions  4 Weeks  greater than 5   Upward estimate revisions add to the optimism  suggesting further bullishness  Value Score of less than or equal to B  Our research shows that stocks with a Style Score of A or B when combined with a Zacks Rank  1  2 or 3  Hold  offer the best upside potential  Here are six stocks that qualified the screening Molina Healthcare  Inc   MOH   Headquartered in Long Beach  CA  Molina Healthcare is a multi state managed care organization  participating exclusively in government sponsored healthcare programs such as Medicaid and State Children s Health Insurance Program  SCHIP  catering to low income persons  The company has an impressive long term historical growth rate of 58 1   The stock currently has a Value Score of A and a Zacks Rank  1  You can see  AngloGold Ashanti Limited   NYSE AU    This is a gold mining company  It also produces silver  uranium  and sulphuric acid  and dore bars  The stock currently sports a Zacks Rank  1 and has a Value Score of A  The company also has an impressive long term expected growth rate of 19 4  AmerisourceBergen Corporation   NYSE ABC    It is one of the world s largest pharmaceutical services companies  which focuses on providing drug distribution and related services to reduce health care costs and improve patient outcomes  Apart from a discounted PEG and P E  the stock has a Zacks Rank  2 and a Value Score of A Tetra Tech  Inc    NASDAQ TTEK    This is a leading provider of consulting  construction management  engineering  program management and technical services  It serves clients by providing cost effective and innovative solutions on dealing with fundamental needs for water  environmental and alternative energy services  The company currently holds a Zacks Rank  2 and has a Value Score of A  The company also has an impressive expected five year growth rate of 15  Wesco Aircraft Holdings  Inc    NYSE WAIR    This is an independent distributor and provider of comprehensive supply chain management services to the global aerospace industry  The company holds a Zacks Rank  2 and has a Value Score of A  The stock also has an impressive earnings growth rate of 12  for the next five years The GEO Group  Inc    NYSE GEO    This is the first fully integrated equity real estate investment trust specializing in design  financing  development  and operation of correctional  detention  and community reentry facilities around the globe  The company currently holds a Zacks Rank  1 and has a Value Score of A  The company also has an impressive expected five year growth rate of 6  The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  Disclosure  Performance information for Zacks  portfolios and strategies are available at   ,2019-06-13,Zacks Investment Research,https://www.investing.com/analysis/6-discounted-peg-stocks-that-value-investors-love-200431671,200431671
103231,324746,ABC,Top Ranked Momentum Stocks To Buy For June 20th,opinion,"Here are four stocks with buy rank and strong momentum characteristics for investors to consider today  June 20th Aaron s  Inc   AAN   This omni channel provider of lease purchase solutions has a Zacks Rank  2  Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 1 1  over the last 60 days Aaron s  Inc  Price and Consensus   Aaron sshares gained 12 5  over the last one month against the S P 500 s rise of 4   The company possesses a of B 
Aaron s  Inc  Price   AmerisourceBergen  NYSE ABC  Corporation  ABC   This distributor of pharmaceutical products has a Zacks Rank  2  Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 1 3  over the last 60 days 
AmerisourceBergen Corporation Price and Consensus   AmerisourceBergen s shares gained 7 8  over the last one month  The company possesses a Momentum Score of B 
AmerisourceBergen Corporation Price   AptarGroup  Inc   ATR   This provider of a variety of packaging  dispensing  and sealing solutions has a Zacks Rank  2  Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 2 6  over the last 60 days 
AptarGroup  Inc  Price and Consensus   AptarGroup s shares gained 6 4  over the last one month  The company possesses a Momentum Score of B 
AptarGroup  Inc  Price   Air Products and Chemicals  NYSE APD   Inc   APD   This provider of atmospheric gases  process and specialty gases and equipment has a Zacks Rank  2  Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0 5  over the last 60 days 
Air Products and Chemicals  Inc  Price and Consensus   Air Products  shares gained 6 5  over the last one month  The company possesses a Momentum Score of B Air Products and Chemicals  Inc  Price   See the  Learn more about the  Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-06-19,Zacks Investment Research,https://www.investing.com/analysis/top-ranked-momentum-stocks-to-buy-for-june-20th-200433384,200433384
103232,324747,ABC,Should Value Investors Buy AmerisourceBergen  ABC  Stock ,opinion,"Here at Zacks  our focus is on the proven Zacks Rank system  which emphasizes earnings estimates and estimate revisions to find great stocks  Nevertheless  we are always paying attention to the latest value  growth  and momentum trends to underscore strong picks 
Of these  value investing is easily one of the most popular ways to find great stocks in any market environment  Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued  leaving room for profits 
Luckily  Zacks has developed its own Style Scores system in an effort to find stocks with specific traits  Value investors will be interested in the system s  Value  category  Stocks with both  A  grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now 
One company to watch right now is AmerisourceBergen  NYSE ABC   ABC is currently sporting a Zacks Rank of  2  Buy  and an A for Value  The stock has a Forward P E ratio of 11 95  This compares to its industry s average Forward P E of 16 83  ABC s Forward P E has been as high as 14 32 and as low as 10 10  with a median of 11 90  all within the past year 
Investors should also note that ABC holds a PEG ratio of 1 58  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  ABC s industry has an average PEG of 1 76 right now  Over the last 12 months  ABC s PEG has been as high as 1 59 and as low as 1 10  with a median of 1 29 
Finally  investors will want to recognize that ABC has a P CF ratio of 11 92  This metric takes into account a company s operating cash flow and can be used to find stocks that are undervalued based on their solid cash outlook  This stock s P CF looks attractive against its industry s average P CF of 15 80  Within the past 12 months  ABC s P CF has been as high as 15 84 and as low as 6 91  with a median of 10 29 
These are just a handful of the figures considered in AmerisourceBergen s great Value grade  Still  they help show that the stock is likely being undervalued at the moment  Add this to the strength of its earnings outlook  and we can clearly see that ABC is an impressive value stock right now ",2019-06-20,Zacks Investment Research,https://www.investing.com/analysis/should-value-investors-buy-amerisourcebergen-abc-stock-200433807,200433807
103257,324772,ABC,Why AmerisourceBergen  ABC  Is Poised To Beat Earnings Estimates Again,opinion,"Have you been searching for a stock that might be well positioned to maintain its earnings beat streak in its upcoming report  It is worth considering AmerisourceBergen  NYSE ABC   which belongs to the Zacks Medical   Dental Supplies industry 
When looking at the last two reports  this prescription drug distributor has recorded a strong streak of surpassing earnings estimates  The company has topped estimates by 3 68   on average  in the last two quarters 
For the last reported quarter  AmerisourceBergen came out with earnings of  1 60 per share versus the Zacks Consensus Estimate of  1 50 per share  representing a surprise of 6 67   For the previous quarter  the company was expected to post earnings of  1 44 per share and it actually produced earnings of  1 45 per share  delivering a surprise of 0 69  
Price and EPS Surprise

For AmerisourceBergen  estimates have been trending higher  thanks in part to this earnings surprise history  And when you look at the stock s positive Zacks Earnings ESP  Expected Surprise Prediction   it s a great indicator of a future earnings beat  especially when combined with its solid Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
AmerisourceBergen has an Earnings ESP of  1 16  at the moment  suggesting that analysts have grown bullish on its near term earnings potential  When you combine this positive Earnings ESP with the stock s Zacks Rank  3  Hold   it shows that another beat is possibly around the corner  The company s next earnings report is expected to be released on May 2  2019 
With the Earnings ESP metric  it s important to note that a negative value reduces its predictive power  however  a negative Earnings ESP does not indicate an earnings miss 
Many companies end up beating the consensus EPS estimate  though this is not the only reason why their shares gain  Additionally  some stocks may remain stable even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-04-09,Zacks Investment Research,https://www.investing.com/analysis/why-amerisourcebergen-abc-is-poised-to-beat-earnings-estimates-again-200405594,200405594
103258,324773,ABC,SAP Q1 Earnings Improve Y Y  Cloud Strength Drives Top Line,opinion,SAP SE  DE SAPG    NYSE SAP   reported first quarter 2019 non IFRS earnings of  0 90  approximately  1 02  per share  which surged 23 3  from the year ago figure  The Zacks Consensus Estimate was pegged at 94 cents On IFRS basis  the company reported loss of  0 10  loss of 11 cents  per share compared with year ago earnings of  0 59 Total revenues  on non IFRS basis  came in at  6 118 billion  around  6 947 billion   up 16 3  year over year  up 12  at constant currency   The Zacks Consensus Estimate was pegged at  6 744 billion On IFRS basis  revenues were  6 091 billion  almost  6 916 billion   up 15 8  year over year New cloud bookings   a key indicator of sales success in cloud business   surged 32 2   26  at cc  to  324 million Stock PerformanceShares of SAP are up approximately 9  in the pre market  This can primarily be attributed to optimism regarding raised guidance for operating profit in 2019 outlook  Moreover  per   U S  based activist investor Elliott recently revealed a  1 2 billion stake in SAP  which is a key catalyst driving momentum in the stock  Notably  SAP stock has returned 15 3  year to date  underperforming the  s rally of 22 5  Upbeat Cloud ResultsCloud and software business includes Cloud subscriptions   support  previously known by  cloud subscriptions   support   and Software licenses   support On a non IFRS basis  Cloud and software business  82 9  of total revenues  reported revenues of  5 07 billion  up 16  year over year  up 12  at cc  Cloud revenues of  1 581 billion  surged 38  on a year over year basis at cc  non IFRS   Software licenses   support reported revenues of  3 489 billion  up 3  at cc on a year over year basis  non IFRS  Cloud revenues   related to Software as a Service  SaaS  Platform as a Service  PaaS    surged 40  at cc to  1 355 billion  Cloud revenues   Infrastructure as a Service  IaaS  related   rallied 45  year over year to  152 million Services revenues  17 2  of total revenues  increased 15  from the year ago quarter  up 11  at cc  to  1 048 billion  non IFRS  SAP provides collaborative commerce capabilities  Ariba   flexible workforce management  Fieldglass  and effortless travel and expense processing  Concur  under its Business Network segment  formerly known as SAP Business Network segment   Approximately   3 1 trillion in global commerce is transacted annually through this platform across more than 180 countries Segment wise  Applications  Technology   Services  AT S  revenues increased 9  at cc to  4 993 billion  Business Network revenues jumped 18  at cc to  740 million  Moreover  Customer and Experience Management  CXM  revenues were up more than 100  year over year at cc to  305 million Expanding Customer Base Remains NoteworthyS 4HANA adoption grew 30  year over year to around 10 900 customers  In the reported quarter  net new customers comprised approximately 40  S 4HANA clientele continues to expand with the addition of CVS Health  NYSE CVS   Schaeffler Technologies  Levi s  and Puma among other notable companies  Notably  companies including AEG  Computacenter  ESL Turtle Entertainment  among others selected S 4HANA solution in the cloud Moreover  SAP s C 4HANA customer experience solution was selected by Groupe PSA Brazil  AmerisourceBergen  NYSE ABC  and Isuzu Motors South Africa in the reported quarter SAP SE Price  Consensus and EPS Surprise   SAP s Human Capital management  HCM  flagship solution   SuccessFactors Employee Central   ended the reported quarter with more than 3 200 customers  Notable deal wins in the quarter comprise Calzedonia Group and Tapestry Management is optimistic on conclusion of SuccessFactors  migration to SAP HANA platform  This move is anticipated to enhance SuccessFactors solution with integrated predictive analytics and other capabilities  Notably  SAP SuccessFactors suite is available across 96 countries in 42 languages Premier Foods and  selected SAP s Leonardo solution in the reported quarter  Notably  Leonardo integrates IoT  Big Data  ML  Analytics and Blockchain capabilities on the SAP Cloud platform Digital Platform comprises SAP Data Management and SAP Cloud Platform solutions  In the reported quarter  a notable deal win for the company s Digital Platform offerings includes Kontinental Hockey League Furthermore  SAP Ariba recently inked deal with American Express   NYSE AXP   with an aim to design new financing and payment options on Ariba Network  Moreover  Omnicom opted for the company s Business Network solutions Management is optimistic regarding the recent acquisition of Qualtrics  concluded on Jan 23  2019  for  8 billion in cash  Financials pertaining to Qualtrics fall under CXM segment  Notably  the company s experience management solutions were selected by Cirque du Soleil and CVS Health in the reported quarter Asia Pacific   Japan  APJ  Witnessed Solid GrowthAPJ Cloud revenues jumped approximately 51  at cc  Cloud   software revenues increased around 12  at cc  The top line benefited from strong cloud revenue growth in Greater China and Japan  Growth in Software license revenues across the U K   Germany and Spain was noteworthy Europe  Middle East   Africa  EMEA  Cloud revenues advanced 39  at cc  Cloud   software revenues increased 11  at cc  The top line was driven by strong cloud revenues in the U K   Spain and Switzerland  Management is elated on robust software revenue growth witnessed in the U K   Germany and Spain Americas  Cloud revenues soared more than 39  at cc  Cloud   software revenues increased 12  at cc  The United States  Mexico and Canada delivered strong performance in cloud revenues in the first quarter  Further  solid adoption of software license solutions across the United States and Canada aided growth SAP SE Revenue  Quarterly    Margin DetailsNon IFRS gross margin of 69 5  contracted 70 basis points  bps  from the year ago figure SAP reported non IFRS operating expense of  4 651 billion  up 15 5  from the year ago quarter  up 12  at cc  Non IFRS operating profit of  1 467 billion grew 19  on a year over year basis  up 13  at cc   However  per IFRS  SAP reported operating loss of  136 million  which management attributed to restructuring expenses of around  886 million in the reported quarter  Additionally  other charges pertaining to Qualtrics acquisition impacted operations negatively Operating margin expanded 20 bps at cc to 23 7   non IFRS  Segment wise  Applications  Technology   Services profit increased 7  at cc to approximately  1 809 billion on a non IFRS basis  Business Network profit surged 51  at cc to  161 million  However  CXM segment reported a loss of  11 million Balance Sheet   Cash FlowThe company ended the first quarter with cash and cash equivalents of approximately  7 332 billion compared with the previous quarter s figure of  8 627 billion The company generated operating cash flow of almost  2 802 billion in the reported quarter compared with previous quarter s reported figure of  818 million Free cash flow came in at  2 365 billion compared with previous quarter s figure of  506 million Updated Operating Profit Guidance for 2019SAP anticipates upbeat pipeline and momentum in cloud to continue through 2019  Non IFRS cloud subscriptions and support revenues are expected in the range of  6 7  7 0 billion  up 33 39  at cc Non IFRS cloud and software revenues are now anticipated between  22 4 million and  22 7 billion  up 8 5 10  at cc Additionally  non IFRS operating profit for 2019 is estimated in the band of  7 85  8 05 billion  previously  7 7  8 0 billion   indicating year over year growth of 9 5 12 5  at cc For 2019  the company now projects total revenues to report robust growth  at a lower rate  previously predicted  slightly lower   than the increase in operating profit Outlook for 2020For 2020  SAP projects non IFRS cloud subscriptions and support revenues to  8 6  9 1 billion  Non IFRS total revenues are expected to come in the range of  28 6  29 2 billion Notably  the company now envisions non IFRS operating profit in the range of  8 8  9 1 billion  compared with earlier predicted range of  8 5  9 0 billion Zacks Rank   Stocks to ConsiderCurrently  SAP carries a Zacks Rank  3  Hold  A couple of better ranked stocks in the same industry are Synopsys  Inc    NASDAQ SNPS   and Pegasystems Inc    NASDAQ PEGA    both sporting a Zacks Rank  1  Strong Buy   You can see  Long term earnings growth rate for Synopsys and Pegasystems is pegged at 10  and 8   respectively Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-04-23,Zacks Investment Research,https://www.investing.com/analysis/sap-q1-earnings-improve-yy-cloud-strength-drives-top-line-200410413,200410413
103259,324774,ABC,AmerisourceBergen  ABC  Reports Next Week  Wall Street Expects Earnings Growth,opinion,"Wall Street expects a year over year increase in earnings on higher revenues when AmerisourceBergen  NYSE ABC  reports results for the quarter ended March 2019  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The earnings report  which is expected to be released on May 2  2019  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This prescription drug distributor is expected to post quarterly earnings of  1 97 per share in its upcoming report  which represents a year over year change of  1 6  
Revenues are expected to be  43 68 billion  up 6 4  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for AmerisourceBergen 
For AmerisourceBergen  the Most Accurate Estimate is lower than the Zacks Consensus Estimate  suggesting that analysts have recently become bearish on the company s earnings prospects  This has resulted in an Earnings ESP of  0 18  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination makes it difficult to conclusively predict that AmerisourceBergen will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that AmerisourceBergen would post earnings of  1 50 per share when it actually produced earnings of  1 60  delivering a surprise of  6 67  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
AmerisourceBergen doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-04-24,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-abc-reports-next-week-wall-street-expects-earnings-growth-200411051,200411051
103260,324775,ABC,Walgreens  WBA  Down 2 1  Since Last Earnings Report  Can It Rebound ,opinion,"A month has gone by since the last earnings report for Walgreens Boots Alliance  NASDAQ WBA   Shares have lost about 2 1  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Walgreens due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  Walgreens Boots Lags Q2 Earnings  Margins DeclineWalgreens Boots reported adjusted earnings per share  EPS  of  1 64 for second quarter fiscal 2019  down 5 4  year over year  down 4 3  at constant exchange rate or CER   The figure missed the Zacks Consensus Estimate of  1 70 by 3 5  On a reported basis  net earnings came in at  1 16 billion  reflecting a 14 1  decline from the prior year quarter  Reported EPS came in at  1 24  down 8 3  on a year over year basis Per management  a difficult macroeconomic environment and market challenges made fiscal second quarter the toughest since the formation of the Walgreens Boots Alliance Total SalesWalgreens Boots recorded total sales of  34 53 billion in the fiscal second quarter  up 4 6  year over year and 6 7  at constant exchange rate or CER  The top line missed the Zacks Consensus Estimate of  34 87 billion Segments in DetailWalgreens Boots reports through three segments  Retail Pharmacy USA  Retail Pharmacy International and Pharmaceutical Wholesale Retail Pharmacy USAThe segment recorded sales of  26 3 billion in the second quarter  highlighting an improvement of 7 3  year over year  Excluding benefits from the acquired Rite Aid stores  organic sales growth was 1 6  year over year Pharmacy sales  which accounted for 71 9  of the Retail Pharmacy USA division s sales in the quarter  increased 9 8  from the year ago quarter on higher prescription volume from the acquisition of Rite Aid stores and central specialty  Pharmacy sales at comparable stores improved 1 9  while prescriptions filled in comparable stores increased 1 8  year over year in the quarter  With the addition of Rite Aid stores  retail sales increased 1 3  year over year  However  comparable retail sales dropped 3 8  Retail Pharmacy InternationalRevenues at the Retail Pharmacy International division dropped 7 1  on a year over year basis to  3 1 billion in the second quarter  Sales were down 1 2  at CER considering a 1 3  decline in Boots UK In the United Kingdom  comparable pharmacy sales dropped 1 5  and comparable retail sales declined 2 3  in the reported quarter Pharmaceutical WholesaleThe Pharmaceutical Wholesale division recorded quarterly sales of  5 7 billion  down 0 3  year over year  up 9 1  at CER banking on continued growth in emerging markets and the U K   MarginsGross profit in the reported quarter declined 4 3  year over year to  7 75 billion  However  gross margin contracted 210 basis points  bps  to 22 4  Selling  general and administrative  SG A  expenses remained relatively flat year over year at  6 32 billion  Adjusted operating income after excluding equity earnings in AmerisourceBergen  NYSE ABC  declined 19 7  to  1 43 billion  Overall  operating margin contracted 130 bps to 4 1  Financial ConditionWalgreens Boots exited the fiscal second quarter with cash and cash equivalents of  818 million  compared with  980 million at the end of first quarter fiscal 2019  Long term debt was  12 69 billion  compared with  11 65 billion at the end of fiscal first quarter  In the six months ending Feb 28  2019  the company generated operating cash flow of  1 20 billion compared with  3 21 billion in the year ago period Guidance TweakedWalgreens Boots lowered its fiscal 2019 adjusted EPS guidance from 7 12  growth at CER to roughly flat  The Zacks Consensus Estimate for the metric is pegged at  6 39 The company had announced the introduction of a transformational cost management program in the last reported quarter  Walgreens Boots has now revised the targeted annual cost savings to more than  1 5 billion from more than  1 billion by fiscal 2022 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  The consensus estimate has shifted  10 16  due to these changes 
VGM Scores
At this time  Walgreens has a nice Growth Score of B  though it is lagging a lot on the Momentum Score front with a D  However  the stock was allocated a grade of A on the value side  putting it in the top quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  It s no surprise Walgreens has a Zacks Rank  4  Sell   We expect a below average return from the stock in the next few months ",2019-05-01,Zacks Investment Research,https://www.investing.com/analysis/walgreens-wba-down-21-since-last-earnings-report-can-it-rebound-200415571,200415571
103261,324776,ABC,AmerisourceBergen  ABC  Surpasses Q2 Earnings Estimates,opinion,"AmerisourceBergen  NYSE ABC  came out with quarterly earnings of  2 11 per share  beating the Zacks Consensus Estimate of  1 96 per share  This compares to earnings of  1 94 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 7 65   A quarter ago  it was expected that this prescription drug distributor would post earnings of  1 50 per share when it actually produced earnings of  1 60  delivering a surprise of 6 67  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
AmerisourceBergen  which belongs to the Zacks Medical   Dental Supplies industry  posted revenues of  43 32 billion for the quarter ended March 2019  missing the Zacks Consensus Estimate by 0 59   This compares to year ago revenues of  41 03 billion  The company has topped consensus revenue estimates two times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
AmerisourceBergen shares have lost about 1 4  since the beginning of the year versus the S P 500 s gain of 16 6  
What s Next for AmerisourceBergen 
While AmerisourceBergen has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for AmerisourceBergen was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 64 on  45 47 billion in revenues for the coming quarter and  6 75 on  180 03 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Dental Supplies is currently in the top 17  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-05-02,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-abc-surpasses-q2-earnings-estimates-200415368,200415368
103262,324777,ABC,Is AmerisourceBergen  ABC  A Great Value Stock Right Now ,opinion,"The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks  Nevertheless  we know that our readers all have their own perspectives  so we are always looking at the latest trends in value  growth  and momentum to find strong picks 
Of these  perhaps no stock market trend is more popular than value investing  which is a strategy that has proven to be successful in all sorts of market environments  Value investors use tried and true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels 
Luckily  Zacks has developed its own Style Scores system in an effort to find stocks with specific traits  Value investors will be interested in the system s  Value  category  Stocks with both  A  grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now 
One company to watch right now is AmerisourceBergen  NYSE ABC   ABC is currently sporting a Zacks Rank of  2  Buy   as well as a Value grade of A  The stock holds a P E ratio of 10 91  while its industry has an average P E of 16 38  Over the past 52 weeks  ABC s Forward P E has been as high as 14 32 and as low as 10 10  with a median of 12 08 
Investors should also note that ABC holds a PEG ratio of 1 44  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  ABC s PEG compares to its industry s average PEG of 1 73  Over the past 52 weeks  ABC s PEG has been as high as 1 55 and as low as 1 10  with a median of 1 27 
Finally  we should also recognize that ABC has a P CF ratio of 10 73  This figure highlights a company s operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook  This company s current P CF looks solid when compared to its industry s average P CF of 15 16  Over the past year  ABC s P CF has been as high as 15 48 and as low as 6 91  with a median of 10 29 
Value investors will likely look at more than just these metrics  but the above data helps show that AmerisourceBergen is likely undervalued currently  And when considering the strength of its earnings outlook  ABC sticks out at as one of the market s strongest value stocks ",2019-05-08,Zacks Investment Research,https://www.investing.com/analysis/is-amerisourcebergen-abc-a-great-value-stock-right-now-200419509,200419509
103265,324780,ABC,ABC Vs  WST  Which Stock Is The Better Value Option ,opinion,"Investors interested in Medical   Dental Supplies stocks are likely familiar with AmerisourceBergen  NYSE ABC  and West Pharmaceutical Services  WST   But which of these two stocks offers value investors a better bang for their buck right now  We ll need to take a closer look 
Everyone has their own methods for finding great value opportunities  but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank  The Zacks Rank favors stocks with strong earnings estimate revision trends  and our Style Scores highlight companies with specific traits 
Right now  AmerisourceBergen is sporting a Zacks Rank of  2  Buy   while West Pharmaceutical Services has a Zacks Rank of  3  Hold   Investors should feel comfortable knowing that ABC likely has seen a stronger improvement to its earnings outlook than WST has recently  But this is just one factor that value investors are interested in 
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels 
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics  These include the long favored P E ratio  P S ratio  earnings yield  cash flow per share  and a variety of other fundamentals that help us determine a company s fair value 
ABC currently has a forward P E ratio of 11 56  while WST has a forward P E of 41 99  We also note that ABC has a PEG ratio of 1 53  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  WST currently has a PEG ratio of 3 67 
Another notable valuation metric for ABC is its P B ratio of 5 47  The P B ratio is used to compare a stock s market value with its book value  which is defined as total assets minus total liabilities  For comparison  WST has a P B of 6 39 
These metrics  and several others  help ABC earn a Value grade of A  while WST has been given a Value grade of D 
ABC has seen stronger estimate revision activity and sports more attractive valuation metrics than WST  so it seems like value investors will conclude that ABC is the superior option right now ",2019-05-08,Zacks Investment Research,https://www.investing.com/analysis/abc-vs-wst-which-stock-is-the-better-value-option-200419475,200419475
103289,324804,ABC,Earnings Preview  AmerisourceBergen  ABC  Q1 Earnings Expected To Decline,opinion,"Wall Street expects a year over year decline in earnings on higher revenues when AmerisourceBergen  NYSE ABC  reports results for the quarter ended December 2018  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The earnings report  which is expected to be released on January 31  2019  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This prescription drug distributor is expected to post quarterly earnings of  1 50 per share in its upcoming report  which represents a year over year change of  3 2  
Revenues are expected to be  43 52 billion  up 7 5  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 69  higher over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is subject to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for AmerisourceBergen 
For AmerisourceBergen  the Most Accurate Estimate is lower than the Zacks Consensus Estimate  suggesting that analysts have recently become bearish on the company s earnings prospects  This has resulted in an Earnings ESP of  0 95  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination makes it difficult to conclusively predict that AmerisourceBergen will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that AmerisourceBergen would post earnings of  1 44 per share when it actually produced earnings of  1 45  delivering a surprise of  0 69  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
AmerisourceBergen doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-01-23,Zacks Investment Research,https://www.investing.com/analysis/earnings-preview-amerisourcebergen-abc-q1-earnings-expected-to-decline-200378961,200378961
103290,324805,ABC,AmerisourceBergen  ABC  Q1 Earnings  What s In The Cards ,opinion,"AmerisourceBergen Corporation s   NYSE ABC   first quarter fiscal 2019 results are scheduled to release on Jan 31  While the company s core Pharmaceutical Distribution unit is likely to drive growth  stiff competition is likely to mar prospects Fiscal Q4 Results AmerisourceBergen posted adjusted earnings of  1 45 per share in fourth quarter fiscal 2018  which exceeded the Zacks Consensus Estimate of  1 44 and improved 9  year over year Revenues increased almost 10 7  to  43 29 billion but missed the Zacks Consensus Estimate of  43 53 billion The company delivered a positive earnings surprise in the trailing four quarters  the average being 6 9  Which Way Are Q1 Estimates Treading For the quarter to be reported  the Zacks Consensus Estimate for revenues is pegged at  43 52 billion  reflecting 7 5  growth year over year  The same for earnings stands at  1 50  indicating year over year decline of 3 2  Let s delve deeper to analyze how things are shaping up before the earnings announcement Pharmaceutical Distribution Unit to Drive Q1Increasing volume and an expanding customer base at this segment are likely to boost revenues  This segment serves healthcare providers in the pharmaceutical supply channel  Not to forget  the Pharmaceutical Distribution segment accounted for 96 4  of the company s net revenues in the last reported quarter  Moreover  the segment s revenues grew 3 9  on a year over year basis to  41 73 billion The Zacks Consensus Estimate for Pharmaceutical Distribution stands at  40 46 billion  mirroring an improvement of 11 5  from the year ago quarter number Per management  the segment surpassed the company s expectations in the past few of quarters  Strong organic growth rates in the U S  pharmaceutical market  improving patient access to medical care  improved economic conditions and population demographics should reflect in first quarter fiscal 2019 results AmerisourceBergen Corporation Price and Consensus
    Other Factors to ConsiderOther SegmentThis segment consists of Global Commercialization Services and Animal Health  and includes World Courier  AmerisourceBergen Consulting and MWI  In the last reported quarter  the Other segment contributed 3 7  to the company s net revenues  Notably  revenues at the segment improved 7 9  year over year to  1 60 billion in the fiscal fourth quarter We expect the segment to witness robust growth in the quarter to be reported  The Zacks Consensus Estimate for first quarter revenues is pegged at  1 64 billion  up 6 1  year over year World Courier unitThe World Courier unit  in particular  is likely to be one of the key growth drivers of the Other segment  The World Courier business delivered excellent results  with record gains in the last reported quarter  The unit witnessed outstanding operating income growth as well  We expect similar trends in the fiscal first quarter What Does Our Model Say Our proven model clearly indicates that a stock needs to have both   a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    to deliver a positive earnings surprise  This is not the case here Earnings ESP  AmerisourceBergen has an Earnings ESP of  0 95   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  AmerisourceBergen carries a Zacks Rank  3 Please note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat in the upcoming releases PerkinElmer  Inc    NYSE PKI   has an Earnings ESP of  0 77  and a Zacks Rank  3 Illumina  Inc    NASDAQ ILMN   has an Earnings ESP of  0 32  and a Zacks Rank  2  You can see  DexCom   NASDAQ DXCM   has an Earnings ESP of  8 93  and a Zacks Rank  2 The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ",2019-01-24,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-abc-q1-earnings-whats-in-the-cards-200379599,200379599
103291,324806,ABC,Medical Products  Earnings Lineup For Jan 31  EW  BAX   More,opinion,The  companies  within the broader  sector  are likely to put up a superb show this earnings season  Focus on research and development is a key growth strategy for companies in this space  Currently  these players are benefiting from R D innovation  courtesy of the 2 3  Medical Device tax abolition earlier in 2018 Solid growth in emerging markets is expected to be an added positive this earnings season  Backed by rising medical awareness and economic prosperity  emerging economies are witnessing solid demand for medical products  Notably  an aging population  relaxed regulations  cheap skilled labor  increasing wealth and government focus on healthcare infrastructure make these markets a happy hunting ground for global medical device players Per the latest  report  the Medical sector is expected to record solid earnings growth this reporting cycle  as of Jan 23   For the quarter under review  earnings growth rate is projected at 7 7  on 6 1  revenue growth However  the U S  Medical Products industry has confronted short term hurdles pertaining to the trade war with China  According to a survey conducted by the Medical Imaging   Technology Alliance  MITA   tariffs will cost the companies nearly  138 million every year What Our Model SaysAccording to the Zacks model  a company with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has a good chance of beating estimates if it also has a positive   Conversely  a Zacks Rank  4  Sell  or 5  Strong Sell  stocks are best avoided  especially if the companies are witnessing negative estimate revisions  You can uncover the best stocks to buy or sell before they re reported with our  Considering the above factors  we take a look at the five Medical Products behemoths that are set to release results on Jan 31 Edwards Lifesciences Corporation   NYSE EW  In the fourth quarter of 2018  the company is expected to gain from strength in Critical Care product group  This segment has been witnessing solid growth across all product categories Edwards Lifesciences is also set to keep benefiting from Critical Care technologies with the rollout of HemoSphere monitoring platform supported by new group purchasing organization contracts in the United States  read more    The Zacks Consensus Estimate for fourth quarter revenues is pinned at  973 7 million  indicating a year over year increase of 9 6   The same for earnings is pegged at  1 17  reflecting a 24 5  rise year over year  In the trailing four quarters  the company exceeded the consensus mark  the average being 7 8  Edwards Lifesciences  Earnings ESP of  0 86  and a Zacks Rank  3  make us confident about an earnings beat this season  You can see  Edwards Lifesciences Corporation Price and Consensus    Baxter International Inc    NYSE BAX   The company is expected to see steady growth in the fourth quarter on the back of strength in its core Renal Care segment  An upbeat earnings view for 2018 also buoys optimism  Baxter s Renal Care segment  which offers improved dialysis solutions for patients  is expected to provide a boost to its fourth quarter results  It is encouraging to note that the Zacks Consensus Estimate for the unit s fourth quarter revenues stands at  951 million  reflecting a sequential rise of 4 5  For the segment s U S  revenues  the consensus mark is pinned at  212 million  up 1 4  sequentially  Meanwhile  the Zacks Consensus Estimate for the segment s international sales is pegged at  728 million  mirroring a sequential rise of 3 9   read more    Baxter has an Earnings ESP of  1 83  and a Zacks Rank  3  which increase the chances of an earnings beat in the to be reported quarter Baxter International Inc  Price and Consensus    McKesson Corporation   NYSE MCK   In the third quarter of fiscal 2019  McKesson s core business units   U S  Pharmaceutical and Specialty Solutions  and European Pharmaceutical Solutions   are likely to boost its quarterly performance Notably  the Pharmaceutical Solutions segment is likely to gain momentum on the back of its branded  generic and over the counter pharmaceuticals  This apart  McKesson s Specialty business is likely to be a major top line contributor  with solid growth in specialty drug distribution  For the quarter to be reported  the Zacks Consensus Estimate for the U S  Pharmaceutical and Specialty Solutions is pegged at  43 01 billion  showing a sequential rise of 3 4   read more    The Zacks Consensus Estimate for the fiscal third quarter revenues is pinned at  55 27billion  indicating a year over year increase of 3 1   The same for earnings is  3 18  reflecting a 6 8  decline year over year  In the trailing four quarters  the company exceeded the consensus mark  the average being 7 8  McKesson has a Zacks Rank  3 and an Earnings ESP of  0 08   a combination that hints at slim chances of a beat in the third quarter of fiscal 2019 McKesson Corporation Price and Consensus    ABIOMED  Inc    NASDAQ ABMD   In the third quarter of fiscal 2019  ABIOMED is set to gain from its flagship Impella product line  Notably  ABIOMED has been progressing well with SmartAssist  Impella Connect  IQ Impella Quality Assurance Database  cVAD and NCSI platforms  Furthermore  there is a growing physician awareness on Impella s ability to protect against acute kidney injury  read more    The Zacks Consensus Estimate for ABIOMED s fiscal third quarter earnings is pegged at 94 cents  mirroring 34 3  improvement year over year  The same for revenues stands at  200 6 million  reflecting an increase of 30 2  year over year Our model predicts a positive earnings surprise by ABIOMED in the third quarter of fiscal 2019  This is because the stock has an Earnings ESP of  2 60  and a Zacks Rank  3 ABIOMED  Inc  Price and Consensus    AmerisourceBergen Corporation   NYSE ABC   Increasing volume and an expanding customer base at the Pharmaceutical Distributionsegment are likely to boost AmerisourceBergen srevenues in the first quarter of fiscal 2019  This segment serves healthcare providers in the pharmaceutical supply channel  The Zacks Consensus Estimate for Pharmaceutical Distribution s revenues stands at  40 46 billion  mirroring an improvement of 11 5  from the year ago quarter number  read more    For the quarter to be reported  the consensus mark for revenues is pegged at  43 52 billion  reflecting 7 5  growth year over year  The same for earnings stands at  1 50  indicating year over year decline of 3 2  AmerisourceBergen has a Zacks Rank  3 and an Earnings ESP of  0 95   a combination that hints at slim chances of a beat in the first quarter of fiscal 2019 AmerisourceBergen Corporation Price and Consensus    Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ,2019-01-29,Zacks Investment Research,https://www.investing.com/analysis/medical-products-earnings-lineup-for-jan-31-ew-bax--more-200381175,200381175
103292,324807,ABC,Cardinal Health Strong On Pharmaceutical  Competition Rife,opinion,"On Feb 11  we issued an updated research report on Cardinal Health  Inc    NYSE CAH    While strength in the core Pharmaceutical segment is a positive  a series of acquisitions is likely to pose integration risks for the company The stock currently carries a Zacks Rank  3  Hold  What s Favoring Cardinal Health Cardinal Health s Pharmaceutical segment is the second largest pharmaceutical distributor in the United States In the recently reported fiscal second quarter  Pharmaceutical revenues increased 8  to  33 74 billion on a year over year basis  The segment witnessed strong growth in the Specialty business and gained a large number of Pharmaceutical distribution customers The company is currently on track to deliver targeted annualized cost savings of  100 million in fiscal 2019 and in excess of  200 million by the end of fiscal year 2020  Management at Cardinal Health announced that benefits from this will continue to build through 2019 Cardinal Health follows an acquisition driven strategy and continues to focus on investment in key growth businesses to gain market traction and boost profits In the recent past  Clayton  Dubilier   Rice  CD R  and Cardinal Health jointly invested in Brentwood  TN based naviHealth  Notably  naviHealth has always been a strong performer for Cardinal Health  Management at Cardinal Health announced that the company is likely to have a competitive edge in the MedTech space with CD R as a partner The company recently completed the acquisition of Medtronic  NYSE MDT  s Patient Care  Deep Vein Thrombosis and Nutritional Insufficiency business for  6 1 billion  which specifically boosted the Medical segment DeterrentsCardinal Health continues to acquire a large number of companies  While this improves the company s revenue opportunities  it adds to integration risks  The Cordis acquisition was financed through a combination of debt and cash and the  1 billion debt financing increased leverage in the near term Additionally  the company faces tough rivalry in each of its business segments  For instance  its pharmaceutical supply chain business faces competition from bigwigs like McKesson   NYSE MCK   and AmerisourceBergen   NYSE ABC   Cardinal Health  Inc  Price and Consensus
    Price PerformanceOver the past year  Cardinal Health s shares have declined 21 8  compared with the  s decline of 3 8   The current level also compares unfavorably with the S P 500 s rally of 2 2  Over the past 60 days  the Zacks Consensus Estimate for the company s fiscal third quarter earnings per share moved down 3 4  to  1 14 Key PickA better ranked stock in the broader medical space is Penumbra  Inc    NYSE PEN   Penumbra s long term earnings growth rate is expected at 20   The stock carries a Zacks Rank  2  Buy   You can see  Zacks  Best Stock Picking StrategyIt s hard to believe  even for us at Zacks  But from 2000 2018  while the market gained  4 8  per year  our top stock picking strategy averaged  54 3  per year How has that screen done lately  From 2017 2018  it sextupled the market s  15 8  gain with a soaring  98 3  return ",2019-02-12,Zacks Investment Research,https://www.investing.com/analysis/cardinal-health-strong-on-pharmaceutical-competition-rife-200386732,200386732
103316,324831,ABC,AmerisourceBergen  ABC  Down 8 7  Since Earnings Report  Can It Rebound ,opinion,"A month has gone by since the last earnings report for AmerisourceBergen Corporation   NYSE ABC    Shares have lost about 8 7  in that time frame 
Will the recent negative trend continue leading up to its next earnings release  or is ABC due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers 
Recent EarningsMaintaining its streak of positive earnings surprises  AmerisourceBergen posted adjusted earnings of  1 94 per share in the second quarter of fiscal 2018  beating the Zacks Consensus Estimate by 6  and improving 9 6  year over year The upside can be attributed to strong growth in the Pharmaceutical Distribution segment and World Courier business Revenues improved almost 10 5  to  41 03 billion in the reported quarter  The figure surpassed the Zacks Consensus Estimate of  40 48 billion Segmental AnalysisPharmaceutical Distribution SegmentRevenues in the segment were  39 5 billion  up 10 4  on a year over year basis  Operating income was  489 1 million  up 0 9  year over year Pharmaceutical Distribution witnessed favorable results in the quarter  courtesy of solid expansion in revenues and gross profit  including the acquisition of H D  Smith However  lower sales in the PharMEDium and the operating loss in the Profarma unit partially offset growth Other SegmentThis segment includes AmerisourceBergen Consulting Services   ABCS    World Courier and MWI Veterinary Supply Revenues in the segment came in at  1 6 billion  up 12 6  year over year  Growth in the segment was driven by consolidation of the specialty joint venture in Brazil and revenues from MWI  ABCS s growth in its Canadian operations and World Courier business However  operating income in the segment was  97 1 million in the quarter  down 6 3  year over year  The downside was primarily caused by lackluster performance at ABCS s Lash Group Margin AnalysisIn the quarter under review  AmerisourceBergen registered gross profit of  1 3 billion  up 9 2  on a year over year basis  As a percentage of revenues  gross margin was 2 8   down 4 basis points  bps  from the prior year quarter  Increase in gross profit in Pharmaceutical Distribution Services boosted the company s margins in the second quarter Operating expenses were  691 5 million  up 18 9  year over year   The upside was caused by H D  Smith buyout and duplicate costs from the implementation of new information technology systems AmerisourceBergen registered operating income of  586 3 million  up 0 4  year over year  As a percentage of revenues  operating margin contracted 15 bps to 1 4  GuidanceFor fiscal 2018  AmerisourceBergen expects revenue growth in the range of 8 11  on a year over year basis  Notably  the Zacks Consensus Estimate for revenues is currently pegged at  167 5 billion  up 9 4  year over year       The company expects adjusted earnings per share in the range of  6 45  6 65  Notably  the Zacks Consensus Estimate for earnings is currently pegged at  6 54 per share  which falls within the guidance   AmerisourceBergen expects adjusted operating expenses to increase in the range of 8 10   up from the previous range of 6 8   Adjusted operating income growth is expected to be flat year over year 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  There have been six revisions lower for the current quarter AmerisourceBergen Corporation Price and Consensus    VGM Scores
At this time  ABC has an average Growth Score of C  though it is lagging a bit on the momentum front with a D  The stock was allocated a grade of A on the value side  putting it in the top quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Our style scores indicate that the stock is more suitable for value investors than growth investors 
Outlook
Estimates have been broadly trending downward for the stock and the magnitude of these revisions indicates a downward shift  Notably  ABC has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-05-31,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-abc-down-87-since-earnings-report-can-it-rebound-200321322,200321322
103317,324832,ABC,Here s Why You Should Hold AmerisourceBergen  ABC  Stock Now,opinion,"With a market capitalization of approximately  20 26 billion  AmerisourceBergen Corporation   NYSE ABC   has been benefiting from consistent solid organic revenue growth  World Courier Business  H D  Smith acquisition and deal with Walgreens  A temporary PharMEDium slowdown  declining dollar  generic inflation  cutthroat competition in the niche space and lower than expected contribution from generic launches are denting growth 
For fiscal 2018  AmerisourceBergen expects revenue growth in the range of 8 11  on a year over year basis  Notably  the Zacks Consensus Estimate for revenues is currently pegged at  167 94 billion  reflecting an increase of 9 7  year over year 
The company expects adjusted earnings per share in the range of  6 45  6 65 for fiscal 2018  Notably  the Zacks Consensus Estimate for earnings is currently pegged at  6 46 per share  which falls within the guidance 
However  the fiscal 2018 earnings estimates declined 0 3  in the last two months  Buoyed by the above mixed trends  the stock has a Zacks Rank  3  Hold  
AmerisourceBergen Corporation Price and Consensus
   So  here we take a quick look at the major factors that have been plaguing AmerisourceBergen  and also the brighter prospects that indicates of a near term recovery 
Factors Plaguing AmerisourceBergen
AmerisourceBergen has recently received a grand jury subpoena from the U S  Attorney s Office for the Western District of Tennessee for documents about the testing of a certain type of syringe made at its PharMEDium lab in Memphis  Memphis is the company s largest highly automated production facility 
Consequently  AmerisorceBergen suspended operations and recalled all products from there that had yet to expire  Recently  the FDA also visited this facility for the same reason  Sluggishness in this unit is likely to hamper the company s specialty distribution segment over the long haul 
In the second quarter of fiscal 2018  the segment s results were negatively impacted by PharMEDium  with the company witnessing lower than expected revenues and profit contribution  Per management  contribution to adjusted EBIT and EPS in fiscal 2018 will be lower than anticipated due to the time and certain ongoing incremental expenses required to perform remedial measures  
Why Should You Hold 
Despite adversities in PharMEDium  AmerisourceBergen s World Courier unit is likely to be the key driver of revenues  The unit is a global leader in specialty logistics that designs and executes world class logistics processes 
Per management  World Courier s position as the leader in global specialty logistics services propelled volume growth and overall performance for the company in the last couple of quarters as well 
Recently  the company announced the designation of its flagship World Courier unit as the first logistics company to obtain global Good Distribution Practices  GDP  certification against three major standards 
The business posted impressive results in the second quarter of fiscal 2018  At the end of the quarter  World Courier s company owned offices were spread across more than 50 countries  with 14 investigational drug depots located in emerging markets worldwide  Solid volume growth and expanding operating margins have favored World Courier unit in the quarter 
Price Performance
AmerisourceBergen outperformed its  in a month s time  The company s shares have gained 10 3  compared with the industry s rise of 5 1   The current level is also higher than the S P 500 index s return of 1 7   

 
Key Picks
A few better ranked stocks in the broader medical space are Genomic Health   NASDAQ GHDX    Abiomed   NASDAQ ABMD   and Stryker Corp    NYSE SYK   
Genomic Health has an expected earnings growth rate of 187 5  for the current quarter  The stock sports a Zacks Rank  1  Strong Buy   You can see  
Abiomed has a projected long term earnings growth rate of 27   The stock sports a Zacks Rank  1 
Stryker has a projected long term earnings growth rate of 9 7   The stock carries a Zacks Rank  2  Buy  
Will You Make a Fortune on the Shift to Electric Cars  
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2018-06-21,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-hold-amerisourcebergen-abc-stock-now-200326930,200326930
103318,324833,ABC,Walgreens  WBA  Tops Q3 Earnings Estimates  Narrows View,opinion,"Walgreens Boots Alliance  Inc    NASDAQ WBA   reported adjusted earnings per share  EPS  of  1 53 in third quarter fiscal 2018  up 15  year over year and 13 5  at constant exchange rate  CER   The figure surpassed the Zacks Consensus Estimate of  1 47 
On a reported basis  net earnings came in at  1 3 billion  reflecting an increase of 15 5  from the prior year quarter  Reported EPS came in at  1 35  up 26 2  on a year over year basis 
Total Sales
Walgreens Boots recorded total sales of  34 33 billion in the fiscal third quarter  up 14  year over year and 11 8  at CER  The top line outpaced the Zacks Consensus Estimate of  33 65 billion 
Segments in Detail
Walgreens Boots reports under three operating segments  Retail Pharmacy USA  Retail Pharmacy International and Pharmaceutical Wholesale 
Retail Pharmacy USA
The segment recorded sales of  25 9 billion in the third quarter  highlighting an improvement of 15  year over year  Within this segment  total sales at comparable stores dropped 1 2   while prescriptions filled in comparable stores were unchanged year over year  Retail sales increased 5 2  year over year  while comparable retail sales dropped 3 8  Walgreens Boots Alliance  Inc  Price  Consensus and EPS Surprise

   Pharmacy sales  which accounted for 72 5  of the Retail Pharmacy USA division s sales in the quarter  increased 19 3  from the year ago quarter on higher prescription volume from the acquisition of Rite Aid stores and central specialty  Pharmacy sales at comparable stores were unchanged year over year 
Retail Pharmacy International
Revenues at the Retail Pharmacy International division rose 6 6  on a year over year basis  down 2 1  at CER  to  3 billion  At CER  comparable store sales in the third quarter declined 1 4  year over year along with a 1 7  decline in comparable pharmacy sales 
Pharmaceutical Wholesale
The Pharmaceutical Wholesale division recorded quarterly sales of  6 billion  up 12 6  year over year  up 4  at CER  
Margins
Gross profit in the reported quarter increased 8 9  year over year to  7 78 billion  However  gross margin contracted 106 basis points  bps  to 22 7  
Selling  general and administrative  SG A  expenses were up 9 1  year over year to  6 23 billion  Operating income  including Equity earnings in AmerisourceBergen  NYSE ABC   increased 5 8  to  1 59 billion  Overall  operating margin contracted 36 bps to 4 7  
Financial Condition
Walgreens Boots exited the third quarter with cash and cash equivalents of  1 82 billion  compared with  1 75 billion at the end of the second quarter  Long term debt was  12 45 billion  compared with  12 53 billion at the end of the preceding quarter 
Year to date  the company has generated operating cash flow of  5 38 billion  compared with  5 24 billion a year ago  The resultant free cash flow was  4 40 billion  as compared to  4 32 billion a year ago 
Guidance Narrowed
Walgreens Boots has raised the low end of its outlook for fiscal 2018 EPS by 5 cents  The new projected range is  5 90 to  6 05  The Zacks Consensus Estimate for earnings is pegged at  5 96  within the company s guided range 
Our Take
Walgreens Boots reported an impressive third quarter of fiscal 2018  The year over year increase in earnings and revenues is encouraging as well 
Also  in a bid to ensure availability of specialty brand drugs  Express Scripts and Walgreens Boots recently announced plans to expand their existing group purchasing efforts 
The company is also upbeat about the recent acquisition of stores from Rite Aid which has already started to strengthen its U S  pharmacies business  Also  the solid guidance buoys optimism The new  10 billion share repurchase program indicates the company s focus on driving long term stockholder value 
Zacks Rank   Key Picks
Walgreens Boots carries a Zacks Rank  3  Hold  
A few better ranked stocks in the broader medical space are  Genomic Health   NASDAQ GHDX    Abiomed   NASDAQ ABMD   and Integer Holdings Corp    NYSE ITGR   
Genomic Health has an expected earnings growth rate of 187 5  for the current quarter  The stock sports a Zacks Rank  1  Strong Buy   You can see  
Abiomed has a projected long term earnings growth rate of 27   The stock sports a Zacks Rank  1 
Integer Holdings has a projected long term earnings growth rate of 15   The stock carries a Zacks Rank  2 
5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2018-06-27,Zacks Investment Research,https://www.investing.com/analysis/walgreens-wba-tops-q3-earnings-estimates-narrows-view-200328326,200328326
103319,324834,ABC,What s In Store For AmerisourceBergen  ABC  In Q4 Earnings ,opinion,AmerisourceBergen Corporation s   NYSE ABC   fourth quarter fiscal 2018 results are scheduled to release on Nov 6  before the market opens While the company s core Pharmaceutical Distribution unit is likely to drive growth  stiff competition is likely to mar prospects Q3 Results at a GlanceIn the last reported quarter  AmerisourceBergen posted adjusted earnings of  1 54 per share  beating the Zacks Consensus Estimate of  1 45 and improving 7 7  year over year  Revenues improved almost 11 5  to  43 14 billion in the reported quarter  The figure surpassed the Zacks Consensus Estimate of  42 96 billion The company delivered positive earnings surprise in the trailing four quarters  the average being 6 9  AmerisourceBergen Corporation Price and Consensus    Which Way are Estimates Treading For the quarter to be reported  the Zacks Consensus Estimate for revenues is pegged at  43 53 billion  reflecting year over year growth of 11 3   The same for earnings is pegged at  1 44  showing year over year growth of 8 3  Let s dig deeper to analyze how things are shaping up before the earnings announcement Factors to ConsiderPharmaceutical Distribution to Drive Q4Fiscal fourth quarter revenues in the segment are likely to witness increasing volume and an expanding customer base  This segment serves healthcare providers in the pharmaceutical supply channel  In the last reported quarter  the Pharmaceutical Distribution segment accounted for 96 4  of the company s net revenues  Moreover  the segment s revenues grew 11 6  on a year over year basis to  41 58 billion It is encouraging to note that the Zacks Consensus Estimate for the quarter to be reported stands at  41 99 billion  showing an improvement of 11 5  from the year ago quarter Per management  the segment surpassed the company s expectations in the last couple of quarters  Strong organic growth rates in the U S  pharmaceutical market  improving patient access to medical care  improved economic conditions and population demographics should reflect in the results for the fiscal fourth quarter Other SegmentThis segment consists of Global Commercialization Services and Animal Health  and includes World Courier  AmerisourceBergen Consulting and MWI In the last reported quarter  the Other segment contributed 3 6  to the company s net revenues  Notably  revenues in the segment improved 8 8  year over year to  1 60 billion in the fiscal third quarter We expect the segment to witness robust growth in the quarter to be reported  The Zacks Consensus Estimate for the quarter under review is pegged at  1 61 billion  showing sequential rise of 0 9  The World Courierunit  in particular  is likely to be one of the key drivers of the Other segment  Not to forget  the World Courier business delivered excellent results  with record gains in the last reported quarter  The unit witnessed outstanding operating income growth as well  We expect similar trends in the fiscal fourth quarter However  the MWI unit within the Other segment remained flat on a year over year basis because of certain internal issues in the last reported quarter Competition Likely to Mar Q4 Top LineCutthroat competition in the MedTech space might mar revenues in the fiscal fourth quarter AmerisourceBergen operates in a highly competitive pharmaceutical distribution and related healthcare services market  The company s primary competitors include Cardinal Health  NYSE CAH  and McKesson  NYSE MCK  along with national generic distributors and regional distributors What our Model SaysPer our proven quantitative model  a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise  This is not the case here as you will see below Earnings ESP  AmerisourceBergen has an Earnings ESP of  0 23   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  AmerisourceBergen currently carries a Zacks Rank  4  Sell  Please note that we caution against stocks with a Zacks Rank  4 or 5  Strong Sell  going into the earnings announcement  especially when the company is witnessing negative estimate revision Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat in their upcoming quarterly results BioLife Solutions  Inc    NASDAQ BLFS   has an Earnings ESP of  36 36  and a Zacks Rank  3 ICU Medical  Inc    NASDAQ ICUI   has an Earnings ESP of  8 65  and a Zacks Rank  2  You can see  OraSure Technologies  Inc    NASDAQ OSUR   has an Earnings ESP of  4 76  and a Zacks Rank  2 Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-11-01,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-amerisourcebergen-abc-in-q4-earnings-200354021,200354021
103320,324835,ABC,AmerisourceBergen  ABC  Beats On Q4 Earnings  Issues  19 View,opinion,Maintaining the streak of positive earnings surprises  AmerisourceBergen Corporation   NYSE ABC   posted adjusted earnings of  1 45 per share in the fourth quarter of fiscal 2018  beating the Zacks Consensus Estimate of  1 44 and improving 9  year over year The upside can be attributed to strong growth in the Pharmaceutical Distribution segment and the World Courier business Revenues improved almost 10 7  to  43 29 billion in the reported quarter  The figure missed the Zacks Consensus Estimate of  43 53 billion The stock has a Zacks Rank  3  Hold  Fiscal 2018 Results at a GlanceAmerisourceBergen registered revenues of  167 9 billion in fiscal 2018  This figure lagged the Zacks Consensus Estimate of  168 10 billion  The Pharmaceutical Distribution Services contributed to 96 3  of net revenues in fiscal 2018  The other segment accounted for 3 7  of net revenues Adjusted earnings came in at  6 49  surpassing the Zacks Consensus Estimate of  6 48 AmerisourceBergen Corporation Price and Consensus    Segmental AnalysisPharmaceutical Distribution SegmentRevenues in the segment were  41 73 billion  up 10 8  on a year over year basis  Operating income was  357 million  down 10 7  year over year Pharmaceutical Distribution witnessed favorable results in the quarter  courtesy of solid expansion in revenues and gross profit  the acquisition of H D  Smith and especially strong oncology product sales However  lower sales in the PharMEDium segment partially offset operating income Other SegmentThis segment includes AmerisourceBergen Consulting Services  ABCS   World Courier and MWI Veterinary Supply Revenues in the segment came in at  1 60 billion  up 7 9  year over year  Growth in the segment was driven by consolidation of the specialty joint venture in Brazil and revenues from MWI  ABCS s growth in Canadian operations and World Courier business Operating income in the segment was  75 million in the quarter  up 5 2  year over year  Lackluster performance in the ABCS s Lash Group partially offset operating income in the segment Margin AnalysisIn the quarter under review  AmerisourceBergen registered gross profit of  1 03 billion  down 11 9  on a year over year basis  As a percentage of revenues  gross margin was 2 4   down 60 basis points  bps  from the prior year quarter s tally AmerisourceBergen registered operating income of  154 1 million However  deducting distribution  selling and administrative expenses from gross profit  AmerisourceBergen registered adjusted operating income of  374 8 million  i e  0 9  of net revenues  This compares with 1 6  registered in the year ago quarter  Thus  adjusted operating margin declined 70 bps year over year GuidanceManagement expects revenue growth in the mid single digit percent range for fiscal 2019  The Zacks Consensus Estimate is currently pegged at  179 83 billion Adjusted earnings per share  EPS  is expected in the range of  6 65  6 95   The Zacks Consensus Estimate is currently pegged at  6 48  which is below the guidance Earnings of Other MedTech Majors at a GlanceA few better ranked stocks in the broader medical space which also reported solid earnings this season are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI    Each of the stocks carry a Zacks Rank  2  You can see  Intuitive Surgical reported third quarter 2018 adjusted EPS of  2 83  which beat the Zacks Consensus Estimate of  2 65  Revenues totaled  920 9 million  also surpassing the consensus estimate of  918 6 million Stryker posted third quarter 2018 adjusted EPS of  1 69  beating the Zacks Consensus Estimate by a penny  Operating margin was 17 8   up 30 bps Merit Medical reported third quarter 2018 adjusted EPS of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus estimate of  218 million Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-11-05,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-abc-beats-on-q4-earnings-issues-19-view-200355481,200355481
103321,324836,ABC,AmerisourceBergen  ABC  Tops Q4 Earnings Estimates,opinion,"AmerisourceBergen  NYSE ABC  came out with quarterly earnings of  1 45 per share  beating the Zacks Consensus Estimate of  1 44 per share  This compares to earnings of  1 33 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 0 69   A quarter ago  it was expected that this prescription drug distributor would post earnings of  1 45 per share when it actually produced earnings of  1 54  delivering a surprise of 6 21  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
AmerisourceBergen  which belongs to the Zacks Medical   Dental Supplies industry  posted revenues of  43 30 billion for the quarter ended September 2018  missing the Zacks Consensus Estimate by 0 53   This compares to year ago revenues of  39 12 billion  The company has topped consensus revenue estimates three times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
AmerisourceBergen shares have lost about 3 5  since the beginning of the year versus the S P 500 s gain of 2 4  
What s Next for AmerisourceBergen 
While AmerisourceBergen has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for AmerisourceBergen was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 58 on  44 60 billion in revenues for the coming quarter and  7 13 on  179 83 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Dental Supplies is currently in the bottom 25  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2018-11-06,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-abc-tops-q4-earnings-estimates-200355285,200355285
103322,324837,ABC,Company News For Nov 7  2018,opinion,e l f  Beauty  Inc  s   NYSE ELF   shares increased 19 2  after the company reported third quarter 2018 earnings of  0 17 per share  beating the Zacks Consensus Estimate of  0 08 per shareShares of AmerisourceBergen Corporation   NYSE ABC   lost 5 2  after the company reported fourth quarter fiscal 2018 revenues of  43 29 billion  missing the Zacks Consensus Estimate of  43 53 billion Mallinckrodt Public Limited Company s   NYSE MNK   shares jumped 9 1  after the company reported third quarter 2018 earnings of  2 10 per share  surpassing the Zacks Consensus Estimate of  1 80 per shareShares of Mylan N V    NASDAQ MYL   surged 16 1  after the company reported third quarter 2018 adjusted earnings of  1 25 per share  beating the Zacks Consensus Estimate of  1 17 per share,2018-11-06,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-nov-7-2018-200356166,200356166
103323,324838,ABC,Why Is Walgreens  WBA  Up 16 2  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Walgreens Boots Alliance  NASDAQ WBA   Shares have added about 16 2  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Walgreens due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Walgreens Boots Beats on Q4 Earnings  Operating Margin DeclinesWalgreens Bootsreported adjusted earnings per share  EPS  of  1 48 for fourth quarter fiscal 2018  up 12 9  year over year  same at constant exchange rate   The figure surpassed the Zacks Consensus Estimate of  1 44 On a reported basis  net earnings came in at  1 5 billion  reflecting an 88 5  surge from the prior year quarter  Reported EPS came in at  1 55  up 103  on a year over year basis Full year adjusted EPS was  6 02  reflecting an 18  rise from the year ago period  The figure also surpassed the Zacks Consensus Estimate of  5 98 per share Total SalesWalgreens Boots recorded total sales of  33 44 billion in the fiscal fourth quarter  up 10 9  year over year and 11 3  at constant exchange rate or CER  However  the top line missed the Zacks Consensus Estimate of  33 64 billion For the full year  the company reported revenues of  131 53 billion  an 11 3  improvement from the year ago period  However  the reported figure lagged the Zacks Consensus Estimate of  131 60 billion Segments in DetailWalgreens Boots reports under three operating segments  Retail Pharmacy USA  Retail Pharmacy International and Pharmaceutical Wholesale Retail Pharmacy USAThe segment recorded sales of  25 5 billion in the fourth quarter  highlighting an improvement of 14 4  year over year  Within this segment  total sales at comparable stores edged up 0 3   while prescriptions filled in comparable stores increased 1 3  year over year  With the addition of Rite Aid stores  retail sales increased 8 3  year over year  However  comparable retail sales dropped 1 9  Pharmacy sales  which accounted for 73 6  of the Retail Pharmacy USA division s sales in the quarter  increased 16 7  from the year ago quarter on higher prescription volume from the acquisition of Rite Aid stores and central specialty  Pharmacy sales at comparable stores improved 1 3  year over year on higher volume Retail Pharmacy InternationalRevenues at the Retail Pharmacy International division dropped 1 9  on a year over year basis  down 2 7  at CER  to  2 9 billion in the fourth quarter  At CER  comparable pharmacy sales declined 3 4  year over year and comparable retail sales dipped 0 9  Pharmaceutical WholesaleThe Pharmaceutical Wholesale division recorded quarterly sales of  5 6 billion  up 2 3  year over year  up 4 7  at CER  MarginsGross profit in the reported quarter increased 3 2  year over year to  7 58 billion  However  gross margin contracted 169 basis points  bps  to 22 6  Selling  general and administrative  SG A  expenses dropped 1 7  year over year to  6 1 billion  Operating income  including Equity earnings in AmerisourceBergen  NYSE ABC   increased 30 3  to  1 46 billion  Overall  operating margin expanded 65 bps to 4 4  Financial ConditionWalgreens Boots exited the fiscal with cash and cash equivalents of  785 million  compared with  1 82 billion at the end of the third quarter  Long term debt was  12 43 billion  compared with  12 45 billion at the end of the third quarter In fiscal 2018  the company generated operating cash flow of  8 27 billion compared with  7 25 billion a year ago  Resultant free cash flow was  6 9 billion  an increase of  1 0 billion from fiscal 2017 Guidance NarrowedWalgreens Boots provided outlook for fiscal 2019  The company projects adjusted EPS in the range of  6 40 to  6 70  a 7  to 12  growth at CER   The Zacks Consensus Estimate of  6 44 per share is within the guided range The guidance assumes continued execution of the company s earlier announced  10 billion share repurchase program  including the expected repurchase of approximately  3 billion worth of shares in fiscal 2019 
How Have Estimates Been Moving Since Then 
Fresh estimates followed a downward path over the past two months 
VGM Scores
Currently  Walgreens has a nice Growth Score of B  though it is lagging a bit on the Momentum Score front with a C  Charting a somewhat similar path  the stock was allocated a grade of B on the value side  putting it in the top 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Walgreens has a Zacks Rank  2  Buy   We expect an above average return from the stock in the next few months ",2018-11-09,Zacks Investment Research,https://www.investing.com/analysis/why-is-walgreens-wba-up-162-since-last-earnings-report-200357868,200357868
103354,324869,ABC,Why Is AmerisourceBergen  ABC  Up 1 5  Since Its Last Earnings Report ,opinion,"A month has gone by since the last earnings report for AmerisourceBergen Corporation   NYSE ABC    Shares have added about 1 5  in that time frame 
Will the recent positive trend continue leading up to its next earnings release  or is ABC due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers 
Recent EarningsAmerisourceBergen posted adjusted earnings of  1 55 per share in the first quarter of fiscal 2018  beating the Zacks Consensus Estimate of  1 35 and improving 14  year over year The upside can be attributed to strong growth in the company s Pharmaceutical Distribution Segment and World Courier business Revenues improved almost 6  to  40 47 billion in the reported quarter  Revenues also beat the Zacks Consensus Estimate of  40 37 billion Segmental AnalysisPharmaceutical Distribution SegmentRevenues in the segment were  38 94 billion  up 5 8  on a year over year basis  Operating income was  388 2 million  up 2 4  year over year However  the segment was affected by lower than expected production at PharMEDium s Memphis 503B outsourcing facility  Notably  operations in the facility were voluntarily suspended by the company following a few inspections by the FDA in the quarter Other SegmentThis segment includes AmerisourceBergen Consulting Services   ABCS    World Courier and MWI Veterinary Supply  Revenues at the segment came in at  1 54 billion  up 11 6  year over year  Operating income in the segment was  100 3 million in the quarter  down 6 4  year over year Despite strong performance in the World Courier unit  sluggishness in the ABCS dampened segmental growth in the first quarter Margin DetailsIn the quarter under review  AmerisourceBergen registered gross profit of  1 1 billion  up 4 5  on a year over year basis  As a percentage of revenues  gross margin was 2 8   down 4 basis points  bps  from the prior year quarter Operating expenses in first quarter fiscal 2018 were  626 million  up 8  year over year AmerisourceBergen registered operating income of  488 1 million  up 0 4  year over year  As a percentage of revenues  operating margin contracted 4 bps to 1 2  Guidance RaisedBased upon the expectations from the recently legislated U S  tax reform  AmerisourceBergen raised guidance for fiscal 2018  The company expects adjusted earnings per share in the range of  6 45  6 65  up from the previously range of  5 90  6 15  Revenue growth for fiscal 2018 is expected in the range of 8 11   higher than the previous range of 7 9  However  the company expects adjusted operating expenses to increase in the range of 6 8   up from the previous range of 4 6   Adjusted operating income growth is estimated in the range of 1 4   lower than the previous range of 3 5  In January  AmerisourceBergen declared that it has completed the acquisition of H D  Smith  the largest independent wholesaler in the United States  for  815 million in cash  The deal was initiated in November 2017   The acquisition is expected to be slightly accretive to adjusted earnings per share in fiscal 2018  Further  the deal is expected to return 15 cents to adjusted earnings per share in fiscal year 2020  It is expected to strengthen the company s support to community pharmacy and drive long term  durable value 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  There have been two revisions higher for the current quarter compared to three lower AmerisourceBergen Corporation  Holding Co  Price and Consensus    VGM Scores
At this time  ABC has a poor Growth Score of F  However  its Momentum is doing a lot better with an A  Charting a somewhat similar path  the stock was allocated a grade of B on the value side  putting it in the top 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Our style scores indicate that the stock is more suitable for momentum investors than value investors 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions looks promising  Notably  ABC has a Zacks Rank  2  Buy   We expect an above average return from the stock in the next few months ",2018-03-07,Zacks Investment Research,https://www.investing.com/analysis/why-is-amerisourcebergen-abc-up-15-since-its-last-earnings-report-200296701,200296701
103355,324870,ABC,Here s Why You Should Invest In AmerisourceBergen Right Now,opinion,AmerisourceBergen Corporation   NYSE ABC   has been on a healthy growth trajectory  of late  Over the past three months  the company has outperformed its   The stock has gained 5 3  compared with the industry s rally of 3 3   Also  the company has outperformed the S P 500 index s 2 2  gain The leading pharmaceutical services company focuses on providing drug distribution and related services to reduce health care costs and improve patient outcomes  AmerisourceBergen has a market cap of  19 48 billion  The companyhas a positive earnings surprise of 5 87  for the last four quarters  Also  it has a long term expected earnings growth rate of 10 2  Backed by such prospects  this Zacks Rank  2  Buy  stock is an attractive pick for investors at the moment The company s estimate revision trend for the current year has been positive  In the past 60 days  seven analysts revised their estimates upward with no movement in the opposite direction  Resultantly  earnings estimates improved around 5 3  to  6 52 per share Per our   AmerisourceBergen sports a Value Score of B which indicates the company s strong prospects  Our research shows that stocks with a Value Style Score of A or B  when combined with a Zacks Rank  1  Strong Buy  or 2  offer the best upside potential In this regard  AmerisourceBergen has favorable Price Earnings to Growth  PEG  ratio of 1 49 compared with the broader industry s 1 85   Moreover  surpassing the industry s 7 96 cash flow per share  AmerisourceBergen s 1 37 signifies that it is a favorable value pick Let s find out whether the recent positive trend is a sustainable one We are upbeat about AmerisourceBergen s active pursuit of acquisitions to strengthen core areas  Recently  the company announced the buyout of H D  Smith   the largest independent wholesaler in the United States   for  815 million in cash The MWI Veterinary acquisition has diversified the company s existing pharmaceutical distribution   services businesses into the attractive animal health market  which holds huge potential at the moment  Meanwhile  the acquisition of PharMEDium enhanced the company s ability to provide market leading services and solutions to its health system customers  a segment that is playing an increasingly important role in the healthcare market in the United States We believe that AmerisourceBergen will benefit from generics growth in the long run  The first quarter of fiscal 2018 marked the company s 16th consecutive quarter with 10  or greater revenue growth for this part of its business  At the end of the first quarter  management confirmed that the company s strategic and focused effort is driving generic product volume growth to offset historic deflation rates Notably  the company is well positioned to ensure that products reach the market and that patients can access traditional and complex new therapies across all sites of care  Strong organic growth rates in the U S  pharmaceutical market  improving patient access to care  improved economic conditions and population demographics  introduction of new innovative drugs like hepatitis C drugs as well as a consistent brand pricing environment should drive growth Also  the company s World Courier business has been faring well  Notably  at the end of first quarter fiscal 2018  World Courier s company owned offices were spread across in more than 50 countries  with 14 investigational drug depots located in emerging markets worldwide Other Key PicksA few other top ranked stocks in the broader medical sector are Bio Rad Laboratories   NYSE BIO    athenahealth  Inc    NASDAQ ATHN   and PerkinElmer   NYSE PKI   Bio Rad Laboratories sports a Zacks Rank of 1  You can see  The company has a long term expected earnings growth rate of 20  athenahealth is a Zacks  1 Ranked player  The company has a long term expected earnings growth rate of 21 5  PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2 The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-03-15,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-invest-in-amerisourcebergen-right-now-200298720,200298720
103356,324871,ABC,Rite Aid Albertsons Merger Crosses First Antitrust Hurdle ,opinion,"Rite Aid Corporation   NYSE RAD    following the completion of transferring stores to Walgreens   NASDAQ WBA     revealed that the waiting period under the Hart Scott Rodino Antitrust Improvements Act of 1976 has expired on Mar 28  2018  satisfying one of the conditions for its merger with Albertsons Companies  Inc Though Rite Aid shares did not react much to this announcement  this Zacks Rank  3  Hold  stock declined 20 4  in the last three months  This marks an underperformance from the  s fall of 12   You can see  
Rite Aid had agreed to merge with the country s largest grocer  Albertsons Companies  in February 2018  The merger will not only help revive the distressed Rite Aid s business but also aid in dispelling the fear of competition from Amazon   NASDAQ AMZN    Per the deal  Rite Aid shareholders have the choice to opt for Albertsons  shares and cash or only the company s shares For every 10 Rite Aid shares  shareholders can get one Albertsons share and  1 83 in cash or 1 079 Albertsons shares  This will leave Rite Aid shareholders with about 28 29 6  stake in the combined company  subject to the outcome of the cash elections  Meanwhile  Albertsons  shareholders will own a 70 4 72  stake in the combined company The combined company is expected to generate annual revenues of about  83 billion  Further  the new entity anticipates delivering annual run rate cost savings of  375 million in the next three years  Of these  the companies expect to realize nearly 60  of the cost synergies in the first two years after closing the transaction  Additionally  the companies anticipate identifying about  3 6 billion of potential revenue opportunities The new company will operate about 4 900 locations including 4 350 pharmacy counters and 320 clinics  across 38 states and Washington D C  The company will serve more than 40 million customers per week  The companies plan to re banner most of the Albertsons pharmacies to Rite Aid Stores following the completion of the transaction  while Rite Aid will continue to operate its stand along pharmacies The merger is also approved by the board of directors of both companies  Further  it is expected to be closed by the second half of calendar year 2018  conditioned upon receipt of approval from Rite Aid shareholders  and other regulatory and customary closing conditions The drugstore industry in general has been witnessing increased consolidation lately  After the failed merger between Walgreens and Rite Aid  the industry has seen CVS Health Corp    NYSE CVS   enter a deal to acquire Aetna  Inc    NYSE AET   in January 2018   Additionally  Walgreens has bid to buy AmerisourceBergen Corp    NYSE ABC    a leading drug wholesale company Can Hackers Put Money INTO Your Portfolio Earlier this year  credit bureau Equifax  NYSE EFX  announced a massive data breach affecting 2 out of every 3 Americans  The cybersecurity industry is expanding quickly in response to this and similar events  But some stocks are better investments than others Zacks has just released Cybersecurity  An Investor s Guide to help Zacks com readers make the most of the  170 billion per year investment opportunity created by hackers and other threats  It reveals 4 stocks worth looking into right away ",2018-04-02,Zacks Investment Research,https://www.investing.com/analysis/rite-aidalbertsons-merger-crosses-first-antitrust-hurdle-200302493,200302493
103357,324872,ABC,Here s Why You Should Steer Clear Of AmerisourceBergen Now,opinion,AmerisourceBergen Corporation   NYSE ABC   has underperformed the  in a year s time  The company s shares grew 1 8  compared with the industry s rally of 8 9  Also  sluggishness in the AmerisourceBergen Consulting Services   ABCS   segment is a concern  AmerisourceBergen continues to witness headwinds  thanks to the slowdown in hepatitis C revenues and conversion of branded drugs to the lower price generics  Further  a temporary slowdown in PharMEDium s growth is expected to mar the bottom line Consequently  the Zacks Consensus Estimate for 2018 adjusted earnings slipped 0 5  to  6 48 per share in the past two months  The company has a Zacks Rank  4  Sell   which indicates expectations of underperformance in the near term Thus  here we take a detailed analysis on the factors that have been plaguing AmerisourceBergen What s Plaguing AmerisourceBergen Recently  AmerisourceBergen received a grand jury subpoena from the U S  Attorney s Office for the Western District of Tennessee for documents about its lab testing of a certain type of syringe made in its PharMEDium lab in Memphis The Memphis based lab is the company s largest highly automated production facility  As a result of the subpoena  AmerisorceBergen suspended operations and recalled all of the products from the facility that had yet to expire  In fact  officials from FDA also visited this facility for the same reason  recently  Sluggishness in this unit is likely to hamper the company s specialty distribution segment over the long haul In the first quarter of fiscal 2018  the segment s results were marred by PharMEDium  wherein the company reportyed lower than expected revenues and profit contribution  Per management  PharMEDium s contribution to adjusted EBIT and EPS in fiscal 2018 will be lower than expected  due to certain ongoing incremental expenses AmerisourceBergen operates in a highly competitive pharmaceutical distribution and related health care services market  The company s primary competitors include Cardinal Health  NYSE CAH   McKesson  NYSE MCK  along with national generic distributors and regional distributors Time to Offload Considering these headwinds  investors might find it to be the right time to dump AmerisourceBergen In this regard  our  model can turn out to be helpful  This is a comprehensive tool that helps investors screen winning stocks from the broader sectors  Further  the score highlights the determining elements in a stock that can drive it higher Unfortunately  AmerisourceBergen has a VGM Style Score of D  indicating it as one of the worst performing stocks in the MedTech space  at least for now In fact  our research shows that stocks with a VGM Score of A or B  when combined with a Zacks Rank  1  Strong Buy  or 2  Buy   offer the best upside potential Key PicksA few better ranked players in the broader medical sector are Bio Rad Laboratories   NYSE BIO    Abaxis  Inc    NASDAQ ABAX   and Edwards Lifesciences Corporation   NYSE EW   Bio Rad Laboratories sports a Zacks Rank of  1  You can see   The company has a long term expected earnings growth rate of 20  Abaxis  a Zacks Rank  2 stock  has a long term earnings growth rate of 5 1  Edwards Lifesciences has a long term expected earnings growth rate of 15 1   The stock has a Zacks Rank of  2 Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-04-12,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-steer-clear-of-amerisourcebergen-now-200305343,200305343
103358,324873,ABC,What s In Store For AmerisourceBergen  ABC  In Q2 Earnings ,opinion,"AmerisourceBergen Corporation s   NYSE ABC   second quarter fiscal 2018 results  scheduled for release on May 2  are expected to show steady growth in the Pharmaceutical Distribution segment  a significant contributor to revenues In the last reported quarter  the company posted adjusted earnings of  1 55 per share  beating the Zacks Consensus Estimate of  1 35 and improving 14  year over year  The upside was attributed to strong growth in the company s Pharmaceutical Distribution Segment and World Courier business  Revenues improved almost 6  to  40 47 billion in the previous quarter and beat the Zacks Consensus Estimate of  40 37 billion For the quarter to be reported  the Zacks Consensus Estimate for revenues is pegged at  40 49 billion  reflecting a rise of 9  year over year  The Zacks Consensus Estimate for earnings is pegged at  1 83  indicating an increase of 3 4  year over year Let s dig deeper to analyze how things are shaping up before the earnings announcements Pharmaceutical Distribution to Boost Q2 ResultsPharmaceutical Distribution accounted for 96 2  of total revenues in the last quarter  Revenues in the segment were  38 94 billion  up 5 8  on a year over year basis  Operating income was  388 2 million  up 2 4  year over year For the upcoming quarterly results  the Zacks Consensus Estimate for Pharmaceutical Distribution segment is pegged at  38 88 billion  The figure reflects an increase of 9 5  from the year ago figure Strong organic growth rates in the U S  pharmaceutical market  improving patient access to medical care  improved economic conditions and population demographics  introduction of new innovative drugs like hepatitis C drugs along with a consistent good brand pricing environment should drive growth for AmerisourceBergen in the quarter to be reported AmerisourceBergen Corporation Price and EPS Surprise 
   Moreover  the company s focus on specialty drugs bodes well  Per the IMS  pharmaceutical sales are estimated to grow approximately 7 1  annually over a five year period through 2020  courtesy of strong demand  favorable pricing and new product introductions The deals signed by AmerisourceBergen look encouraging  which are likely to boost the top line  The company entered into a strategic agreement with Walgreen Boots Alliance  The deal includes a 10 year pharmaceutical distribution contract  under which the company will distribute branded and generic pharmaceutical products to Walgreens However  the segment is likely to be affected by lower than expected production at PharMEDium s Memphis 503B outsourcing facility  Notably  operations in the facility were voluntarily suspended by the company in the last quarter following a few inspections by the FDA Other Factors to ConsiderGenerics   Product Launches to Drive Growth  We believe that AmerisourceBergen will benefit from generics growth in the long run  In the last quarter  AmerisourceBergen marked its 16th consecutive quarter with 10  or greater revenue growth in the business  Management confirmed that its strategic and focused effort is driving generic product volume growth to offset historic deflation rates However  it s important to highlight that AmerisourceBergen will have about a 25  increase in quarterly interest expense beginning from the second quarter Operational Efficiencies  The recent U S  tax legislation has enhanced AmerisourceBergen s ability to invest in business  innovate and deliver value to its shareholders  Over the long term  this enables AmerisourceBergen to boost its U S  business Recently  the company made strategic investments in IT systems to realize greater operational efficiency and increase operating leverage  This is likely to boost the company s results in the second quarter In fact  AmerisourceBergen also announced its plans to roll out eight new IT systems and a new e commerce platform at MWI  These should enhance the company s results in the quarter to be reported Guidance  Based upon the expectations from the recently legislated U S  tax reform  AmerisourceBergen raised guidance for fiscal 2018  Notably  AmerisourceBergen s strong guidance for fiscal 2018 indicates that the company expects to deliver solid results from the second quarter itself The company expects adjusted earnings per share in the range of  6 45  6 65  up from the previously range of  5 90  6 15  Revenue growth for fiscal 2018 is expected in the range of 8 11   up from the previous band of 7 9  PharMEDium Slows Down  Recently  AmerisourceBergen received a grand jury subpoena from the U S  Attorney s Office for the Western District of Tennessee for documents about its lab testing of a certain type of syringe made at its PharMEDium lab in Memphis  which is the company s largest highly automated production facility  As a result of the subpoena  AmerisorceBergen suspended operations and recalled all of the products that had yet to expire  In fact  the FDA also visited this facility for the same reason  Sluggishness in this unit is likely to hamper the company s specialty distribution segment in the quarter to be reported In the last reported quarter  the segment s results were negatively impacted by PharMEDium  wherein the company had lower than expected revenues and profit contribution Per management  because of the time and certain ongoing incremental expenses required to perform remedial measures  PharMEDium s contribution to adjusted EBIT and EPS in the second quarter will be lower than anticipated Earnings WhispersOur proven model does not show an earnings beat for AmerisourceBergen in the second quarter  This is because a stock needs to have a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP  AmerisourceBergen has an Earnings ESP of  1 55   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  AmerisourceBergen carries a Zacks Rank  3 Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter The Cooper Companies  Inc    NYSE COO   has an Earnings ESP of  0 26  and a Zacks Rank  3  You can see  Teleflex Incorporated   NYSE TFX   has an Earnings ESP of  0 58  and a Zacks Rank  3 AbbVie Inc    NYSE ABBV   has an Earnings ESP of  0 06  and a Zacks Rank  3 Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-04-23,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-amerisourcebergen-abc-in-q2-earnings-200308272,200308272
103393,324908,ABC,Is A Beat In Store For Kforce  KFRC  This Earnings Season ,opinion,Kforce Inc    NASDAQ KFRC   is scheduled to report fourth quarter 2017 results after the market closes on Feb 6 Last quarter  the company reported adjusted earnings of  11 5 million or 45 cents per share compared with adjusted earnings of  11 6 million or 44 cents per share in the year ago quarter  Adjusted earnings per share beat the Zacks Consensus Estimate by 17 cents  The company s financial results were hurt in the previous quarter due to the impact of hurricanes The company has surpassed earnings estimates once in the trailing four quarters  with an average positive earnings surprise of 2  Let s see how things are shaping up prior to this announcement Factors at PlayKForce expects skilled technology demand to be high as companies are becoming increasingly dependent on the efficiencies provided by technology along with the need for innovation and strategies  Particularly  technology investment  mobility  cloud computing  cyber security  eCommerce  digital marketing  Big Data and business intelligence contributed to the demand landscape for technology resources Also  the company has completed rolling out its new customer relationship management system to all its offices during the previous quarter  This is expected to improve client services and enhance business operations going forward The Zacks Consensus Estimate for KForce s fourth quarter revenues is  340 million  higher than reported revenues of  326 million in the prior year quarter Revenues from the Technology segment are expected to be higher  with estimates pegged at  226 million compared with reported revenues of  217 million in the prior year quarter  Robust demand along with a couple of valuable new contracts secured by the company in the previous quarter make us particularly optimistic about revenues from this segment The Zacks Consensus Estimate for revenues from the Finance   Accounting segment is  87 million compared with reported revenues of  86 million in the prior year quarter  The Government solutions segment is expected to generate revenues of  26 7 million compared with  23 4 million reported in the year ago quarter However  due to the introduction of Tax Cuts and Jobs Act in 2017  the company is expecting an adverse impact on its earnings in the impending quarterly results Earnings WhispersOur proven model conclusively shows that KForce is likely to beat earnings this quarter as it possesses the key components  A stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  This is perfectly the case here as you will see below Zacks ESP  Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  0 47   You can uncover the best stocks to buy or sell before they re reported with our  Kforce  Inc  Price and EPS Surprise    Zacks Rank  KForce has a Zacks Rank  2  This increases the predictive power of ESP and makes us reasonably confident of an earnings beat Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing a negative estimate revisions momentum Other Stocks to ConsiderHere are some other companies that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter Zendesk  Inc    NYSE ZEN   has an Earnings ESP of  9 91  and a Zacks Rank  3  You can see  AmerisourceBergen Corporation   NYSE ABC   has an Earnings ESP of  1 28  and a Zacks Rank  3 The Home Depot  Inc    NYSE HD   has an Earnings ESP of  0 29  and a Zacks Rank  3 Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks  has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ,2018-02-01,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-store-for-kforce-kfrc-this-earnings-season-200286478,200286478
103394,324909,ABC,Will Higher Revenues Aid TransUnion s  TRU  Q4 Earnings ,opinion,TransUnion   NYSE TRU   is slated to report fourth quarter 2017 results before the opening bell on Feb 13 Last quarter  the company reported revenues of  498 million  comfortably beating the Zacks Consensus Estimate of  474 million  TransUnion delivered an impressive average positive surprise of 10 3  in the trailing four quarters  beating estimates in each Let s see how things are shaping up for this announcement Factors at PlayTransUnion s attractive business model with diversified revenue streams  significant operating leverage  low capital requirements  and strong and stable cash flow have produced consistent operating results in the recent times During the quarter  the acquisition of Factor Trust   one of the fastest growing companies specializing in the field of alternative credit data  analytics and risk scoring information   was a strategic move by TransUnion  We anticipate the buyout to have a favorable impact on the company s results Top Line ExpansionThe Zacks Consensus Estimate for TransUnion s fourth quarter revenues is  488 million  higher than reported revenues of  436 million in the prior year quarter  Higher revenues are expected across all the segments of the company The U S  Information Services segment   the largest revenue generating segment of the company   is expected to generate  297 million  higher than the reported figure of  268 million in the prior year quarter Also  the International and Consumer Interactive segments are expected to generate revenues of  97 million and  105 million  respectively  up from  86 million and  97 million reported in the prior year quarter Higher consumer awareness of the risks of identity theft propelled by a greater frequency of cyber attacks are driving demand in TransUnion s Consumer Interactive segment Earnings WhispersOur proven model does not conclusively show that TransUnion is likely to beat earnings this quarter as it does not possess the key components  A stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  This is not the case here as you will see below Zacks ESP  Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  0 12   You can uncover the best stocks to buy or sell before they re reported with our  TransUnion Price and EPS Surprise   Zacks Rank  TransUnion has a Zacks Rank  3  While this increases the predictive power of ESP  we need to have a positive ESP to be confident about an earnings surprise Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing a negative estimate revisions momentum Stocks to ConsiderHere are some companies that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter Zendesk  Inc    NYSE ZEN   has an Earnings ESP of  14 04  and a Zacks Rank  3  You can see  AmerisourceBergen Corporation   NYSE ABC   has an Earnings ESP of  0 73  and a Zacks Rank  2 The Home Depot  Inc    NYSE HD   has an Earnings ESP of  0 27  and a Zacks Rank  2 Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-02-07,Zacks Investment Research,https://www.investing.com/analysis/will-higher-revenues-aid-transunions-tru-q4-earnings-200288400,200288400
103395,324910,ABC,5 Best PEG Stocks Value Investors Love,opinion,With externalities impacting stock markets every second day  investors with varied risk appetite prefer to go for value investing  In the event of a market crash   investors often end up to selling their holdings in a panic  But Warren Buffett advises investors to grab the opportunity and buy bargain stocks at cheap prices  However  this apparently simple to  understand investing discipline has historically shown dangerous outcomes owing to people s oversight of the basics Warren Buffett believes that proper understanding of the  intrinsic value  of a stock will make the task easier  Yardsticks such as dividend yield  the ratio of price to earnings or to book value are the most common forms of intrinsic value calculation  which can easily single out the stocks that the market is currently undervaluing  However  these ratios fail to consider the future potential of a stock  And here comes the importance of a not so popular value investing metric  the PEG ratio  This ratio with earnings growth component in it may help to determine the prospects of a stock The PEG ratio is defined as   Price  Earnings  Earnings Growth RateA lower PEG ratio is always better for value investors While P E alone fails to identify a true value stock  PEG helps to find the intrinsic value of a stock Unfortunately  this ratio is often neglected due to investors  limitation to calculate the future earnings growth rate of a stock There are some drawbacks to using the PEG ratio though  It doesn t consider the very common situation of changing growth rates such as the forecast of the first three years at a very high growth followed by a sustainable but lower growth rate in the long term Hence  PEG based investing can turn out to be even more rewarding if some other relevant parameters are also taken into consideration Here are the screening criteria for a winning strategy PEG Ratio less than X Industry Median P E Ratio  using F1  less than X Industry Median  For more accurate valuation purpose  Zacks Rank of 1  Strong Buy   2  Buy  or 3  Hold   whether good market conditions or bad  stocks with a Zacks Rank  1   2 and  3 have a proven history of success  Market Capitalization greater than  1 Billion  This helps us to focus on companies that have strong liquidity Average 20 Day Volume greater than 50 000  A substantial trading volume ensures that the stock is easily tradable Percentage Change F1 Earnings Estimate Revisions  4 Weeks  greater than 5   Upward estimate revisions add to the optimism  suggesting further bullishness  of less than or equal to B  Our research shows that stocks with a Style Score of A or B when combined with a Zacks Rank  1 or 2 offer the best upside potential  Here are five of the 12 stocks that qualified the screening Banco Bilbao Vizcaya Argentaria  S A    NYSE BBVA    BBVA  MC BBVA  Compass ranks among the top 25 largest U S  commercial banks based on deposit market share and ranks among the largest banks in Alabama  2nd   Texas  4th  and Arizona  5th   The stock also can be an impressive value investment pick with its Zacks Rank  2 and Value Score of A  Apart from a discounted PEG and P E  the stock also has an impressive long term expected growth rate of 9 2  Cosan Limited   NYSE CZZ    Cosan was established as the controlling shareholder of Cosan S A   a Brazilian company that is engaged in the cultivation  harvesting and processing of sugarcane  the main raw material used for producing sugar and ethanol  The company has an impressive expected five year growth rate of 25   The stock has a Value Score of A and carries a Zacks Rank  1 Teck Resources Limited   NYSE TECK     This popular name in the field of natural resources with its business spread across the Americas  the Asia Pacific  and Europe holds a Zacks Rank  1 and has a Value Score of A  The company also has an impressive growth rate of 162  for the current year  You can seeHill Rom Holdings  Inc    NYSE HRC    This medical technology company works in five core areas   Advancing Mobility  Wound Care and Prevention  Patient Monitoring and Diagnostics  Surgical Safety and Efficiency  and Respiratory Health  The company has an impressive long term expected growth rate of 13   The stock has a Value Score of B and a Zacks Rank  2 AmerisourceBergen Corporation   NYSE ABC    AmerisourceBergen is one of the world s largest pharmaceutical services companies  which focuses on providing drug distribution and related services to reduce health care costs and improve patient outcomes  The stock carries a Zacks Rank  2 and has a Value Score of B  It also has an impressive historical growth rate of 15 5  Get the rest of the stocks on the list and start putting this and other ideas to the test  It can all be done with the Research Wizard stock picking and backtesting software The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  Disclosure  Performance information for Zacks  portfolios and strategies are available at   Zacks Restaurant Recommendations  In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector ,2018-02-08,Zacks Investment Research,https://www.investing.com/analysis/5-best-peg-stocks-value-investors-love-200289012,200289012
103396,324911,ABC,AmerisourceBergen  ABC  Gains On World Courier Unit Strength,opinion,"On Feb 8  we issued an updated research report on AmerisourceBergen Corporation   NYSE ABC    The company continues to gain form solid organic growth  World Courier Business  H D  Smith Acquisition and deal with Walgreens Based in Chesterbrook  PA  AmerisourceBergen is one of the world s largest pharmaceutical services companies  focusing on provision of drug distribution and related services to reduce health care costs and improve patient outcomes In recent times  the company has been delivering stellar performances on the back of the World Courier Business alliance  World Courier s position as the leader in global specialty logistics services drove volume growth and overall performance Operational efficiency of the company is also a key catalyst  It offers an innovative platform and invested nearly  1 billion in the last two years in capital expenditures  The company enjoys the leverage scale  which enables it to provide the best in class customer service Acquisition driven growth strategy has also been a growth propeller  Recently  the company completed the acquisition of H D  Smith   the largest independent wholesaler in the United States   for  815 million in cash In this regard we note that the company s first quarter fiscal 2018 results marks its 16th consecutive quarter with 10  or greater revenue growth  The generic product volume growth is being driven by the company s focus and strategic efforts Over the last year  AmerisourceBergen had an unfavorable run in the broader   The stock lost 0 1  against the industry s rally of 11 6   The company s commercial business continues to face pressure  High bad debts are a concern   Zacks Rank   Other Stocks to ConsiderThe stock carries a Zacks Rank  2  Buy  
A few other top ranked stocks in the broader medical space are Amphastar Pharmaceuticals   NASDAQ AMPH    BIOVERATIV   NASDAQ BIVV   and HCA Healthcare   NYSE HCA    All the stocks sport a Zacks Rank  1  Strong Buy   You can see  Amphastar has an impressive expected long term growth rate of 25   In the last six months  the stock has returned 16 9  against the industry s decline BIOVERATIV has an expected long term growth rate of 14   The stock has returned a whopping 92 2  compared with its industry s rally HCA has a long term projected growth rate of 11 5   Over the last six months  the stock has returned 23 3  compared with the industry s gain The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-02-08,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-abc-gains-on-world-courier-unit-strength-200288987,200288987
103397,324912,ABC,Walgreens  WBA  May Buy Remaining Stake In AmerisourceBergen,opinion,Per a report in The Wall Street Journal  Walgreens Boots Alliance  Inc    NASDAQ WBA   is in early stage talks to buy the remaining stake in the leading pharmaceutical services company  AmerisourceBergen Corporation   NYSE ABC    Soon after the takeover rumor surfaced on Feb 12  shares of AmerisourceBergen gained 15 7  in after hours trading and subsequently  closed with a 0 3  rise  However  the stock price of Walgreens remained unchanged In this regard  we remind investors that the drugstore retailer and pharmacy led  health and wellbeing enterprise already holds a 26  stake in AmerisourceBergen  which is part of their long term strategic relationship  formed in 2013  That relationship comprises a 10 year pharmaceutical distribution contract with AmerisourceBergen Walgreens Boots Alliance  Inc  Price    We believe  Walgreen s latest decision to acquire AmerisourceBergen s remaining stake  comes close on the heels of its rival CVS Health s   NYSE CVS   gigantic  69 billion acquisition deal of health insurer  Aetna Inc   NYSE AET    According to a Reuters report  the Walgreens AmerisourceBergen integration  similar to the CVS Aetna deal  is likely to move toward a vertical consolidation  combining all members of a supply chain This apart  some analysts believe that this move may be in response to Amazon s latest decision to step into the multibillion dollar pharmaceutical industry  Notably  in December 2017  Amazon com  Inc   NASDAQ AMZN   had acquired pharmacy licenses in a dozen states As far as the news revolving around Walgreens AmerisourceBergen agreement is concerned  many market researchers view this takeover rumor to be strategic  although the companies themselves have remained silent on this speculative issue Significantly  Walgreens has a market capitalization of  67 82 billion while the same for AmerisourceBergen remains at  19 65 billion The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-02-12,Zacks Investment Research,https://www.investing.com/analysis/walgreens-wba-may-buy-remaining-stake-in-amerisourcebergen-200290089,200290089
103398,324913,ABC,AmerisourceBergen  ABC  Jumps  Stock Rises 9 3 ,opinion,"AmerisourceBergen Corporation   NYSE ABC   was a big mover last session  as the company saw its shares rise more than 9  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This reverses the recent trend for the company as the stock is now down 1 2  in the past one month time frame The stock gained after reports that Walgreens Boots Alliance  NASDAQ WBA  may consider purchasing the drug wholesaler The company has seen five positive estimate revisions in the past few weeks  while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks  suggesting that more solid trading could be ahead for AmerisourceBergen  So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road AmerisourceBergen currently has a Zacks Rank  2  Buy  while its  is negative AmerisourceBergen Corporation Price   Another stock worth considering in the Medical   Dental Supplies industry is Becton  Dickinson and Company   NYSE BDX    which also carries a Zacks Rank  2  You can see  
Is ABC going up  Or down  Predict to see what others think   or 
Don t Even Think About Buying Bitcoin Until You Read This 
The most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 
Zacks  has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ",2018-02-13,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-abc-jumps-stock-rises-93-200290364,200290364
103399,324914,ABC, Company News For Feb 14  2018,opinion,Shares of Pepsico  Inc    NASDAQ PEP   increased 0 2  after posting fourth quarter core earnings of  1 31 per share  beating the Zacks Consensus Estimate by a centThe Dun   Bradstreet Corporation s   NYSE DNB   shares rose 8  after reporting fourth quarter adjusted earnings of  3 22 per share  surpassing the Zacks Consensus Estimate of  3 03Shares of AmerisourceBergen Corporation   NYSE ABC   advanced 9 3  on reports that Walgreens Boots Alliance  Inc    NASDAQ WBA   is in early stage talks to buy the remaining stake in the companyChegg  Inc s   NYSE CHGG   shares jumped 17 1  after posting fourth quarter non GAAP earnings of  0 15 per share  beating the Zacks Consensus Estimate by a couple of cent,2018-02-13,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-feb-14-2018-200290440,200290440
103428,324943,ABC,5 Value Stocks Breaking Out Right Now,opinion," 0     Historic Record Highs Just Keep Coming 2     Stock Screener For Hot Value Stocks 5     Tracey s Top Stock Picks 17     Episode Roundup  Welcome to Episode  78 of the Value Investor Podcast
Every week  Tracey Ryniec  the editor of Zacks   shares some of her top value investing tips and stock picks 
The stock market is off to a historic start in 2018 with the S P 500 closing at new record highs in 13 out of the first 16 sessions  Not only that  but it hasn t had a 5  pullback in well over a year 
Even the small caps  which have been slightly more volatile  haven t seen much sustained weakness either 
But it s not just the growth stocks that are sizzling  Many value names are also breaking out to new 52 week and all time highs to start the year 
Screening for Value Stocks Hitting New Highs
Tracey ran a basic screen which looked for stocks that had Zacks Ranks of  1  Strong Buy  or  2  Buy   which usually means rising earnings estimates  along with a Zacks Value Style Score of A  the highest score 
She then combined it with stocks that were trading at or within a few percent of their 52 week high 
Surprisingly  the screen returned 77 companies  Who knew there was that much value in this hot market 
Tracey selected 5 stocks from the screen that she thought value investors would be especially interested in 
5 Value Stocks Breaking Out Right Now
1       AmerisourceBergen Corp    NYSE ABC    the pharmaceutical products provider  has a forward P E of 16 4  Many healthcare stocks lagged in 2017 but ABC shares are up 11  in 2018  It s expected to report earnings on Feb 6 
2       GATXCorp    NYSE GATX   has a forward P E of 15 9  It already reported earnings and said there s still an industry wide railcar overcapacity issue  However  its managing the downward part of the cycle  Analysts have recently gotten more bullish that the worst may be over in the industry  as it raised 2018 earnings estimates after the earnings report 
3      Gap  Inc    NYSE GPS   is more expensive than it was in the middle of last year but it still trades with a forward P E of 16 8  which is under that of the S P 500  Shares spiked in November and December and started off 2018 hot  Is the worst over for the apparel retailers 
4      SonyCorp    NYSE SNE   is more than just electronics  PlayStation 4 and movies  It recently presented at CES 2018 in Las Vegas for its image sensors  The sensors can detect their 360 degree surroundings  which is helpful for automobiles  It has a forward P E of just 17 6 
5      Lithia Motors   NYSE LAD   has been a value stock for years  In 2015 and 2016  the shares plunged on peak auto concerns but they re back to new 5 year highs  This auto retailer has a forward P E of just 13 and a PEG ratio of 0 6  It s a rare combination of both a value  growth AND momentum stock 
Most of these companies haven t yet reported earnings  Investors should be sure to tune into those earnings reports and the conference calls to find out how 2018 is shaping up 
This list of stocks proves you don t have to pay 50x or 100x earnings to get one of the hot stocks  Many value stocks are sizzling too 
It s possible to find the values out there  You just have to know where to look 
What else should you know about these hot value stocks 
Tune into this week s podcast to find out 
Exclusive Buffett Report for Podcast Listeners
What 3 secrets drive the success of arguably the world s greatest value investor  Which 5 stocks might he buy right now if he weren t already a billionaire 
Today  podcast listeners are invited to download Zacks  Special Report  Invest Like Warren Buffett for free  At the same time  you may also look inside Tracey Ryniec s personal Value Investor portfolio to see more stocks at exceptional  discounts  ",2018-01-24,Zacks Investment Research,https://www.investing.com/analysis/5-value-stocks-breaking-out-right-now-200283329,200283329
103429,324944,ABC,Is AmerisourceBergen  ABC  Poised For A Beat In Q1 Earnings ,opinion,AmerisourceBergen Corp  s   NYSE ABC   first quarter fiscal 2018 results  scheduled for release on Feb 6  are expected to show steady growth in the pharmaceutical distribution segment  a significant contributor to revenues Last quarter  the company posted a positive earnings surprise of 0 8   AmerisourceBergen has outperformed the Zacks Consensus Estimate in all of the preceding four quarters  the average beat being 4 6   Let s take a look at how things are shaping up prior to this announcement AmerisourceBergen s earnings in the preceding quarter surpassed the Zacks Consensus Estimate  courtesy of strong growth in Consulting Services  MWI Animal Health and World Courier businesses  Revenues rose almost 4 2  from the year ago quarter AmerisourceBergen Corporation  Holding Co  Price and EPS Surprise     The Zacks Consensus Estimate for the Pharmaceutical Distribution segment stands at  38 74 billion for the quarter under review  This reflects an improvement of almost 5 9  from the year ago quarter Other Factors to ConsiderAmerisourceBergen s Specialty Group performed impressively over the recent past with revenues rising 10 3  year over year in the last reported quarter  The upside can be attributed to strong oncology product sales and solid performance by third party logistics businesses  These factors are expected to play a pivotal role in boosting the segmental revenue in the first quarter as well Other segment  this segment includes AmerisourceBergen Consulting Services  World Courier and MWI Veterinary Supply  also performed well in the last quarter  Revenues at the segment were up 12 2  on a year over year basis  driven by a record number of shipments in World Courier and strong volume and revenue growth at MWI  This segment is expected to maintain the performance in the quarter to be reported Meanwhile  the Zacks Consensus Estimate for AmerisourceBergen s first quarter earnings stands at  1 35 per share  down a penny year over year  The company expects EPS growth in the second half of fiscal 2018 to be much better than the first half  courtesy of benefits from the gradual onboarding of the Walgreens Rite Aid stores The company also expects a slight rise in tax rate in fiscal 2018 as it had seen one time benefits from R D tax credits in fiscal 2017 Although generic inflation has been nominal  the rate of deflation is rising gradually  These factors  combined with an anticipated shift in product mix toward lower margin and higher priced specialty and branded drugs along with lack of generic inflation  will affect the company s bottom line The temporary slowdown in the PharMEDium segment is expected to mar AmerisourceBergen s bottom line in the first quarter  Notably  the company aims to boost its investments to enhance PharMEDium s quality assurance  QA  and quality control  QC  systems in terms of product quality and patient safety  Although this lends the company a competitive edge  it might affect the bottom line in first quarter fiscal 2018 Here is what our quantitative model predicts AmerisourceBergen has the right combination of two main ingredients   a positive  and Zacks Rank  3  Hold  or higher   for increasing the odds of an earnings beat Zacks ESP  The Earnings ESP for AmerisourceBergen is  1 50   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  AmerisourceBergen carries a Zacks Rank  2  Buy  Other Stocks to ConsiderHere are a few other medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter Bio Rad Laboratories   NYSE BIO   has an Earnings ESP of  4 45  and a Zacks Rank  1  Strong Buy   You can see  Myriad Genetics   NASDAQ MYGN   has an Earnings ESP of  0 42  and a Zacks Rank  3 Henry Schein   NASDAQ HSIC   has an Earnings ESP of  0 09  and a Zacks Rank  3 Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-01-24,Zacks Investment Research,https://www.investing.com/analysis/is-amerisourcebergen-abc-poised-for-a-beat-in-q1-earnings-200283528,200283528
103430,324945,ABC,Why Earnings Season Could Be Great For AmerisourceBergen  ABC ,opinion,Investors are always looking for stocks that are poised to beat at earnings season and AmerisourceBergen Corporation   NYSE ABC   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because AmerisourceBergen is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings with the most up to date information possible is a pretty good indicator of some favorable trends underneath the surface for ABC in this report Analysts have very recently bumped up their estimates for ABC  giving the stock a Zacks Earnings ESP of  1 28  heading into earnings season  AmerisourceBergen Corporation  Holding Co  Price and EPS Surprise    Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that ABC has a Zacks Rank  3 and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see  Clearly  recent earnings estimate revisions suggest that good things are ahead for AmerisourceBergen  and that a beat might be in the cards for the upcoming report Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks  has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ,2018-02-01,Zacks Investment Research,https://www.investing.com/analysis/why-earnings-season-could-be-great-for-amerisourcebergen-abc-200286446,200286446
103431,324946,ABC,Can Solid Medicaid Business Boost Centene  CNC  Q4 Earnings ,opinion,Centene Corporation   NYSE CNC   will release fourth quarter 2017 results on Feb 6  before the market opens Centene has been witnessing consistent growth in its membership over the past few quarters that has significantly boosted the top line   This uptrend is expected to continue in the fourth quarter as well  The Zacks Consensus Estimate for total membership is currently pegged at 12 2 billion  reflecting 7  year over year growth Centene s membership has been continuously increasing on the back of its solid Medicaid expansion  The company s intention to continue with its public exchange business while other health insurers are exiting it  has boosted its Medicaid membership  The trend is expected to continue in the fourth quarter  The Zacks Consensus Estimate for Medicaid membership stands at 5 9 billion  reflecting year over year growth of 4  In addition  Centene s cost saving initiatives are likely to aid the margins in the fourth quarter  The Zacks Consensus Estimate for total general and administrative expense ratio is currently pegged at 0 10 compared with 9 00 in the third quarter of 2017 Other FactorsThe company s growing Medicare beneficiaries are also likely to boost the top line in the fourth quarter Centene expects its exchange business to perform well in the to be reported quarter  continuing the previous trend We also expect Centene s international business to boost the top line in the quarter The company s share repurchase programs intended to enhance shareholders  value might impact margins positively by reducing the outstanding share count Why a Likely Positive Surprise Our proven model shows that Centene has the right combination of two key ingredients to beat estimates this quarter Zacks ESP   which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  1 24   This is because the Most Accurate estimate of 95 cents is higher than the Zacks Consensus Estimate of 94 cents  The positive ESP is a leading indicator of a likely earnings beat  You can uncover the best stocks to buy or sell before they re reported with our  Centene Corporation Price and EPS Surprise   Zacks Rank  Centene sports a Zacks Rank  1  Strong Buy   Note that stocks with a Zacks Rank  1  2  Buy  or 3  Hold  have a significantly higher chance of beating on earnings  The combination of Centene s favorable Zacks Rank and positive Earnings ESP makes us reasonably confident of an earnings beat Conversely  the Sell rated stocks  Zacks Rank  4 or 5  should never be considered going into an earnings announcement Other Stocks to ConsiderHere are some other companies from the medical sector that you may want to consider as these have the right combination of elements to post an earnings beat this quarter AmerisourceBergen Corporation   NYSE ABC    which is set to report fourth quarter earnings on Feb 6  has an Earnings ESP of  1 28  and a Zacks Rank  3  You can see  LifePoint Health Inc   NASDAQ LPNT   has an Earnings ESP of  1 28  and a Zacks Rank  3  The company is set to report fourth quarter earnings on Feb 23 Community Health Systems  Inc    NYSE CYH   has an Earnings ESP of  6 46  and a Zacks Rank  3  The company is expected to report fourth quarter earnings on Feb 19  Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ,2018-02-01,Zacks Investment Research,https://www.investing.com/analysis/can-solid-medicaid-business-boost-centene-cnc-q4-earnings-200286439,200286439
103432,324947,ABC,Can Higher Research Revenues Drive Gartner  IT  Q4 Earnings ,opinion,"Information technology services provider Gartner  Inc    NYSE IT   is scheduled to report fourth quarter 2017 results before the opening bell on Feb 6  The company s Research segment  which accounts for nearly 79  of total revenues  is likely to report higher revenues due to improved demand for its products  Whether this could result in higher earnings for the quarter remains to be seen Top Line ImprovementWith diligent execution of operational plans  Gartner has recorded double digit growth in key metrics for more than a decade  In addition  this performance driven firm has a strong cash flow and a healthy balance sheet position  It has a vast  untapped market opportunity worth an estimated  61 billion  The acquisition of CEB  an industry leader in providing best practice and talent management insights  further reinforces Gartner s market strength  The combination of its analyst driven  syndicated research and advisory services with CEB s expertise is likely to provide a comprehensive and differentiated suite of services portfolio across the globe Gartner has a recurring revenue stream with 75  of its total revenues generated through subscription and long term contracts  In addition  the company has a large and diverse addressable market with low customer concentration that mitigates operating risks  Operating in an industry with low barriers to entry  Gartner has an integrated research and consulting team designed to best serve client needs  This enables it to have a competitive advantage against its rivals  Leveraging its intellectual capital  Gartner creates and distributes proprietary research content as broadly as possible via published reports  interactive tools  facilitated peer networking  briefings  consulting and advisory services  and events  These facilitate a steady improvement in the company s revenue stream The Zacks Consensus Estimate for the Research segment s revenues is currently pegged at  721 million  up from  479 million reported in the year ago quarter  Revenues from the Event segment are expected to be  169 million compared with reported revenues of  136 million in the year earlier quarter  However  revenues from the Consulting segment are anticipated to be marginally down to  86 million from  88 million generated in the year ago quarter Other Key FactorsGartner is relatively immune to the vagaries of the market due to secular growth of information technology spend and its increasing market penetration rate  However  some of its services are cyclically sensitive  In addition  revenues from the federal government business are exposed to lengthy approval times and other austerity measures  which often increase operating risks  These factors undermine the long term growth potential of the company to some extent Our proven model conclusively shows that Gartner is likely to beat earnings this quarter as it possesses the key components  A stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  This is perfectly the case here as you will see below Zacks ESP  Earnings ESP  which represents the difference between the Most Accurate estimate and Zacks Consensus Estimate  is  0 62   You can uncover the best stocks to buy or sell before they re reported with our  Gartner  Inc  Price and EPS Surprise
    Zacks Rank  Gartner has a Zacks Rank  2  This increases the predictive power of ESP and makes us reasonably confident about an earnings surprise Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing a negative estimate revisions momentum Other Stocks to ConsiderHere are some other companies that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter Zendesk  Inc    NYSE ZEN   has an Earnings ESP of  9 91  and a Zacks Rank  3 AmerisourceBergen Corporation   NYSE ABC   has an Earnings ESP of  1 28  and a Zacks Rank  3  You can see  The Home Depot  Inc    NYSE HD   has an Earnings ESP of  0 29  and a Zacks Rank  3 Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks  has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ",2018-02-01,Zacks Investment Research,https://www.investing.com/analysis/can-higher-research-revenues-drive-gartner-it-q4-earnings-200286434,200286434
103433,324948,ABC,S P Global  SPGI  To Post Q4 Earnings  Is A Beat In Store ,opinion,S P Global Inc    NYSE SPGI   is slated to report fourth quarter 2017 results before the opening bell on Feb 6  Last quarter  the company reported adjusted earnings from continued operations of  274 million or  1 04 per share compared with  264 million or  1 00 per share in the year ago quarter  The figure beat the Zacks Consensus Estimate by 19 cents The company surpassed earnings estimates in each of the trailing four quarters  with an average positive earnings surprise of 11 1  Let s see how things are shaping up prior to this earnings season Key FactorsThe company s strategic portfolio restructuring and focus on core business will continue to drive long term growth The Zacks Consensus Estimate for S P Capital IQ revenues is currently pegged at  433 million  up from  414 million reported in the third quarter  The successful integration of SNL Financial and corresponding synergies generated are likely to aid this rise  Total revenues are expected to be  1 503 million compared with reported revenues of  1 513 million in the previous quarter  Operating profit for Commodities   Commercial markets is expected to be  234 million  up from the third quarter tally of  208 million  Also  Zacks Consensus Estimate for earnings per share is  1 63 compared with  1 71 in the prior quarter S P Global has been consistently making strategic investments in businesses to facilitate long term profitability  The formation of S P Dow Jones Indices coupled with S P Capital IQ s acquisitions of Credit Market Analysis Limited  QuantHouse  R2 Financial Technologies and TheMarkets com along with a significant stake in India s leading rating agency CRISIL  position it well  This gives it an edge over competitors and allows it to grab a wider market through superior functionality and investor oriented services Earnings WhispersOur proven model conclusively shows that S P Global is likely to beat earnings this quarter as it possesses the key components  A stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  This is perfectly the case here as you will see below Zacks ESP  Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  0 72   with the former currently pegged at  1 64 and the latter at  1 63  You can uncover the best stocks to buy or sell before they re reported with our  S P Global Inc  Price and EPS Surprise    Zacks Rank  S P Global has a Zacks Rank  2  This increases the predictive power of ESP and makes us reasonably confident of an earnings beat Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing a negative estimate revisions momentum Other Stocks to ConsiderHere are some other companies that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter Zendesk  Inc    NYSE ZEN   has an Earnings ESP of  9 91  and a Zacks Rank  3  You can see  AmerisourceBergen Corporation   NYSE ABC   has an Earnings ESP of  1 28  and a Zacks Rank  3 The Home Depot  Inc    NYSE HD   has an Earnings ESP of  0 29  and a Zacks Rank  3 Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ,2018-02-01,Zacks Investment Research,https://www.investing.com/analysis/sp-global-spgi-to-post-q4-earnings-is-a-beat-in-store-200286480,200286480
103464,324979,ABC,AmerisourceBergen  ABC  Beats Q4 Earnings  Issues FY18 View,opinion,"AmerisourceBergen Corporation   NYSE ABC   posted adjusted earnings of  1 33 per share in the fourth quarter of fiscal 2017  beating the Zacks Consensus Estimate by a penny and increasing 2 3  on a year over year basis  The upside was primarily driven by strong growth in the company s Consulting Services  MWI Animal Health and World Courier businesses Revenues improved almost 4 2  to  39 1 billion in the reported quarter  However  revenues lagged the Zacks Consensus Estimate of  40 1 billion FY17 at a GlanceIn fiscal 2017  AmerisourceBergen reported adjusted earnings of  5 88 per share  up 4 6  year over year  Revenues increased 4 3  to  153 1 billion on a year over year basis Major HighlightsIn the fourth quarter  AmerisourceBergen collaborated with Blue Cross Blue Shield Association  Pfizer   NYSE PFE    Prime Therapeutics and Walgreens Boots Alliance   NASDAQ WBA   to combat the opioid abuse crisis in the United States  The companies aim to expand the availability of safe medication disposal kiosks to Walgreens stores  particularly in areas where the opioid epidemic has hit communities In the reported quarter  AmerisourceBergen initiated product shipments to Walgreens  retail pharmacies Added to this  AmerisourceBergen launched an online  interactive cell and gene therapy resource that provides insights for patients facing challenges pertaining to treatment procedures  AmerisourceBergen Corporation  Holding Co  Price and Consensus
     Segmental AnalysisPharmaceutical Distribution Segment  The Pharmaceutical Distribution Services segment historically included AmerisourceBergen Drug Corporation   ABDC   and AmerisourceBergen Specialty Group   ABSG    In the reported quarter  revenues at the segment were  37 7 billion  up 3 9  on a year over year basis  ABDC revenues were up 4 2   primarily on the back of solid organic sales growth The ABSG unit performed impressively during the quarter  with revenues rising 10 3  year over year  The increase can be attributed to strong oncology product sales and solid performance by the third party logistics business Other Segment  This segment includes AmerisourceBergen Consulting Services   ABCS    World Courier and MWI Veterinary Supply  Revenues at the segment came in at  1 5 billion  up 12 2  on a year over year basis Margin DetailsIn the fourth quarter  AmerisourceBergen registered gross profit of  1 1 billion  up 4 4  on a year over year basis  As a percentage of revenues  gross margin in the fourth quarter was 2 8   flat year over year Operating expenses in the fourth quarter were  626 million  reflecting an increase of 6 8  year over year  As a percentage of revenues  operating margin expanded 4 basis points  bps  to 1 6  in the quarter GuidanceAmerisourceBergen issued guidance for fiscal 2018  The company expects adjusted earnings per share for fiscal 2018 in the band of  5 90 to  6 15  Revenue growth for the fiscal is expected in the range of 7  to 9  AmerisourceBergen expects adjusted operating expenses to increase in the range of 4  to 6   while adjusted operating income growth is estimated in the band of 3  to 5  Meanwhile  operating income growth at the pharmaceutical distribution services segment is anticipated in the range of 3  to 5  Peer ReleasePetMed Express  Inc  s   NASDAQ PETS   adjusted earnings per share of 43 cents in the second quarter of fiscal 2018 were up 79 2  from the year ago quarter  Also  earnings surpassed the Zacks Consensus Estimate by 43 3   The stock sports a Zacks Rank  1  Strong Buy   You can see Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-11-01,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-abc-beats-q4-earnings-issues-fy18-view-200257937,200257937
103465,324980,ABC,AmerisourceBergen To Take Over H  D  Smith For  815 Million,opinion,AmerisourceBergen Corporation   NYSE ABC   signed a definitive agreement to acquire H  D  Smith for  815 million in cash  H  D  Smith is a privately held national wholesaler offering a complete line of healthcare products and solutions  AmerisourceBergen expects this deal to contribute nominally to adjusted diluted earnings per share  EPS  in fiscal 2018 and to achieve full run rate synergies in fiscal 2020  The deal is expected to close in early calendar year 2018  on approval from regulators This acquisition  post closure  is expected to expand and improve AmerisourceBergen s Pharmaceutical Distribution segment  In the last reported fourth quarter  revenues at the segment improved 3 9  on a year over year basis  In May  the company signed a new five year agreement to supply pharmaceuticals to Express Scripts Holding Company  NASDAQ ESRX    Taking the buyout into consideration  the company expects revenue growth in fiscal 2018 in the range of 8 11  and adjusted operating income growth in the band of 4 7   AmerisourceBergen has reiterated the rest of the fiscal 2018 financial guidance Market research firm  Evaluate Pharma estimates that the pharma industry will see a CAGR of 6 3  by 2022  Looking at the bountiful opportunities in this niche space  we believe the company s latest development is strategic AmerisourceBergen s shares have declined 3 7  in the past month  comparing unfavorably with thebroader  s fall of only 0 4  Estimate Revision TrendThe estimate revision trend has been favorable for the company  For the current year  four estimates moved north compared with one movement in the opposite direction over the last month  As a result  the Zacks Consensus Estimate for the full year has risen to  6 04 per share from  6 02 Zacks Rank   Key PicksAmerisourceBergen carries a Zacks Rank  3  Hold  A few better ranked medical stocks are PetMed Express  Inc    NASDAQ PETS    Align Technology  Inc    NASDAQ ALGN   and Myriad Genetics  Inc    NASDAQ MYGN    Notably  PetMed  Align Technology and Myriad Genetics sport a Zacks Rank  1  Strong Buy   You can see PetMed has a long term expected earnings growth rate of 10   The stock has rallied roughly 79 4  in a year Align Technology has a long term expected earnings growth rate of 28 9   The stock has gained 168 4  over a year Myriad Genetics has a long term expected earnings growth rate of 15   The stock has gained 91 6  in a year Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-11-21,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-to-take-over-h-d-smith-for-815-million-200267581,200267581
103466,324981,ABC,AmerisourceBergen Banks On Strategic Deals  Competition Rife,opinion,On Dec 19  we issued an updated research report on AmerisourceBergen Corporation   NYSE ABC    one of the world s largest pharmaceutical service companies  The company focuses on providing drug distribution and related services to reduce health care costs and improve patient outcome We are positive on the deals signed by AmerisourceBergen  which should boost its top line  The company entered into a strategic agreement with Walgreen Boots Alliance   NASDAQ WBA    The agreement includes a 10 year pharmaceutical distribution contract with Walgreens Boot Alliance  under which the company will distribute branded and generic pharmaceutical products to Walgreen Boots We believe that AmerisourceBergen will benefit from generics growth in the long run  The company is well positioned to help products get to market efficiently AmerisourceBergen has been actively pursuing acquisitions to strengthen its core areas  The MWI Veterinary acquisition has diversified the company s existing pharmaceutical distribution   services businesses into the highly lucrative animal health market   On the flip side  cutthroat competition in the niche space is a concern  AmerisourceBergen operates in a highly competitive pharmaceutical distribution and related health care services market  The company s primary competitors are national generic and regional distributors  The generic industry is witnessing consolidation of customers and manufacturers  globalization and increasing quality along with regulatory challenges  The company also faces competition from manufacturers  chain drugstores  specialty distributors and packaging and health care technology companies In the last six months  AmerisourceBergen has been trading below the  in terms of price  Shares of the company have lost 2 7  compared with the industry s rally of 2 4  Zacks Rank   Key PicksAmerisourceBergen carries a Zacks Rank  3  Hold  A few better ranked medical stocks are athenahealth  Inc    NASDAQ ATHN   and Align Technology  Inc    NASDAQ ALGN    Notably  athenahealth and Align Technology sport a Zacks Rank  1  Strong Buy   You can see athenahealth has a long term expected earnings growth rate of 22 3   The stock has rallied roughly 27 3  over a year Align Technology has a long term expected earnings growth rate of 28 9   The stock has gained 137 9  in a year Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-12-20,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-banks-on-strategic-deals-competition-rife-200275109,200275109
103491,325006,ABC,Generic Drug Stocks Take A Hit  Here s Why,opinion,"It s been a tough week for generic drugmakers which saw their shares tumbling following the release of disappointing second quarter results from Israel based Teva Pharmaceutical Industries Limited   NYSE TEVA    Teva not only missed on earnings and revenue expectations  the company also slashed its 2017 outlook and announced a 75  cut in its dividend Teva s shares plunged 34 1  in the two trading sessions following the release of second quarter results reflecting concerns about the company s business and debt burden which triggered a few analyst downgrades  Year to date  YTD   Teva has lost 43 2  of its value versus the 12  decline of its 

Challenging Generic Pricing EnvironmentA key reason for Teva s dismal performance was generic pricing erosion  The sharp decline in generic drug prices  while a blessing for patients  is proving to be a major challenge for generic drugmakers as well as drug distributors On its second quarter conference call  Teva said that the ongoing consolidation of customers has led to increasing price erosion and decreasing volume  The consolidation in the industry has increased the ability to negotiate lower prices for generic drugs  Moreover  the FDA is speeding up the approval of generic drugs which means more competition  increasing price cuts and decreasing volume  Generic drugs are basically cheaper versions of branded drugs which have gone off patent Teva said that price erosion was around 6  in the second quarter and is expected to increase to high single digits over the remainder of the year And it s not just Teva that was affected by the tough generic pricing environment in the U S  AmerisourceBergen Corporation   NYSE ABC    which reported a mixed quarter  saw its shares decline 11 4  over the two trading sessions following the release of third quarter fiscal 2017 results  The company mentioned that generic deflation remains a headwind and is yet to ease from the high single digits  where it s been for about three quarters  Generic deflation is expected to remain a headwind for the remainder of fiscal 2017 in the range of  7  to  9   The situation may continue in fiscal 2018 as well Cardinal Health  Inc    NYSE CAH   too mentioned that generic drugs pricing was a material headwind for the company s Pharma Distribution business in the fourth quarter of fiscal 2017  The company expects generic deflation in mid single digits in fiscal 2018 Stocks in FocusFollowing the release of Teva s second quarter results  companies with a presence in the generics market saw their shares declining on concerns that these companies too will be affected by the generic drug pricing environment  Companies like Mylan NV   NASDAQ MYL    down 10 8    Lannett Company  Inc    NYSE LCI    10 9  down   Perrigo Company plc   NYSE PRGO    down 6 5   and Impax Laboratories  Inc    NASDAQ IPXL    down 10 7   were down over the last two trading sessions  This week  investors will be focused on Mylan s second quarter results including the company s take on the generic pricing situation  Impax and Perrigo will also be reporting results this week  While Mylan  Perrigo and Impax are all Zacks Rank  3  Hold  stocks  Lannett is a Zacks Rank  2  Buy  stock  You can see   Medical   Generic Drugs Industry 5YR   ReturnIn our view  generic price erosion will remain a headwind for the remainder of the year and affect the margins of generic players  With the FDA focusing on speeding up the generic drug approval process  the market will continue to witness additional competition and escalating generic price erosion 
5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-08-06,Zacks Investment Research,https://www.investing.com/analysis/generic-drug-stocks-take-a-hit-heres-why-200205694,200205694
103492,325007,ABC,Is AmerisourceBergen  ABC  A Great Stock For Value Investors ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put AmerisourceBergen Corporation   NYSE ABC   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  AmerisourceBergen has a trailing twelve months PE ratio of 14 1  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 compares in at about 20 5  If we focus on the stock s long term PE trend  the current level puts AmerisourceBergen s current PE ratio considerably below its midpoint  which is 18 9  over the past five years Further  the stock s PE also compares favorably with the industry s trailing twelve months PE ratio  which stands at 19 5  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers We should also point out that AmerisourceBergen has a forward PE ratio  price relative to this year s earnings  of just 13 8  so it is fair to say that a slightly more value oriented path may be ahead for AmerisourceBergen s stock in the near term too   P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  AmerisourceBergen has a P S ratio of about 0 1  This is significantly lower than the S P 500 average  which comes in at 3 2 right now  Also  as we can see in the chart below  this is somewhat below the highs for this stock in particular over the past few years If anything  this suggests some level of undervalued trading at least compared to historical norms    Broad Value OutlookIn aggregate  AmerisourceBergen currently has a Value Style Score of A  putting it into the top 20  of all stocks we cover from this look  This makes ABC a solid choice for value investors  and some of its other key metrics make this pretty clear too For example  the PEG ratio for AmerisourceBergen is just 1 5  a level that is noticeably lower than the industry average of 2 2  The PEG ratio is a modified PE ratio that takes into account the stock s earnings growth rate  Additionally  its P CF ratio  another great indicator of value  comes in at 10 9  which is considerably better than the industry average of 12 8  Clearly  ABC is a solid choice on the value front from multiple angles What About the Stock Overall Though AmerisourceBergen might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth grade of F and a Momentum score of D  This gives ABC a VGM score or its overarching fundamental grade of C   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been mixed at best  The current quarter has seen five estimates go lower in the past sixty days  compared to none higher  while the full year estimate has seen six upward and one downward revisions in the same time period This has had a noticeable impact on the consensus estimate  as the current quarter consensus estimate has fallen about 2 2  in the past two months  while the full year estimate has inched up 0 2   You can see the consensus estimate trend and recent price action for the stock in the chart below AmerisourceBergen Corporation  Holding Co  Price and Consensus    This somewhat mixed trend is why the stock has just a Zacks Rank  3  Hold  and why we are looking for in line performance from the company in the near term Bottom LineAmerisourceBergen is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  However  with a sluggish industry rank  bottom 32  out of more than 250 industries  and a Zacks Rank  3  it is hard to get too excited about this company overall  In fact  over the past one year  the sector has clearly underperformed the broader market  as you can see below So  value investors might want to wait for estimates  analyst sentiment and broader factors to turn favorable in this name first  but once that happen  this stock could be a compelling pick Today s Stocks from Zacks  Hottest Strategies It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-10-01,Zacks Investment Research,https://www.investing.com/analysis/is-amerisourcebergen-abc-a-great-stock-for-value-investors-200216490,200216490
103493,325008,ABC,AmerisourceBergen  ABC  Q4 Earnings  Will It Disappoint ,opinion,AmerisourceBergen Corp  s   NYSE ABC   fourth quarter fiscal 2017 results  scheduled for release on Nov 2  are expected to show steady growth in pharmaceutical distribution segment  a significant contributor to revenues  While this could majorly drive fourth quarter earnings  let us take a look at the broader factors that are expected to influence the quarterly release AmerisourceBergen s earnings in the preceding quarter surpassed the Zacks Consensus Estimate  courtesy of strong growth in Consulting Services  MWI Animal Health and World Courier businesses  Revenues rose almost 4 9  to  38 7 billion in the quarter The Zacks Consensus Estimate for the Pharmaceutical Distribution segment stands at  38 34 billion for the quarter under review  This reflects an improvement of almost 6 5  from the year ago quarter AmerisourceBergen Corporation  Holding Co  Price  Consensus and EPS Surprise    Other Factors to ConsiderMeanwhile  the Zacks Consensus Estimate for AmerisourceBergen s earnings stands at  1 32 per share  up 1 8  year over year  The company should benefit from continued solid organic revenue growth  MWI and PharMedium acquisition  The consensus estimate for net revenues is pegged at  40 1 billion  signifying growth of 6 7  on a year over year basis On the flipside  although generic inflation has been nominal  the rate of deflation is rising gradually  These factors  combined with an anticipated shift in product mix toward lower margin and higher priced specialty and branded drugs and lack of generic inflation  will affect the company s bottom line The temporary slowdown in the PharMEDium segment is expected to mar AmerisourceBergen s bottom line in the fourth quarter  Notably  the company aims to boost its investments to enhance PharMEDium s quality assurance  QA  and quality control  QC  systems in terms of product quality and patient safety  Although this lends the company a competitive edge  it might affect the bottom line in fourth quarter fiscal 2017 However  our quantitative model does not conclusively show an earnings beat for AmerisourceBergen this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  This is not the case here  as you will see below Zacks ESP  Earnings ESP for AmerisourceBergen is  0 54   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  AmerisourceBergen currently carries a Zacks Rank  3  Though a favorable Zacks Rank increases the predictive power of ESP  the company s negative ESP makes surprise prediction difficult Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter INC Research Holdings  Inc    NASDAQ INCR   has an Earnings ESP of  1 74  and a Zacks Rank  3  You can see  Medpace Holdings Inc    NASDAQ MEDP   has an Earnings ESP of  0 47  and a Zacks Rank  3 Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  1 00  and a Zacks Rank  3 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-10-30,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-abc-q4-earnings-will-it-disappoint-200257339,200257339
103503,325018,ABC,AmerisourceBergen  ABC  Up 4 1  Since Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for AmerisourceBergen Corporation  Holding Co    NYSE ABC    Shares have added about 4 1  in that time frame  underperforming the market 
Will the recent positive trend continue leading up to the stock s next earnings release  or is it due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers AmerisourceBergen Q1 Earnings Beat  Revenues LagAmerisourceBergen posted earnings  excluding one time items  of  1 36 per share in the first quarter of fiscal 2017  ended Dec 31  2016   beating the Zacks Consensus Estimate of  1 24 and increasing from  1 27 earned in the year ago quarter Moreover  revenues improved 4 0  to  38 2 billion in the reported quarter  However  reported revenues were below the Zacks Consensus Estimate of  39 1 billion Quarter in DetailIn the reported quarter  revenues at the Pharmaceutical Distribution segment  including AmerisourceBergen Drug Corp   ABDC  and AmerisourceBergen Specialty Group  ABSG   increased 3 9  to  36 6 billion  Within the segment  ABDC revenues were up 3 6  primarily on the back of solid organic sales growth The ABSG unit also performed impressively during the quarter  with revenues surging 10 3  year over year on the back of overall strong performance  Of this  sales of oncology products benefited greatly owing to higher intake from community oncologists  Increased sales in the company s third party logistics business also contributed to the rise Revenues at the Other segment  AmerisourceBergen Consulting Services  ABCS   World Courier and MWI Veterinary Supply  came in at  1 7 billion  up 5 4  In the first quarter of fiscal 2017  operating expenses were  638 million compared with  1 1 billion in the same period last fiscal year  Operating expenses as a percentage of revenue in the fiscal 2017 first quarter were 1 67  compared with 3 11  for the same period in the year ago quarter GuidanceAmerisourceBergen expects fiscal 2017 revenue growth in the range of 6 5  to 8   The company expects adjusted diluted earnings per share for fiscal 2017 in the range of  5 72 to  5 92 
How Have Estimates Been Moving Since Then 
Analysts were quiet during the last one month period as none of them issued any earnings estimate revisions AmerisourceBergen Corporation  Holding Co  Price and Consensus
    VGM Scores
At this time  AmerisourceBergen s stock has a nice Growth Score of  B   a grade with the same score on the momentum front  Charting a somewhat similar path  the stock was allocated a grade of  A  on the value side  putting it in the top 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of  A   If you aren t focused on one strategy  this score is the one you should be interested in 
Based on our scores  the stock is more suitable for value investors than growth and momentum investors 
Outlook
The stock has a Zacks Rank  3  Hold   We are expecting an inline return from the stock in the next few months ",2017-04-19,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-(abc)-up-4.1-since-earnings-report:-can-it-continue-200183645,200183645
103505,325020,ABC,Dividend Aristocrat Cardinal Health Drops 12 ,opinion,"Cardinal Health  NYSE CAH   its guidance Tuesday morning  causing its stock price to plunge nearly 12  on the day 
The company previously  its profit guidance in October 2016  but today s news was clearly still a big surprise 
Many investors like owning dividend aristocrats such as Cardinal Heath because they have been less volatile than the broader market    
Let s take a closer look at why the market was so disappointed with Cardinal Health s business update and if the stock could be an attractive investment opportunity for our Top 20 Dividend Stocks portfolio 
How does Cardinal Health make money 
Founded in 1971  Cardinal Health is one of the largest healthcare companies in the world  The business primarily makes money by distributing a wide range of pharmaceutical products and medical supplies  2 8 billion healthcare products are manufactured or sourced by Cardinal Health each year  
Over 70  of U S  hospitals use Cardinal Health s resources  and the company serves more than 25 000 pharmacies 
Cardinal Health splits its business into two segments  The Pharmaceutical segment accounts for 90  of sales and 85  of profits  This unit distributes a wide range of branded and generic drugs  specialty pharmaceuticals  and over the counter products 
The company s Medical segment accounts for 10  of sales and 15  of profit  It distributes medical  surgical  and laboratory products to hospitals and other healthcare providers 
Cardinal Health is essentially a middleman in the healthcare sector  making purchases from drug manufacturers and selling its acquired inventory for a small profit to pharmacies and hospitals 
The company s operating margin typically sits between 1  and 2   reflecting the small sliver of profit Cardinal Health makes on each sale  The firm therefore depends on generating a high volume of sales to turn a meaningful profit 
The most attractive distributors are able to offer a wide range of products with competitive prices and dependable delivery standards 
They tend to benefit from having substantial distribution networks  long standing customer contracts  and economies of scale 
Why did Cardinal Health s stock drop 
Cardinal Health announced that its fiscal 2017 non GAAP earnings per share will be at the bottom of its previous guidance range 
The largest factor dragging down results is generic drug price deflation  which management now expects to be in the low double digits for the full fiscal year 
Investors were perhaps even more concerned with the company s guidance for fiscal 2018  which calls for non GAAP earnings to be flat to down mid single digits compared to 2017 
Cardinal Health s fiscal 2018 earnings guidance essentially missed analysts  expectations by around 10  and was nowhere close to management s long term goal of 10 15  annual non GAAP earnings per share growth 
In addition to slashing its guidance due to greater than expected generic drug price deflation  Cardinal Health announced it is acquiring Medtronic s Patient Care  Deep Vein Thrombosis  and Nutritional Insufficiency businesses for  6 1 billion 
Here s a look at some of the key medical products Cardinal Health is acquiring 

Management hopes this business will provide economies of scale in medical products manufacturing and sourcing  helping profitability  while increasing the company s product breadth 
Is Cardinal Health s stock price decline news or noise 
If the drop in Cardinal Health s stock price was driven by short term factors that have no bearing on the company s long term earnings outlook  and the stock s valuation now looks reasonable   this week s events could be a buying opportunity for long term dividend investors 
However  I think the issues weighing on Cardinal Health could structurally impact the company s future profitability and growth opportunities 
Let s start with the main issue   declining profitability in Cardinal Health s Pharmaceutical segment  which generates 85  of profits 
Cardinal Health benefited from the boom in generic drugs over the past five years  Tens of billions of dollars worth of brand name drugs lost patent protection in 2012  for example  resulting in a boom in generic competition over the following years 
Generic drugs carry higher margins for Cardinal Health compared to branded drugs  As generic drug pricing increased  the company enjoyed a boost to its gross profits 
However  the tide is now going back out  Most of the entire pharmaceutical value chain is under pressure to cut costs and make healthcare more affordable 
Many pharma businesses are moderating price increases on their drugs in response to increased political pressure  Generic drug prices have also been hit by because of faster approvals by the Food and Drug Administration  resulting in more generic drug supply  and a price fixing investigation  according to The Wall Street Journal 
The Wall Street Journal went on to note that  drug distributors had feasted for years on stable or rising drug prices  which allow them to more easily mark up prices while profiting by arbitraging annual price increases  Now  the more rapidly prices fall  the more difficult it becomes for distributors like Cardinal to resell drugs from manufacturers to pharmacies at a profit  
Equally important  pharmacies have meaningfully consolidated in recent years as they faced increased margin pressure from lower reimbursement rates 
As a result  they have been able to exert more pressure on the prices they pay Cardinal Health for the drugs it resells to them  In fact  Cardinal Health s CEO noted on the company s earnings call that pricing pressures are on the  sell side downstream to the customers  It s still a little bit more than what we modeled  
I think the economics of the drug distribution business are structurally changing  A company like Cardinal Health will always play a role  but the middlemen seem increasingly likely to bear the brunt of healthcare reform and sell side consolidation 
DrugChannels net provided an excellent review of the margin pressures that wholesale distributors face 
Assuming sell side price pressure remains high  there is increased risk that competition will only increase between the three companies that control almost all of the drug distribution business  McKesson  NYSE MCK  and AmerisourceBergen  NYSE ABC  are the other two  
Since distribution is largely a scale game  these rivals might battle even harder with each other for market share  and the stakes are high 
For example  CVS Health  NYSE CVS  accounted for 25  of Cardinal Health s sales last year  and two group purchasing organizations  GPOs  combined for another 17  of revenue  Losing major customers or having to further concede on pricing to retain them could really impact the company s bottom line  especially if Cardinal Health is unable to negotiate better terms with its drug manufacturers 
Management s decision to take on substantial debt to acquire some of Medtronic s medical products is another signal that Cardinal Health s core pharma distribution business might not have the favorable long term outlook that the company once thought  thus there was increased pressure to diversify  
I am not a medical products expert  but this seems to be a price sensitive business that can be challenging to compete in  I m not sure that Cardinal Health will have much of a durable competitive advantage here either 
Closing Thoughts on Cardinal Health
The healthcare sector is undergoing a number of structural changes  many of which seem likely to continue causing disruption for drug distributors such as Cardinal Health 
The issues that caused the drop in Cardinal Health s stock price seem more like news than noise to me  and the increasing complexities of the drug distribution chain only further serve to keep me out of the stock 
I would rather own businesses with greater pricing power and more controllable competitive advantages  Drug distributors seem to be largely commodity type businesses  and their margins could be further squeezed as both drug buyers and manufacturers look to preserve their margins in an increasingly cost conscious healthcare world 
I expect Cardinal Health to retain its favorable Dividend Safety Score  indicating that its payout remains very secure  but I have my doubts about the company s long term growth profile 
While the stock s forward P E multiple of about 14 looks tempting  I think Cardinal Health is cheap for a reason ",2017-04-23,Modest Money,https://www.investing.com/analysis/dividend-aristocrat-cardinal-health-(cah)-drops-12--buying-opportunity-200184465,200184465
103509,325024,ABC,AmerisourceBergen  ABC  Q2 Earnings  Will It Disappoint ,opinion,"AmerisourceBergen Corp    NYSE ABC   is set to report second quarter fiscal 2017 results on May 4  before the opening bell AmerisourceBergen s track record has been quite impressive  with the company comfortably beating estimates in each of the trailing four trailing quarters  In the last reported quarter  it delivered a positive earnings surprise of 9 68   bringing the four quarter average to 7 66   Let s see how things are shaping up prior to this release Factors at PlayAmerisourceBergen s pharmaceutical distribution segment continues to face headwinds in the form of contract renewals and lower generic inflation  The AmerisourceBergen Drug Corporation   ABDC   business is also being hurt by several factors  including accelerating deflation of generic drugs and lower contribution from generic launches Although generic inflation has been nominal  the rate of deflation is rising gradually  These factors  combined with an anticipated shift in product mix toward lower margin and higher priced specialty and branded drugs  and lack of generic inflation will adversely impact the bottom line However  the company renewed its relationship with the largest health systems  customer and has been making persistent efforts to address the headwinds in the ABDC segment  This can boost the top line to some extent in the fiscal second quarter Over the past three months  AmerisourceBergen lost almost 6 30   which is higher than the Zacks categorized  sub industry s gain of roughly 6 55   Also  AmerisourceBergen is apprehensive about its earnings and revenue growth expectations for fiscal 2017 due to the uncertainty surrounding drug pricing trends  The company currently expects fiscal 2017 revenue growth in the range of 6 5  to 8   The company expects adjusted diluted earnings per share for fiscal 2017 in the range of  5 72 to  5 92 AmerisourceBergen Corporation  Holding Co  Price and EPS Surprise
    Earnings WhispersOur quantitative model doesn t point to an earnings beat this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP  The Earnings ESP for AmerisourceBergen is  1 75   This is because the Most Accurate estimate stands at  1 68 and the Zacks Consensus Estimate stand at  1 71  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  AmerisourceBergen carries a Zacks Rank  3 which increases the predictive power of ESP  However  the company s ESP of  1 75  makes surprise prediction difficult We caution against stocks with a Zacks Ranks  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are some companies you may want to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter Best Buy Co  Inc    NYSE BBY   has an Earnings ESP of  12 50  and a Zacks Rank  3  On average  the stock delivered a positive surprise of almost 27 70  in the last four quarters Global Partners LP   NYSE GLP   delivered a positive surprise of almost 96 55  in the trailing four quarters  It has an Earnings ESP of  233 33  and a Zacks Rank  1  You can see  Raymond James Financial  Inc    NYSE RJF   has an Earnings ESP of  3 45  and a Zacks Rank  1  The stock delivered a positive surprise of almost 14 4  in the last four trailing quarters 5 Trades Could Profit   Big League   from Trump Policies If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-05-01,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-(abc)-q2-earnings:-will-it-disappoint-200186588,200186588
103510,325025,ABC,AmerisourceBergen  ABC  Beats On Q2 Earnings  Lags Revenues,opinion,"AmerisourceBergen Corporation   NYSE ABC   posted adjusted earnings of  1 77 per share in the second quarter of fiscal 2017  beating the Zacks Consensus Estimate of  1 71 and increasing 5 4  on a year over year basis  The upside was primarily driven by a lower tax rate Revenues improved almost 4  to  37 1 billion in the reported quarter  However  reported revenues were lower than the Zacks Consensus Estimate of  38 3 billion AmerisourceBergen Corporation  Holding Co  Price  Consensus and EPS Surprise
    Stock Price   Estimate Revision TrendAmerisourceBergen has had an impressive run on the bourse over the last six months  The company gained roughly 15   higher than the Zacks categorized  sub industry s addition of almost 11 9  Moreover  the current level compares favorably with the S P 500 s return of 12 7  over the same time frame  This  together with a long term expected earnings growth rate of 9 1   instills confidence in investors However  the estimate revision for the stock has been unfavorable  Two analysts moved downward over the last one month  compared to one movement in the opposite direction  As a result  the current year estimates fell 0 2  to  5 82 AmerisourceBergen carries a Zacks Rank  3  Hold  Revenue SegmentsPharmaceutical Distribution segment  In the reported quarter  revenues at the segment increased 4  to  35 5 billion  Within the segment  AmerisourceBergen Drug Corp  revenues were up 3 6   primarily on the back of solid organic sales growth The AmerisourceBergen Specialty Group unit in the segment performed impressively during the quarter  with revenues rising 11  year over year  courtesy of strong oncology product sales and solid performance by the third party logistics business Other segment  This segment includes AmerisourceBergen Consulting Services  ABCS   World Courier and MWI Veterinary Supply  Revenues at the segment came in at  1 7 billion  up 6  on a year over year basis Operating PerformanceOperating expenses  as a percentage of revenues  in the second quarter were 1 57   compared to 1 61  in the year ago quarter Operating income  as a percentage of revenue  contracted 8 basis points  bps  to 1 58  in the quarter under review As a percentage of revenues  gross profit declined 12 bps in the reported quarter on a year over year basis to 3 15  GuidanceAmerisourceBergen expects fiscal 2017 revenue growth in the range of 5 5  to 6 5   significantly lower than the previously provided band of 6 5  to 8  The company expects adjusted diluted earnings per share for fiscal 2017 in the band of  5 77 to  5 92  up from the previously provided  5 72 to  5 92 Meanwhile  AmerisourceBergen expects brand drug inflation in the range of 7  to 9  Key PicksBetter ranked stocks in the broader medical sector include Neovasc Inc    NASDAQ NVCN    Hologic  Inc    NASDAQ HOLX   and Sunshine Heart Inc   NASDAQ SSH    Notably  Neovasc and Hologic sport a Zacks Rank  1  Strong Buy   while Sunshine Heart has a Zacks Rank  2  Buy   You can see  Hologic has a long term expected earnings growth rate of 11 33   The stock has a solid one year return of roughly 33 6  Sunshine Heart posted a positive earnings surprise of 58 24  in the last reported quarter  The stock recorded a stellar EPS growth rate  last 3 5 years of actual earnings  of almost 22  Neovasc saw a stellar gain of 11 8  over the last three months  The company projects sales growth of 102 88  for the current year Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2017-05-03,Zacks Investment Research,"https://www.investing.com/analysis/amerisourcebergen-(abc)-beats-on-q2-earnings,-lags-revenues-200187099",200187099
103516,325031,ABC,AmerisourceBergen  ABC  Up 7 6  Since Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for AmerisourceBergen Corporation  Holding Co    NYSE ABC    Shares have added about 7 6  in that time frame  outperforming the market 
Will the recent positive trend continue leading up to the stock s next earnings release  or is it due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts AmerisourceBergen Beats on Q2 Earnings  Lags RevenuesAmerisourceBergen Corporation posted adjusted earnings of  1 77 per share in the second quarter of fiscal 2017  beating the Zacks Consensus Estimate of  1 71 and increasing 5 4  on a year over year basis  The upside was primarily driven by a lower tax rate Revenues improved almost 4  to  37 1 billion in the reported quarter  However  reported revenues were lower than the Zacks Consensus Estimate of  38 3 billion Revenue SegmentsPharmaceutical Distribution segment  In the reported quarter  revenues at the segment increased 4  to  35 5 billion  Within the segment  AmerisourceBergen Drug Corp  revenues were up 3 6   primarily on the back of solid organic sales growth The AmerisourceBergen Specialty Group unit in the segment performed impressively during the quarter  with revenues rising 11  year over year  courtesy of strong oncology product sales and solid performance by the third party logistics business Other segment  This segment includes AmerisourceBergen Consulting Services  ABCS   World Courier and MWI Veterinary Supply  Revenues at the segment came in at  1 7 billion  up 6  on a year over year basis Operating PerformanceOperating expenses  as a percentage of revenues  in the second quarter were 1 57   compared to 1 61  in the year ago quarter Operating income  as a percentage of revenue  contracted 8 basis points  bps  to 1 58  in the quarter under review As a percentage of revenues  gross profit declined 12 bps in the reported quarter on a year over year basis to 3 15  GuidanceAmerisourceBergen expects fiscal 2017 revenue growth in the range of 5 5  to 6 5   significantly lower than the previously provided band of 6 5  to 8  The company expects adjusted diluted earnings per share for fiscal 2017 in the band of  5 77 to  5 92  up from the previously provided  5 72 to  5 92 Meanwhile  AmerisourceBergen expects brand drug inflation in the range of 7  to 9  
How Have Estimates Been Moving Since Then  
Analysts were quiet during the last one month period as none of them issued any earnings estimate revisions AmerisourceBergen Corporation  Holding Co  Price and Consensus
    VGM Scores
At this time  AmerisourceBergen s stock has a nice Growth Score of  B   though it is lagging a lot on the momentum front with a  D   However  the stock was allocated a grade of  A  on the value side  putting it in the top quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of  A   If you aren t focused on one strategy  this score is the one you should be interested in 
Based on our scores  the stock is more suitable for value investors than growth investors 
Outlook
The stock has a Zacks Rank  3  Hold   We are expecting an inline return from the stock in the next few months ",2017-06-07,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-(abc)-up-7.6-since-earnings-report:-can-it-continue-200194073,200194073
103517,325032,ABC,Is AmerisourceBergen  ABC  Stock A Good Value Pick Now ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put AmerisourceBergen Corporation   NYSE ABC   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  AmerisourceBergen has a trailing twelve months PE ratio of 16 49  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 stands at about 20 34  If we focus on the long term PE trend  AmerisourceBergen s current PE level puts it below its midpoint over the past five years  Moreover  the current level is fairly below the highs for this stock  suggesting it might be a good entry point Further  the stock s PE also compares favorably with the Zacks classified Medical   Dental Supplies industry s trailing twelve months PE ratio  which stands at 19 85  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers We should also point out that AmerisourceBergen has a forward PE ratio  price relative to this year s earnings  of just 15 90  so it is fair to say that a slightly more value oriented path may be ahead for AmerisourceBergen stock in the near term too P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  AmerisourceBergen has a P S ratio of about 0 14  This is significantly lower than the S P 500 average  which comes in at 3 15 right now  Also  as we can see in the chart below  this is below the highs for this stock in particular over the past few years As we can see  the stock is trading around its median value for the time period from a P S metric  This does not provide us with a conclusive direction as to the relative valuation of the stock in comparison to its historical trend Broad Value OutlookIn aggregate  AmerisourceBergen currently has a Zacks Value Style Score of  A   putting it into the top 20  of all stocks we cover from this look  This makes AmerisourceBergen a solid choice for value investors  and some of its other key metrics make this pretty clear too For example  the PEG ratio for AmerisourceBergen is just 1 64  a level that is lower than the industry average of 2 11  The PEG ratio is a modified PE ratio that takes into account the stock s earnings growth rate  Additionally  its P CF ratio  another great indicator of value  comes in at 7 82  which is far better than the industry average of 13 92  Clearly  ABC is a solid choice on the value front from multiple angles What About the Stock Overall Though AmerisourceBergen might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth grade of  B  and a Momentum score of  C   This gives ABC a Zacks VGM score or its overarching fundamental grade of  A    You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been mixed at best  The current fiscal quarter has seen one estimate go higher in the past sixty days compared to four lower  while the fiscal full year estimate has seen three upward and two downward revisions in the same time period As a result  the current fiscal quarter consensus estimate has fallen by 2 1  in the past two months  while the fiscal full year estimate has inched up by 0 2   You can see the consensus estimate trend and recent price action for the stock in the chart below AmerisourceBergen Corporation  Holding Co  Price and Consensus    This somewhat mixed trend is why the stock has just a Zacks Rank  3  Hold  and why we are looking for in line performance from the company in the near term Bottom LineAmerisourceBergen is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  Moreover  a strong industry rank  Top 29  out of more than 250 industries  further supports the growth potential of the stock  In fact  over the past three years  the Zacks Medical   Dental Supplies industry has outperformed the broader market  as you can see below However  with a Zacks Rank  3  it is hard to get too excited about this company overall  So  value investors might want to wait for estimates and analyst sentiment to turn around in this name first  but once that happens  this stock could be a compelling pick  Moreover  broader factors at the industry level support the growth potential of the company as well Looking for Ideas with Even Greater Upside Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ,2017-06-21,Zacks Investment Research,https://www.investing.com/analysis/is-amerisourcebergen-(abc)-stock-a-good-value-pick-now-200196881,200196881
103518,325033,ABC,AmerisourceBergen  ABC  Beats On Q3 Earnings  Revenues Lag,opinion,"AmerisourceBergen Corporation   NYSE ABC   posted adjusted earnings of  1 43 per share in the third quarter of fiscal 2017  beating the Zacks Consensus Estimate of  1 37 and increasing 4 4  on a year over year basis  The upside was primarily driven by strong growth in its Consulting Services  MWI Animal Health and World Courier businesses Revenues improved almost 4 9  to  38 7 billion in the reported quarter  However  reported revenues were lower than the Zacks Consensus Estimate of  39 3 billion Revenue SegmentsPharmaceutical Distribution segment  In the reported quarter  revenues at the segment increased 4 7  to  37 0 billion  Within the segment  AmerisourceBergen Drug Corp  revenues were up 4 5   primarily on the back of solid organic sales growth The AmerisourceBergen Specialty Group unit in the segment performed impressively during the quarter  with revenues rising 10 3  year over year  The increase can be attributed to strong oncology product sales and solid performance by the third party logistics business Other segment  This segment includes AmerisourceBergen Consulting Services  ABCS   World Courier and MWI Veterinary Supply  Revenues at the segment came in at  1 7 billion  up 10 6  on a year over year basis Operating PerformanceOperating expenses  as a percentage of revenues  in the third quarter were 2 35  compared with 1 57  in the year ago quarter Operating income  as a percentage of revenue  contracted 99 basis points  bps  to 0 44  in the quarter under review As a percentage of revenues  gross profit declined 21 bps in the reported quarter on a year over year basis to 2 79  AmerisourceBergen Corporation  Holding Co  Price  Consensus and EPS Surprise
    GuidanceAmerisourceBergen expects fiscal 2017 revenue growth in the range of approximately 5   significantly lower than the previously provided band of 5 5  to 6 5  The company expects adjusted diluted earnings per share for fiscal 2017 in the band of  5 82 to  5 92  up from the previously provided  5 77 to  5 92 The company expects brand drug inflation in the range of 7  to 9  Zacks Rank   Stocks to ConsiderAmerisourceBergen has a Zacks Rank  4  Sell  Better ranked medical stocks include Edwards Lifesciences Corporation   NYSE EW    Abiomed Inc    NASDAQ ABMD   and Fresenius Medical Care Corporation   NYSE FMS    Fresenius Medical Care and Edwards Lifesciences sport a Zacks Rank  1  Strong Buy   while Abiomed has a Zacks Rank  2  Buy   You can see  Edwards Lifesciences has a long term expected earnings growth rate of 15 2   The stock has a one year return of 1 5  Abiomed delivered a strong return of 23 4  over the last one year  The stock has a long term expected earnings growth rate of 30 5  Fresenius Medical Care represents a return of 2 5  over the last one year  The company delivered a solid earnings surprise of 20 5  in the last reported quarter More Stock News  Tech Opportunity Worth  386 Billion in 2017From driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity  Most importantly  it reveals 4 stocks with massive profit potential ",2017-08-03,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-abc-beats-on-q3-earnings-revenues-lag-200205067,200205067
103554,325069,ABC,VWR Posts Inline Earnings In Q2  Revenues Beat The Mark,opinion,"VWR Corporation   NASDAQ VWR   reported second quarter 2016 adjusted earnings per share  EPS  of 42 cents  reflecting a 23 5  rise from the year ago quarter  The quarter s earnings  however  remained at par with the Zacks Consensus Estimate  We note that  strong top line growth prompted the year over year growth in earnings 
Including one time items  the company reported second quarter 2016 net EPS of 32 cents  a 128 6  surge year over year 
Revenues in the reported quarter were up 6 3  year over year at  1 15 billion  Revenues edged past the Zacks Consensus Estimate of  1 14 billion  Foreign exchange headwinds impacted revenues by 0 3  year over year  On an organic basis  revenues increased 4 4   while recent acquisitions boosted revenues by 2 2  

Revenues in the Americas totalled  694 9 million  up 6 6  year over year  up 3 9  organically  in the second quarter  The top line increase was supported by strong biopharma performance  on high single digits on growth in large pharma  biotech  medical devices and sales to CRO customers 
EMEA APAC revenues in the second quarter were  454 6 million  up 5 9  year over year  up 5 1  year over year on an organic basis   on strong sales to biopharma and industrial customers  EMEA APAC performance was also benefitted from a shift in the timing of Easter 
VWR reported a gross margin of 28 1   up 53 basis points  bps  year over year  on account of a stable pricing environment  favorable product mix and solid growth in private label and services  Sales  general and administrative expenses rose 8 1  to  238 8 million  VWR posted operating income of  84 6 million in the reported quarter  reflecting a 9  rise from the year ago quarter  Accordingly  operating margin expanded 18 bps to 7 4  in the quarter under review 
VWR exited the second quarter with cash and cash equivalents of  112 9 million  down from  129 7 million at the end of the first quarter  Year to date operating cash flow was  119 6 million  compared with  97 1 million in the year ago period VWR CORP Price  Consensus and EPS Surprise
   Outlook
VWR reiterated its 2016 earnings guidance of adjusted EPS in the band of  1 68  1 74  annualized growth of 11  to 15   
Our Take
VWR posted a moderate second quarter with earnings in line with the Zacks Consensus Estimate and revenues ahead of the mark  Segment wise  management witnessed strong sales growth in both Americas as well as the EMEA APAC region  accompanied by strong growth in equipment and instrumentation  The extent of currency fluctuations on the company s EMEA APAC sales was low in the second quarter  On the profitability front  VWR posted slightly improved margin figures in spite of the competitive landscape 
Zacks Rank   Key Picks
Currently  the company bears a Zacks Rank  4  Sell   Better ranked medical stocks are Align Technology Inc    NASDAQ ALGN    AmerisourceBergen Corporation   NYSE ABC   and DENTSPLY International Inc    NASDAQ XRAY    All the three stocks carry a Zacks Rank  2  Buy  ",2016-08-05,Zacks Investment Research,"https://www.investing.com/analysis/vwr-posts-inline-earnings-in-q2,-revenues-beat-the-mark-200146446",200146446
103555,325070,ABC,3 Stock Picks For Aug 23  ABC  STX And VFC,opinion,"AmerisourceBergen  NYSE ABC  As a holding company  the AmerisourceBergen Corporation markets pharmaceutical products and health systems on the American market  Since the AmerisourceBergen Corporation does not produce any medicinal products itself  its main tasks consist in the storage and nation wide distribution of these products  In April of last year  this stock met an early high at approx   120  After the break of the last point three at  93 60  this stock transitioned into a valid downtrend  The current course low is located at  73 31  the correction zone runs between  80 50 and  92 48  In the last few days  the price came very close to the upper edge of the red box  where it is now forming our DowHow signals  This could definitely be a sign for a renewed trend continuation 
Seagate  STX  Seagate Technology  NASDAQ STX  LLC is one of the leading manufacturers of hard drives  The company offers internal and external storage solutions for notebooks as well as desktop computers  The focal point of the group lies in the development and distribution of storage media for companies  which aims to be applicable irrespective of the branch  The chart of the technology company has also been in a stable downward trend for quite some time  however  this trend is now quickly reaching maturity  We are currently in the 7th correction  and the DowHow signals are displaying an 8th movement  As long as the price does not leave the red zone by means of the closing price  this trend can absolutely continue on once more 
Consumer Goods  VFC  VF Corporation  NYSE VFC  is one of the leading global retail companies in the clothing industry  It regularly has its own designers develop new products  which it then manufactures and markets via department stores and specialised trend stores  Among the branded goods produced are  for example  jeans  Wrangler  Lee   lingerie  children s clothing  sporting goods  outdoor clothing  Timberland  Napapijri  The North Face  etc   as well as products for the lines 7 for all Mankind  Ella Moss or splendid  Although the chart for this company was not quite able to withdraw from the current correction  it fared better than several other companies  The price is currently in its last valid correction zone  where it has been forming new DowHow signals over the past couple of days  This makes a trend continuation very probable  However  the price also still has a little more potential for recovery  since the end of the correction box is only at about  70 35  Patience may well pay off here 
Disclaimer 
Exchange transactions are associated with significant risks  Those who trade on the financial and commodity markets must familiarize themselves with these risks  Possible analyses  techniques and methods presented here are not an invitation to trade on the financial and commodity markets  They serve only for illustration  further education  and information purposes  and do not constitute investment advice or personal recommendations in any way  They are intended only to facilitate the customer s investment decision  and do not replace the advice of an investor or specific investment advice  The customer trades completely at his or her own risk ",2016-08-23,Markus Gabel,"https://www.investing.com/analysis/trading-opportunities-for-abc,-stx-and-vfc---stock-picking-200149508",200149508
103556,325071,ABC,AmerisourceBergen  ABC  Q3 Earnings  Will It Disappoint ,opinion,AmerisourceBergen Corporation   NYSE ABC   is set to report fourth quarter and fiscal 2016 results on Nov 2  before the opening bell AmerisourceBergen s track record has been quite impressive  with the company comfortably beating estimates in three of the four trailing quarters  In the last reported quarter  it recorded a positive earnings surprise of 8 73   bringing the four quarter average to 3 79  AMERISOURCEBRGN Price and EPS Surprise    Let s see how things are shaping up for this announcement Factors Influencing this QuarterAmerisourceBergen s pharmaceutical distribution segment continues to face headwinds in the form of contract renewals and lower generic inflation  The AmerisourceBergen Drug Corporation  ABDC  business is also being hurt by several factors  including accelerating deflation of generic drugs and lower contribution from generic launches  Although generic inflation has been nominal  the rate of deflation is rising gradually  These factors  combined with an anticipated shift in product mix toward lower margin and higher priced specialty and branded drugs  and the lack of generic inflation  will adversely impact the bottom line  Moreover  incremental expenses related to some key investments in the company s information technology systems and infrastructure are expected to dampen growth in the near term However  the company renewed its relationship with the largest health systems customer for an additional five years in the second quarter and has been making persistent efforts on addressing the headwinds in ABDC segment  This can boost the top line to an extent in the fourth quarter We also remind investors that at the third quarter conference call  AmerisourceBergen raised its earnings guidance for the fiscal 2016  to the range of  5 52  5 57 from the previous projection of  5 44  5 54 What Our Model IndicatesOur proven model does not conclusively show that AmerisourceBergen is likely to beat earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to be able to beat estimates  Unfortunately  that is not the case  as you will see below Zacks ESP  The Earnings ESP for AmerisourceBergen is  0 82   as the Most Accurate estimate and the Zacks Consensus Estimate stand at  1 21 and  1 22  respectively  Please check our that enables you find stocks that are expected to come out with earnings surprises Zacks Rank  AmerisourceBergen carries a Zacks Rank  4  As it is  we caution against stocks with a Zacks Rank  4 or  5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks That Warrant a LookHere are a few companies that you may want to consider instead  as our model shows that they have the right combination of elements to post an earnings beat this quarter Ariad Pharmaceuticals Inc    NASDAQ ARIA   is expected to report earnings on Nov 1 The company has an Earnings ESP of  5 26  and a Zacks Rank  1  You can see ImmunoGen  Inc    NASDAQ IMGN   has an Earnings ESP of  5 41  and a Zacks Rank  3  The company is scheduled to report third quarter results on Oct 28 Infinity Pharmaceuticals  Inc    NASDAQ INFI   has an Earnings ESP of  5 81  and a Zacks Rank  1  The company is scheduled to report results on Nov 3 Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-26,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-(abc)-q3-earnings:-will-it-disappoint-200161090,200161090
103557,325072,ABC,Moving Average Crossover Alert  AmerisourceBergen  ABC ,opinion,AmerisourceBergen Corporation   NYSE ABC   could be a stock to avoid from a technical perspective  as the firm is seeing unfavorable trends on the moving average crossover front  Recently  the 50 Day Moving Average for ABC broke out below the 200 Day Simple Moving Average  suggesting short term bearishness This has already started to take place  as the stock has moved lower by 12 2  in the past four weeks  And with the recent moving average crossover  investors have to think that more unfavorable trading is ahead for ABC stock If that wasn t enough  AmerisourceBergen isn t looking too great from an earnings estimate revision perspective either  It appears as though many analysts have been reducing their earnings expectations for the stock lately  which is usually not a good sign of things to come Consider that in the last 30 days  3 estimates have been reduced  while none has moved higher  Add this in to a similar move lower in the consensus estimate  and there is plenty of reason to be bearish here That is why we currently have a Zacks Rank  4  Sell  on this stock and are looking for it to underperform in the weeks ahead  So either avoid this stock or consider jumping ship until the estimates and technical factors turn around for ABC  You can see  Confidential from Zacks Beyond this Tale of the Tape  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-31,Zacks Investment Research,https://www.investing.com/analysis/moving-average-crossover-alert:-amerisourcebergen-(abc)-200162018,200162018
103593,325108,ABC,Big Data Short Week Continues,opinion,Wednesday  July 6  2016The big data short week narrative continues this morning  two days ahead of the big June Jobs Report that investors and economists will be watching very closely  Until that time  we have plenty to chew on Today ahead of the bell we see a May Trade Deficit in the U S  of  41 1 billion  up from April s read of  37 4 billion  No alarm bells sounded in he immediate aftermath  the Dow  Nasdaq and S P 500 were  101   29 and  12 points  respectively  ahead of the release  and are  108   31 and  13 since We will spend more time considering the results of ISM Services  Non Manufacturing  data at 9am CT today  These numbers have been trading downward as of late  and analysts are looking for a figure somewhere around 53  over 50 indicates expansion   The ISM Manufacturing survey last Friday surprised to the upside  but the U S  economy is far more Services than Manufacturing driven these days  so today s report is the more consequential Later today   1pm Central  to be exact   the latest minutes from the Federal Open Market Committee  FOMC  will be released  giving some insight into why the Fed resisted raising interest rates another quarter percent  This most recent meeting last month followed the heavily disappointing May Jobs Report  which showed the U S  only gaining 38K jobs  more than 100K off estimates  Many observers maintain that this poor employment showing helped seal the fate to keep interest rates unchanged in June  and perhaps all summer  maybe beyond   but today s minutes will tell us for sure Normally in the first full week of a new month  Wednesday awaits the ADP    NASDAQ ADP    private sector jobs report  but this Independence Day shortened week is pushing this read back until tomorrow  Part of the big jobs miss last month was due to the May ADP read which saw 173K private sector jobs in the month  We look to either see a big adjustment either when ADP reports these June numbers before the bell or on Friday s BLS non farm payroll report  Over time  these two reports tend to move in line We are still a week away from the big first week of Q2 earnings  but we get a taste this morning with Walgreens Boots Alliance    NASDAQ WBA    posting sales improvements year over year  but lower than consensus expectations  Earnings were down year over year  but Walgreens is operating with lots of moving parts these days  it has ended its alliance with maligned pharma company Theranos  as well as the  9 4 billion acquisition of Rite Aid  expected to close sometime in 2H 2016  and Walgreens attempt to buy a significant stake in AmerisourceBergen    NYSE ABC    Mark VickerySenior Editor,2016-07-05,Zacks Investment Research,https://www.investing.com/analysis/big-data-short-week-continues-200140330,200140330
103594,325109,ABC,May Trade Deficit Up,opinion,"The big data short week narrative continues this morning  two days ahead of the big June Jobs Report that investors and economists will be watching very closely  Until that time  we have plenty to chew on 

Today ahead of the bell we see a May Trade Deficit in the U S  of  41 1 billion  up from April s read of  37 4 billion  No alarm bells sounded in he immediate aftermath  the Dow  Nasdaq and S P 500 were  101   29 and  12 points  respectively  ahead of the release  and are  108   31 and  13 since 

We will spend more time considering the results of ISM Services  Non Manufacturing  data at 9am CT today  These numbers have been trading downward as of late  and analysts are looking for a figure somewhere around 53  over 50 indicates expansion   The ISM Manufacturing survey last Friday surprised to the upside  but the U S  economy is far more Services than Manufacturing driven these days  so today s report is the more consequential 

Later today   1pm Central  to be exact   the latest minutes from the Federal Open Market Committee  FOMC  will be released  giving some insight into why the Fed resisted raising interest rates another quarter percent  This most recent meeting last month followed the heavily disappointing May Jobs Report  which showed the U S  only gaining 38K jobs  more than 100K off estimates  Many observers maintain that this poor employment showing helped seal the fate to keep interest rates unchanged in June  and perhaps all summer  maybe beyond   but today s minutes will tell us for sure 

Normally in the first full week of a new month  Wednesday awaits the ADP    private sector jobs report  but this Independence Day shortened week is pushing this read back until tomorrow  Part of the big jobs miss last month was due to the May ADP read which saw 173K private sector jobs in the month  We look to either see a big adjustment either when ADP reports these June numbers before the bell or on Friday s BLS non farm payroll report  Over time  these two reports tend to move in line 

We are still a week away from the big first week of Q2 earnings  but we get a taste this morning with Walgreens Boots Alliance  NASDAQ WBA     posting sales improvements year over year  but lower than consensus expectations  Earnings were down year over year  but Walgreens is operating with lots of moving parts these days  it has ended its alliance with maligned pharma company Theranos  as well as the  9 4 billion acquisition of Rite Aid  expected to close sometime in 2H 2016  and Walgreens attempt to buy a significant stake in AmerisourceBergen  NYSE ABC     ",2016-07-05,Zacks Investment Research,https://www.investing.com/analysis/may-trade-deficit-up-200140287,200140287
103595,325110,ABC,Zacks com Featured Highlights  Asbury Automotive Group  AmerisourceBergen  AutoNation  Global Brass   Copper And Bunge,opinion,"For Immediate Release

Chicago  IL   July 07  2016   Stocks in this week s article include   Asbury Automotive Group  Inc      AmerisourceBergen  NYSE ABC      AutoNation  NYSE AN   Inc      Global Brass   Copper Holdings  Inc       and Bunge Ltd     

Screen of the Week of Zacks Investment Research  

5 Stocks Set to Gain from Recent Broker Rating Upgrades

Sometimes in life  one ends up taking incorrect decisions in the absence of proper guidance  The same is often true in the investing world  With stocks flooding the investing space  it is very hard if not impossible for investors to add the right bunch to their portfolio for handsome returns without proper pointers 

After all  no one wants to see his hard earned money go down the drain  which is usually the result if one invests in stocks arbitrarily  To avoid such a fiasco  one should pay heed to what analysts are saying about a stock before investing in it 

Of the three types of analysts  sell side  buy side and independent  present in the investment world  sell side analysts are most common  Various brokerage firms employ them to provide unbiased opinion to investors after thorough research  Buy side analysts are employed by hedge funds  mutual funds etc  while the independent ones simply sell their reports to investors  So  an analyst  irrespective of the type  does extensive research on the company s  followed 

Broker Ratings Hold the Key to Buy Sell Decisions

Given the time crunch that we all face  it is impossible for investors to follow each stock minutely  So  it is best to follow expert advice  Brokers  by virtue of their detailed study  are armed with information on various aspects of the companies they follow  They have a lot more information on a company and its prospects than normal people as they not only scrutinize publicly available financial documents but also attend company conference calls and other presentations 

Since brokers arrive at their recommendation  buy  sell or hold  on a stock after thoroughly analyzing the nitty gritties associated with the company  it is natural that if investors them improving their recommendation on a particular stock  they are inclined to believe that there is a solid reason logic behind it  In fact  a rating upgrade generally leads to stock price appreciation  Similarly  the price of a stock may plummet following a rating downgrade 

For example  in the event of oil prices plummeting  analysts are likely to become bullish on an airline stock which might lead them to raise their earnings estimates and improve their target price  The bullish stance adopted by analysts on the stock serves as an important guide for investors on whether they should spend their hard earned money on it  On the other hand  in the event of estimates moving south  which can happen due to lower than expected earnings modest sales or pipeline failure  for a biotech company   investors tend to offload the stock from their portfolio 

The Winning Strategy

Our screen based on improving analyst recommendation and upward revisions to earnings estimates over the last four weeks takes care of the bottom line performance of stocks  But what about the top line  To take care of its revenue performance  we have included the price sales ratio which serves as a strong complementary valuation metric 

Screening Criteria

   Up  Down Rating   Total  4 weeks   Top  75   This gives the list of top 75 companies that have witnessed net upgrades over the last 4 weeks 

  change in Q  1  est   4 weeks    Top  10   This gives the top 10 stocks that have witnessed earnings estimate revisions over the past 4 weeks for the upcoming quarter 

To ensure that the strategy is a full proof and winning one  we have added the following screening parameters 

Price to Sales   Bot 10   The lower the ratio the better  companies meeting this criteria are in bottom 10  of our universe of over 7 700 stocks with respect to this ratio 

Price greater than 5   A stock trading below  5 will not likely create significant interest for mostinvestors 

Average Daily Volume greater than 100 000 shares over the last 20 trading days   Volume has to be significant to ensure that these are easily traded 

Market value    mil    Top  3000   This gives us stocks that are the top 3000 if one judges by market capitalization 

Com ADR Canadian  Com   This takes out the ADR and Canadian stocks 

Here are five of the 10 stocks that made it through the screen 

Asbury Automotive Group  Inc        Headquartered in Duluth  GA  Asbury Automotive is a premium auto dealership company  Increasing employment  auto credit facilities and higher per capita disposable income levels give the company scope for growth  The 2016 earnings per share growth rate for the company is 9 10   a lot higher than the industry average 

AmerisourceBergen       Headquartered in Chesterbrook  PA  this is one of the world s largest pharmaceutical services companies  which focuses on providing drug distribution and related services to reduce health care costs and improve patient outcome  The company has an impressive track record with respect to earnings  having surpassed the Zacks Consensus Estimate in three of the last four quarters by an average of 2 69  

AutoNation  Inc        The company  based in Fort Lauderdale  FL  is the largest automotive retailer in the U S  and about twice the size of its nearest competitor  The company also offers vehicle maintenance and repair services  vehicle parts  extended service contracts  vehicle protection products and other aftermarket products  In addition  it arranges financing for vehicle purchases through third party sources  The company s 2016 earnings are projected to grow at 7 30   which is higher than the industry average of 5 50  

Global Brass   Copper Holdings  Inc        The company  based in Schaumburg  IL  is a converter  fabricator  distributor and processor of copper and brass products primarily in North America  The company also engages in metal melting and casting  rolling  drawing  extruding and stamping to fabricate finished and semi finished alloy products  The company s 2016 earnings are projected to grow at 4 10   which compares favorably to the industry average of a loss of 3 10  

Bunge Ltd        Based in White Plains  NY  Bunge is a leading agribusiness and food company with over 35 000 employees and operations in about 40 countries  It is a global leader in oilseed processing  and grain   oilseed marketing  The company s 2016 earnings are projected to grow at 10 60   which is higher than the industry average of 9 90  

You can get the rest of the stocks on this list by signing up now for your 2 week free trial to the Research Wizard and start using this screen in your own trading  Further  you can also create your own strategies and test them first before taking the investment plunge 

The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out 

  

Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material 

Disclosure  Performance information for Zacks  portfolios and strategies are available at   

Zacks Restaurant Recommendations    In   addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector  

Sign up now for your free trial today and start picking better stocks immediately  And with the backtesting feature  you can test your ideas to see how you can improve your trading in both up markets and down markets  Don t wait for the market to get better before you decide to do better  Start learning how to be a better trader today  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  

About Screen of the Week 

Zacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine  But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use  Each week  Zacks Profit from the Pros free email newsletter shares a new screening strategy  Learn more about it here 

About Zacks 

Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

Follow us on Twitter  

Join us on Facebook  

Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

Contact  Jim Giaquinto
	Company  Zacks com
	Phone  312 265 9268
	Email  

Visit  

Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer    

Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-07-06,Zacks Investment Research,"https://www.investing.com/analysis/zacks.com-featured-highlights:-asbury-automotive-group,-amerisourcebergen,-autonation,-global-brass---copper-and-bunge-200140558",200140558
103596,325111,ABC,Top 7 Research Reports For July 13  2016,opinion,"Wednesday  July 13  2016
Today s must read reports are for Bristol Myers  BMY   ConocoPhillips  NYSE COP   COP  and eBay  EBAY  
Bristol Myers shares are up  11  year to date  with this Zacks Rank   2  Buy  rated stock getting a boost when its cancer drug  Opdivo  became the first PD 1 immune checkpoint inhibitor to gain regulatory approval anywhere in the world   The analyst likes the company s higher guidance for 2016 and its concerted efforts to develop its pipeline are also encouraging   You can   
Zacks Rank   2  Buy  rated ConocoPhillips shares have been laggards lately  but the analyst likes ConocoPhillips  greater focus on North America  Australia and Asia which is expected to improve its risk profile  Additionally  ConocoPhillips  initiatives towards liquids rich plays are starting to bear fruit buoyed by the Eagle Ford  Bakken and Permian plays   You can   
Despite lingering in the red year to date  shares of eBay have gained more than 5  over the last one month  The analyst likes the Zacks Rank   2  Buy  rated stock s opportunities in the fast growing mobile space  international expansion and a strong balance sheet  The company s concerted efforts to squeeze additional costs out of its operations hold the promise of a boost to margins in the coming quarters   You can   
Other noteworthy reports we are featuring today include Pepsi  PEP   Viacom  VIAB  and Suncor Energy  SU  You can find all of today s stock research reports  
Sheraz Mian
Director of Research
Note  Sheraz Mian regularly provides earnings analysis on Zacks com and appears frequently in the print and electronic media  His weekly earnings related articles include  and   He also provides weekly commentary to subscribers and manages the and portfolios  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read









Featured Reports

Pepsi raised its full year earnings growth target based on strong performance in the first half and a favorable outlook  which encourages the Zacks analyst 


The Zacks analyst thinks Annaly s acquisition of Hatteras is likely to boost its status in the REIT space  


The covering analyst thinks that though Brexit related volatility affected assets under management in June  its solid business model and strong distribution platform support growth prospects 


Chubb expects to incur catastrophe loss of  315 million   390 million pre tax  net of reinsurance and including reinstatement premiums in the second quarter 


Solid performance of key products like Vimizim and Kuvan will drive BioMarin s top line  according to the Zacks analyst  also has a promising pipeline 


Illinois expects its financials to be boosted by Enterprise Strategy and other initiatives  However  the Zacks analyst feels unfavorable currency movements and intense competition might hurt results 


The Zacks analyst thinks despite pressure on expenses  the company stands to benefit from a diverse business model  launch of new funds and substantial liquidity 

New Upgrades

The Zacks Analyst believes Align s expected incremental investments in Invisalign during 2H16 to successfully boost its business in 2016  Recent adoption of digital scanners also buoys optimism 


The covering analyst thinks Suncor s prospects have improved after the company significantly increased its stake in the Syncrude oilsands project  Oil recovery also acts as a catalyst 


AmerisourceBergen should benefit from strategic acquisitions which have diversified its target markets and should help combat the slowdown in generics  according to the Zacks analyst 

New Downgrades

The Zacks analyst believes that following a prolonged period of high differentials  crack spreads are set to weaken  which will lead to a decline in earnings and cash flows for MPC 


The covering analyst thinks Viacom remains embroiled in corporate issues and the company s future prospects and a positive turnaround remain doubtful 


Twitter s multiple efforts at boosting the user base including live streaming deals with the likes of NFL are impressive but questions remain about whether they will yield results ",2016-07-13,Zacks Investment Research,"https://www.investing.com/analysis/top-7-research-reports-for-july-13,-2016-200141806",200141806
103597,325112,ABC,AmerisourceBergen  ABC  Q3 Earnings  Stock To Surprise ,opinion,AmerisourceBergen Corporation   NYSE ABC   is set to report third quarter fiscal 2016 results on Aug 2  before the opening bell AmerisourceBergen s track record has been quite impressive  with the company comfortably beating estimates in three of the four trailing quarters  In the last reported quarter  it recorded a positive earnings surprise of 5 66   bringing the four quarter average to 2 69  Let s see how things are shaping up for this announcement Factors Influencing this Quarter Concurrent with its fiscal second quarter results  AmerisourceBergen had narrowed its guidance  Its pharmaceutical distribution segment continues to experience headwinds in the form of contract renewals and lower generic inflation  The AmerisourceBergen Drug Corporation  ABDC  business was also hurt by several factors  including accelerating deflation of generic drugs and lower contribution from generic launches  Although generic inflation has been nominal  the rate of deflation is on a gradual uptrend  now hovering at levels above the company s expectations  These factors  combined with the anticipated impact of a shift in product mix toward lower margin and higher priced specialty and branded drugs  as well as the lack of generic inflation will adversely impact the bottom line  Moreover  the company s efforts to increase sales of PRxO generics and revenues from independent retail segment are progressing slower than projected  Keeping these factors in consideration  the company lowered its earnings guidance to the range of  5 44  5 54 from its previous projection of  5 73  5 83 Headwinds in the form of the Kaiser and TPA contract renewals could also impact results  On the other hand  AmerisourceBergen expects revenues to grow around 8  in fiscal 2016   Market growth in the U S  is being driven by new brand product introductions  both in more traditional therapies and innovative specialty products The company recently extended the term of its 10 year pharmaceutical distribution agreement with Walgreens Boot Alliance   NASDAQ WBA   for three years  The contract will now expire in 2026  The company also extended its global sourcing arrangement with Walgreens Boots Alliance Development GmbH by three years  which will expire in 2026 as well AMERISOURCEBRGN Price and EPS Surprise   What Our Model IndicatesOur proven model does not conclusively show that AmerisourceBergen is likely to beat earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to be able to beat estimates  Unfortunately  that is not the case  as you will see below Zacks ESP  The Earnings ESP for AmerisourceBergen is 0 00   as both the Most Accurate estimate and the Zacks Consensus Estimate stand at  1 26 Zacks Rank  AmerisourceBergen carries a favorable Zacks Rank  2  which when combined with a 0 00  ESP  makes a surprise prediction difficult Note that we caution against stocks with a Zacks Rank  4 or  5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks That Warrant a LookHere is a company that you may want to consider  as our model shows that it has the right combination of elements to post an earnings beat this quarter Bristol Myers Squibb Co    NYSE BMY   has an Earnings ESP of  1 49  and a Zacks Rank  1  The company is scheduled to report second quarter results on Jul 28 Ironwood Pharmaceuticals   NASDAQ IRWD   has an Earnings ESP of 13 3  and a Zacks Rank  2  The company is expected to report earnings on Aug 4 ,2016-07-27,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-(abc)-q3-earnings:-stock-to-surprise-200144376,200144376
103598,325113,ABC,McKesson  MCK  Beats On Q1 Earnings  Maintains Guidance,opinion,McKesson Corporation   NYSE MCK   reported first quarter fiscal 2017  ended Jun 30  2016  earnings of  3 50 per share  higher than both the Zacks Consensus Estimate of  3 35 and the year ago figure of  3 14 Revenues increased 4 6  from the year ago quarter to  49 7 billion but failed to meet the Zacks Consensus Estimate of  50 1 billion All growth rates given below are on a year over year basis The Quarter in DetailMcKesson operates through two segments  Distribution Solutions and Technology Solutions Revenues from the Distribution Solutions business grew 4 7  to  49 0 billion  North America pharmaceutical distribution and services increased sales of  41 2 billion  up 4 2   reflecting market growth  acquisitions and customer mix across the retail  institutional and independent channels  Revenues from International pharmaceutical distribution and services were up 8 4  to  6 3 billion driven by acquisitions and market growth  Medical Surgical distribution and services generated sales of  1 5 billion  up 2  backed by the sale of ZEE Medical in the second quarter However  revenues from the Technology Solutions business declined 1 6  to  724 million due to the divestiture of the nurse triage business and an anticipated decrease in the hospital software business  McKesson has collaborated with Change Healthcare Holdings to create a new healthcare information technology company  McKesson will offer majority of its Technology Solutions businesses for the new company  It will  however  retain RelayHealth Pharmacy and Enterprise Information Solutions  McKesson s Technology Business has been facing challenging conditions for quite some time now as revenues continued to decline  Hence  a spin off of the business was around the corner as the company was looking to focus on its core distribution business  The company is also evaluating strategic alternatives for its Enterprise Information Solutions business Fiscal 2017 Outlook ReiteratedMcKesson expects earnings in the range of  13 43  13 93 per share  The guidance excludes approximately 12 15 cents of expected charges related to the cost alignment plan  The company expects revenues from the Distribution Solutions to grow in the high single digits  The company expects a nominal contribution from increase in price  of generic pharmaceuticals  Branded pharmaceutical pricing trends are expected to be modestly below the fiscal 2016 levels  The company anticipates foreign exchange impact of approximately 10 cents per share during fiscal 2017 MCKESSON CORP Price and EPS Surprise   Our TakeMcKesson reported mixed results for the fiscal first quarter  with earnings surpassing estimates but revenues missing the same McKesson s acquisitions of Biologics  Vantage Oncology and UDG Healthcare have strengthened its portfolio to a large extent  The impending Rexall transaction  scheduled to close later in 2016  will further strengthen the company s portfolio However  the operating performance of Celesio was disappointing  Management stated that while scheduled reimbursement cuts were expected  there were more unanticipated cuts made effective by the UK government in April and June  These cuts impacted the first quarter and continue to do so through the rest of the year  The UK s decision to exit the EU will also impact reimbursement results  Weaker generic pricing trends will significantly impact the first half of fiscal 2017 McKesson currently carries a Zacks Rank  2  Buy   Other favorably placed stocks in the healthcare sector include AmerisourceBergen Corporation   NYSE ABC    Johnson   Johnson   NYSE JNJ   and Bristol Myers Squibb Company   NYSE BMY    All the three stocks carry the same rank as McKesson ,2016-07-27,Zacks Investment Research,"https://www.investing.com/analysis/mckesson-(mck)-beats-on-q1-earnings,-maintains-guidance-200144668",200144668
103599,325114,ABC,AmerisourceBergen  ABC  Tops Earnings In Q3,opinion,"Chesterbrook  PA based AmerisourceBergen Corporation   NYSE ABC   is one of the world s largest pharmaceutical services companies  which focuses on providing drug distribution and related services to reduce healthcare costs and improve patient outcomes  AmerisourceBergen serves healthcare providers and pharmaceutical manufacturers in the pharmaceutical supply channel The company has been actively pursuing acquisitions to strengthen its core areas and diversify  The MWI Veterinary acquisition diversified its existing pharmaceutical distribution   services businesses into the attractive animal health market  while the PharMedium buyout added to its ability to provide market leading services and solutions to health system customers  The company entered into a strategic agreement with Walgreen Boots Alliance in 2013 and extended the term of its 10 year pharmaceutical distribution agreement by three years AmerisourceBergen s track record has been mixed with the company comfortably beating estimates in three of the last four quarters with an average positive surprise of 2 7   Estimates for fiscal 2016 have been more or less static in the last 30 days AMERISOURCEBRGN Price and EPS Surprise   Currently  AmerisourceBergen has a Zacks Rank  2  Buy  but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings  AmerisourceBergen topped earnings in the reported quarter  Our consensus called for EPS of  1 26  and the company reported EPS of  1 37 Revenue  AmerisourceBergen posted revenues of  36 9 billion in the reported quarter  slightly above the consensus estimate of  36 6 billion 
Key Stats  The acquisitions of MWI Veterinary Supply and PharMEDium have boosted performance  AmerisourceBergen now expects earnings per share in the range of 5 52    5 57 
Check back later for our full write up on this AmerisourceBergen earnings report later ",2016-08-02,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-(abc)-tops-earnings-in-q3-200145657,200145657
103600,325115,ABC,S P 500  9 Healthcare Dividend Growth Stocks  Part 1,opinion,"Introduction
Most everyone would agree that the stock market as measured by the S P 500 is not cheap today  However  there might be a great deal of disagreement regarding precisely how overvalued the S P 500 currently is  Nevertheless  I would agree that in the general sense  stocks are not exactly bargains today  This might especially be true regarding best of breed blue chip dividend growth stocks  Low interest rates have enhanced the attraction for high quality dividend paying stocks 
On the other hand  suggesting that the S P 500 is fully valued or even overvalued  is not the same as saying that all stocks in the S P 500 are overvalued  As I ve often stated  I believe it is a market of stocks and not a stock market  Additionally  I would also confidently state that it is also a market of various sectors as well  In this regard  there will be times when certain sectors are in favor while others are out of favor  Consequently  even in an overheated market  it is not unusual to find companies in specific sectors that are out of favor at the same time  Furthermore  this would also apply to certain companies in various subsectors within the larger sector 
The bottom line for me is that I never make individual common stock investment decisions based on where I think the level of the overall market is  Instead  I believe in looking for value when and wherever I can find it  Since I believe in building a stock portfolio one company at a time  it logically follows that I also believe in analyzing stocks one company at a time  Simply stated  I invest based on my determination and evaluation of the fundamental value I would be receiving from investing in the individual company I am scrutinizing 
The Commonsense Benefits of Sound Valuation
Long running bull markets  like the one we have been experiencing over the past 7 or 8 years  has a tendency to elicit overconfidence and even complacency  The longer stocks go up  the more confident people tend to become  This concept has recently hit home with me by reading startling comments by dividend growth investors that I highly respect  For example  several comments have promoted and supported the notion that the strong just keep getting stronger  They use this refrain to justify a willingness to pay high valuations for best of breed dividend growth stocks  I believe this is a serious mistake for reasons I will next present 
The concept of only being willing to invest in even the greatest of companies at or below sound valuation is mathematically supported  For starters  with any given amount of money  you will purchase more shares of a great company at a lower valuation than you will at a higher valuation  Owning more shares over the long run will lead to more dividend income and greater capital appreciation 
Moreover  when you invest at lower valuations  each share that you purchase will have a higher current dividend yield than had you purchased it at a higher valuation  So not only do you get more shares at lower valuations  each share also provides you a higher current yield  In the long run  this pays off handsomely  in addition to simple math  it is also common sense  On the other hand  in matters of investing  common sense is often not all that common 
But most importantly  the willingness to overpay for even the best company either ignores or denies the inevitable reality that a company s stock price will eventually move into alignment with fundamental value  In other words  when a stock is undervalued based on fundamentals  it will inevitably move up to fundamental value   and vice versa  Consequently  to me at least  it seems prudent and intelligent to only invest in any company  no matter its quality  at times when its valuation is sound and attractive 
The reader should note the use of the plural  times   In other words  I am not suggesting perfect timing because I consider that virtually impossible  Instead  there will be a period or periods of time when a stock is valued at sound levels  However  over those periods of time there will still be volatility  Therefore  there will be short periods of time when valuation might get a little better or a little worse  In other words  a soundly valued stock could drop in price temporarily over the short run  or immediately rise a little in price  Nevertheless  the important point is that you initially purchased it at a sound valuation regardless of what happens over the short term  In the long run  this will work for your benefit as long as fundamentals remain intact 
9 Attractive S P 500 Healthcare Dividend Growth Stocks
There are over 50 healthcare stocks in the S P 500  However  there are numerous subsectors within the larger broader healthcare sector  Consequently  a little more than approximately 10  of the names in the S P 500 are healthcare companies  However  that does not follow that 10  of the S P 500 is comprised of healthcare  S P 500 index is a weighted index 
Moreover  of the 50  healthcare stocks in the S P 500  they also come in many different flavors  Some are pure growth stocks  some are dividend growth stocks  Additionally  some offer higher yields and lower growth  while others offer lower yield and higher growth  My point being  that choices should be made according to the individual investor s own goals and objectives 
With this article I will be sharing my preliminary research on 9 reasonably valued dividend paying S P 500 stocks in the healthcare sector  However  I do want to point out that some of these names are attractive for their current yield  while others more for total return  Nevertheless  I leave it up to the reader to decide if any of these companies are worthy of conducting further research  The following portfolio review lists these 9 research candidates in order of highest dividend yield to lowest   and lists additional fundamental metrics and attributes on each 

F A S T  Graphs and Fundamentals Underlying Numbers Review
The following earnings and price correlated F A S T  Graphs and FUN Graphs on each of these 9 research candidates illustrate why I was attracted to learning more about these companies  First of all  I was interested in finding investable attractively valued dividend growth stocks in the healthcare sector  Whenever I am conducting preliminary research prior to a more comprehensive effort  there are certain fundamentals that I personally like to evaluate 
Of course  the relationship of stock price to earnings is my first check  If the stock appears reasonably valued on that basis  I am motivated and willing to dig deeper  Therefore  I offer an earnings and price correlated F A S T  Graphs on each candidate 
When looking for dividend paying stocks specifically  I like to examine cash flow and free cash flow per share relative to dividends paid  This gives me a quick overview of how well the dividends are covered  Consequently  my second graph on each candidate provides a FUN Graph on each of these important metrics over the past five years 
Since I understand that I can learn from the past  but only invest in the future  I also find it useful to review consensus analyst estimates over the next few years and over the longer 3 to 5 year time frame  Therefore  utilizing the  Custom  forecasting calculator I present a quick look at analyst expectations on each company 
Finally  since future profitability is what I m most concerned with  I also like to examine gross and net profit margins and return on equity  Therefore  the final graph on each research candidate reviews those important metrics over the past 5 years  Although I will not do it for all of the following research candidates  I will interject appropriate commentary where I think it s necessary 
AbbVie Inc  NYSE ABBV 
Below is a short business description courtesy of Morningstar 

AbbVie Inc is a research based biopharmaceutical company  The Company is engaged in the discovery  development  manufacture and sale of a broad line of pharmaceutical products for treating chronic autoimmune diseases  virology and neurological disorders 

AbbVie is offered as a fairly valued high yield dividend growth stock  The only negative is the high debt to capital ratio  However  as seen below  the company produces strong cash flow and free cash flow more than adequate to cover its dividend and support its debt 

Cash Flow Per Share  cflps   Free Cash Flow Per Share  fcflps   Dividends Paid Per Share  dvpps 

Gross Profit Margin  gpm   Net Profit Margin  npm   Return On Equity  roe 

AmerisourceBergen Corporation  NYSE ABC 
Below is a short business description courtesy of Morningstar 

AmerisourceBergen Corp is a pharmaceutical services company  It provides drug distribution and related healthcare services and solutions to pharmacy  physician  and manufacturer customers based in the United States and Canada 


Cash Flow Per Share  cflps   Free Cash Flow Per Share  fcflps   Dividends Paid Per Share  dvpps 

Gross Profit Margin  gpm   Net Profit Margin  npm   Return On Equity  roe 
AmerisourceBergen saw the complete elimination of their net profit margin in 2015 due to non recurring headwinds of acquisitions and a DOD settlement  However  adjusted operating results remained strong  FAST Graphs subscribers can see the effects of these headwinds by drawing a graph utilizing GAAP accounting  diluted earnings metric  

Amgen Inc   NASDAQ AMGN 
Below is a short business description courtesy of Morningstar 

Amgen Inc is a biotechnology company that discovers  develops  manufactures and delivers human therapeutics  The Company s business segment is human therapeutics 

Amgen is moderately overvalued currently  However  it would only take a modest pullback for this stock to be attractive and sound 

Cash Flow Per Share  cflps   Free Cash Flow Per Share  fcflps   Dividends Paid Per Share  dvpps 

Gross Profit Margin  gpm   Net Profit Margin  npm   Return On Equity  roe 

Anthem Inc  NYSE ANTM 
Below is a short business description courtesy of Morningstar 

Anthem Inc is a health benefits company offering a network based managed care plans to the large and small employer  individual  Medicaid and Medicare markets 

I believe that Anthem is currently undervalued due to the controversy surrounding their Cigna  NYSE CI  deal  However  I believe that risk is already reflected in the company s low valuation 

Cash Flow Per Share  cflps   Free Cash Flow Per Share  fcflps   Dividends Paid Per Share  dvpps 

Gross Profit Margin  gpm   Net Profit Margin  npm   Return On Equity  roe 

Cardinal Health Inc  NYSE CAH 
Below is a short business description courtesy of Morningstar 

Cardinal Health Inc is a healthcare services company  It provides pharmaceutical   medical products   services that help pharmacies  hospitals and other healthcare providers focus on patient care  It also provides medical products to patients in the home 

Cardinal Health appears moderately overvalued  but only by a little  Consequently  even a small pullback would make this stock attractive  in my opinion  The reader should note that this represents a clear example of an overvalued stock moving back to fair value as previously discussed 

Cash Flow Per Share  cflps   Free Cash Flow Per Share  fcflps   Dividends Paid Per Share  dvpps 


Gross Profit Margin  gpm   Net Profit Margin  npm   Return On Equity  roe 

Gilead Sciences Inc  NASDAQ GILD 
Below is a short business description courtesy of Morningstar 

Gilead Sciences Inc is a research based biopharmaceutical company that discovers  develops and commercializes new medicines for different medical sectors 

Gilead is offered based on the potential for a P E expansion to more reasonable levels  However  the company s growth prospects are very vague  Nevertheless  this biotechnology company is extremely cheap at these levels  regardless of future growth 

Cash Flow Per Share  cflps   Free Cash Flow Per Share  fcflps   Dividends Paid Per Share  dvpps 

Gross Profit Margin  gpm   Net Profit Margin  npm   Return On Equity  roe 

McKesson Corporation  NYSE MCK 
Below is a short business description courtesy of Morningstar 

McKesson Corporation distributes pharmaceuticals  medical supplies and healthcare information technology that make healthcare safer while reducing costs  Its segments include McKesson Distribution Solutions and McKesson Technology Solutions 

McKesson represents another example of the pitfalls of investing in a great company when it is overvalued  This company is overvalued for part of 2013  most of 2014  and into the late spring of 2015  However  the inevitable movement in price down to fair value and below was swift 

Cash Flow Per Share  cflps   Free Cash Flow Per Share  fcflps   Dividends Paid Per Share  dvpps 


Gross Profit Margin  gpm   Net Profit Margin  npm   Return On Equity  roe 

Perrigo Company plc  NYSE PRGO 
Below is a short business description courtesy of Morningstar 

Perrigo Co  NYSE PRGO  PLC develops  manufactures and distributes over the counter and generic prescription pharmaceuticals  nutritional products and active pharmaceutical ingredients 

Perrigo is offered as a potential P E ratio expansion candidate  Although the company looks extremely undervalued based on its historical earnings growth  earnings growth more recently has faltered  which appears to be the source of the drop in stock price 

Cash Flow Per Share  cflps   Free Cash Flow Per Share  fcflps   Dividends Paid Per Share  dvpps 


Gross Profit Margin  gpm   Net Profit Margin  npm   Return On Equity  roe 

Universal Health Services Inc  NYSE UHS 
Below is a short business description courtesy of Morningstar 

Universal Health Services Inc through its subsidiaries is engaged in the business of owning and operating acute care hospitals  behavioral health centers  surgical hospitals  ambulatory surgery centers and radiation oncology centers 


Cash Flow Per Share  cflps   Free Cash Flow Per Share  fcflps   Dividends Paid Per Share  dvpps 


Gross Profit Margin  gpm   Net Profit Margin  npm   Return On Equity  roe 

Summary and Conclusions
With this article I ve attempted to identify 9 S P 500 healthcare constituents that appeared reasonably valued in today s overheated market  I am personally conducting deeper research on each of the ones that I do not already have a position in  However  I believe it s important that the reader conduct their own research and due diligence and determine if any of these names are appropriate relative to their own goals and objectives  In part 2  I will be sharing research candidates in the growth category 
Disclosure  Long ABBV ABC AMGN GILD MCK
Disclaimer  The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients  Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted  The information in this document is believed to be accurate  but under no circumstances should a person act upon the information contained within  We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation ",2016-08-05,Chuck Carnevale,https://www.investing.com/analysis/finding-value-in-the-s-p-500:-9-healthcare-dividend-growth-stocks-part-1-200146252,200146252
103625,325140,ABC,WBA  An Iconic Dividend Aristocrat In Healthcare,opinion,"Walgreens Boots Alliance  NASDAQ WBA  has steadily grown its dividend for 40 straight years and has an operating history that dates back more than 100 years 
Few businesses have demonstrated such durability  and the ones that have are always worth a look for our Top 20 Dividend Stocks portfolio  After all  it takes meaningful competitive advantages for a company to survive for such a long period of time 
Walgreens scores extremely well for Dividend Safety  97  and Dividend Growth  88   but there is a lot more to this drugstore s business drivers than many dividend growth investors perhaps realize Business OverviewWalgreens is a global leader in the retail pharmacy market with more than 13 100 stores in 11 countries  Walgreens Boots Alliance s drugstores sell a range of prescription and non prescription drugs in addition to a number of consumer products in categories such as beauty  personal care  and grocery 
Walgreens  roots can be traced back to humble beginnings in Chicago in 1901  but the business has since expanded organically and through major acquisitions to become a leading international player 
Walgreens Boots Alliance operates in three segments  Retail Pharmacy USA is its largest segment and accounted for 69  of sales and 72  of segment income in its first quarter of fiscal 2016  This division consists of Walgreens and Duane Reade branded drugstores in the U S 
Retail Pharmacy International represented approximately 12  of sales and 18  of segment profits and consists of Alliance Boots  one of the largest drugstores in Europe that Walgreens fully acquired in 2014 
The company also has a Pharmaceutical Wholesale business that generated 20  of sales and about 10  of segment income  This segment operates under the Alliance Healthcare brand and supplies medicines and a variety of healthcare products to over 200 000 pharmacies and other healthcare institutions from more than 350 distribution centers Business AnalysisRetail pharmacy is a highly competitive and relatively mature industry  There are few noticeable differences inside of a Walgreens or CVS store  which causes companies in the industry to compete largely on price  brand recognition  and convenience of store locations 
The two major drugstores that dominate the market are Walgreens and CVS  Each player has done its part in consolidating the market 
Walgreens acquired U S  drugstore chain Duane Reade for  1 1 billion in 2010 and bought a 45  interest in Alliance Boots  a major pharmacy player in Europe  for  6 7 billion in 2012 
The company purchased the rest of Alliance Boots in 2014 to give it a presence in faster growing international markets and further expand its scale  With Alliance Boots  Walgreens became the biggest buyer of generic drugs in the world and expects to generate at least  1 billion in cost savings 
Most recently  Walgreens announced a deal to acquire Rite Aid  NYSE RAD  for  17 2 billion in 2015  This acquisition is expected to close in late 2016 and will provide better national coverage for Walgreens  customers 
Why is the industry consolidating  Essentially  there is a building amount of pressure to take costs out of the healthcare system  Falling government reimbursement rates for prescriptions and consolidation throughout other parts of the healthcare chain are putting pressure on players like Walgreens to take costs out of their businesses 
By acquiring other drugstores  Walgreens gains significant cost synergies from procurement savings on the purchase of drugs and merchandise  With more than 720 million prescriptions filled last fiscal year  Walgreens is one of the biggest purchasers of prescription drugs and healthcare products 
As such  the company can offer customers lower costs compared to its smaller rivals  Its 2013 supply deal with distributor AmerisourceBergen  NYSE ABC  is one example of the favorable contracts a company of Walgreens  size can attain  Smaller retail pharmacy companies will become increasingly uncompetitive as their scale becomes even smaller compared to Walgreens 
In addition to economies of scale  Walgreens benefits from owning some of the best real estate in the country  According to the company s annual report  approximately 76  of the U S  population lives within five miles of a Walgreens or Duane Reade retail pharmacy 
Once its acquisition of Rite Aid closes later this year  that number will increase even further as the company s national coverage further expands 
Convenient store locations have helped Walgreens generate one of the top 100 most powerful brands in the world and make it an obvious shopping choice for many consumers  It also benefits from lengthy operating histories dating back to the early 1900s for Walgreens and 1849 for Boots Alliance 
In addition to its strong brand recognition and convenient store locations  Walgreens Boots Alliance s websites receive about 68 million visits per month  providing a convenient platform for customers to refill their prescriptions 
By making it easy to refill orders  Walgreens gets more traffic through its doors  While prescriptions account for over 65  of revenue in the company s U S  stores  sales of retail merchandise carry higher margins 
As long as Walgreens makes it easy and affordable for customers to fill prescriptions with the company  it enjoys a steady base of sales 
Finally  it s worth mentioning that Walgreens Boots Alliance should benefit as the elderly population continues to grow in size and healthcare reform results in more insured Americans  driving more demand for prescriptions 
While healthcare reform is resulting in several benefits for the company  it also poses several risks Walgreens  Key RisksChange is often the biggest risk that companies face  and the U S  healthcare sector is undergoing a major evolution as a result of the Affordable Care Act and a need to reduce costs 
In the U S   96 8  of Walgreens  prescription sales last fiscal year were third party sales  where reimbursement is primarily received from managed care organizations  The government is doing all it can to reduce prescription drug costs and pharmacy reimbursement rates  The way drugs are priced is also rapidly changing 
Changes in Medicare and Medicaid funding and continued consolidation throughout the entire healthcare chain could pose unexpected challenges to Walgreens  pharmacy operations  Margins could be compressed  or competition from low cost retailers such as Walmart  NYSE WMT  could increase and take away some store traffic 
The market s growth can also be impacted by changes in the number and price of generic drugs  The generic drug wave has largely played out  and future trends are uncertain  Walgreens does best when new generics hit the market 
Walgreens Boots Alliance also faces risk from its acquisition binge  Big acquisitions often fail to create shareholder value  and Walgreens has made its biggest bets ever in recent years  If management fails to generate expected synergies or encounters unexpected integration challenges  the company will be challenged Dividend Analysis  Walgreens Boots AllianceWe analyze 25  years of dividend data and 10  years of fundamental data to understand the safety and growth prospects of a dividend  Dividend Safety ScoreOur Safety Score answers the question   Is the current dividend payment safe   We look at factors such as current and historical EPS and FCF payout ratios  debt levels  free cash flow generation  industry cyclicality  ROIC trends  and more  Scores of 50 are average  75 or higher is very good  and 25 or lower is considered weak 
Walgreens Boots Alliance has one of the safest dividend payments in the market with a Dividend Safety Score of 97  The company s strong safety rating starts with its payout ratio  which sits near 30  today  While Walgreens  earnings payout ratio has nearly doubled over the last decade  it remains at a very healthy level Source  Simply Safe Dividends
Source  Simply Safe Dividends
The drugstore industry is also resistant to recessions  Consumers still need their prescriptions regardless of how the economy is doing  which helped Walgreens grow its sales during the recession  This is one reason why we consider healthcare to be one of the best stock sectors for dividend income Source  Simply Safe Dividends
Walgreens  business model also generates plenty of stable and growing free cash flow  which is needed to fund the dividend  The company s mature store base and economies of scale throw off a lot of cash Source  Simply Safe Dividends
While Walgreens  operations have a low operating margin near 5   the company turns over its inventory rapidly to earn a strong return on invested capital  As seen below  Walgreens has created economic value by generating a double digit return for most of the last decade  which is often the sign of a moat Source  Simply Safe Dividends
Turning to the balance sheet  Walgreens has about  2 6 billion in cash on hand compared to  13 2 billion in debt  After the deal for Rite Aid closes  the balance sheet will become a bit overleveraged  Moody s has placed Walgreens  credit ratings on review for a downgrade 
While the company s large acquisitions have increased risk  the company s consistent cash flow generation reduces some of our concern and easily protects the dividend Source  Simply Safe Dividends
Overall  Walgreens  dividend is very safe for several reasons  The company sells recession resistant products  maintains low payout ratios  and generates predictable free cash flow  Its iconic brand and convenient store locations will continue to serve it well for many years to come Dividend Growth ScoreOur Growth Score answers the question   How fast is the dividend likely to grow   It considers many of the same fundamental factors as the Safety Score but places more weight on growth centric metrics like sales and earnings growth and payout ratios  Scores of 50 are average  75 or higher is very good  and 25 or lower is considered weak 
Walgreens  Dividend Growth Score of 88 indicates that the company has very strong dividend growth potential  Walgreens has increased its dividend for 40 consecutive years and is a member of the dividend aristocrats list  Perhaps even more impressively  Walgreens has paid uninterrupted dividends for 83 straight years 
As seen below  Walgreens has recorded impressive dividend growth  The company s dividend has increased by 20  per year over its last 10 fiscal years  although growth has slowed to a high single digit pace more recently Source  Simply Safe Dividends
With the company working on integrating several major acquisitions and restoring its balance sheet  dividend growth will likely remain at a mid  to high single digit pace for the time being 
Walgreens Boots Alliance also targets a long term dividend payout ratio of 30 35   which is where the company is at today  In other words  dividend growth will more closely align with earnings growth going forward ValuationWBA s stock trades at 18 2x forward earnings estimates and has a dividend yield of 1 8   which is below its five year average dividend yield of 2 2  
Investors are betting on Walgreens achieving substantial synergies from its recent acquisitions  which could help drive its earnings growth rate into the high single digits or low double digits 
Given the number of moving parts to Walgreens  story  we think the stock appears to be at least fairly valued today ConclusionThe healthcare landscape is rapidly evolving  While more Americans are now insured  driving prescription volumes higher  there is immense pressure to make the healthcare system more efficient and take out costs 
Government funded reimbursement models are changing and putting pressure on lucrative rates enjoyed in many pharmaceuticals markets  These changes  amongst others  are causing the entire distribution chain that delivers drugs from manufacturers to patients to consolidate 
While Walgreens is much better positioned than its smaller rivals  its large acquisitions of Alliance Boots and Rite Aid come with integration risks and are a signal of the need for further consolidation to protect profits 
We think Walgreens Boots Alliance is still a blue chip dividend stock  but we would prefer to buy at a more favorable valuation or receive more clarity on how healthcare reform will reshape the business over the next few years ",2016-03-12,Brian Bollinger,https://www.investing.com/analysis/wba:-an-iconic-dividend-aristocrat-in-healthcare-200121316,200121316
103626,325141,ABC,AmerisourceBergen  ABC  Q2 Earnings  Stock To Surprise ,opinion,AmerisourceBergen Corporation   NYSE ABC   is set to report second quarter fiscal 2016 results on May 5  before the opening bell AmerisourceBergen s track record has been mixed with the company comfortably beating estimates in three of the last four quarters  In the last reported quarter  it recorded a positive earnings surprise of 1 60   Overall  the company has posted an average positive earnings surprise of 7  over the past four quarters  Let s see how things are shaping up for this announcement Factors Influencing this QuarterDuring its first quarter fiscal 2016 call  AmerisourceBergen announced that it has signed a new distribution agreement with privately held Publix  Moreover  the company has renewed and extended the long term contract with its largest independent pharmacy group purchasing organization customer  Compliant Pharmacy Alliance Cooperative  earlier than scheduled AmerisourceBergen had to narrow its guidance to include the impact of this renewal  along with a decline in generic inflation and lower than expected contribution from generic launches in fiscal 2016  Consequently  the company now expects earnings per share in the range of  5 73 to  5 83  compared to the previous projection of  5 73  5 90  Generic inflation is projected to be modest in the remaining three quarters of fiscal 2016 Additionally  based on a recent court ruling  generic launch of certain oncology drugs has been delayed by a couple of years Repricing of the U S  Department of Defense contract also casts a shadow on the company s results  The contract was renewed at less favorable terms and lower generic price appreciation On the other hand  AmerisourceBergen continues to expect revenues to grow around 8 10  in fiscal 2016  Solid organic growth rates in the pharmaceutical market in the U S   improved health reform initiatives and better generic launches should positively impact AmerisourceBergen s results in the quarter  Additionally  the business will likely be positively impacted by incremental benefit from the MWI Supply acquisition  Meanwhile  contributions from the company s largest customer  Walgreens Boot Alliance   NASDAQ WBA    were strong in fiscal 2015 and the business is estimated to grow further in fiscal 2016 AmerisourceBergen acquired privately held PharMEDium Healthcare Holdings  Inc  in Nov 2015  The acquisition will be accretive to its fiscal 2016 earnings What Our Model IndicatesOur proven model does not conclusively show that AmerisourceBergen is likely to beat earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to be able to beat estimates  Unfortunately  that is not the case  as you will see below Zacks ESP  The Earnings ESP for AmerisourceBergen is 0 00   as both the Most Accurate estimate and the Zacks Consensus Estimate stand at  1 62 Zacks Rank  AmerisourceBergen carries a Zacks Rank  3  which when combined with a 0 00  ESP  makes a surprise prediction difficult Note that we caution against stocks with a Zacks Rank  4 or  5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks That Warrant a LookHere are some companies you may want to consider  as our model shows that they have the right combination of elements to post an earnings beat this quarter Jazz Pharmaceuticals plc   NASDAQ JAZZ   has an Earnings ESP of  4 58  and a Zacks Rank  3  The company is expected to release first quarter results on May 10 Impax Laboratories Inc    NASDAQ IPXL   has an Earnings ESP of  8 89  and a Zacks Rank  3  The company is expected to release first quarter results on May 10 ,2016-05-01,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-(abc)-q2-earnings:-stock-to-surprise-200127220,200127220
103627,325142,ABC,Drug Stocks Reporting Mid Week  MRK  ABC  ENDP   More,opinion,"First quarter earnings season is well underway with results from 62  of the S P 500 members already out  By the end of this week  more than 88  of the index s total membership will have reported results  According to our  report  Q1 is on track to be the 4th quarter in a row of earnings declines for the index However  Medical is one of the sectors expected to witness earnings and revenue growth in the first quarter  Our Q1 scorecard shows that 60 4  of the Medical sector has reported results with earnings growth of 6 3  and revenue growth of 11 8  This week  drug companies like Zoetis Inc    NYSE ZTS    Exelixis  Inc    NASDAQ EXEL    McKesson Corporation   NYSE MCK    Merck   Co  Inc    NYSE MRK    Endo International plc   NASDAQ ENDP    and AmerisourceBergen Corporation   NYSE ABC   will be reporting results Let s see how these stocks are poised ahead of the scheduled announcements Zoetis  focused on animal health medicines and vaccines  is scheduled to report first quarter 2016 results on May 4  before the opening bell  This Zacks Rank  3  Hold  stock s track record has been impressive with the company beating earnings estimates consistently  With an  of  2 44  and Zacks Rank  3  Zoetis looks poised to beat earnings expectations in the first quarter as well  Read more    
Biotech company  Exelixis  will also be reporting results on May 4  The company  which is focused on cancer treatments  has a mixed earnings track record  Exelixis  Zacks Rank  3 and ESP of  8 00  does not conclusively show that the company is likely to beat earnings estimates this quarter   Read more    
Healthcare services and information technology company  McKesson  is scheduled to report fourth quarter fiscal 2016 results on May 4  after the market closes  McKesson has an impressive track record  having beaten estimates comfortably in all of the last four quarters  But the company s combination of Zacks Rank  4  Sell  and ESP of  20 81  makes a surprise prediction difficult   Read more    
While most of its large cap pharma peers have already reported results  Merck will be presenting first quarter results on May 5  before the opening bell  Focus will remain on the performance of new products and whether they will be able to lessen the impact of genericization and currency movement  Although Merck s track record is pretty impressive  our proven model does not conclusively show that the company is likely to beat earnings estimates this quarter given the combination of Zacks Rank  3 and ESP of 0 00   Read more    
Specialty pharma company  Endo  had already provided weaker than expected first quarter guidance last month  Seasonality  investment in new product launches  inventory fluctuations  unfavorable currency movement and continued erosion in the generics base business are some of the factors that will impact first quarter results  which will be out on May 5 after the market closes  Endo s Zacks Rank  4 and ESP of 0 00  does not conclusively show that the company is likely to beat earnings estimates this quarter  Read more    
Pharmaceutical sourcing and distribution services company  AmerisourceBergen will be reporting second quarter fiscal 2016 results on May 5  before the opening bell  ABC s Zacks Rank  4 and ESP of 0 00  make a surprise prediction difficult  Read more    
Stay tuned and check later on our full write up on earnings releases of these stocks Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-05-02,Zacks Investment Research,"https://www.investing.com/analysis/drug-stocks-reporting-mid-week:-mrk,-abc,-endp---more-200127651",200127651
103628,325143,ABC,The Zacks Analyst Blog Highlights  Zoetis  McKesson  Merck  Endo International And AmerisourceBergen,opinion,"For Immediate Release 

Chicago  IL   May 04  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include the Zoetis Inc     NYSE ZTS     McKesson Corporation    NYSE MCK     Merck   Co  Inc     NYSE MRK     Endo International plc    NASDAQ ENDP    and AmerisourceBergen Corporation     NYSE ABC    

Today  Zacks is promoting its   Buy   stock recommendations   

Here are highlights from Tuesday s Analyst Blog  

Watch for These Drug Stocks Reporting This Week

First quarter earnings season is well underway with results from 62  of the S P 500 members already out  By the end of this week  more than 88  of the index s total membership will have reported results  According to our  report  Q1 is on track to be the 4th quarter in a row of earnings declines for the index 

However  Medical is one of the sectors expected to witness earnings and revenue growth in the first quarter  Our Q1 scorecard shows that 60 4  of the Medical sector has reported results with earnings growth of 6 3  and revenue growth of 11 8  
	This week  drug companies like Zoetis Inc     NYSE ZTS     McKesson Corporation    NYSE MCK     Merck   Co  Inc     NYSE MRK     Endo International plc    NASDAQ ENDP    and AmerisourceBergen Corporation     NYSE ABC    will be reporting results 
	Let s see how these stocks are poised ahead of the scheduled announcements 
	Zoetis  focused on animal health medicines and vaccines  is scheduled to report first quarter 2016 results on May 4  before the opening bell  This Zacks Rank  3  Hold  stock s track record has been impressive with the company beating earnings estimates consistently  With an  of  2 44  and Zacks Rank  3  Zoetis looks poised to beat earnings expectations in the first quarter as well  Read more     

Healthcare services and information technology company  McKesson  is scheduled to report fourth quarter fiscal 2016 results on May 4  after the market closes  McKesson has an impressive track record  having beaten estimates comfortably in all of the last four quarters  But the company s combination of Zacks Rank  4  Sell  and ESP of  20 81  makes a surprise prediction difficult   Read more     

While most of its large cap pharma peers have already reported results  Merck will be presenting first quarter results on May 5  before the opening bell  Focus will remain on the performance of new products and whether they will be able to lessen the impact of genericization and currency movement  Although Merck s track record is pretty impressive  our proven model does not conclusively show that the company is likely to beat earnings estimates this quarter given the combination of Zacks Rank  3 and ESP of 0 00   Read more     

Specialty pharma company  Endo  had already provided weaker than expected first quarter guidance last month  Seasonality  investment in new product launches  inventory fluctuations  unfavorable currency movement and continued erosion in the generics base business are some of the factors that will impact first quarter results  which will be out on May 5 after the market closes  Endo s Zacks Rank  4 and ESP of 0 00  does not conclusively show that the company is likely to beat earnings estimates this quarter  Read more     

Pharmaceutical sourcing and distribution services company  AmerisourceBergen will be reporting second quarter fiscal 2016 results on May 5  before the opening bell  ABC s Zacks Rank  4 and ESP of 0 00  make a surprise prediction difficult  Read more     

Stay tuned and check later on our full write up on earnings releases of these stocks 

Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days   

About Zacks Equity Research 

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Zacks  Profit from the Pros  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research    Find out What is happening in the  on zacks com ",2016-05-03,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-zoetis,-mckesson,-merck,-endo-international-and-amerisourcebergen-200127986",200127986
103629,325144,ABC,AmerisourceBergen  ABC  Tops Earnings In Q2,opinion,"Chesterbrook  PA based AmerisourceBergen Corporation   NYSE ABC   is one of the world s largest pharmaceutical services companies  which focuses on providing drug distribution and related services to reduce healthcare costs and improve patient outcomes  AmerisourceBergen serves healthcare providers and pharmaceutical manufacturers in the pharmaceutical supply channel AmerisourceBergen entered into a strategic agreement with Walgreen Boots Alliance in fiscal 2013  The agreement included a 10 year pharmaceutical distribution contract with Walgreen and access to generic drugs and related pharmaceutical products through the Walgreen Boots Alliance Development joint venture  The company also acquired leading animal health distribution company  MWI Veterinary Supply  Inc  to further diversify its portfolio AmerisourceBergen s track record has been mixed with the company comfortably beating estimates in three of the last four quarters with an average positive surprise of 7   Estimates for fiscal 2016 have been more or less static in the last 30 days Currently  AmerisourceBergen has a Zacks Rank  4  Sell  but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings  AmerisourceBergen topped earnings in the second quarter of fiscal 2016  Our consensus called for EPS of  1 62  and the company reported EPS of  1 68 Revenue  AmerisourceBergen posted revenues of  35 7 billion in the reported quarter  roughly in line with our consensus estimate Key Stats  The company announced that it has extended the term of its strategic agreement with Walgreens Boots Alliance  NASDAQ WBA  for an additional three years  However  AmerisourceBergen slashed its guidance for fiscal 2016 and now expects earnings per share in the range of  5 44 to  5 54  down from the earlier estimate of  5 73 to  5 83 
Check back later for our full write up on this AmerisourceBergen earnings report later ",2016-05-05,Zacks Investment Research,https://www.investing.com/analysis/amerisourcebergen-(abc)-tops-earnings-in-q2-200128180,200128180
103630,325145,ABC,Bull Of The Day  PharMerica  PMC ,opinion,"PharMerica Corporation  PMC  is an  800 million pharmacy services provider for institutional customers and patients in long term care settings 

The stock became a Zacks  1 Rank recently after another solid earnings report where they once again beat analyst EPS estimates by 20  for the fourth consecutive quarter 

On May 6 the company reported total revenue of  524 5 million  up 2 5  from last year s first quarter  and beating the analyst consensus by 3   The top line beat was driven by a higher than expected number of prescriptions dispensed  which totaled 8 6 million  Revenue per prescription dispensed in the quarter came in at  60 66 

Analysts Prescribe Better Outlook

In response to the company s outlook and reaffirmed 2016 guidance of revenue in the range of  2 125 billion to  2 150 billion and adjusted EPS in the range of  1 95 to  2 05  analysts scrambled to raise estimates 

In the past 30 days  the 2016 consensus went from  1 74 to  2 02 and full year 2017 projections rose 15  from  1 96 to  2 26 

Analysts at KeyBanc Capital Markets described the quarter as offering solid evidence of PharMerica s value proposition  Specifically they noted  The company remains on track toward creating value by expanding its mix of faster growing specialty diversified pharmacy services and using its cash flow to fold in small LTC and home infusion pharmacy acquisitions   The analysts reiterated their Overweight rating and raised their price target from  33 to  34 

Under the Hood of a Key Pharmacy Player

PharMerica offers a broad range of pharmacy services across multiple settings of care ranging from hospitals to nursing facilities and even in home pharmacy services required after a hospital stay  The specialize in senior long term care and specialty oncology services that traditional community pharmacies don t address 

PharMerica was formed as a public company in 2007 through the combination of the institutional pharmacy business of national healthcare services company Kindred Healthcare  Inc  and pharmaceutical services company AmerisourceBergen  NYSE ABC  Corporation 

According to Wikipedia   In August 2011  pharmacy services provider Omnicare made a bid of  457 million for all outstanding shares of PharMerica  The Federal Trade Commission sued Omnicare to block the deal on the basis that the FTC believed the acquisition would lead to higher drug prices  In February 2012  Omnicare allowed its offer to the shareholders of PharMerica to expire   

I m sure that PMC shareholders since 2012 are quite satisfied with this result as the shares have advanced from the low teens  And I think that the recently tested multi year support tested in March at  20 gives a good risk reward reference for the stock 

Bottom Line  PMC Delivers

PharMerica ranks as an industry leading U S  provider of institutional pharmacy services in terms of annual revenues  

And those strong revenues create a compelling value case with a remarkable Price to Sales ratio of 0 40 

This is why PMC has one of the top Zacks composite style scores of  A  for all three metrics of Value  Growth  and Momentum  

And it s why you should consider PMC one of your top plays in the pharmacy industry 

Kevin Cook is a Senior Stock Strategist for Zacks where he runs the  portfolio ",2016-05-17,Zacks Investment Research,https://www.investing.com/analysis/bull-of-the-day:-pharmerica-(pmc)-200130739,200130739
103631,325146,ABC,PharMerica  AbbVie  Red Robin Gourmet Burgers  Habit Restaurants And Shake Shack Highlighted As Zacks Bull And Bear Of The Day ,opinion,"For Immediate Release

Chicago  IL   May 18  2016   highlights PharMerica Corporation    as the Bull of the Day and AbbVie    as the Bear of the Day  In addition  Zacks Equity Research provides analysis on   Red Robin Gourmet Burgers  Inc      Habit Restaurants  Inc      and Shake Shack  NYSE SHAK   Inc     

Here is a synopsis of all five stocks  

  

PharMerica Corporation    is an  800 million pharmacy services provider for institutional customers and patients in long term care settings 

The stock became a Zacks  1 Rank recently after another solid earnings report where they once again beat analyst EPS estimates by 20  for the fourth consecutive quarter 

On May 6 the company reported total revenue of  524 5 million  up 2 5  from last year s first quarter  and beating the analyst consensus by 3   The top line beat was driven by a higher than expected number of prescriptions dispensed  which totaled 8 6 million  Revenue per prescription dispensed in the quarter came in at  60 66 

Analysts Prescribe Better Outlook

In response to the company s outlook and reaffirmed 2016 guidance of revenue in the range of  2 125 billion to  2 150 billion and adjusted EPS in the range of  1 95 to  2 05  analysts scrambled to raise estimates 

In the past 30 days  the 2016 consensus went from  1 74 to  2 02 and full year 2017 projections rose 15  from  1 96 to  2 26 

Analysts at KeyBanc Capital Markets described the quarter as offering solid evidence of PharMerica s value proposition  Specifically they noted  The company remains on track toward creating value by expanding its mix of faster growing specialty diversified pharmacy services and using its cash flow to fold in small LTC and home infusion pharmacy acquisitions   The analysts reiterated their Overweight rating and raised their price target from  33 to  34 

Under the Hood of a Key Pharmacy Player

PharMerica offers a broad range of pharmacy services across multiple settings of care ranging from hospitals to nursing facilities and even in home pharmacy services required after a hospital stay  The specialize in senior long term care and specialty oncology services that traditional community pharmacies don t address 

PharMerica was formed as a public company in 2007 through the combination of the institutional pharmacy business of national healthcare services company Kindred Healthcare  Inc  and pharmaceutical services company AmerisourceBergen  NYSE ABC  Corporation 

According to Wikipedia   In August 2011  pharmacy services provider Omnicare made a bid of  457 million for all outstanding shares of PharMerica  The Federal Trade Commission sued Omnicare to block the deal on the basis that the FTC believed the acquisition would lead to higher drug prices  In February 2012  Omnicare allowed its offer to the shareholders of PharMerica to expire  

I m sure that PMC shareholders since 2012 are quite satisfied with this result as the shares have advanced from the low teens  And I think that the recently tested multi year support tested in March at  20 gives a good risk reward reference for the stock 

Bottom Line  PMC Delivers

PharMerica ranks as an industry leading U S  provider of institutional pharmacy services in terms of annual revenues 

And those strong revenues create a compelling value case with a remarkable Price to Sales ratio of 0 40 

This is why PMC has one of the top Zacks composite style scores of  A  for all three metrics of Value  Growth  and Momentum 

And it s why you should consider PMC one of your top plays in the pharmacy industry 

  

AbbVie    was big in the news this week after Federal regulators agreed to review a key patent for the anti inflammatory drug Humira  knocking the stock down 3 5  on over three times the average volume of 9 million shares 

According to a story from Dow Jones on Tuesday by Anne Steele  the US Patent and Trademark Office s Patent Trial and Appeal Board took up a petition by hopeful rival Coherus BioSciences to look at AbbVie s patent on a Humira dosing regimen to treat rheumatoid arthritis 

But ABBV shares were already pushed into the cellar of the Zacks Rank before this news because of a slide in earnings estimates over the past 30 days  Full year 2106 profit projections fell from  5 00 to  4 77 and the 2017 consensus EPS estimate dropped from  5 99 to  5 73 

And that loss of earnings momentum is what makes ABBV today s Bear of the Day by virtue of its Zacks  5 Rank  Strong Sell   This simply means that relative to over 4 000 other stocks across all sectors  ABBV has poor prospects for a price advance because of the magnitude and agreement of negative EPS revisions from analysts 

The Coherus Challenge

Part of this action by analysts in the past month may have been in anticipation of the move by Federal patent authorities  Coherus management revealed at an investor conference in January that the company planned to file an application this year to market a biosimilar  generic  version of Humira 

On Tuesday  Coherus Chief Executive Denny Lanfear said they are  confident that this will lead to a final decision nullifying  the patent 

Shares Coherus shot up nearly 16  to  18 83 on very strong volume of 1 6 million shares  over five times their daily average 

AbbVie responded  we are confident in the validity of our patents and will vigorously defend them  

 Humira is protected by many patents covering all aspects of its manufacture  formulation and indications  and the patents are the result of AbbVie s investment in biologic innovation and the unique attributes of Humira   a spokesperson said 

According to the Dow Jones article by Anne Steele  Humira was the second best selling drug in the U S  in 2015 and is AbbVie s largest source of revenue 

AbbVie has also been preparing for this competitive battle by taking out about 70 patents for Humira  one of the largest patent portfolios ever assembled for a single drug 

Again from Steele   The drug s primary U S  patent is due to expire in December  but AbbVie says the additional patents should keep copycat versions of Humira off the U S  market until at least 2022  and possibly longer  

Bottom Line for ABBV  Watch the Zacks Rank

While this patent battle could actually become a multi year war  after today s big news the analysts may continue to revise ABBV estimates downward  And that could keep it in the basement of the Zacks Rank for a while 

Additional content 

Burger Stocks Earnings Recap  HABT  RRGB  SHAK

Red Robin Gourmet Burgers  Inc     reported its  before the market opened on Tuesday  capping off the earnings season for the niche burger stocks 

For Red Robin  quarter one was not too friendly  Although the company reported earnings of  1 27 per share  which beat the Zacks Consensus Estimate of  1 10  shares tumbled over 18  on weak sales numbers and lowered guidance 

The sit down burger chain posted revenues of  402 1 million  which missed our consensus estimate of  416 million  Furthermore  the company lowered its revenue guidance from its previously expected 8 5  to 9 5  growth range  Red Robin now expects its 2016 revenue to grow by just 8  

Another burger specialist  The Habit Restaurants  Inc       also reported its    The Irvine  California based chain posted earnings of 10 cents per share  which was in line with the Zacks Consensus Estimate 

The Habit narrowly missed revenue expectations  posting  67 million versus our consensus estimate of  68 million  Additionally  the company said it expects 2016 revenue to be within the range of  286 million to  290 million  Our consensus estimate currently sits at  288 million 

Finally  Shake Shack  Inc     also  last week  The burger chain from New York posted earnings of eight cents per share  which just beat the Zacks Consensus Estimate of seven cents  The company also edged out our revenue estimate of  53 million with its reported  54 million in quarterly revenue 

Shake Shack also raised its guidance  The company now expects revenues in the range of  245 million to  249 million  up from  237  242 million projected earlier  Shake Shack also said it now plans to open 16 stores this year  up from its previous goal of 13 

Stay tuned for the latest on all things burger stock related  as well as the rest of the restaurant business 

Want the latest recommendations from Zacks Investment Research  Today  you can download7 Best Stocks for the Next 30 Days   

About the Bull and Bear of the Day

Every day  the analysts at Zacks Equity Research select two stocks that are likely to outperform  Bull  or underperform  Bear  the markets over the next 3 6 months 

About the Analyst Blog

Updated throughout every trading day  the  provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets 

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

Continuous analyst coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Zacks  Profit from the Pros  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research    Find out What is happening in the  on zacks com ",2016-05-17,Zacks Investment Research,"https://www.investing.com/analysis/pharmerica,-abbvie,-red-robin-gourmet-burgers,-habit-restaurants-and-shake-shack-highlighted-as-zacks-bull-and-bear-of-the-day-200130719",200130719
103658,325173,ABC,AmerisourceBergen  In Value Based On Historical Earnings Growth,opinion,Before analyzing a company for investment  it s important to have a perspective on how well the business has performed  Because at the end of the day  if you are an investor  you are buying the business  The FAST Graphs  presented with this article will focus first on the business behind the stock  The orange line on the graph plots earnings per share since 1999  A quick glance vividly reveals the historical operating record of the company AmerisourceBergen Corp  ABC  is one of the world s largest pharmaceutical services companies serving the United States  Canada and selected global markets This article will reveal the business prospects of AmerisourceBergen Corp through the lens of FAST Graphs   fundamentals analyzer software tool  Therefore  it is offered as the first step before a more comprehensive research effort  Our objective is to provide companies that have excellent historical records and appear reasonably priced based on past  present and future data and expectations  A quick glance at the graph itself and the orange earnings justified valuation line will tell the readers volumes about how well the company has historically been managed and performed as an operating business  Simply put  the reader should ask whether this example is worthy of a greater investment of their time and effort based on the data as presented and organized  The FAST Graphs  unique advantage is the graphical articulation of the price value proposition  Earnings Determine Market Price  The following earnings and price correlated FAST Graphs  clearly illustrates the importance of earnings  The Earnings Growth Rate Line or True Worth  Line  orange line with white triangles  is correlated with the historical stock price line  On graph after graph the lines will move in tandem  If the stock price strays away from the earnings line  over or under   inevitably it will come back to earnings  Earnings   Price Correlated Fundamentals at a GlanceA quick glance at the historical earnings and price correlated FAST Graphs  on AmerisourceBergen Corp shows a picture of in value based upon the historical earnings growth rate of 15 6  and a current P E of 15 7  Analysts are forecasting the earnings growth to continue at about 12   and when you look at the forecasting graph below  the stock appears overvalued  it s inside of the value corridor of the five orange lines   based on future growth  AmerisourceBergen Corp  Historical Earnings  Price  Dividends and Normal P E Since 1999Performance Table AmerisourceBergen CorpThe associated performance results with the earnings and price correlated graph  validates the principles regarding the two components of total return  capital appreciation and dividend income  Dividends are included in the total return calculation and are assumed paid  but not reinvested  When presented separately like this  the additional rate of return a dividend paying stock produces for shareholders becomes undeniably evident  In addition to the 13 2  capital appreciation  green circle   long term shareholders of AmerisourceBergen Corp  assuming an initial investment of  1 000  would have received an additional  257 25 in dividends  blue highlighting  that increased their total return from 13 2  to 13 5  per annum versus 2 7  in the S P 500 The following graph plots the historical P E ratio  the dark blue line  in conjunction with 10 year Treasury note interest  Notice that the current price earnings ratio on this quality company is as normal as it has been since 1999 A further indication of valuation can be seen by examining a company s current P S ratio relative to its historical P S ratio  The current P S ratio for AmerisourceBergen Corp is  14 which is historically normal  Looking to the FutureExtensive research has provided a preponderance of conclusive evidence that future long term returns are a function of two critical determinants 1  The rate of change  growth rate  of the company s earnings2  The price or valuation you pay to buy those earningsForecasting future earnings growth  bought at sound valuations  is the key to safe  sound and profitable performance The Estimated Earnings and Return Calculator Tool is a simple yet powerful resource that empowers the user to calculate and run various investing scenarios that generate precise rate of return potentialities  Thinking the investment through to its logical conclusion is an important component towards making sound and prudent commonsense investing decisions The consensus of 17 leading analysts reporting to Capital IQ forecast AmerisourceBergen Corp s long term earnings growth at 12   orange circle   AmerisourceBergen Corp has medium long term debt at 37  of capital  red circle   AmerisourceBergen Corp is currently trading at a P E of 15 7  which is inside the value corridor  defined by the five orange lines  of a maximum P E of 18  If the earnings materialize as forecast  based upon forecasted earnings growth of 12   AmerisourceBergen Corp s share price would  82 61 at the end of 2018  brown circle on EYE Chart   which would represent a 12 2  annual rate of total return which includes dividends paid  yellow highlighting  Earnings Yield EstimatesDiscounted Future Cash Flows  All companies derive their value from the future cash flows  earnings  they are capable of generating for their stakeholders over time  Therefore  because Earnings Determine Market Price in the long run  we expect the future earnings of a company to justify the price we pay Since all investments potentially compete with all other investments  it is useful to compare investing in any prospective company to that of a comparable investment in low risk Treasury bonds  Comparing an investment in AmerisourceBergen Corp to an equal investment in 10 year Treasury bonds illustrates that AmerisourceBergen Corp s expected earnings would be 6 2  purple circle  times that of the 10 year T bond interest  see EYE chart below   This is the essence of the importance of proper valuation as a critical investing component Summary   ConclusionsThis report presented essential  fundamentals at a glance  illustrating the past and present valuation based on earnings achievements as reported  Future forecasts for earnings growth are based on the consensus of leading analysts  Although with just a quick glance you can know a lot about the company  it s imperative that the reader conducts their own due diligence in order to validate whether the consensus estimates seem reasonable or not Disclosure  Long ABC at the time of writing Disclaimer  The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients  Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted  The information in this document is believed to be accurate  but under no circumstances should a person act upon the information contained within  We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation  A comprehensive due diligence effort is recommended ,2013-02-06,F.A.S.T. Graphs,https://www.investing.com/analysis/amerisourcebergen:-in-value-based-on-historical-earnings-growth-154145,154145
103659,325174,ABC,Dow Records Slight Gain  Nasdaq And S P Close Lower,opinion,The U S  stock market was slightly lower on Tuesday as investors reacted to news that lawmakers in Cyprus have rejected a bailout plan which would include a tax on bank accounts in the country   Investors are concerned that the banking crisis in Cyprus could trigger more problems in the euro zone  although the country only accounts for around 0 2 percent of the EU s economy  The turmoil in Cyprus  however  has caused the euro to trade through the  1 30 level to the downside with the EUR USD last trading at  1 2875   The developments in the island nation have also caused a significant two day rise in the CBOE Volatility Index  VIX   suggesting that market complacency could be coming to an end   Major Averages The Dow Jones Industrial Average added around 4 points  or 0 03 percent  to close just below 14 456   The S P 500 lost almost 4 points  or 0 24 percent  to 1 548   The Nasdaq Composite shed around 8 points or 0 26 percent  to 3 229   Housing Starts Housing starts in the United States rose 0 8 percent for the month of February to 917 000 compared to a decline of 7 3 percent in January  This came in above consensus expectations which called for a rise to 911 000   Housing starts have been in an uptrend since August 2011 and the most recent data shows that the market has finally stabilized with an upward trajectory   Building Permits Building permits were 946 000 in February  which was a 4 65 percent increase over a downwardly revised 904 000 in January  This easily topped consensus estimates which called for 925 000 building permits in February   Commodities Crude oil fell on Tuesday as investors are concerned about a potential re flaring of the European sovereign debt crisis in the wake of the banking problems in Cyprus  Late in the day  NYMEX crude futures were down around 1 75 percent to  92 11  Brent futures were last down a little less than 2 percent to  107 53  Natural gas bucked the trend in the energy market  rising around 2 percent to  3 96   Precious metals were mixed on the session with gold rising and silver falling slightly  At last check  COMEX gold futures were up 0 29 percent to  1 609 20  Silver was down 0 24 percent to  28 81  Copper was around 1 percent lower on the day to  3 3950   In the agricultural complex  both corn and wheat rose better than 1 percent on the session while soybeans were slightly lower  In soft commodities  cocoa  sugar  orange juice  and cotton all climbed less than 1 percent  while coffee futures lost a little less than 1 percent   Bonds Near the close for equities  the iShares Barclays 20  Year Treasury Bond ETF  TLT  was up around 0 71 percent to  117 49  Inflows into Treasuries sent yields lower on U S  government debt   Although the 2 Year Note was unchanged at 0 24 percent  the 5 Year yield fell three basis points to 0 78 percent  The yields on the 10 Year Note and 30 Year Bond both fell five basis points to 1 91 percent and 3 13 percent  respectively   Currencies The U S  dollar was higher on Tuesday  which may have helped restrain risk appetite  The PowerShares DB US Dollar Index Bullish ETF  UUP   which tracks the performance of the greenback versus a basket of foreign currencies  had climbed 0 31 percent to  22 61 heading the equity close   The closely watched EUR USD pair was last trading down 0 54 percent to  1 2875  Other movers among currency pairs included the USD JPY which fell 0 29 percent  and the USD CAD  which added around 0 50 percent   Volatility and Volume The VIX jumped a little less than 8 percent to 14 37 on Tuesday after rising more than 20 percent on Monday  The spike in the VIX comes despite only moderate losses on the major averages at the beginning of the week   Volume finally picked up on Tuesday as investors are getting more active in the wake of higher volatility  Around 156 million SPDR S P 500 ETF  SPY  shares traded hands compared to a 3 month daily average of just over 130 million   Stock Movers Lululemon Athletica  LULU  fell almost 3 percent after the company recalled a new line of yoga pants  The stock  however  finished well off of its worst levels of the day   Shares of Cardinal Health  CAH  fell around 8 percent on Tuesday after Walgreen Co   WAG  and Alliance Boots GmbH reached an agreement to source branded and generic drugs from AmerisourceBergen  ABC   In return  the companies will have the right to buy a minority stake in the drug wholesaler  The deal hurts Cardinal Health which use to provide branded drugs to Walgreen   In the wake of the news  Walgreen was trading up better than 5 percent while Amerisource Bergen shares added more than 3 percent  but fell on an intra day basis after gapping sharply higher at the open   Both the Federal National Mortgage Association  Fannie Mae   OTC  FNMA  and the Federal Home Loan Mortgage Corp   Freddie Mac   OTC  FMCC  continued to rally on Tuesday after a sharp jump to start the trading week on Monday  Fannie Mae was last up better than 30 percent while Freddie Mac had climbed 29 percent   NPS Pharmaceuticals  NPSP  climbed more than 9 percent after the company announced that it had revised its collaboration agreements with Takeda Pharmaceuticals  NPS will pay Takeda  50 million in stock for the full global rights to its drug Gattex   Walter Investment Management  WAC  plunge on the session plummeted almost 21 percent after the company released its fiscal fourth quarter earnings results   DSW  DSW  lost more than 6 percent after the company s fiscal fourth quarter earnings results   Skullcandy  SKUL  added around 7 percent on the session after the company named Hoby Darling as its new president and CEO  Darling previously worked at Nike  NKE  as a digital executive   Video game publisher Electronic Arts  EA  fell more than 8 percent after the company s CEO John Riccitiello resigned  Electronic Arts also warned investors that its quarterly results would come in at or below the bottom end of its previous guidance range   Affymax  AFFY  plunged more than 63 percent after the company said it will cut 75 percent of its workforce and potentially sell itself  Previously  Affymax recalled its antianemia drug following reports of severe allergic reactions in some kidney disease patients  resulting in five deaths BY Scott Rubin,2013-03-20,Benzinga ,"https://www.investing.com/analysis/dow-records-slight-gain,-nasdaq-and-s-p-close-lower-159645",159645
103660,325175,ABC,Trading   the ABC s of ABC,opinion,"Looking for a good stock set up or if you are in fear mode a  place to hide out  until the dust settles  Well AmerisourceBergen  AmerisourceBergen  NYSE ABC   looks good on multiple timeframes  The weekly longer term picture shows that the price is moving higher out of the pullback and over the 20 week SMA  The RSI is rising and moving towards the bullish range while the MACD is also rising and nearing a bullish cross up  The move above the channel triggers a buy signal and the longer view shows the potential to be near 100 if the AB CD plays out 

Zooming in on the daily timeframe also looks good  The RSI and MACD are rising in this timeframe as well but the 100 day SMA seems to be providing some short term resistance  A move over that would confirm more upside with resistance at 69 15 and 71 50 

I am hitting the road now  but will be monitoring this and may enter tomorrow 
Disclosure  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2014-05-16,Gregory W. Harmon,https://www.investing.com/analysis/trading---the-abcs-of-abc-213050,213050
103661,325176,ABC,Top Trade Ideas  AAP  ABC  AXAS  NPSP  WLP,opinion,"Advance Auto Parts Inc  NYSE AAP 

Advanced Auto Parts  has been in a sideways consolidation since February  and rising the 100 day SMA higher as support  The RSI is in the bullish zone and the MACD is rising  both supporting a push higher 
AmerisourceBergen  NYSE ABC 
Amerisource Bergen  had a long run higher from September to December in 2013  but a slow pullback that lasted until May after that  The leap higher made a new high and pulled back slightly before the current reversal higher  Higher prices are supported by a rising and bullish RSI 
Abraxas Petroleum Corporation  NASDAQ AXAS 
Abraxas Petroleum  is testing resistance at 5 60 after a pullback that formed a double bottom at 4 60  The move Friday on strong volume is bullish and has support from the rising RSI and MACD for more upside price movement 
NPS Pharmaceuticals Inc  NASDAQ NPSP 
NPS Pharmaceuticals  started a pullback in March that found support at prior lows and reversed higher to start June  It is consolidating that move in a bull flag with a bullish RSI and a MACD that is leveling after a small pullback 
WellPoint Inc  NYSE WLP 
WellPoint  started a move higher in February that has had 2 legs  The recent consolidation now sees it testing resistance with a rising RSI and a MACD turning back higher and near a cross up 
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Friday which  as the last full week of June kicks off into Summer  sees the equity markets looking strong  Elsewhere look for Gold to continue higher while Crude Oil joins it to the upside  The US Dollar Index has a short term downward bias while US Treasuries consolidate but also are biased lower  The Shanghai Composite looks like it has more consolidation in store for it while Emerging Markets are biased to the upside with possible consolidation  Volatility looks to remain very low keeping the bias higher for the equity index ETF s SPY  IWM  and QQQ  Their charts are also biased to move higher on the longer timeframe with the shorter timeframe strongest in the IWM and with the SPY and QQQ looking like they could consolidate in the short term  Use this information as you prepare for the coming week and trad em well 
Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2014-06-23,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas:-aap,-abc,-axas,-npsp,-wlp-216939",216939
103662,325177,ABC,Five Stocks To Watch,opinion,Here are five stocks digesting big moves whose patterns indicate continued momentum  AmerisourceBergen Corporation  NYSE ABC   Alnylam Pharmaceuticals  Inc   NASDAQ ALNY   DepoMed Inc   NASDAQ DEPO   The Home Depot  Inc   NYSE HD   and Aspen Technology  Inc   NASDAQ AZPN    SHORT ,2014-10-07,"Sinisa Persic, CMT",https://www.investing.com/analysis/five-stocks-to-watch-228266,228266
103663,325178,ABC,5 Stocks To Trade This Week  ABC  ANTM  COL  GNRC  IBKR,opinion,"Here are the Rest of the Top 10 
AmerisourceBergen  NYSE ABC 
AmerisourceBergen   ABC   has been a monster of a stock since moving higher in late October  The last two weeks it has been consolidating again  but with an expanding range to the downside  This is as the RSI has worked off an overbought condition and the MACD is crossing down  It is noticeably extended from the SMA s  Watch for a range break top the downside 
Anthem   NYSE ANTM 


Anthem  has been trending higher for over a year  In stocks like this a consolidation period  like what is happening now  is a possible opportunity to get a good entry  The RSI remains strong and bullish while the MACD has crossed down  it too is extended from the longer SMA s  but the 20 day SMA close by has acted as support  Watch this for a break either way 
Rockwell Collins  NYSE COL 

Rockwell Collins  rose off of the double bottom at 71 50 and consolidated for a while around 85 before moving up again  Now hitting resistance after a slight pullback it has support for an upside breakout from a rising and bullish RSI and a MACD about to cross up 
Generac   NYSE GNRC 

Generac  moved up out of a rounded bottom to end 2014  but pulled back early in 2015  Now having retraced the pullback and advanced it is consolidating in a tight range  As it churns the RSI is working lower  but remains bullish while the MACD has crossed down  This is normal for a consolidation and you could see this break the range in either direction  Be prepared 
Interactive Brokers   NASDAQ IBKR 

Interactive Brokers  has been in a long trend higher  Recently it is consolidating in a narrow range with the Bollinger Bands  squeezing  This is often a precursor to a move  The RSI is falling but in the bullish zone while the MACD is falling  This could break the range either way and the strong rising SMA s suggest that any pullback be watched as a possible buying opportunity 
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Friday which  Heading into next week sees the equity markets looking vulnerable 
Elsewhere look for Gold to continue lower while Crude Oil churns in a consolidation zone  The US dollar Index looks to continue higher while US Treasuries continue lower  The Shanghai Composite looks to continue its broad consolidation with a short term downside bias and Emerging Markets are biased to the downside 
Volatility looks to remain low keeping the bias higher for the equity index ETF s  ARCA SPY    ARCA IWM  and  NASDAQ QQQ   Their charts look better to the downside though with the SPY the weakest and the IWM and QQQ a bit stronger on the longer timeframe  Use this information as you prepare for the coming week and trad em well 
Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my Disclaimer page for my full disclaimer ",2015-03-09,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas-for-the-week-of-march-9,-2015:-the-rest-244296",244296
103693,325208,ABC,Olympic Calm Before Coming Financial Storm ,opinion,Today s AM fix was USD 1 622 25  EUR 1 317 30  and GBP 1 035 33 per ounce   Friday s AM fix was USD 1 608 50  EUR 1 310 92 and GBP 1 030 69 per ounce   Gold rose  2 70 or 0 17  in New York on Friday and closed at  1 620 40 oz  Silver fell and then recovered to  28 32  but finished on Friday in New York with a loss of just 0 4     For the week  gold rose 1 1  and silver rose 1 2  Gold inched up again on Monday  continuing the climb for its 7th session as world economies falter   increasing the likelihood of further central bank policy action   which may again prove futile The yellow metal will become sought out by investors as an inflation hedge when quantitative easing is pursued again and huge amounts of money are again dumped into the financial system in what seems like an increasingly vain attempt to stimulate growth In line with China s poor data on Friday  Japanese data earlier today showed that their economy slowed greater than expected in 2Q Gold and silver markets have been extremely subdued of late with Bloomberg terminals abandoned in favour of the marvellous spectacle that was the London Olympics  Many traders  decision makers and institutional participants were off on holidays and or enjoying watching the Olympics The precious metals have been strangely becalmed despite significant volatility being seen in stock markets  Economic data has been poor and largely gold positive and this could result in a bout of buying with the return of important market participants The distracting spectacle of the Olympics may have led to market complacency and the cocktail of macro risks and geopolitical risks such as the eurozone debt crisis and events in Syria and Iran could lead to the Olympic calm giving way to a volatile and stormy Fall It is important to note that markets were also unusually calm during the two weeks of the Chinese Olympics in 2008  The 2008 Summer Olympic Games took place slightly later in August than the London Olympics   starting August 8 and ending August 24 Only days after the ending of the Chinese Olympics came massive market volatility in September and then seven months of market turmoil  Similarly to this Olympic year  in Olympic year 2008  gold traded sideways to down in a period of consolidation prior to further gains  Gold bottomed in September 2008 in euro and sterling terms  Another brief bout of dollar strength saw gold bottom in November 2008 in dollar terms  Besides the eurozone crisis  and the significant risk of the German Constitutional Court deciding on September 12th to reject the recently cobbled together alphabet soup response to the crisis  ESM etc etc  and significant instability in the Middle East  there is also the not inconsequential risk from the US Presidential campaign and the upcoming  fiscal cliff  These factors should see gold well supported again in the coming months NEWSWIRE Bloomberg     Syria Government Relaxes Tax on Pure Gold Imports  State TV Says Syrian President Bashar Al Assad announced measures facilitating imports of pure gold  Syrian state run television said All custom duties and storage  insurance and administrative costs levied on gold imports will be replaced by a single fee of  100 per one kilogram  the channel said citing a presidential decree today Pure gold imports no longer require a special permit and travelers are allowed to bring the metal with them into the country  it said  Bloomberg     Economist Dennis Gartman Says He s Buying Gold Priced in PoundsEconomist Dennis Gartman is adding to his gold position by buying the metal priced in British pounds  he wrote today in his daily Gartman Letter  Bloomberg     Gold Traders Trim Bets on Price Rise  CFTC Data Shows Hedge fund managers and other large speculators decreased their net long position in New York gold futures in the week ended August 7  according to U S  Commodity Futures Trading Commission data Speculative long positions  or bets prices will rise  outnumbered short positions by 115 500 contracts on the Comex division of the New York Mercantile Exchange  the Washington based commission said in its Commitments of Traders report  Net long positions fell by 10 564 contracts  or 8 percent  from a week earlier  Gold futures rose this week  gaining 0 8 percent to  1 622 80 a troy ounce at today s close  Miners  producers  jewelers and other commercial users were net short 146 418 contracts  down 9 594 contracts  or 6 percent  from the previous week  Each Friday the CFTC publishes aggregate numbers for long and short positions for speculators such as hedge funds and institutional investors  as well as commercial companies that buy or sell futures to protect against price moves  Analysts and investors follow changes in speculators  positions because such transactions can reflect an expectation of a change in prices  Bloomberg     Silver Traders Increase Bets on Price Rise  CFTC Data ShowsHedge fund managers and other large speculators increased their net long position in New York silver futures in the week ended Aug  7  according to U S  Commodity Futures Trading Commission data Speculative long positions  or bets prices will rise  outnumbered short positions by 13 680 contracts on the Comex division of the New York Mercantile Exchange  the Washington based commission said in its Commitments of Traders report  Net long positions rose by 644 contracts  or 5 percent  from a week earlier  Silver futures rose this week  gaining 0 9 percent to  28 06 a troy ounce at today s close  Miners  producers  jewelers and other commercial users were net short 21 852 contracts  an increase of 490 contracts  or 2 percent  from the previous week  Each Friday the CFTC publishes aggregate numbers for long and short positions for speculators such as hedge funds and institutional investors  as well as commercial companies that buy or sell futures to protect against price moves  Analysts and investors follow changes in speculators  positions because such transactions can reflect an expectation of a change in prices  ABC     UBS buys stake in Silver Lake ResourcesSwiss bank banker UBS has bought a 5 per cent share in Kalgoorlie based gold producer Silver Lake Resources At the Diggers and Dealers conference in Kalgoorlie  Silverlake announced it intends to buy fellow Goldfields miner Integra Mining for  426 million  The new entity would produce about 200 000 ounces of gold a year  Bloomberg     Gold ETP Holdings Climb to Record 2 417 32 Metric TonsGold holdings in exchange traded products backed by the metal rose 4 82 metric tons to a record 2 417 32 tons  data tracked by Bloomberg showed ,2012-08-14,Mark O'Byrne,https://www.investing.com/analysis/olympic-calm-before-coming-financial-storm-132818,132818
103694,325209,ABC,Amerisource Bergen Corp  Stock Undervalued At This Time,opinion,With this company appearing currently undervalued  the prudent dividend investor might want to conduct their own due diligence on AmerisourceBergen Corp  ABC  to see if it s a fit for their portfolio   AmerisourceBergen is one of the world s largest pharmaceutical services companies serving the United States  Canada and selected global markets  Servicing both healthcare providers and pharmaceutical manufacturers in the pharmaceutical supply channel  the Company provides drug distribution and related services designed to reduce costs and improve patient outcomes  AmerisourceBergen s service solutions range from niche premium logistics and pharmaceutical packaging to reimbursement and pharmaceutical consulting services  With more than  80 billion in annual revenue  AmerisourceBergen is headquartered in Valley Forge  PA  and employs approximately 13 000 people  AmerisourceBergen is ranked  29 on the Fortune 500 list   Earnings Determine Market Price  The following earnings and price correlated  clearly illustrates the importance of earnings  The Earnings Growth Rate Line or True Worth  Line  orange line with white triangles  is correlated with the historical stock price line  On graph after graph the lines will move in tandem  If the stock price strays away from the earnings line  over or under   inevitably it will come back to earnings   Earnings   Price Correlated Fundamentals at a Glance A quick glance at the historical earnings and price correlated FAST Graphs  on AmerisourceBergen Corp shows a picture of undervaluation based upon the historical earnings growth rate of 16 6  and a current PE of 13 5  Analysts are forecasting the earnings growth to continue at about 12   and when you look at the forecasting graph below  the stock appears undervalued   it s inside of the value corridor of the five orange lines   based on future growth   AmerisourceBergen Corp  Historical Earnings  Price  Dividends and Normal PE Since 1998 Performance Table AmerisourceBergen CorpThe associated performance results with the earnings and price correlated graph  validates the principles regarding the two components of total return  capital appreciation and dividend income  Dividends are included in the total return calculation and are assumed paid  but not reinvested  When presented separately like this  the additional rate of return a dividend paying stock produces for shareholders becomes undeniably evident  In addition to the 11 9  capital appreciation  green circle   long term shareholders of AmerisourceBergen Corp  assuming an initial investment of  1 000  would have received an additional  186 77 in dividends  blue highlighting  that increased their total return from 11 9  to 12 2  per annum versus 3 7  in the S P 500 The following graph plots the historical PE ratio  the dark blue line  in conjunction with 10 year Treasury note interest  Notice that the current price earnings ratio on this quality company is as low as it has been since 1998 A further indication of valuation can be seen by examining a company s current price to sales ratio relative to its historical price to sales ratio  The current price to sales ratio for AmerisourceBergen Corp is  12 which is historically normal  Looking to the FutureExtensive research has provided a preponderance of conclusive evidence that future long term returns are a function of two critical determinants 1  The rate of change  growth rate  of the company s earnings2  The price or valuation you pay to buy those earningsForecasting future earnings growth  bought at sound valuations  is the key to safe  sound  and profitable performance The Estimated Earnings and Return Calculator Tool is a simple yet powerful resource that empowers the user to calculate and run various investing scenarios that generate precise rate of return potentialities  Thinking the investment through to its logical conclusion is an important component towards making sound and prudent commonsense investing decisions The consensus of 17 leading analysts reporting to Capital IQ forecast AmerisourceBergen Corp s long term earnings growth at 12   orange circle   AmerisourceBergen Corp has low long term debt at 25  of capital  red circle   AmerisourceBergen Corp is currently trading at a P E of 13 5  which is inside the value corridor  defined by the five orange lines  of a maximum P E of 18  If the earnings materialize as forecast  AmerisourceBergen Corp s True Worth  valuation would be  74 35 at the end of 2017  brown circle on EYE Chart   which would be a 15 4  annual rate of return from the current price  yellow highlighting  Earnings Yield EstimatesDiscounted Future Cash Flows  All companies derive their value from the future cash flows  earnings  they are capable of generating for their stakeholders over time  Therefore  because Earnings Determine Market Price in the long run  we expect the future earnings of a company to justify the price we pay Since all investments potentially compete with all other investments  it is useful to compare investing in any prospective company to that of a comparable investment in low risk Treasury bonds  Comparing an investment in AmerisourceBergen Corp to an equal investment in 10 year Treasury bonds  illustrates that AmerisourceBergen Corp s expected earnings would be 7 6  purple circle  times that of the 10 Year T Bond Interest   See EYE chart below   This is the essence of the importance of proper valuation as a critical investing component Summary   ConclusionsThis report presented essential  fundamentals at a glance  illustrating the past and present valuation based on earnings achievements as reported  Future forecasts for earnings growth are based on the consensus of leading analysts  Although  with just a quick glance you can know a lot about the company  it s imperative that the reader conducts their own due diligence in order to validate whether the consensus estimates seem reasonable or not Disclosure  Long ABC at the time of writing Disclaimer  The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients  Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted  The information in this document is believed to be accurate  but under no circumstances should a person act upon the information contained within  We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation  A comprehensive due diligence effort is recommended ,2012-09-13,F.A.S.T. Graphs,https://www.investing.com/analysis/amerisource-bergen-corp:-stock-undervalued-at-this-time-136262,136262
103695,325210,ABC,5 Long Ideas  A Follow Up,opinion,In an effort to jinx the market  I ll talk about some bullish stuff in this post  Here are five long ideas I ve shared over the past couple of weeks that seem to be coming along nicely  Amerisource Bergen  ABC   AIG  AIG   Alpha Natural Resources  ANR   Walter Energy  WLT   EXCO Resources  XCO   I ve included volume for one of these  since I think it is a vital part of that particular chart ,2012-10-18,Tim Knight,https://www.investing.com/analysis/5-long-ideas:-a-follow-up-140207,140207
103696,325211,ABC,Precious Metals And Miners Making Waves  And New Trends ,opinion,The precious metals sector has been dormant since both gold and silver topped in 2011  But the long term bull market remains intact  As long as we do not have the price of gold close below the lower yellow box on the monthly chart then technically speaking  precious metals should continue much higher Large consolidation periods  yellow boxes  provide investors with great insight for investments looking forward 6 18 months upon a breakout in either direction  up or down   The issue with investing during these times is the passage of time  One can hold a position for months and sometimes years having their investments fluctuate adding extra stress to their life when they really do not need to Once a breakout takes place a powerful rally or decline will start putting an investors  money to work within days of committing to that particular investment compared to money invested waiting months for the breakout and new capital gains to occur Gold Price Chart   MonthlyGold Price Chart   DailyThe chart of gold continues to form a large bull flag pattern with a potential 3 or 5 wave correction  If price reverses this week and breaks above the upper resistance trend line then it will be a 3  ABC  wave correction which is very bullish  But there is potential for a full 5 wave correction which is still bullish  but it just means we have another month or two before metals bottom Gold Miner Stocks   GDX ETF Chart   DailyThe Gold miners do not have the sexiest looking chart  It has formed a strong looking bull flag but continues to correct and is not nearing a key support level  This level could act as a triple bottom  bullish  or if price breaks below  then it would be breaking the neckline of a massive head and shoulders pattern which points to a 50  decline  I remain bullish with the longer term gold trend until proven wrong Silver Price Chart   DailySilver remains in a long term bull market much like the monthly chart of gold shown earlier in this report  Silver continues to work its way through a large bull flag pattern with a positive outlook at this time Silver Miner Stocks   SIL ETF   Daily ChartReviewing the precious metals sector  it seems that silver miners have the sexiest looking chart  All price patterns are showing strength and are in proportion to one other  If this chart plays out to what technical analysis is pointing to then we could see the precious metals sector put in a bottom and rally within the next week or two  And if this is the case then silver miner stocks should provide the most opportunity going forward Precious Metals Trading Conclusion In short  what you need to focus on is the yellow consolidation box on the monthly gold chart  A break in either direction will trigger a massive move that should last 6 18 months  Until then  long term investors can simply sit back and watch the sector while they put their money to work in other active sectors From a short term traders point of view  I am looking for signs of a bottom on the daily chart to get my money working earlier  and to play the bounce rally that takes place and to actively manage the position until a breakout occurs  The charts overall are not that clear as to when a breakout will take place  Metals could start to rally next week or in a few months and all we can do is wait for a reversal to the upside before we get active Knowing the big picture trends and patterns at play along with major support and resistance levels  breakout levels  is crucial for success and peace of mind ,2013-01-28,Chris Vermeulen,https://www.investing.com/analysis/precious-metals-and-miners-making-waves-(and-new-trends)-152622,152622
